<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18037885</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11.</ArticleTitle><Pagination><StartPage>1434</StartPage><EndPage>1436</EndPage><MedlinePgn>1434-6</MedlinePgn></Pagination><Abstract><AbstractText>The microtubule-associated protein tau (encoded by MAPT) and several tau kinases have been implicated in neurodegeneration, but only MAPT has a proven role in disease. We identified mutations in the gene encoding tau tubulin kinase 2 (TTBK2) as the cause of spinocerebellar ataxia type 11. Affected brain tissue showed substantial cerebellar degeneration and tau deposition. These data suggest that TTBK2 is important in the tau cascade and in spinocerebellar degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. h.houlden@ion.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Janel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gardner-Thorpe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Worth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Hilton</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Giunti</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G108/638</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.11</RegistryNumber><NameOfSubstance UI="C095903">tau-tubulin kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2008 Feb;40(2):255</RefSource><Note>Giunti, Paolo [corrected to Giunti, Paola]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="Y">Codon, Nonsense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016368" MajorTopicYN="N">Frameshift Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013132" MajorTopicYN="N">Spinocerebellar Degenerations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18037885</ArticleId><ArticleId IdType="doi">10.1038/ng.2007.43</ArticleId><ArticleId IdType="pii">ng.2007.43</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18042730</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>49</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.</ArticleTitle><Pagination><StartPage>19232</StartPage><EndPage>19237</EndPage><MedlinePgn>19232-7</MedlinePgn></Pagination><Abstract><AbstractText>The formation of amyloid fibrils is a common biochemical characteristic that occurs in Alzheimer's disease and several other amyloidoses. The unifying structural feature of amyloid fibrils is their specific type of beta-sheet conformation that differentiates these fibrils from the products of normal protein folding reactions. Here we describe the generation of an antibody domain, termed B10, that recognizes an amyloid-specific and conformationally defined epitope. This antibody domain was selected by phage-display from a recombinant library of camelid antibody domains. Surface plasmon resonance, immunoblots, and immunohistochemistry show that this antibody domain distinguishes Abeta amyloid fibrils from disaggregated Abeta peptide as well as from specific Abeta oligomers. The antibody domain possesses functional activity in preventing the formation of mature amyloid fibrils by stabilizing Abeta protofibrils. These data suggest possible applications of B10 in the detection of amyloid fibrils or in the modulation of their formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Habicht</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Leibniz Institut f&#xfc;r Altersforschung, Fritz-Lipmann-Institut, 07745 Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Ralf P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Hortschansky</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sachse</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Meinhardt</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wieligmann</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gellermann</LastName><ForeName>Gerald P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Brodhun</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Halbhuber</LastName><ForeName>Karl-J&#xfc;rgen</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>R&#xf6;cken</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002161" MajorTopicYN="N">Camelids, New World</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019151" MajorTopicYN="Y">Peptide Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18042730</ArticleId><ArticleId IdType="pmc">PMC2148273</ArticleId><ArticleId IdType="doi">10.1073/pnas.0703793104</ArticleId><ArticleId IdType="pii">0703793104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dobson CM. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark P. FEBS J. 2005;272:5942&#x2013;5949.</Citation><ArticleIdList><ArticleId IdType="pubmed">16302959</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepys MB. Annu Rev Med. 2006;57:223&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409147</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;cken C, Ernst J, Hund E, Michels H, Perz J, Saeger W, Sezer O, Spuler S, Willig F, Schmidt HH. Dtsch Med Wochenschr. 2006;131:S45&#x2013;S66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;ndrich M, Fletcher MA, Dobson CM. Nature. 2001;410:165&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, Glabe CG, Butler PC. Diabetes. 2007;56:1324&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353506</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Neuron. 2005;46:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Am J Pathol. 2000;157:1239&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850152</ArticleId><ArticleId IdType="pubmed">11021828</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Frenkel D. Nat Rev Immunol. 2006;6:404&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A. Science. 2001;294:178&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">11546838</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, et al. Nature. 2001;412:739&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11507642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Nat Med. 2002;8:1270&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379846</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Wetzel R. Proc Natl Acad Sci USA. 2002;99:1485&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122217</ArticleId><ArticleId IdType="pubmed">11818542</ArticleId></ArticleIdList></Reference><Reference><Citation>White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Nature. 2003;422:80&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621436</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, et al. Nature. 2003;424:783&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917687</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Holliger P, Hudson PJ. Nat Biotechnol. 2005;23:1126&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151406</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;ckthun A. Immunol Rev. 1992;130:151&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">1286869</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Mol Immunol. 1997;34:1121&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566760</ArticleId></ArticleIdList></Reference><Reference><Citation>Riechmann L, Muyldermans S. J Immunol Methods. 1999;231:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, Xu C, Wieligmann K, Diekmann S, Grigorieff N, Fandrich M. J Mol Biol. 2006;362:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner P, Bauer K, Krebber A, Nieba L, Kremmer E, Krebber C, Honegger A, Klinger B, Mocikat R, Pl&#xfc;ckthun A. BioTechniques. 1997;22:140&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994661</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Pettegrew JW, Abraham DJ. J Histochem Cytochem. 1989;37:1273&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">2666510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawatake S, Nishimura Y, Sakaguchi S, Iwaki T, Doh-Ura K. Biol Pharm Bull. 2006;29:927&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651721</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., III Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbhuber KJ, Schulze M, Rhode H, Bublitz R, Feuerstein H, Walter M, Linss W, Meyer HW, Horn A. Cell Mol Biol (Noisy-le-grand) 1994;40:1077&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">7873980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandomeneghi G, Krebs MR, McCammon MG, Fandrich M. Protein Sci. 2004;13:3314&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287307</ArticleId><ArticleId IdType="pubmed">15537750</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniolo C, Palumbo M. Biopolymers. 1977;16:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">843593</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON. Magn Reson Chem. 2004;42:231&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745804</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT., Jr Annu Rev Biochem. 1997;66:385&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Annu Rev Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochet JC, Lansbury PT., Jr Curr Opin Struct Biol. 2000;10:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679462</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. J Biol Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT., Jr Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury CS, Wirtz S, Muller SA, Sunderji S, Wicki P, Aebi U, Frey P. J Struct Biol. 2000;130:217&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940227</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Proc Natl Acad Sci USA. 1997;94:4109&#x2013;4112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20576</ArticleId><ArticleId IdType="pubmed">9108113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. J Biol Chem. 2007;282:18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Hanan E, Katzav T. Proc Natl Acad Sci USA. 1996;93:452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40256</ArticleId><ArticleId IdType="pubmed">8552659</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner M, Shirahama T, Cohen AS, Deal CL. Prep Biochem. 1982;12:461&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">6302659</ArticleId></ArticleIdList></Reference><Reference><Citation>McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Nature. 1990;348:552&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">2247164</ArticleId></ArticleIdList></Reference><Reference><Citation>Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Nature. 1991;352:624&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fandrich M. Protein Sci. 2005;14:1753&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253354</ArticleId><ArticleId IdType="pubmed">15937275</ArticleId></ArticleIdList></Reference><Reference><Citation>De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L. Proc Natl Acad Sci USA. 2006;103:4586&#x2013;4591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450215</ArticleId><ArticleId IdType="pubmed">16537393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellermann GP, Ullrich K, Tannert A, Unger C, Habicht G, Sauter SR, Hortschansky P, Horn U, Mollmann U, Decker M, et al. J Mol Biol. 2006;360:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">16765377</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzielanek S, Smirnovas V, Winter R. J Mol Biol. 2006;356:497&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18042918</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>20</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Dementia screening in primary care: is it time?</ArticleTitle><Pagination><StartPage>2409</StartPage><EndPage>2411</EndPage><MedlinePgn>2409-11</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Boustani</LastName><ForeName>Malaz</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG026770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG029884-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG 26770-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2008 Feb 13;299(6):634</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2008 Mar 12;299(10):1132-3; author reply 1133-4. doi: 10.1001/jama.299.10.1132-b.</RefSource><PMID Version="1">18334685</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2008 Mar 12;299(10):1132; author reply 1133-4. doi: 10.1001/jama.299.10.1132-a.</RefSource><PMID Version="1">18334686</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005194" MajorTopicYN="Y">Family Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18042918</ArticleId><ArticleId IdType="doi">10.1001/jama.298.20.2409</ArticleId><ArticleId IdType="pii">298/20/2409</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18044984</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.</ArticleTitle><Pagination><StartPage>e338</StartPage><MedlinePgn>e338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e338</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical entity, clinical trials have been conducted in the attempt to study the role of cholinesterase inhibitors (ChEIs) currently approved for symptomatic treatment of mild to moderate Alzheimer disease (AD), in preventing progression from MCI to AD. The objective of this review is to assess the effects of ChEIs (donepezil, rivastigmine, and galantamine) in delaying the conversion from MCI to Alzheimer disease or dementia.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">The terms "donepezil", "rivastigmine", "galantamine", and "mild cognitive impairment" and their variants, synonyms, and acronyms were used as search terms in four electronic databases (MEDLINE, EMBASE, Cochrane, PsycINFO) and three registers: the Cochrane Collaboration Trial Register, Current Controlled Trials, and ClinicalTrials.gov. Published and unpublished studies were included if they were randomized clinical trials published (or described) in English and conducted among persons who had received a diagnosis of MCI and/or abnormal memory function documented by a neuropsychological assessment. A standardized data extraction form was used. The reporting quality was assessed using the Jadad scale. Three published and five unpublished trials met the inclusion criteria (three on donepezil, two on rivastigmine, and three on galantamine). Enrolment criteria differed among the trials, so the study populations were not homogeneous. The duration of the trials ranged from 24 wk to 3 y. No significant differences emerged in the probability of conversion from MCI to AD or dementia between the treated groups and the placebo groups. The rate of conversion ranged from 13% (over 2 y) to 25% (over 3 y) among treated patients, and from 18% (over 2 y) to 28% (over 3 y) among those in the placebo groups. Only for two studies was it possible to derive point estimates of the relative risk of conversion: 0.85 (95% confidence interval 0.64-1.12), and 0.84 (0.57-1.25). Statistically significant differences emerged for three secondary end points. However, when adjusting for multiple comparisons, only one difference remained significant (i.e., the rate of atrophy in the whole brain).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia. Moreover, the safety profile showed that the risks associated with ChEIs are not negligible. The uncertainty regarding MCI as a clinical entity raises the question as to the scientific validity of these trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raschetti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Center for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Rome, Italy. roberto.raschetti@iss.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Maggini</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests:</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18044984</ArticleId><ArticleId IdType="pmc">PMC2082649</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0040338</ArticleId><ArticleId IdType="pii">07-PLME-RA-0189</ArticleId><ArticleId IdType="sici">plme-04-11-19</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2002;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. World Health Report 2003-Shaping the future. Geneva: WHO; 2003.  Available at:  http://www.who.int/whr/2003/en/index.html. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>Langa KM, Chernew ME, Kabeto MU, Herzog AR, Ofstedal MB, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495283</ArticleId><ArticleId IdType="pubmed">11722692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005;331:321&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183129</ArticleId><ArticleId IdType="pubmed">16081444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosi AJ, McNulty SV, Jackson GA. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ. 2006;333:491&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557932</ArticleId><ArticleId IdType="pubmed">16946340</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mount C, Downton C. Alzheimer's disease: progress or profit? Nat Med. 2006;12:780&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829947</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000;355:225&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, et al. Mild cognitive impairment. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment. Lancet. 2006;367:1979.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782484</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse P, Brodaty H. Mild cognitive impairment. Lancet. 2006;367:1979.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782483</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2005;76:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739362</ArticleId><ArticleId IdType="pubmed">16170074</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557506</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12451203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transition from normal to mild cognitive impairment and dementia. Neurology. 2006;66:828&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567698</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry. 2006;77:429&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077499</ArticleId><ArticleId IdType="pubmed">16306154</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006. 2006. p. CD001747. Available:  http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001747/frame.html. Accessed 31 October 2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961200</ArticleId><ArticleId IdType="pubmed">16437436</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006;3:CD006104. Available:  http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006104/frame.html. Accessed 31 October 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">16856114</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Alert for healthcare professionals on galantamine hydrochloride (marketed as Razadyne formerly Reminyl) [FDA Alert] 2005.  Available:  http://www.fda.gov/cder/drug/InfoSheets/HCP/galantamineHCP.htm. Accessed 16 February 2006.</Citation></Reference><Reference><Citation>Gauthier S, Touchon J. Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005;62:1164&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PB, Johnston D, Lyketsos C. A clinical approach to mild cognitive impairment. Am J Psychiatry. 2006;163:1884&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074938</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62:1160&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirshner HS. Mild cognitive impairment: to treat or not to treat. Curr Neurol Neurosci Rep. 2005;5:455&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263056</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994;271:992&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139084</ArticleId></ArticleIdList></Reference><Reference><Citation>Galisteo M, Rissel M, Sergent O, Chevanne M, Cillard J, et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther. 2000;294:160&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10871308</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Mental Health. Treatment for early memory loss. 2005.  Available:  http://clinicaltrials.gov/ct/show/NCT00042172. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>[No authors listed] A prospective, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of the effect of rivastigmine on the time to clinical diagnosis of Alzheimer's disease in subjects with mild cognitive impairment (MCI) 2006.  Available:  http://www.novartisclinicaltrials.com/webapp/clinicaltrialrepository/displayFile.do?trialResult=1886. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>De Kosky S. A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's disease. Protocol No. GAL-INT-11. 2004.  Available:  http://www.clinicalstudyresults.org/documents/company-study_96_1.pdf. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>Winblad B. A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's disease. Protocol No. GAL-INT-18. 2004.  Available:  http://www.clinicalstudyresults.org/documents/company-study_96_2.pdf. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen. 2005;20:295&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833248</ArticleId><ArticleId IdType="pubmed">16273995</ArticleId></ArticleIdList></Reference><Reference><Citation>Novartis. Efficacy and safety of rivastigmine in patients with mild cognitive impairment. 2006.  Available:  http://clinicaltrials.gov/ct/show/NCT00134953. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326237</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sob&#xf3;w T, Ktoszewska I. Cholinesterase inhibitors in mild cognitive impairment: a met-analysis of randomized controlled trials. Neurol Neurochirurgia Polska. 2006;41:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17330176</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701&#x2013;2711.</Citation><ArticleIdList><ArticleId IdType="pubmed">10819955</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish J. Alzheimer's disease&#x2014;clinical trials and logic of clinical purpose. N Engl J Med. 2006;355:1604&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ. 2005;330:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548208</ArticleId><ArticleId IdType="pubmed">15695272</ArticleId></ArticleIdList></Reference><Reference><Citation>ADRAC. Deaths with galantamine in mild cognitive impairment studies. Aust Adv Drug Reactions Bull. 2006;25(1) Available:  http://www.tga.gov.au/adr/aadrb/aadr0602.htm#a1. Accessed 31 October 2007.</Citation></Reference><Reference><Citation>De Carli C, Frisoni GB, Clark CM, Harvey D, Grundman M, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210817</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Canu E, Geroldi C, Zanetti O, Zacchi V. Drug prescription in mild cognitive impairment: the physicians' perspective in Italy. Int J Geriatr Psychiatry. 2006;21:1071&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">16955446</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1122833</ArticleId><ArticleId IdType="pubmed">11950740</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med. 2006;3:e191.  doi: 10.1371/journal.pmed.0030191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030191</ArticleId><ArticleId IdType="pmc">PMC1434508</ArticleId><ArticleId IdType="pubmed">16597180</ArticleId></ArticleIdList></Reference><Reference><Citation>House of Commons Health Committee. The influence of the pharmaceutical industry. Fourth Report of Session 2004&#x2013;05. Volume I. 2005.  Available:  http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf. Accessed 31 October 2007.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18055549</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>171</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice.</ArticleTitle><Pagination><StartPage>2012</StartPage><EndPage>2020</EndPage><MedlinePgn>2012-20</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease presents morphologically with senile plaques, primarily made of extracellular amyloid-beta (A beta) deposits, and neurofibrillary lesions, which consist of intracellular aggregates of hyperphosphorylated tau protein. To study the in vivo induction of tau pathology, dilute brain extracts from aged A beta-depositing APP23 transgenic mice were intracerebrally infused in young B6/P301L tau transgenic mice. Six months after the infusion, tau pathology was induced in the injected hippocampus but also in brain regions well beyond the injection sites such as the entorhinal cortex and amygdala, areas with neuronal projection to the injection site. No or only modest tau induction was observed when brain extracts from aged nontransgenic control mice and aged tau-depositing B6/P301L transgenic mice were infused. To further study A beta-induced tau lesions B6/P301L tau transgenic mice were crossed with APP23 mice. Although A beta deposition in double-transgenic mice did not differ from single APP23 transgenic mice, double-transgenic mice revealed increased tau pathology compared to single B6/P301L tau transgenic mice predominately in areas with high A beta plaque load. The present results suggest that both extract-derived A beta species and deposited fibrillary A beta can induce the formation of tau neurofibrillary pathology. The observation that infused A beta can trigger the tau pathology in the absence of A beta deposits provides an explanation for the discrepancy between the neuroanatomical location of A beta deposits and the development and spreading of tau lesions in Alzheimer's disease brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, Otfried-M&#xfc;ller Str.27, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clavaguera</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herzig</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Radde</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jada</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tolnay</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS046355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS46355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002457">Cell Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002457" MajorTopicYN="N">Cell Extracts</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18055549</ArticleId><ArticleId IdType="pmc">PMC2111123</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2007.070403</ArticleId><ArticleId IdType="pii">S0002-9440(10)62461-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer&#x2019;s disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, Staufenbiel M, Huther G, Ruther E, Kornhuber J. Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis. 1997;18:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F. Silver staining of Alzheimer&#x2019;s neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung. 1971;19:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231:482&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G. New York: Academic Press,; The Mouse Brain in Stereotaxic Coordinates. 2001</Citation></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Phinney AL, Deller T, Stalder M, Calhoun ME, Frotscher M, Sommer B, Staufenbiel M, Jucker M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci. 1999;19:8552&#x2013;8559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783025</ArticleId><ArticleId IdType="pubmed">10493755</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Lorenzo A, Yeh J, Yankner BA. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14:879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides. 2002;23:1241&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12128081</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2006;103:1953&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413647</ArticleId><ArticleId IdType="pubmed">16446437</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer&#x2019;s neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O&#x2019;Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18057069</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>A genome-wide association study of sporadic ALS in a homogenous Irish population.</ArticleTitle><Pagination><StartPage>768</StartPage><EndPage>774</EndPage><MedlinePgn>768-74</MedlinePgn></Pagination><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive limb or bulbar weakness. Efforts to elucidate the disease-associated loci have to date produced conflicting results. One strategy to improve power in genome-wide studies is to genotype a genetically homogenous population. Such a population exhibits extended linkage disequilibrium (LD) and lower allelic heterogeneity to facilitate disease gene mapping. We sought to identify associated variants for ALS in the Irish, a stable population of relatively homogenous genetic background, and to replicate these findings in larger genetically out-bred populations. We conducted a genome-wide association study in 432 Irish individuals using Illumina HumanHap 550K single nucleotide polymorphism chips. We demonstrated extended LD and increased homogeneity in the Irish sample when compared to an out-bred population of mixed European ancestry. The Irish scan identified 35 loci associated with P-values below 0.0001. For replication, we identified seven chromosomal regions commonly associated in a joint analysis of genome-wide data on 958 ALS cases and 932 controls from Ireland and the previously published datasets from the US and The Netherlands. When pooled, the strongest association was a variant in the gene encoding DPP6, a component of type A neuronal transmembrane potassium channels. Further confirmation of the candidate loci is warranted in additional genome-wide datasets. We have made our individual genotyping data publicly available, contributing to a powerful world-wide resource to refine our understanding of the genetics of sporadic ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cronin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland. scronin@rcsi.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schymick</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Washecka</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Greenway</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C503535">DPP6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.14.-</RegistryNumber><NameOfSubstance UI="D004152">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002897" MajorTopicYN="N">Chromosomes, Human, Pair 7</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004152" MajorTopicYN="N">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005828" MajorTopicYN="Y">Genetics, Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007494" MajorTopicYN="N" Type="Geographic">Ireland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18057069</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddm361</ArticleId><ArticleId IdType="pii">ddm361</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18059262</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4469</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature chemical biology</Title><ISOAbbreviation>Nat Chem Biol</ISOAbbreviation></Journal><ArticleTitle>An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>50</EndPage><MedlinePgn>42-50</MedlinePgn></Pagination><Abstract><AbstractText>Muscarinic acetylcholine receptors (mAChRs) provide viable targets for the treatment of multiple central nervous system disorders. We have used cheminformatics and medicinal chemistry to develop new, highly selective M4 allosteric potentiators. VU10010, the lead compound, potentiates the M4 response to acetylcholine 47-fold while having no activity at other mAChR subtypes. This compound binds to an allosteric site on the receptor and increases affinity for acetylcholine and coupling to G proteins. Whole-cell patch clamp recordings revealed that selective potentiation of M4 with VU10010 increases carbachol-induced depression of transmission at excitatory but not inhibitory synapses in the hippocampus. The effect was not mimicked by an inactive analog of VU10010 and was absent in M4 knockout mice. Selective regulation of excitatory transmission by M4 suggests that targeting of individual mAChR subtypes could be used to differentially regulate specific aspects of mAChR modulation of function in this important forebrain structure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shirey</LastName><ForeName>Jana K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Vanderbilt Program in Drug Discovery, 23rd Avenue South at Pierce, Nashville, Tennessee 37232-6600, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Zixiu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Orton</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Ashley E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ayala</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Alice L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Wess</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Niswender</LastName><ForeName>Colleen M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Conn</LastName><ForeName>P Jeffrey</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PubChem-Substance</DataBankName><AccessionNumberList><AccessionNumber>26746577</AccessionNumber><AccessionNumber>26746578</AccessionNumber><AccessionNumber>26746579</AccessionNumber><AccessionNumber>26746580</AccessionNumber><AccessionNumber>26746581</AccessionNumber><AccessionNumber>26746582</AccessionNumber><AccessionNumber>26746583</AccessionNumber><AccessionNumber>26746584</AccessionNumber><AccessionNumber>26746585</AccessionNumber><AccessionNumber>26746586</AccessionNumber><AccessionNumber>26746587</AccessionNumber><AccessionNumber>26746588</AccessionNumber><AccessionNumber>26746589</AccessionNumber><AccessionNumber>26746590</AccessionNumber><AccessionNumber>26746591</AccessionNumber><AccessionNumber>26746592</AccessionNumber><AccessionNumber>26746593</AccessionNumber><AccessionNumber>26746594</AccessionNumber><AccessionNumber>26746595</AccessionNumber><AccessionNumber>26746596</AccessionNumber><AccessionNumber>26746597</AccessionNumber><AccessionNumber>26746598</AccessionNumber><AccessionNumber>26746599</AccessionNumber><AccessionNumber>26746600</AccessionNumber><AccessionNumber>26746601</AccessionNumber><AccessionNumber>26746602</AccessionNumber><AccessionNumber>26746603</AccessionNumber><AccessionNumber>26746604</AccessionNumber><AccessionNumber>26746605</AccessionNumber><AccessionNumber>26746606</AccessionNumber><AccessionNumber>26746607</AccessionNumber><AccessionNumber>26746608</AccessionNumber><AccessionNumber>26746609</AccessionNumber><AccessionNumber>26746610</AccessionNumber><AccessionNumber>26746611</AccessionNumber><AccessionNumber>26746612</AccessionNumber><AccessionNumber>26746613</AccessionNumber><AccessionNumber>26746614</AccessionNumber><AccessionNumber>26746615</AccessionNumber><AccessionNumber>26746616</AccessionNumber><AccessionNumber>26746617</AccessionNumber><AccessionNumber>26746618</AccessionNumber><AccessionNumber>26746619</AccessionNumber><AccessionNumber>26746620</AccessionNumber><AccessionNumber>26746621</AccessionNumber><AccessionNumber>26746622</AccessionNumber><AccessionNumber>26746623</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH065215</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Chem Biol</MedlineTA><NlmUniqueID>101231976</NlmUniqueID><ISSNLinking>1552-4450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043588">Receptor, Muscarinic M4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000495" MajorTopicYN="N">Allosteric Site</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043588" MajorTopicYN="N">Receptor, Muscarinic M4</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18059262</ArticleId><ArticleId IdType="doi">10.1038/nchembio.2007.55</ArticleId><ArticleId IdType="pii">nchembio.2007.55</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18066057</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Prefrontal cortex and basal ganglia control access to working memory.</ArticleTitle><Pagination><StartPage>103</StartPage><EndPage>107</EndPage><MedlinePgn>103-7</MedlinePgn></Pagination><Abstract><AbstractText>Our capacity to store information in working memory might be determined by the degree to which only relevant information is remembered. The question remains as to how this selection of relevant items to be remembered is accomplished. Here we show that activity in the prefrontal cortex and basal ganglia preceded the filtering of irrelevant information and that activity, particularly in the globus pallidus, predicted the extent to which only relevant information is stored. The preceding frontal and basal ganglia activity were also associated with inter-individual differences in working memory capacity. These findings reveal a mechanism by which frontal and basal ganglia activity exerts attentional control over access to working memory storage in the parietal cortex in humans, and makes an important contribution to inter-individual differences in working memory capacity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNab</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Developmental Cognitive Neuroscience, Stockholm Brain Institute, Karolinska Institutet, MR Centrum, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klingberg</LastName><ForeName>Torkel</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18066057</ArticleId><ArticleId IdType="doi">10.1038/nn2024</ArticleId><ArticleId IdType="pii">nn2024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18076286</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age.</ArticleTitle><Pagination><StartPage>e325</StartPage><MedlinePgn>e325</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e325</ELocationID><Abstract><AbstractText>Parkinson disease affects more than 1% of the population over 60 y old. The dominant models for Parkinson disease are based on the use of chemical toxins to kill dopamine neurons, but do not address the risk factors that normally increase with age. Forkhead transcription factors are critical regulators of survival and longevity. The forkhead transcription factor, foxa2, is specifically expressed in adult dopamine neurons and their precursors in the medial floor plate. Gain- and loss-of-function experiments show this gene, foxa2, is required to generate dopamine neurons during fetal development and from embryonic stem cells. Mice carrying only one copy of the foxa2 gene show abnormalities in motor behavior in old age and an associated progressive loss of dopamine neurons. Manipulating forkhead function may regulate both the birth of dopamine neurons and their spontaneous death, two major goals of regenerative medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kittappa</LastName><ForeName>Raja</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Wendy W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Awatramani</LastName><ForeName>Rajeshwar B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>Ronald D G</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496503">Foxa2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C465570">Shh protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>135845-92-0</RegistryNumber><NameOfSubstance UI="D051542">Hepatocyte Nuclear Factor 3-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Biol. 5:e334.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051542" MajorTopicYN="N">Hepatocyte Nuclear Factor 3-beta</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036801" MajorTopicYN="N">Parturition</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18076286</ArticleId><ArticleId IdType="pmc">PMC2121110</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.0050325</ArticleId><ArticleId IdType="pii">07-PLBI-RA-1556</ArticleId><ArticleId IdType="sici">plbi-05-12-08</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lewis SJ, Dove A, Robbins TW, Barker R, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J. Neurosci. 2003;23:6351&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740550</ArticleId><ArticleId IdType="pubmed">12867520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange KW, Paul GM, Robbins TW, Marsden CD. L-dopa and frontal cognitive function in Parkinson's disease. Adv Neurol. 1993;60:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">8420173</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, et al. Prevalence of Parkinson's Disease in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S21&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854357</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman J, Bayer S.A. Development of the brain stem in the rat. V. Thymidine-radiographic study of the time of origin of neurons in the midbrain tegmentum. J Comp Neurol. 1981;198:677&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">7251936</ArticleId></ArticleIdList></Reference><Reference><Citation>Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci. 1998;1:290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18:675&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">10835609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki H, Suemori H, Mizuseki K, Watanabe K, Urano F, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28:31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-H, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12077607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakayama T, Tabar V, Rodriguez I, Perry AC, Studer L, et al. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science. 2001;292:740&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11326103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pernaute R, Studer L, Bankiewicz KS, Major EO, McKay RD. In vitro generation and transplantation of precursor-derived human dopamine neurons. J. Neurosci Res. 2001;65:284&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">11494363</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Nat Acad Sci U S A. 2004;101:12543&#x2013;12548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515094</ArticleId><ArticleId IdType="pubmed">15310843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E, Prezioso VR, Tao WF, Chen WS, Darnell JE. Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene fork head. Genes Dev. 1991;5:416&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki H, Hogan BL. HNF-3 beta as a regulator of floor plate development. Cell. 1994;76:103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287471</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein DC, Ruiz i Altaba A, Chen WS, Hoodless P, Prezioso VR, et al. The winged-helix transcription factor HNF-3 beta is required for notochord development in the mouse embryo. Cell. 1994;78:575&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang SL, Rossant J. HNF-3 beta is essential for node and notochord formation in mouse development. Cell. 1994;78:561&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069909</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein DJ, McMahon AP, Joyner AL. Regionalization of Sonic hedgehog transcription along the anteroposterior axis of the mouse central nervous system is regulated by Hnf3-dependent and -independent mechanisms. Development. 1999;126:281&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9847242</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410&#x2013;7425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16288288</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Datta SR, Greenberg ME. Transcription-dependent and independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 2001;11:297&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell. 2007;1:140&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371346</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth C, Rajput M, Rajput AH. Anomalies of asymmetry of clinical signs in parkinsonism. Mov Disord. 2004;19:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">14978669</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, et al. Identification of intrinsic determinants of midbrain dopamine neurons. Cell. 2006;124:393&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">16439212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynes M, Poulsen K, Tessier-Lavigne M, Rosenthal A. Control of neuronal diversity by the floor plate: contact-mediated induction of midbrain dopaminergic neurons. Cell. 1995;80:95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7813022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MZ, Jin P, Bumcrot DA, Marigo V, McMahon AP, et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat Med. 1995;1:1184&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">7584992</ArticleId></ArticleIdList></Reference><Reference><Citation>Harfe BD, Scherz PJ, Nissim S, Tian H, McMahon AP, et al. Evidence for an expansion-based temporal Shh gradient in specifying vertebrate digit identities. Cell. 2004;118:517&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">15315763</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaess S, Corrales JD, Joyner AL. Sonic hedgehog regulates gli activator and repressor functions with spatial and temporal precision in the mid/hindbrain region. Development. 2006;133:1799&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">16571630</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton WH, Mangoli M, Lele Z, Pogoda HM, Diamond B, et al. Monorail/Foxa2 regulates floorplate differentiation and specification of oligodendrocytes, serotonergic raphe neurones and cranial motoneurones. Development. 2005;132:645&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790417</ArticleId><ArticleId IdType="pubmed">15677724</ArticleId></ArticleIdList></Reference><Reference><Citation>Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res. 2005;1053:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922062</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffery P, Drager UC. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A. 1994;91:7772&#x2013;7776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44484</ArticleId><ArticleId IdType="pubmed">8052659</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process. Lancet Neurol. 2004;3:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261611</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006;2:679&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117171</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba Y, Markopoulou K, Putzke JD, Whaley NR, Farrer MJ, et al. Phenotypic commonalities in familial and sporadic Parkinson disease. Arch Neurol. 63:579&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606772</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102273</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">14976264</ArticleId></ArticleIdList></Reference><Reference><Citation>Panowski SH, Wolff S, Aguilaniu H, Durieux J, Dillin A. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature. 2007;447:550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476212</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx. 2004;1:139&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534919</ArticleId><ArticleId IdType="pubmed">15717014</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996;274:1197&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8895469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfrum C, Besser D, Luca E, Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci U S A. 2003;100:11624&#x2013;11629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208808</ArticleId><ArticleId IdType="pubmed">14500912</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff F, Noelker C, Eggert K, Schlegel J. Signaling pathways mediate the neuroprotective effects of GDNF. Ann N Y Acad Sci. 2002;973:70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer. 2006;94:620&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2361204</ArticleId><ArticleId IdType="pubmed">16495927</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol. 2006;8:834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862145</ArticleId></ArticleIdList></Reference><Reference><Citation>Galter D, Buervenich S, Carmine A, Anvret M, Olson L. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's Disease and in the ventral tegmental area in schizophrenia. Neurobiol. Dis. 2003;14:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, et al. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's Disease. J Neurol Neurosurg Psychiatry. 2005;76:1204&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739780</ArticleId><ArticleId IdType="pubmed">16107352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's Disease. NeuroRx. 2005;2:484&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1144492</ArticleId><ArticleId IdType="pubmed">16389312</ArticleId></ArticleIdList></Reference><Reference><Citation>Murase S, McKay RD. A specific survival response in dopamine neurons at most risk in Parkinson's disease. J Neurosci. 2006;26:9750&#x2013;9760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674460</ArticleId><ArticleId IdType="pubmed">16988046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121:465&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying QL, Stavridis M, Griffiths D, Li M, Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol. 2003;21:183&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524553</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18077357</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>51</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus.</ArticleTitle><Pagination><StartPage>20558</StartPage><EndPage>20563</EndPage><MedlinePgn>20558-63</MedlinePgn></Pagination><Abstract><AbstractText>The lifelong addition of neurons to the hippocampus is a remarkable form of structural plasticity, yet the molecular controls over proliferation, neuronal fate determination, survival, and maturation are poorly understood. Expression of Notch1 was found to change dynamically depending on the differentiation state of neural precursor cells. Through the use of inducible gain- and loss-of-function of Notch1 mice we show that this membrane receptor is essential to these distinct processes. We found in vivo that activated Notch1 overexpression induces proliferation, whereas gamma-secretase inhibition or genetic ablation of Notch1 promotes cell cycle exit, indicating that the level of activated Notch1 regulates the magnitude of neurogenesis from postnatal progenitor cells. Abrogation of Notch signaling in vivo or in vitro leads to a transition from neural stem or precursor cells to transit-amplifying cells or neurons. Further, genetic Notch1 manipulation modulates survival and dendritic morphology of newborn granule cells. These results provide evidence for the expansive prevalence of Notch signaling in hippocampal morphogenesis and plasticity, suggesting that Notch1 could be a target of diverse traumatic and environmental modulators of adult neurogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breunig</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Kavli Institute for Neuroscience, and Child Study Center, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silbereis</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vaccarino</LastName><ForeName>Flora M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Sestan</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rakic</LastName><ForeName>Pasko</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD045481</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD045481</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH067715</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS047200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18077357</ArticleId><ArticleId IdType="pmc">PMC2154470</ArticleId><ArticleId IdType="doi">10.1073/pnas.0710156104</ArticleId><ArticleId IdType="pii">0710156104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rakic P. Limits of neurogenesis in primates. Science. 1985;227(4690):1054&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">3975601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj RD, et al. From the cover: Neocortical neurogenesis in humans is restricted to development. Proc Natl Acad Sci USA. 2006;103(33):12564&#x2013;12568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567918</ArticleId><ArticleId IdType="pubmed">16901981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10688783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437(7063):1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K, et al. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci. 2003;6(1):21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12469128</ArticleId></ArticleIdList></Reference><Reference><Citation>Machold R, et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron. 2003;39(6):937&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lledo PM, Alonso M, Grubb MS. Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci. 2006;7(3):179&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495940</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science. 1999;284(5415):770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221902</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393(6683):382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray SJ. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921404</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JP, et al. Transient expression of doublecortin during adult neurogenesis. J Comp Neurol. 2003;467(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14574675</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumpe T, et al. Variability of doublecortin-associated dendrite maturation in adult hippocampal neurogenesis is independent of the regulation of precursor cell proliferation. BMC Neurosci. 2006;7:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1657022</ArticleId><ArticleId IdType="pubmed">17105671</ArticleId></ArticleIdList></Reference><Reference><Citation>Britz O, et al. A role for proneural genes in the maturation of cortical progenitor cells. Cereb Cortex. 2006;16(Suppl 1):i138&#x2013;i151.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766700</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro DS, et al. Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev Cell. 2006;11(6):831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17141158</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleasure SJ, Collins AE, Lowenstein DH. Unique expression patterns of cell fate molecules delineate sequential stages of dentate gyrus development. J Neurosci. 2000;20(16):6095&#x2013;6105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772596</ArticleId><ArticleId IdType="pubmed">10934259</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959515</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, et al. Gamma-secretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity. Drugs R D. 2006;7(2):87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16542055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganat YM, et al. Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo. J Neurosci. 2006;26(33):8609&#x2013;8621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674357</ArticleId><ArticleId IdType="pubmed">16914687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutolf S, et al. Development. 2. Vol. 129. UK: Cambridge; 2002. Notch1 is required for neuronal and glial differentiation in the cerebellum. pp. 373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, et al. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004;269(1):81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081359</ArticleId></ArticleIdList></Reference><Reference><Citation>Breunig JJ, et al. Everything that glitters is not gold: A critical review of analysis of neural precursor / stem cells. Cell Stem Cell. in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297(5580):365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130776</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega CJ, Peterson DA. Stem cell proliferative history in tissue revealed by temporal halogenated thymidine analog discrimination. Nat Methods. 2005;2(3):167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15782184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Colbert MC, Robbins J. Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system. Circ Res. 2006;98(12):1547&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709902</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns KA, et al. Nestin-CreER mice reveal DNA synthesis by nonapoptotic neurons following cerebral ischemia-hypoxia. Cereb Cortex. 2007;17(11):2585&#x2013;2592.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sestan N, Artavanis-Tsakonas S, Rakic P. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science. 1999;286(5440):741&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531053</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, et al. Notch1 inhibits neurite outgrowth in postmitotic primary neurons. Neuroscience. 1999;93(2):433&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10465425</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond L, et al. Nuclear Notch1 signaling and the regulation of dendritic development. Nat Neurosci. 2000;3(1):30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607392</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SP, et al. Maturation of granule cell dendrites after mossy fiber arrival in hippocampal field CA3. Hippocampus. 2003;13(3):413&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722981</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. Neuron. 2000;26(2):395&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10839358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanigaki K, et al. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron. 2001;29(1):45&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182080</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav AP, Mason HA, Cepko CL. Development. 5. Vol. 133. UK: Cambridge; 2006. Notch 1 inhibits photoreceptor production in the developing mammalian retina. pp. 913&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers CB, et al. Development. 5. Vol. 128. UK: Cambridge; 2001. Spatiotemporal selectivity of response to Notch1 signals in mammalian forebrain precursors. pp. 689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani K, Saito T. Development. 6. Vol. 132. UK: Cambridge; 2005. Progenitors resume generating neurons after temporary inhibition of neurogenesis by Notch activation in the mammalian cerebral cortex. pp. 1295&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillard I, et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood. 2004;104(6):1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187027</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng AP, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003;23(2):655&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151540</ArticleId><ArticleId IdType="pubmed">12509463</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce JP, et al. Mossy fibers are the primary source of afferent input to ectopic granule cells that are born after pilocarpine-induced seizures. Exp Neurol. 2005;196(2):316&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1431686</ArticleId><ArticleId IdType="pubmed">16342370</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharfman HE, Goodman JH, Sollas AL. Granule-like neurons at the hilar/CA3 border after status epilepticus and their synchrony with area CA3 pyramidal cells: Functional implications of seizure-induced neurogenesis. J Neurosci. 2000;20(16):6144&#x2013;6158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772593</ArticleId><ArticleId IdType="pubmed">10934264</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM, et al. Aberrant seizure-induced neurogenesis in experimental temporal lobe epilepsy. Ann Neurol. 2006;59(1):81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261566</ArticleId></ArticleIdList></Reference><Reference><Citation>Overstreet-Wadiche LS, et al. Seizures accelerate functional integration of adult-generated granule cells. J Neurosci. 2006;26(15):4095&#x2013;4103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673901</ArticleId><ArticleId IdType="pubmed">16611826</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott RC, et al. Differential regulation of basic helix-loop-helix mRNAs in the dentate gyrus following status epilepticus. Neuroscience. 2001;106(1):79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11564418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, et al. Changes in the expression of Hes5 and Mash1 mRNA in the adult rat dentate gyrus after transient forebrain ischemia. Neurosci Lett. 2005;380(1&#x2013;2):17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15854743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, et al. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci. 2006;26(1):3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674324</ArticleId><ArticleId IdType="pubmed">16399667</ArticleId></ArticleIdList></Reference><Reference><Citation>Felling RJ, et al. Neural stem/progenitor cells participate in the regenerative response to perinatal hypoxia/ischemia. J Neurosci. 2006;26(16):4359&#x2013;4369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673988</ArticleId><ArticleId IdType="pubmed">16624956</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery DL, et al. Newly born granule cells in the dentate gyrus rapidly extend axons into the hippocampal CA3 region following experimental brain injury. J Neurotrauma. 2005;22(9):978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">16156713</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam TV, et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med. 2006;12(6):621&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">16680150</ArticleId></ArticleIdList></Reference><Reference><Citation>Givogri MI, et al. Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. Dev Neurosci. 2006;28(1&#x2013;2):81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508306</ArticleId></ArticleIdList></Reference><Reference><Citation>Eadie BD, Redila VA, Christie BR. Voluntary exercise alters the cytoarchitecture of the adult dentate gyrus by increasing cellular proliferation, dendritic complexity, and spine density. J Comp Neurol. 2005;486(1):39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834963</ArticleId></ArticleIdList></Reference><Reference><Citation>Redila VA, Christie BR. Exercise-induced changes in dendritic structure and complexity in the adult hippocampal dentate gyrus. Neuroscience. 2006;137(4):1299&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani K, et al. Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature. 2007;449(7160):351&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">17721509</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner AL, Zervas M. Genetic inducible fate mapping in mouse: Establishing genetic lineages and defining genetic neuroanatomy in the nervous system. Dev Dyn. 2006;235(9):2376&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pubmed">16871622</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mouedden M, et al. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: A novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des. 2006;12(6):671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Fujiwara Y, Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA. 1999;96(9):5037&#x2013;5042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21812</ArticleId><ArticleId IdType="pubmed">10220414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18077675</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>50</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms.</ArticleTitle><Pagination><StartPage>13635</StartPage><EndPage>13648</EndPage><MedlinePgn>13635-48</MedlinePgn></Pagination><Abstract><AbstractText>Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary tangles found in Alzheimer's disease (AD) brains, and tau hyperphosphorylation is thought to be a critical event in the pathogenesis of the disease. The large majority of AD cases is late onset and sporadic in origin, with aging as the most important risk factor. Insulin resistance, impaired glucose tolerance, and diabetes mellitus (DM) are other common syndromes in the elderly also strongly age dependent, and there is evidence supporting a link between insulin dysfunction and AD. To investigate the possibility that insulin dysfunction might promote tau pathology, we induced insulin deficiency and caused DM in mice with streptozotocin (STZ). A mild hyperphosphorylation of tau could be detected 10, 20, and 30 d after STZ injection, and a massive hyperphosphorylation of tau was observed after 40 d. The robust hyperphosphorylation of tau was localized in the axons and neuropil, and prevented tau binding to microtubules. Neither mild nor massive tau phosphorylation induced tau aggregation. Body temperature of the STZ-treated mice did not differ from control animals during 30 d, but dropped significantly thereafter. No change in beta-amyloid (Abeta) precursor protein (APP), APP C-terminal fragments, or Abeta levels were observed in STZ-treated mice; however, cellular protein phosphatase 2A activity was significantly decreased. Together, these data indicate that insulin dysfunction induced abnormal tau hyperphosphorylation through two distinct mechanisms: one was consequent to hypothermia; the other was temperature-independent, inherent to insulin depletion, and probably caused by inhibition of phosphatase activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Planel</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory for Alzheimer's Disease, The Institute of Physical and Chemical Research, Saitama 351-0198, Japan. emmanuel@planel.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatebayashi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Miyasaka</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>W Haung</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Luchsinger</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wadzinski</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>5W494URQ81</RegistryNumber><NameOfSubstance UI="D013311">Streptozocin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007035" MajorTopicYN="N">Hypothermia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019581" MajorTopicYN="N">Neuropil</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013311" MajorTopicYN="N">Streptozocin</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18077675</ArticleId><ArticleId IdType="pmc">PMC6673606</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3949-07.2007</ArticleId><ArticleId IdType="pii">27/50/13635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:5562&#x2013;5566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44036</ArticleId><ArticleId IdType="pubmed">8202528</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA. 2001;98:6923&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34454</ArticleId><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem. 2004;279:34873&#x2013;34881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148141</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044677</ArticleId></ArticleIdList></Reference><Reference><Citation>Baharians Z, Schonthal AH. Autoregulation of protein phosphatase type 2A expression. J Biol Chem. 1998;273:19019&#x2013;19024.</Citation><ArticleIdList><ArticleId IdType="pubmed">9668082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989;477:90&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">2495152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj SK, Kaur G. Effect of diabetes on calcium/calmodulin dependent protein kinase-II from rat brain. Neurochem Int. 1999;35:329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482353</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res. 2006;3:437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168643</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994;87:554&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances &#x3b2;-amyloid production in vivo. J Neurosci. 2003;23:5645&#x2013;5649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741250</ArticleId><ArticleId IdType="pubmed">12843267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP, Buee L, Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol (Berl) 1999;97:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chohan MO, Haque N, Alonso A, El-Akkad E, Grundke-Iqbal I, Grover A, Iqbal K. Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J Neural Transm. 2005;112:1035&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">15583961</ArticleId></ArticleIdList></Reference><Reference><Citation>Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes. 2006;55:3320&#x2013;3325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851885</ArticleId><ArticleId IdType="pubmed">17130475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem. 1989;58:453&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">2549856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol. 2007;42:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17049785</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D., Jr Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuthbertson RA, Koulmanda M, Mandel TE. Detrimental effect of chronic diabetes on growth and function of fetal islet isografts in mice. Transplantation. 1988;46:650&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">2973668</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787&#x2013;835. ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth A, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motil Cytoskeleton. 1999;44:209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542369</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein SC, Wilson L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta. 2005;1739:268&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615645</ArticleId></ArticleIdList></Reference><Reference><Citation>Festa A, Williams K, D'Agostino R, Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567536</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DP, Dorsa D, Ikeda H, Stein LJ, Baskin D, Woods SC. Brain insulin binding and contents are altered by streptozotocin treatment in rats. Diabetes. 1983;32:134a.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Cohen DM. Aging, metabolism, and Alzheimer disease: review and hypotheses. Exp Neurol. 1997;143:82&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000448</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank HJ, Pardridge WM, Jankovic-Vokes T, Vinters HV, Morris WL. Insulin binding to the blood-brain barrier in the streptozotocin diabetic rat. J Neurochem. 1986;47:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">3525751</ArticleId></ArticleIdList></Reference><Reference><Citation>Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci. 1999;893:290&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Netzer WJ, Greengard P, Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci. 2002;23:288&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084635</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Cohen ES, Jakes R, Cohen P. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease. FEBS Lett. 1992;312:95&#x2013;99. [Erratum (1992) 313:203]</Citation><ArticleIdList><ArticleId IdType="pubmed">1330687</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J. 1994;301:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137067</ArticleId><ArticleId IdType="pubmed">7519852</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem. 1993;61:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett. 1994;341:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137929</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem. 1995;65:732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem. 2000;275:5535&#x2013;5544.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681533</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007;101:757&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448147</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83:4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman D. Alzheimer's disease: role of aging in pathogenesis. Ann NY Acad Sci. 2002;959:384&#x2013;395. discussion 463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11976212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996;384:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797796</ArticleId></ArticleIdList></Reference><Reference><Citation>Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci. 2000;11:213&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11065271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004;18:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 1997;272:19547&#x2013;19553.</Citation><ArticleIdList><ArticleId IdType="pubmed">9235959</ArticleId></ArticleIdList></Reference><Reference><Citation>Howarth FC, Jacobson M, Naseer O, Adeghate E. Short-term effects of streptozotocin-induced diabetes on the electrocardiogram, physical activity and body temperature in rats. Exp Physiol. 2005;90:237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15640274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol. 2000;35:1363&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm. 2002;109:991&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490:115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M, Kondo Y, Nakatani A, Naruse A. New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin. Biol Pharm Bull. 1999;22:988&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">10513628</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001;50:150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506396</ArticleId></ArticleIdList></Reference><Reference><Citation>Janke C, Beck M, Stahl T, Holzer M, Brauer K, Bigl V, Arendt T. Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Brain Res Mol Brain Res. 1999;68:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320789</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353:417&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221586</ArticleId><ArticleId IdType="pubmed">11171037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgour RD, Williams PA. Effects of diabetes and food deprivation on shivering activity during progressive hypothermia in the rat. Comp Biochem Physiol A Physiol. 1996;114:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">8925431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgour RD, Williams PA. Diabetes affects blood pressure and heart rate responses during acute hypothermia. Acta Physiol Scand. 1998;162:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9492899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science. 1997;278:419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334293</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 1997;145:301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054233</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience. 2000;99:305&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">10938436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem. 1999;72:576&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2006;9:13&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16627931</ArticleId></ArticleIdList></Reference><Reference><Citation>Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J. 1996;316:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217397</ArticleId><ArticleId IdType="pubmed">8687413</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA. 2004;101:10804&#x2013;10809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490015</ArticleId><ArticleId IdType="pubmed">15249677</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Mayeux R. Adiposity and Alzheimer's disease. Curr Alzheimer Res. 2007;4:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890025</ArticleId><ArticleId IdType="pubmed">17430235</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581097</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem. 2000;275:15733&#x2013;15740.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747907</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccioni RB, Otth C, Concha II, Munoz JP. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem. 2001;268:1518&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">11248668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of clapains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, Lee VM. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ, Delacourte A. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol (Berl) 2003;105:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536218</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier-Ruge W, Bertoni-Freddari C. The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease. Rev Neurosci. 1996;7:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">8736675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2006;3:449&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Neil HA, Dawson JA, Baker JE. Risk of hypothermia in elderly patients with diabetes. Br Med J (Clin Res Ed) 1986;293:416&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1341235</ArticleId><ArticleId IdType="pubmed">3091139</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003;38:555&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765608</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990&#x2013;6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007&#x2013;4021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874754</ArticleId><ArticleId IdType="pubmed">236308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacold ST, Blackard WG. Central nervous system insulin receptors in normal and diabetic rats. Endocrinology. 1979;105:1452&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">499083</ArticleId></ArticleIdList></Reference><Reference><Citation>Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11916953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzino V, Costantino A, Russo P, Gullo D, Papa V. Insulin receptor content in tissues of normal and diabetic rats measured by radioimmunoassay. J Endocrinol Invest. 1996;19:593&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957742</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides Tau protein kinase I/glycogen synthase kinase 3beta and Cyclin-dependant kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem. 2001;276:34298&#x2013;34306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441005</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Sun X, Takashima A. Role of GSK-3 beta in Alzheimer's disease pathology. Drug Development Res. 2002;56:491&#x2013;510.</Citation></Reference><Reference><Citation>Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci. 2004;24:2401&#x2013;2411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729502</ArticleId><ArticleId IdType="pubmed">15014115</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Richter KEG, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau L-F, Duff KE. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27:3090&#x2013;3097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672474</ArticleId><ArticleId IdType="pubmed">17376970</ArticleId></ArticleIdList></Reference><Reference><Citation>Price NE, Wadzinski B, Mumby MC. An anchoring factor targets protein phosphatase 2A to brain microtubules. Brain Res Mol Brain Res. 1999;73:68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10581399</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8:247&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16340083</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Swaab DF. Diminished neuronal metabolic activity in Alzheimer's disease. Review article. J Neural Transm. 1999;106:955&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, Planel E, Tanemura K, Sun X, Hashikawa T, Yoshioka K, Ishiguro K, Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem. 2002;277:42060&#x2013;42065.</Citation><ArticleIdList><ArticleId IdType="pubmed">12191990</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun. 2005;334:979&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16039605</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Nixon RA, Mathews PM. ELISA method for measurement of amyloid-beta levels. Methods Mol Biol. 2005;299:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994;43:1326&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">7926307</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23:7084&#x2013;7092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740672</ArticleId><ArticleId IdType="pubmed">12904469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA. 2004;101:3100&#x2013;3105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365750</ArticleId><ArticleId IdType="pubmed">14981233</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott AR, Bennett T, Macdonald IA. Diabetes mellitus and thermoregulation. Can J Physiol Pharmacol. 1987;65:1365&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">3304596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechi LA, Griffin CA, Grady EF, Grunfeld C, Kalinyak JE, Schambelan M. Tissue-specific regulation of insulin receptor mRNA levels in rats with STZ-induced diabetes mellitus. Diabetes. 1992;41:1113&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">1386819</ArticleId></ArticleIdList></Reference><Reference><Citation>Seydoux J, Chinet A, Schneider-Picard G, Bas S, Imesch E, Assimacopoulos-Jeannet F, Giacobino JP, Girardier L. Brown adipose tissue metabolism in streptozotocin-diabetic rats. Endocrinology. 1983;113:604&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">6223804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalaby TH, Yousef MK, Dupre RK. Thermoregulatory responses of diabetic rats. Comp Biochem Physiol A. 1989;94:153&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">2571449</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ, Smith QR. Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem. 1999;72:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I, Iqbal K. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 1998;436:471&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801171</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith OL, Davidson SB. Shivering thermogenesis and glucose uptake by muscles of normal or diabetic rats. Am J Physiol. 1982;242:R109&#x2013;R115.</Citation><ArticleIdList><ArticleId IdType="pubmed">7036756</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, III, Mumby MC, Bloom GS. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999;274:25490&#x2013;25498.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464280</ArticleId></ArticleIdList></Reference><Reference><Citation>Strack S, Zaucha JA, Ebner FF, Colbran RJ, Wadzinski BE. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J Comp Neurol. 1998;392:515&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">9514514</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW. Identification and distribution of axonal dystrophic neurites in Alzheimer's disease. Brain Res. 1993;625:228&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275305</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. NeuroReport. 1994;5:2358&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533559</ArticleId></ArticleIdList></Reference><Reference><Citation>Szendrei GI, Lee VM, Otvos L., Jr Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J Neurosci Res. 1993;34:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol. 2005;166:1761&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602412</ArticleId><ArticleId IdType="pubmed">15920161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals. 2002;11:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566927</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjalve H. Streptozotocin: distribution, metabolism and mechanisms of action. Uppsala J Med Sci Suppl. 1983;39:145&#x2013;157.</Citation></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol. 1994;144:449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887092</ArticleId><ArticleId IdType="pubmed">8129030</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol. 2001;168:402&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17:27&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12467491</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber C, Pernis B, Ting W, Rosenkrantz K, Reemtsma K. Murine streptozotocin diabetes: influences of the major histocompatibility complex, genetic background and blood transfusion. Diabetologia. 1984;27(Suppl):160&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">6479490</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SK, Howarth NL, Devenny JJ, Bitensky MW. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA. 1982;79:6546&#x2013;6550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC347164</ArticleId><ArticleId IdType="pubmed">6959136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Pei JJ, Ji ZJ, Zhao ZW, Qian YY, Sheng SL. Effect of amyloid precursor protein 17mer peptide on microtubule structure and tau protein hyperphosphorylation in hippocampal neurons of experimental diabetic mice. NeuroReport. 2003;14:61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 2002;11:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18083105</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>131</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>The classical complement cascade mediates CNS synapse elimination.</ArticleTitle><Pagination><StartPage>1164</StartPage><EndPage>1178</EndPage><MedlinePgn>1164-78</MedlinePgn></Pagination><Abstract><AbstractText>During development, the formation of mature neural circuits requires the selective elimination of inappropriate synaptic connections. Here we show that C1q, the initiating protein in the classical complement cascade, is expressed by postnatal neurons in response to immature astrocytes and is localized to synapses throughout the postnatal CNS and retina. Mice deficient in complement protein C1q or the downstream complement protein C3 exhibit large sustained defects in CNS synapse elimination, as shown by the failure of anatomical refinement of retinogeniculate connections and the retention of excess retinal innervation by lateral geniculate neurons. Neuronal C1q is normally downregulated in the adult CNS; however, in a mouse model of glaucoma, C1q becomes upregulated and synaptically relocalized in the adult retina early in the disease. These findings support a model in which unwanted synapses are tagged by complement for elimination and suggest that complement-mediated synapse elimination may become aberrantly reactivated in neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA. beths@standfordmedalumni.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Vazquez</LastName><ForeName>Luis E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Gareth R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Christopherson</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Nouri</LastName><ForeName>Navid</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Micheva</LastName><ForeName>Kristina D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Mehalow</LastName><ForeName>Adrienne K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Huberman</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Litke</LastName><ForeName>Alan M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lambris</LastName><ForeName>John D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Simon W M</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA015043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA15043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2007 Dec 14;131(6):1034-6. doi: 10.1016/j.cell.2007.11.031.</RefSource><PMID Version="1">18083091</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="Y">Complement Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005829" MajorTopicYN="N">Geniculate Bodies</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005901" MajorTopicYN="N">Glaucoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="Y">Long-Term Synaptic Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="Y">Synapses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2007.10.036</ArticleId><ArticleId IdType="pii">S0092-8674(07)01355-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18084291</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>31</EndPage><MedlinePgn>29-31</MedlinePgn></Pagination><Abstract><AbstractText>We identified a SNP in the DPP6 gene that is consistently strongly associated with susceptibility to amyotrophic lateral sclerosis (ALS) in different populations of European ancestry, with an overall P value of 5.04 x 10(-8) in 1,767 cases and 1,916 healthy controls and with an odds ratio of 1.30 (95% confidence interval (CI) of 1.18-1.43). Our finding is the first report of a genome-wide significant association with sporadic ALS and may be a target for future functional studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vught</LastName><ForeName>Paul W J</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Blauw</LastName><ForeName>Hylke M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Lude</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Saris</LastName><ForeName>Christiaan G J</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Van den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Vianney</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Baas</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>van't Slot</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lemmens</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schelhaas</LastName><ForeName>Helenius J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Birve</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schymick</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Wokke</LastName><ForeName>John H J</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Wijmenga</LastName><ForeName>Cisca</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Ophoff</LastName><ForeName>Roel A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM68875</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH078075</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C503535">DPP6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.14.-</RegistryNumber><NameOfSubstance UI="D004152">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002897" MajorTopicYN="N">Chromosomes, Human, Pair 7</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004152" MajorTopicYN="N">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18084291</ArticleId><ArticleId IdType="doi">10.1038/ng.2007.52</ArticleId><ArticleId IdType="pii">ng.2007.52</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18093519</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Correction of fragile X syndrome in mice.</ArticleTitle><Pagination><StartPage>955</StartPage><EndPage>962</EndPage><MedlinePgn>955-62</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X syndrome (FXS) is the most common form of heritable mental retardation and the leading identified cause of autism. FXS is caused by transcriptional silencing of the FMR1 gene that encodes the fragile X mental retardation protein (FMRP), but the pathogenesis of the disease is unknown. According to one proposal, many psychiatric and neurological symptoms of FXS result from unchecked activation of mGluR5, a metabotropic glutamate receptor. To test this idea we generated Fmr1 mutant mice with a 50% reduction in mGluR5 expression and studied a range of phenotypes with relevance to the human disorder. Our results demonstrate that mGluR5 contributes significantly to the pathogenesis of the disease, a finding that has significant therapeutic implications for fragile X and related developmental disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xf6;len</LastName><ForeName>G&#xfc;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterweil</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>B S Shankaranarayana</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gordon B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Auerbach</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Chattarji</LastName><ForeName>Sumantra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bear</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH058880</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD046943</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497684">Fmr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578935">GRM5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578936">Grm5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2009 Jul-Aug;9(4):116-8. doi: 10.1111/j.1535-7511.2009.01311.x.</RefSource><PMID Version="1">19693330</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18093519</ArticleId><ArticleId IdType="mid">NIHMS36585</ArticleId><ArticleId IdType="pmc">PMC2199268</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.12.001</ArticleId><ArticleId IdType="pii">S0896-6273(07)00964-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bear MF, Dolen G, Osterweil E, Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology. 2008;33:84&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4327813</ArticleId><ArticleId IdType="pubmed">17940551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardet M, Crusio WE. Fmr1 KO mice as a possible model of autistic features. ScientificWorldJournal. 2006;6:1164&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917219</ArticleId><ArticleId IdType="pubmed">16998604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjarnadottir TK, Schioth HB, Fredriksson R. The phylogenetic relationship of the glutamate and pheromone G-protein-coupled receptors in different vertebrate species. Ann N Y Acad Sci. 2005;1040:230&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">15891031</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown V, Jin P, Ceman S, Darnell JC, O&#x2019;Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107:477&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci. 2005;25:8048&#x2013;8055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725444</ArticleId><ArticleId IdType="pubmed">16135762</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium TDBFX. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell. 1994;78:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8033209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek SM, Bear MF. A biochemical correlate of the critical period for synaptic modification in the visual cortex. Science. 1989;246:673&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">2573152</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel MY, Bear MF. How monocular deprivation shifts ocular dominance in visual cortex of young mice. Neuron. 2004;44:917&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603735</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci. 2006;26:7151&#x2013;7155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673953</ArticleId><ArticleId IdType="pubmed">16822971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice. Neuron. 2004;42:773&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182717</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidbreder CA, Bianchi M, Lacroix LP, Faedo S, Perdona E, Remelli R, Cavanni P, Crespi F. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse. 2003;50:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron. 2006;51:441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908410</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99:7746&#x2013;7750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124340</ArticleId><ArticleId IdType="pubmed">12032354</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science. 2000;288:1254&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818003</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Roder JC, Bear MF. Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol. 2001;86:321&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431513</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W, Wojtowicz JM, Roder J. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem. 1998;5:331&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311253</ArticleId><ArticleId IdType="pubmed">10454358</ArticleId></ArticleIdList></Reference><Reference><Citation>Karachot L, Shirai Y, Vigot R, Yamamori T, Ito M. Induction of long-term depression in cerebellar Purkinje cells requires a rapidly turned over protein. J Neurophysiol. 2001;86:280&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431509</ArticleId></ArticleIdList></Reference><Reference><Citation>Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, De Graaf W, Smit AE, VanderWerf F, Bakker CE, et al. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron. 2005;47:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea PMt, Faden AI. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 2006;12:149&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494124</ArticleId><ArticleId IdType="pubmed">16958988</ArticleId></ArticleIdList></Reference><Reference><Citation>Loesch DZ, Huggins RM, Hoang NH. Growth in stature in fragile X families: a mixed longitudinal study. Am J Med Genet. 1995;58:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8533827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, Roder JC. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci. 1997;17:5196&#x2013;5205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573299</ArticleId><ArticleId IdType="pubmed">9185557</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron. 2005;45:753&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748850</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlin LR, Bergold PJ, Wong RK. Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J Neurophysiol. 1998;80:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9705485</ArticleId></ArticleIdList></Reference><Reference><Citation>Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet. 2000;9:1145&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767339</ArticleId></ArticleIdList></Reference><Reference><Citation>Power AE, Berlau DJ, McGaugh JL, Steward O. Anisomycin infused into the hippocampus fails to block &#x201c;reconsolidation&#x201d; but impairs extinction: the role of re-exposure duration. Learn Mem. 2006;13:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360130</ArticleId><ArticleId IdType="pubmed">16452651</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci. 2005;25:5087&#x2013;5095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724856</ArticleId><ArticleId IdType="pubmed">15901791</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Thompson VL, Tate WP, Abraham WC. Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci. 2000;20:969&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774154</ArticleId><ArticleId IdType="pubmed">10648701</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson HA. Audiogenic seizures: increased benzodiazepin receptor binding in a susceptible strain of mice. Eur J Pharmacol. 1980;66:249&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">6108226</ArticleId></ArticleIdList></Reference><Reference><Citation>Storto M, Sallese M, Salvatore L, Poulet R, Condorelli DF, Dell&#x2019;Albani P, Marcello MF, Romeo R, Piomboni P, Barone N, et al. Expression of metabotropic glutamate receptors in the rat and human testis. J Endocrinol. 2001;170:71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431139</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha S, Stryker MP. Rapid ocular dominance plasticity requires cortical but not geniculate protein synthesis. Neuron. 2002;34:425&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988173</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker B, Richards RI, Lardelli M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet. 2006;15:3446&#x2013;3458.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065172</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderklish PW, Edelman GM. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci U S A. 2002;99:1639&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122243</ArticleId><ArticleId IdType="pubmed">11818568</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiler IJ, Greenough WT. Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A. 1993;90:7168&#x2013;7171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47097</ArticleId><ArticleId IdType="pubmed">8102206</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49:1053&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zho WM, You JL, Huang CC, Hsu KS. The group I metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine induces a novel form of depotentiation in the CA1 region of the hippocampus. J Neurosci. 2002;22:8838&#x2013;8849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757695</ArticleId><ArticleId IdType="pubmed">12388590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18094238</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>51</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration.</ArticleTitle><Pagination><StartPage>13997</StartPage><EndPage>14006</EndPage><MedlinePgn>13997-4006</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease is a neurodegenerative disorder characterized by the preferential loss of midbrain dopaminergic neurons in the substantia nigra (SN). One of the earliest detectable biochemical alterations that occurs in the Parkinsonian brain is a marked reduction in SN levels of total glutathione (glutathione plus glutathione disulfide), occurring before losses in mitochondrial complex I (CI) activity, striatal dopamine levels, or midbrain dopaminergic neurodegeneration associated with the disease. Previous in vitro data from our laboratory has suggested that prolonged depletion of dopaminergic glutathione results in selective impairment of mitochondrial complex I activity through a reversible thiol oxidation event. To address the effects of depletion in dopaminergic glutathione levels in vivo on the nigrostriatal system, we created genetically engineered transgenic mouse lines in which expression of gamma-glutamyl cysteine ligase, the rate-limiting enzyme in de novo glutathione synthesis, can be inducibly downregulated in catecholaminergic neurons, including those of the SN. A novel method for isolation of purified dopaminergic striatal synaptosomes was used to study the impact of dopaminergic glutathione depletion on mitochondrial events demonstrated previously to occur in vitro as a consequence of this alteration. Dopaminergic glutathione depletion was found to result in a selective reversible thiol-oxidation-dependent mitochondrial complex I inhibition, followed by an age-related nigrostriatal neurodegeneration. This suggests that depletion in glutathione within dopaminergic SN neurons has a direct impact on mitochondrial complex I activity via increased nitric oxide-related thiol oxidation and age-related dopaminergic SN cell loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chinta</LastName><ForeName>Shankar J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Buck Institute for Age Research, Novato, California 94945, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Subramanian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Deepinder</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rane</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nicholls</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jinah</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Julie K</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012141</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 AG012141</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12141</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18094238</ArticleId><ArticleId IdType="pmc">PMC6673525</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3885-07.2007</ArticleId><ArticleId IdType="pii">27/51/13997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen JK. Translational and post-translational modifications to mitochondrial complex I in the post-mortem Parkinsonian midbrain. post-genomic symposium; May; Beijing, China. 2006. Paper presented at.</Citation></Reference><Reference><Citation>Andersen JK, Mo JQ, Hom DG, Lee FY, Harnish P, Hamill RW, McNeill TH. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J Neurochem. 1996;67:2164&#x2013;2171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannon MJ, Goedert M, Williams B. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem Pharmacol. 1984;33:2697&#x2013;2698.</Citation><ArticleIdList><ArticleId IdType="pubmed">6331828</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol. 2002;64:1037&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213603</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolanos JP, Heales SJ, Peuchen S, Barker JE, Land JM, Clark JB. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med. 1996;21:995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">8937884</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd DC, Nicholls DG. Protein kinase C-mediated suppression of the presynaptic adenosine A1 receptor by a facilitatory metabotropic glutamate receptor. J Neurochem. 1995;65:615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616216</ArticleId></ArticleIdList></Reference><Reference><Citation>Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS. Direct evidence for S-nitrosation of mitochondrial complex I. Biochem J. 2006;394:627&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383712</ArticleId><ArticleId IdType="pubmed">16371007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ, Andersen JK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med. 2006;41:1442&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023271</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett. 2006;402:137&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">16644116</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Liu RM, Kundu RK, Sangiorgi F, Wu W, Maxson R, Forman HJ. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem. 2000;275:3693&#x2013;3698.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652368</ArticleId></ArticleIdList></Reference><Reference><Citation>Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA. 1998;95:7631&#x2013;7636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22706</ArticleId><ArticleId IdType="pubmed">9636201</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JA, Kim SY, Teague D, Krishna MC, Pacelli R, Mitchell JB, Vodovotz Y, Nims RW, Christodoulou D, Miles AM, Grisham MB, Wink DA. Convenient colorimetric and fluorometric assays for S-nitrosothiols. Anal Biochem. 1996;238:150&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AJ, Pulsinelli WA, Duffy TE. Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. J Neurochem. 1980;35:1242&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">7452315</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahm CC, Moore K, Murphy MP. Persistent S-nitrosation of complex I and other mitochondrial membrane proteins by S-nitrosothiols but not nitric oxide or peroxynitrite: implications for the interaction of nitric oxide with mitochondria. J Biol Chem. 2006;281:10056&#x2013;10065.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med. 2004;37:1511&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477003</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Hernandez JI, Almeida A, Delgado-Esteban M, Fernandez E, Bolanos JP. Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. J Biol Chem. 2005;280:38992&#x2013;39001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183645</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty M, Bradford HF, Cash CD, Ehret M, Maitre M, Joh TH. Isolation of monoaminergic synaptosomes from rat brain by immunomagnetophoresis. J Neurochem. 1991;56:1569&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672882</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000;62:649&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880854</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem. 2003;384:505&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12751781</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R, Pfeiffer B, Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci. 1999;19:562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782200</ArticleId><ArticleId IdType="pubmed">9880576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Zeevalk GD. Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. J Neurochem. 2001;77:1496&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Zeevalk GD. Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J Neurochem. 2003;86:1487&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pubmed">12950457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol. 1987;143:101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">3657520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord. 2003;18:969&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, Stamler JS. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem. 2002;277:9637&#x2013;9640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796706</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco TM, Hodara R, Parastatidis I, Heijnen HF, Dennehy MK, Liebler DC, Ischiropoulos H. Identification of S-nitrosylation motifs by site-specific mapping of the S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc Natl Acad Sci USA. 2006;103:7420&#x2013;7425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464354</ArticleId><ArticleId IdType="pubmed">16648260</ArticleId></ArticleIdList></Reference><Reference><Citation>Heales SJ, Davies SE, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res. 1995;20:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">7739756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan B, Costantini F, Lacy E. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1986. Manipulating the mouse embryo.</Citation></Reference><Reference><Citation>Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J Neurochem. 2005;92:1091&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715660</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem. 1993;268:19675&#x2013;19680.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103521</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Martensson J, Stole E, Auld PA, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA. 1991;88:1913&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51136</ArticleId><ArticleId IdType="pubmed">2000395</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:6&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8333254</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem. 2000;275:26096&#x2013;26101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670420</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M, Ferrandiz ML, Diez A, Miquel J. Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mech Ageing Dev. 1995;84:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8719779</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002;10:119&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127150</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister A. Glutathione metabolism and its selective modification. J Biol Chem. 1988;263:17205&#x2013;17208.</Citation><ArticleIdList><ArticleId IdType="pubmed">3053703</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister A. Glutathione biosynthesis and its inhibition. Methods Enzymol. 1995;252:26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7476360</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadtochiy SM, Burwell LS, Brookes PS. Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2-mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J Mol Cell Cardiol. 2007;42:812&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2134894</ArticleId><ArticleId IdType="pubmed">17350035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm. 1997;104:661&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">9444566</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett. 1986;67:269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">3737015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling B, Bharath MMS, Row RH, Murray J, Cusack MP, Capaldi RA, Freed CR, Prasad KN, Andersen JK, Gibson BW. Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (Complex I) from rodent brain and a dopaminergic neuronal cell line. Mol Cell Proteomics. 2005;4:84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15591592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:1159&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938817</ArticleId></ArticleIdList></Reference><Reference><Citation>Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080242</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DW, Friedmann T. Discrepant effects of culture conditions on survival and function of dopaminergic neurons. NeuroReport. 2004;15:1025&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">15076727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompkins AJ, Burwell LS, Digerness SB, Zaragoza C, Holman WL, Brookes PS. Mitochondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. Biochim Biophys Acta. 2006;1762:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16278076</ArticleId></ArticleIdList></Reference><Reference><Citation>Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996;264:484&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">8965721</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci. 2001;21:9519&#x2013;9528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763046</ArticleId><ArticleId IdType="pubmed">11739563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadava N, Houchens T, Potluri P, Scheffler IE. Development and characterization of a conditional mitochondrial complex I assembly system. J Biol Chem. 2004;279:12406&#x2013;12413.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol. 2007;203:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839874</ArticleId><ArticleId IdType="pubmed">17049515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18159057</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>24</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Incidence and prognosis of transient neurological attacks.</ArticleTitle><Pagination><StartPage>2877</StartPage><EndPage>2885</EndPage><MedlinePgn>2877-85</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Transient neurological attacks (TNAs) are attacks with temporary (&lt;24 hours) neurological symptoms. These symptoms can be focal, nonfocal, or a mixture of both. The prognostic significance of TNAs with focal symptoms (better known as transient ischemic attacks [TIAs]) is well understood. Conversely, hardly anything is known about the prognostic significance of TNAs with nonfocal or mixed symptoms.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the incidence and prognosis of focal TNAs (or TIAs), nonfocal TNAs, and mixed TNAs.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The study population comprised 6062 community-dwelling Rotterdam Study participants who were aged 55 years or older and free from stroke, myocardial infarction, and dementia at baseline (1990-1993). They were followed up for events until January 1, 2005. We analyzed the associations between incident TNAs and subsequent adverse events with age- and sex-adjusted Cox regression models.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Stroke, ischemic heart disease, or dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 60 535 person-years, 548 participants developed TNA (282 focal, 228 nonfocal, and 38 mixed). The incidence rate per 1000 person-years was 4.7 (95% confidence interval [CI], 4.1-5.2) for focal TNA, 3.8 (95% CI, 3.3-4.3) for nonfocal TNA, and 0.6 (95% CI, 0.4-0.9) for mixed TNA. Participants with focal TNA were at higher risk of subsequent stroke than participants without TNA (n = 46 vs 540; hazard ratio [HR], 2.14; 95% confidence interval [CI]; 1.57-2.91) but had an equal risk of ischemic heart disease and dementia. Nonfocal TNA patients were at higher risk of stroke (27 vs 540; HR, 1.56; 95% CI, 1.08-2.28) and dementia (30 vs 552; HR, 1.59; 95% CI, 1.11-2.26) than participants without TNA. Mixed TNA patients were at higher risk of stroke (6 vs 540; HR, 2.48; 95% CI, 1.11-5.56), ischemic heart disease (8 vs 779; HR, 2.26; 95% CI, 1.07-4.78), vascular death (8 vs 594; HR, 2.54; 95% CI, 1.31-4.91), and dementia (7 vs 552; HR, 3.46; 95% CI, 1.72-6.98) than participants without TNA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients who experience nonfocal TNAs, and especially those with mixed TNAs, have a higher risk of major vascular diseases and dementia than persons without TNA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bos</LastName><ForeName>Michiel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Erasmus Medical Center, Dr Molewaterplein 50, PO Box 2040, 3000 CA Rotterdam, the Netherlands. m.breteler@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rijn</LastName><ForeName>Marie Josee E</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Witteman</LastName><ForeName>Jacqueline C M</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2007 Dec 26;298(24):2912-3. doi: 10.1001/jama.298.24.2912.</RefSource><PMID Version="1">18159062</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2008 Apr 16;299(15):1771-2; author reply 1772-3. doi: 10.1001/jama.299.15.1771-c.</RefSource><PMID Version="1">18413869</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2008 Apr 16;299(15):1771; author reply 1772-3. doi: 10.1001/jama.299.15.1771-b.</RefSource><PMID Version="1">18413870</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18159057</ArticleId><ArticleId IdType="doi">10.1001/jama.298.24.2877</ArticleId><ArticleId IdType="pii">298/24/2877</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18160654</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>52</Issue><PubDate><Year>2007</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference.</ArticleTitle><Pagination><StartPage>14459</StartPage><EndPage>14469</EndPage><MedlinePgn>14459-69</MedlinePgn></Pagination><Abstract><AbstractText>Physiological processing of the beta-amyloid precursor protein (APP) generates amyloid beta-protein, which can assemble into oligomers that mediate synaptic failure in Alzheimer's disease. Two decades of research have led to human trials of compounds that chronically target this processing, and yet the normal function of APP in vivo remains unclear. We used the method of in utero electroporation of shRNA constructs into the developing cortex to acutely knock down APP in rodents. This approach revealed that neuronal precursor cells in embryonic cortex require APP to migrate correctly into the nascent cortical plate. cDNAs encoding human APP or its homologues, amyloid precursor-like protein 1 (APLP1) or APLP2, fully rescued the shRNA-mediated migration defect. Analysis of an array of mutations and deletions in APP revealed that both the extracellular and cytoplasmic domains of APP are required for efficient rescue. Whereas knock-down of APP inhibited cortical plate entry, overexpression of APP caused accelerated migration of cells past the cortical plate boundary, confirming that normal APP levels are required for correct neuronal migration. In addition, we found that Disabled-1 (Dab1), an adaptor protein with a well established role in cortical cell migration, acts downstream of APP for this function in cortical plate entry. We conclude that full-length APP functions as an important factor for proper migration of neuronal precursors into the cortical plate during the development of the mammalian brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Jilin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jessica B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>LoTurco</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS053320-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R0I AG06173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018274" MajorTopicYN="N">Electroporation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18160654</ArticleId><ArticleId IdType="pmc">PMC6673432</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4701-07.2007</ArticleId><ArticleId IdType="pii">27/52/14459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anliker B, Muller U. The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegener Dis. 2006;3:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047363</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J. Trophic effect of &#x3b2;-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun. 1991;181:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">1958195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J, Ramos RL, Ackman JB, Thomas AM, Lee RV, LoTurco JJ. RNAi reveals doublecortin is required for radial migration in rat neocortex. Nat Neurosci. 2003;6:1277&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">14625554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer SA, Altman J. Development of the endopiriform nucleus and the claustrum in the rat brain. Neuroscience. 1991;45:391&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">1762685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer SA, Altman J, Russo RJ, Dai XF, Simmons JA. Cell migration in the rat embryonic neocortex. J Comp Neurol. 1991;307:499&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">1856333</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen KC. APP-collagen interaction is mediated by a heparin bridge mechanism. Mol Chem Neuropathol. 1992;16:109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">1520400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem. 2004;279:24601&#x2013;24611.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulabon L, Olson EC, Taglienti MG, Eisenhuth S, McGrath B, Walsh CA, Kreidberg JA, Anton ES. Reelin binds &#x3b1;3&#x3b2;1 integrin and inhibits neuronal migration. Neuron. 2000;27:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Caceres A, Kosik K. Intraneuronal compartments of the amyloid precursor protein. J Neurosci. 1993;13:3112&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576677</ArticleId><ArticleId IdType="pubmed">8331388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore F, Zambrano N, Minopoli G, Donini V, Duilio A, Russo T. The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. J Biol Chem. 1995;270:30853&#x2013;30856.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537337</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenette SY, Chang Y, Hyman BT, Tanzi RE, Rebeck GW. Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. J Neurochem. 2002;82:755&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass MR, Yankner BA. A &#x3b3;-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J Biol Chem. 2005;280:36895&#x2013;36904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1562327</ArticleId><ArticleId IdType="pubmed">16103124</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, M&#xfc;ller U. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A, Sudhof TC. Binding of F-spondin to amyloid-&#x3b2; precursor protein: a candidate amyloid-&#x3b2; precursor protein ligand that modulates amyloid-&#x3b2; precursor protein cleavage. Proc Natl Acad Sci USA. 2004;101:2548&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC356987</ArticleId><ArticleId IdType="pubmed">14983046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. J Biol Chem. 2006;281:35176&#x2013;35185.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951405</ArticleId></ArticleIdList></Reference><Reference><Citation>Homayouni R, Rice DS, Sheldon M, Curran T. Disabled-1 binds to the cytoplasmic domain of amyloid precursor-like protein 1. J Neurosci. 1999;19:7507&#x2013;7515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782519</ArticleId><ArticleId IdType="pubmed">10460257</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol. 1999;19:5179&#x2013;5188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84361</ArticleId><ArticleId IdType="pubmed">10373567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibbey MC, Jucker M, Weeks BS, Neve RL, Van Nostrand WE, Kleinman HK. &#x3b2;-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. Proc Natl Acad Sci USA. 1993;90:10150&#x2013;10153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47731</ArticleId><ArticleId IdType="pubmed">8234269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci. 2005;25:5533&#x2013;5543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724978</ArticleId><ArticleId IdType="pubmed">15944381</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia&#x2014;focus on inflammation. Brain Res Brain Res Rev. 2005;48:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850663</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 2003;278:34427&#x2013;34437.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Berezovska O, Ramdya P, Fukumoto H, Raju S, Shah T, Hyman BT. Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression. J Biol Chem. 2003;278:47370&#x2013;47375.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorent K, Overbergh L, Moechars D, De Strooper B, Van Leuven F, Van den Berghe H. Expression in mouse embryos and in adult mouse brain of three members of the amyloid precursor protein family, of the &#x3b1;-2-macroglobulin receptor/low density lipoprotein receptor-related protein and of its ligands apolipoprotein E, lipoprotein lipase, &#x3b1;-2-macroglobulin and the 40,000 molecular weight receptor-associated protein. Neuroscience. 1995;65:1009&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Cellular actions of &#x3b2;-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997;77:1081&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 1992;9:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">1632967</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller HT, Borg JP, Margolis B, Turner RS. Modulation of amyloid precursor protein metabolism by X11alpha/Mint-1. A deletion analysis of protein-protein interaction domains. J Biol Chem. 2000;275:39302&#x2013;39306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11010978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, Crawford F, Houlden H, Axelman K, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of &#x3b2;-amyloid. Nat Genet. 1992;1:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991;254:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">1925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B, Kisilevsky R. High affinity interactions between the Alzheimer's &#x3b2;-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem. 1991;266:12878&#x2013;12883.</Citation><ArticleIdList><ArticleId IdType="pubmed">1906461</ArticleId></ArticleIdList></Reference><Reference><Citation>Narindrasorasak S, Lowery DE, Altman RA, Gonzalez-DeWhitt PA, Greenberg BD, Kisilevsky R. Characterization of high affinity binding between laminin and Alzheimer's disease amyloid precursor proteins. Lab Invest. 1992;67:643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">1434542</ArticleId></ArticleIdList></Reference><Reference><Citation>Narindrasorasak S, Altman RA, Gonzalez-DeWhitt P, Greenberg BD, Kisilevsky R. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest. 1995;72:272&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I, Hirose Y, Ishiguro M, Imai Y, Ishiura S, Kohsaka S. Expression, purification, and neurotrophic activity of amyloid precursor protein-secreted forms produced by yeast. Biochem Biophys Res Commun. 1995;213:52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">7639761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I, Takamura C, Kohsaka S. The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. Biochem Biophys Res Commun. 1997;236:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">9223426</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson EC, Kim S, Walsh CA. Impaired neuronal positioning and dendritogenesis in the neocortex after cell-autonomous Dab1 suppression. J Neurosci. 2006;26:1767&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793623</ArticleId><ArticleId IdType="pubmed">16467525</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisiadou L, Efthimiopoulos S. Expression of mDab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11alpha. Neurobiol Aging. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16458391</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The &#x3b2;-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997;17:9407&#x2013;9414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski BL, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH. Mutagenesis identifies new signals for &#x3b2;-amyloid precursor protein endotycosis, turnover and the generation of secreted fragments, including A42. J Biol Chem. 1999;274:18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;26:7212&#x2013;7221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard C, Hebert SS, De Strooper B. The amyloid-&#x3b2; precursor protein: integrating structure with biological function. EMBO J. 2005;24:3996&#x2013;4006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356301</ArticleId><ArticleId IdType="pubmed">16252002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte M, Wolfer DP, M&#xfc;ller UC. The secreted &#x3b2;-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D, Hesse L, Multhaup G, Beyreuther K, Masters CL, Parker MW. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol. 1999;6:327&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10201399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol. 2001;153:1403&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150733</ArticleId><ArticleId IdType="pubmed">11425871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo . J Neurosci. 2003;23:5407&#x2013;5415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert D, Jin LW, Saitoh T, Cole G. The regulation of amyloid &#x3b2; protein precursor secretion and its modulatory role in cell adhesion. Neuron. 1989;3:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">2518372</ArticleId></ArticleIdList></Reference><Reference><Citation>Slunt HH, Thinakaran G, Von Koch C, Lo ACY, Tanzi RE, Sisodia SS. Expression of a ubiquitous, cross-reactive homologue of the mouse &#x3b2;-amyloid precursor protein (APP) J Biol Chem. 1994;269:2637&#x2013;2644.</Citation><ArticleIdList><ArticleId IdType="pubmed">8300594</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J Neurosci. 1994;14:2117&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577125</ArticleId><ArticleId IdType="pubmed">8158260</ArticleId></ArticleIdList></Reference><Reference><Citation>Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Lower A, Langer A, Merdes G, Paro R, Masters CL, M&#xfc;ller U, Kins S, Beyreuther K. Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 2005;24:3624&#x2013;3634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276707</ArticleId><ArticleId IdType="pubmed">16193067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabata H, Nakajima K. Efficient in utero gene transfer system to the developing mouse brain using electroporation: visualization of neuronal migration in the developing cortex. Neuroscience. 2001;103:865&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">11301197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissir F, Goffinet AM. Reelin and brain development. Nat Rev Neurosci. 2003;4:496&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778121</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556&#x2013;33560.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837937</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gassen G, Annaert W, Van Broeckhoven C. Binding partners of Alzheimer's disease proteins: are they physiologically relevant? Neurobiol Dis. 2000;7:135&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860781</ArticleId></ArticleIdList></Reference><Reference><Citation>von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg LH, Price DL, Sisodia SS. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18:661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace WC, Akar CA, Lyons WE. Amyloid precursor protein potentiates the neurotrophic activity of NGF. Brain Res Mol Brain Res. 1997;52:201&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9495541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware ML, Fox JW, Gonzalez JL, Davis NM, Lambert de Rouvroit C, Russo CJ, Chua SC, Jr, Goffinet AM, Walsh CA. Aberrant splicing of a mouse disabled homolog, mdab1, in the scrambler mouse. Neuron. 1997;19:239&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">9292716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Gurubhagavatula S, Paradis MD, Romano DM, Sisodia SS, Hyman BT, Neve RL, Tanzi RE. Isolation and characterization of the human APLP2 gene encoding a homologue of the Alzheimer's associated amyloid &#x3b2; protein precursor. Nat Genet. 1993;5:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, De Los Angeles J, Miller DD, Xia W, Selkoe DJ. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry. 1999;38:11223&#x2013;11230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471271</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Koo EH, Selkoe DJ. Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. J Neurosci. 1997;17:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573178</ArticleId><ArticleId IdType="pubmed">8994055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van der Ploeg LH. &#x3b2;-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">18182109</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2008</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Presenilins are required for maintenance of neural stem cells in the developing brain.</ArticleTitle><Pagination><StartPage>2</StartPage><MedlinePgn>2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1750-1326-3-2</ELocationID><Abstract><AbstractText>The early embryonic lethality of mutant mice bearing germ-line deletions of both presenilin genes precluded the study of their functions in neural development. We therefore employed the Cre-loxP technology to generate presenilin conditional double knockout (PS cDKO) mice, in which expression of both presenilins is inactivated in neural progenitor cells (NPC) or neural stem cells and their derivative neurons and glia beginning at embryonic day 11 (E11). In PS cDKO mice, dividing NPCs labeled by BrdU are decreased in number beginning at E13.5. By E15.5, fewer than 20% of NPCs remain in PS cDKO mice. The depletion of NPCs is accompanied by severe morphological defects and hemorrhages in the PS cDKO embryonic brain. Interkinetic nuclear migration of NPCs is also disrupted in PS cDKO embryos, as evidenced by displacement of S-phase and M-phase nuclei in the ventricular zone of the telencephalon. Furthermore, the depletion of neural progenitor cells in PS cDKO embryos is due to NPCs exiting cell cycle and differentiating into neurons rather than reentering cell cycle between E13.5 and E14.5 following PS inactivation in most NPCs. The length of cell cycle, however, is unchanged in PS cDKO embryos. Expression of Notch target genes, Hes1 and Hes5, is significantly decreased in PS cDKO brains, whereas Dll1 expression is up-regulated, indicating that Notch signaling is effectively blocked by PS inactivation. These findings demonstrate that presenilins are essential for neural progenitor cells to re-enter cell cycle and thus ensure proper expansion of neural progenitor pool during embryonic neural development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woo-Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham &amp; Women's Hospital, Program in Neuroscience, Harvard Medical School, Boston, MA, 02115, USA. jshen@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18182109</ArticleId><ArticleId IdType="pmc">PMC2235867</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-3-2</ArticleId><ArticleId IdType="pii">1750-1326-3-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sidman RL, Miale IL, Feder N. Cell proliferation and migration in the primitive ependymal zone: an autoradiographic study of histogenesis in the nervous system. Exp Neurol. 1959;1:322&#x2013;333. doi: 10.1016/0014-4886(59)90024-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-4886(59)90024-X</ArticleId><ArticleId IdType="pubmed">14446424</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman SABJ. Neocortical Development. New York , Raven Press; 1991.</Citation></Reference><Reference><Citation>Takahashi T, Goto T, Miyama S, Nowakowski RS, Caviness VS., Jr. Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci. 1999;19:10357&#x2013;10371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782435</ArticleId><ArticleId IdType="pubmed">10575033</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr. Early ontogeny of the secondary proliferative population of the embryonic murine cerebral wall. J Neurosci. 1995;15:6058&#x2013;6068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577693</ArticleId><ArticleId IdType="pubmed">7666189</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr. Cell cycle parameters and patterns of nuclear movement in the neocortical proliferative zone of the fetal mouse. J Neurosci. 1993;13:820&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576626</ArticleId><ArticleId IdType="pubmed">8426239</ArticleId></ArticleIdList></Reference><Reference><Citation>Temple S. The development of neural stem cells. Nature. 2001;414:112&#x2013;117. doi: 10.1038/35102174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35102174</ArticleId><ArticleId IdType="pubmed">11689956</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DJ. Stem cells and pattern formation in the nervous system: the possible versus the actual. Neuron. 2001;30:19&#x2013;35. doi: 10.1016/S0896-6273(01)00260-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00260-4</ArticleId><ArticleId IdType="pubmed">11343642</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, Davis AA, Goderie SK, Temple S. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron. 1997;18:81&#x2013;93. doi: 10.1016/S0896-6273(01)80048-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)80048-9</ArticleId><ArticleId IdType="pubmed">9010207</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, Shen Q, Goderie SK, He W, Capela A, Davis AA, Temple S. Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. Neuron. 2000;28:69&#x2013;80. doi: 10.1016/S0896-6273(00)00086-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00086-6</ArticleId><ArticleId IdType="pubmed">11086984</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Zhong W, Jan YN, Temple S. Asymmetric Numb distribution is critical for asymmetric cell division of mouse cerebral cortical stem cells and neuroblasts. Development. 2002;129:4843&#x2013;4853.</Citation><ArticleIdList><ArticleId IdType="pubmed">12361975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002;16:846&#x2013;858. doi: 10.1101/gad.975202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.975202</ArticleId><ArticleId IdType="pmc">PMC186324</ArticleId><ArticleId IdType="pubmed">11937492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutolf S, Radtke F, Aguet M, Suter U, Taylor V. Notch1 is required for neuronal and glial differentiation in the cerebellum. Development. 2002;129:373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807030</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Pompa JL, Wakeham A, Correia KM, Samper E, Brown S, Aguilera RJ, Nakano T, Honjo T, Mak TW, Rossant J, Conlon RA. Conservation of the Notch signalling pathway in mammalian neurogenesis. Development. 1997;124:1139&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9102301</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr. Interkinetic and migratory behavior of a cohort of neocortical neurons arising in the early embryonic murine cerebral wall. J Neurosci. 1996;16:5762&#x2013;5776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578981</ArticleId><ArticleId IdType="pubmed">8795631</ArticleId></ArticleIdList></Reference><Reference><Citation>Caric D, Gooday D, Hill RE, McConnell SK, Price DJ. Determination of the migratory capacity of embryonic cortical cells lacking the transcription factor Pax-6. Development. 1997;124:5087&#x2013;5096.</Citation><ArticleIdList><ArticleId IdType="pubmed">9362466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet. 1997;6:1639&#x2013;1646. doi: 10.1093/hmg/6.10.1639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/6.10.1639</ArticleId><ArticleId IdType="pubmed">9300655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Shen J. Presenilins in the developing, adult, and aging cerebral cortex. Neuroscientist. 2005;11:441&#x2013;451. doi: 10.1177/1073858405278922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858405278922</ArticleId><ArticleId IdType="pubmed">16151045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005;8:709&#x2013;715. doi: 10.1038/nn1475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1475</ArticleId><ArticleId IdType="pubmed">15917835</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770&#x2013;776. doi: 10.1126/science.284.5415.770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.284.5415.770</ArticleId><ArticleId IdType="pubmed">10221902</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice NJ, Jan YN. Variations on the Notch pathway in neural development. Curr Opin Neurobiol. 2002;12:64&#x2013;70. doi: 10.1016/S0959-4388(02)00291-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(02)00291-X</ArticleId><ArticleId IdType="pubmed">11861166</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuurmans C, Guillemot F. Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol. 2002;12:26&#x2013;34. doi: 10.1016/S0959-4388(02)00286-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(02)00286-6</ArticleId><ArticleId IdType="pubmed">11861161</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in presnilin-1 deficient mice. Cell. 1997;89:629&#x2013;639. doi: 10.1016/S0092-8674(00)80244-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80244-5</ArticleId><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, Citron M, Kopan R, Pesold B, Keck S, Baader M, Tomita T, Iwatsubo T, Baumeister R, Haass C. A loss of function mutation of presenilin-2 interferes with amyloid &#xdf;-peptide production and Notch signaling. J Biol Chem. 1999;274:28669&#x2013;28673. doi: 10.1074/jbc.274.40.28669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.40.28669</ArticleId><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel DB, Hadjantonakis A, Ikeda M, Zheng H, St George Hyslop P, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes &amp; Dev. 1999;13:2801&#x2013;2810. doi: 10.1101/gad.13.21.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.13.21.2801</ArticleId><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Handler M, Shen J. Role of presenilin-1 in cortical lamination and survival of Cajal-Retzius neurons. Dev Biol. 2005;277:332&#x2013;346. doi: 10.1016/j.ydbio.2004.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2004.09.024</ArticleId><ArticleId IdType="pubmed">15617678</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36. doi: 10.1016/S0896-6273(04)00182-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00182-5</ArticleId><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes NL, Nowakowski RS. Exploiting the dynamics of S-phase tracers in developing brain: interkinetic nuclear migration for cells entering versus leaving the S-phase. Developmental neuroscience. 2000;22:44&#x2013;55. doi: 10.1159/000017426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017426</ArticleId><ArticleId IdType="pubmed">10657697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowakowski RS, Lewin SB, Miller MW. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J Neurocytol. 1989;18:311&#x2013;318. doi: 10.1007/BF01190834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01190834</ArticleId><ArticleId IdType="pubmed">2746304</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuasa S, Nakajima M, Aizawa H, Sahara N, Koizumi K, Sakai T, Usami M, Kobayashi S, Kuroyanagi H, Mori H, Koseki H, Shirasawa T. Impaired cell cycle control of neuronal precursor cells in the neocortical primordium of presenilin-1-deficient mice. J Neurosci Res. 2002;70:501&#x2013;513. doi: 10.1002/jnr.10430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10430</ArticleId><ArticleId IdType="pubmed">12391611</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Nowakowski RS, Caviness VS., Jr. The cell cycle of the pseudostratified ventricular epithelium of the embryonic murine cerebral wall. J Neurosci. 1995;15:6046&#x2013;6057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577667</ArticleId><ArticleId IdType="pubmed">7666188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer FC. Mitosis in the neural tube. 1935. pp. 377&#x2013;405.</Citation></Reference><Reference><Citation>Soriano S, Kang DE, Fu M, Pestell R, Chevallier N, Zheng H, Koo EH. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol. 2001;152:785&#x2013;794. doi: 10.1083/jcb.152.4.785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.152.4.785</ArticleId><ArticleId IdType="pmc">PMC2195782</ArticleId><ArticleId IdType="pubmed">11266469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell. 2002;110:751&#x2013;762. doi: 10.1016/S0092-8674(02)00970-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)00970-4</ArticleId><ArticleId IdType="pubmed">12297048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297:365&#x2013;369. doi: 10.1126/science.1074192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1074192</ArticleId><ArticleId IdType="pubmed">12130776</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks AL, Curtis D. Presenilin diversifies its portfolio. Trends Genet. 2007;23:140&#x2013;150. doi: 10.1016/j.tig.2007.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2007.01.008</ArticleId><ArticleId IdType="pubmed">17280736</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004;269:81&#x2013;94. doi: 10.1016/j.ydbio.2004.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2004.01.014</ArticleId><ArticleId IdType="pubmed">15081359</ArticleId></ArticleIdList></Reference><Reference><Citation>Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442:823&#x2013;826. doi: 10.1038/nature04940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04940</ArticleId><ArticleId IdType="pubmed">16799564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi M, Ang SL, Shiota K, Nakanishi S, Kageyama R, Guillemot F. Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES-1) leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and severe neural tube defects. Genes Dev. 1995;9:3136&#x2013;3148. doi: 10.1101/gad.9.24.3136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.9.24.3136</ArticleId><ArticleId IdType="pubmed">8543157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kageyama R, Ohtsuka T. The Notch-Hes pathway in mammalian neural development. Cell Res. 1999;9:179&#x2013;188. doi: 10.1038/sj.cr.7290016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290016</ArticleId><ArticleId IdType="pubmed">10520600</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata K, Hattori M, Hirai N, Shinozuka Y, Hirata H, Kageyama R, Sakai T, Minato N. Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol Cell Biol. 2005;25:4262&#x2013;4271. doi: 10.1128/MCB.25.10.4262-4271.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.10.4262-4271.2005</ArticleId><ArticleId IdType="pmc">PMC1087711</ArticleId><ArticleId IdType="pubmed">15870295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka T, Sakamoto M, Guillemot F, Kageyama R. Roles of the basic helix-loop-helix genes Hes1 and Hes5 in expansion of neural stem cells of the developing brain. J Biol Chem. 2001;276:30467&#x2013;30474. doi: 10.1074/jbc.M102420200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102420200</ArticleId><ArticleId IdType="pubmed">11399758</ArticleId></ArticleIdList></Reference><Reference><Citation>Berechid BE, Kitzmann M, Foltz DR, Roach AH, Seiffert D, Thompson LA, Olson RE, Bernstein A, Donoviel DB, Nye JS. Identification and characterization of presenilin-independent Notch signaling. J Biol Chem. 2002;277:8154&#x2013;8165. doi: 10.1074/jbc.M108238200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M108238200</ArticleId><ArticleId IdType="pubmed">11756438</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert SS, Ilagan MX, De Strooper B, Kopan R. Analysis of notch function in presomitic mesoderm suggests a gamma-secretase-independent role for presenilins in somite differentiation. Dev Cell. 2005;8:677&#x2013;688. doi: 10.1016/j.devcel.2005.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2005.02.019</ArticleId><ArticleId IdType="pubmed">15866159</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder JN, Jan LY, Jan YN. A rat gene with sequence homology to the Drosophila gene hairy is rapidly induced by growth factors known to influence neuronal differentiation. Mol Cell Biol. 1993;13:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358890</ArticleId><ArticleId IdType="pubmed">8417318</ArticleId></ArticleIdList></Reference><Reference><Citation>Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron. 2001;31:557&#x2013;568. doi: 10.1016/S0896-6273(01)00395-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00395-6</ArticleId><ArticleId IdType="pubmed">11545715</ArticleId></ArticleIdList></Reference><Reference><Citation>Roegiers F, Younger-Shepherd S, Jan LY, Jan YN. Two types of asymmetric divisions in the Drosophila sensory organ precursor cell lineage. Nat Cell Biol. 2001;3:58&#x2013;67. doi: 10.1038/35050568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35050568</ArticleId><ArticleId IdType="pubmed">11146627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceron J, Gonzalez C, Tejedor FJ. Patterns of cell division and expression of asymmetric cell fate determinants in postembryonic neuroblast lineages of Drosophila. Dev Biol. 2001;230:125&#x2013;138. doi: 10.1006/dbio.2000.0110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2000.0110</ArticleId><ArticleId IdType="pubmed">11161567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer L, Rao M. Neural stem cells and regulation of cell number. Prog Neurobiol. 2002;66:1&#x2013;18. doi: 10.1016/S0301-0082(01)00022-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-0082(01)00022-3</ArticleId><ArticleId IdType="pubmed">11897403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wodarz A, Huttner WB. Asymmetric cell division during neurogenesis in Drosophila and vertebrates. Mech Dev. 2003;120:1297&#x2013;1309. doi: 10.1016/j.mod.2003.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mod.2003.06.003</ArticleId><ArticleId IdType="pubmed">14623439</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki F. Asymmetric division of Drosophila neural stem cells: a basis for neural diversity. Curr Opin Neurobiol. 2000;10:38&#x2013;44. doi: 10.1016/S0959-4388(99)00052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(99)00052-5</ArticleId><ArticleId IdType="pubmed">10679433</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PH, Zou K, Hwang JK, Jan YN, Zhong W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature. 2002;419:929&#x2013;934. doi: 10.1038/nature01124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01124</ArticleId><ArticleId IdType="pubmed">12410312</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HS, Wang D, Shen Q, Schonemann MD, Gorski JA, Jones KR, Temple S, Jan LY, Jan YN. Inactivation of Numb and Numblike in embryonic dorsal forebrain impairs neurogenesis and disrupts cortical morphogenesis. Neuron. 2003;40:1105&#x2013;1118. doi: 10.1016/S0896-6273(03)00755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00755-4</ArticleId><ArticleId IdType="pubmed">14687546</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PH, Zou K, Krauss S, Zhong W. Continuing role for mouse Numb and Numbl in maintaining progenitor cells during cortical neurogenesis. Nat Neurosci. 2004;7:803&#x2013;811. doi: 10.1038/nn1289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1289</ArticleId><ArticleId IdType="pubmed">15273690</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima M, Yuasa S, Ueno M, Takakura N, Koseki H, Shirasawa T. Abnormal blood vessel development in mice lacking presenilin-1. Mech Dev. 2003;120:657&#x2013;667. doi: 10.1016/S0925-4773(03)00064-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(03)00064-9</ArticleId><ArticleId IdType="pubmed">12834865</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99&#x2013;103. doi: 10.1038/12703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/12703</ArticleId><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauvageot CM, Stiles CD. Molecular mechanisms controlling cortical gliogenesis. Curr Opin Neurobiol. 2002;12:244&#x2013;249. doi: 10.1016/S0959-4388(02)00322-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(02)00322-7</ArticleId><ArticleId IdType="pubmed">12049929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer SA, Altman J. Development of the endopiriform nucleus and the claustrum in the rat brain. Neuroscience. 1991;45:391&#x2013;412. doi: 10.1016/0306-4522(91)90236-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(91)90236-H</ArticleId><ArticleId IdType="pubmed">1762685</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Conley FK, Kilshaw PJ, Butcher EC. Lymphocytes infiltrating the CNS during inflammation display a distinctive phenotype and bind to VCAM-1 but not to MAdCAM-1. Int Immunol. 1995;7:481&#x2013;491. doi: 10.1093/intimm/7.3.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/7.3.481</ArticleId><ArticleId IdType="pubmed">7540864</ArticleId></ArticleIdList></Reference><Reference><Citation>Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987;325:253&#x2013;257. doi: 10.1038/325253a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/325253a0</ArticleId><ArticleId IdType="pubmed">3543687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieckmann P, Engelhardt B. Building up the blood-brain barrier. Nat Med. 2003;9:828&#x2013;829. doi: 10.1038/nm0703-828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0703-828</ArticleId><ArticleId IdType="pubmed">12835697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim KW. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med. 2003;9:900&#x2013;906. doi: 10.1038/nm889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm889</ArticleId><ArticleId IdType="pubmed">12808449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Kessler J, Shen J. Heterogeneous populations of ES cells in the generation of a floxed Presenilin-1 allele. Genesis. 2000;26:5&#x2013;8. doi: 10.1002/(SICI)1526-968X(200001)26:1&lt;5::AID-GENE3&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1526-968X(200001)26:1&lt;5::AID-GENE3&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10660668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B, Wilson MA, Younkin S, Kandel ER, Kirkwood A, Shen J. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 2001;31:713&#x2013;726. doi: 10.1016/S0896-6273(01)00417-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00417-2</ArticleId><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18189141</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>115</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Curcumin inhibits aggregation of alpha-synuclein.</ArticleTitle><Pagination><StartPage>479</StartPage><EndPage>489</EndPage><MedlinePgn>479-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-007-0332-4</ELocationID><Abstract><AbstractText>Aggregation of amyloid-beta protein (Abeta) is a key pathogenic event in Alzheimer's disease (AD). Curcumin, a constituent of the Indian spice Turmeric is structurally similar to Congo Red and has been demonstrated to bind Abeta amyloid and prevent further oligomerization of Abeta monomers onto growing amyloid beta-sheets. Reasoning that oligomerization kinetics and mechanism of amyloid formation are similar in Parkinson's disease (PD) and AD, we investigated the effect of curcumin on alpha-synuclein (AS) protein aggregation. In vitro model of AS aggregation was developed by treatment of purified AS protein (wild-type) with 1 mM Fe3+ (Fenton reaction). It was observed that the addition of curcumin inhibited aggregation in a dose-dependent manner and increased AS solubility. The aggregation-inhibiting effect of curcumin was next investigated in cell culture utilizing catecholaminergic SH-SY5Y cell line. A model system was developed in which the red fluorescent protein (DsRed2) was fused with A53T mutant of AS and its aggregation examined under different concentrations of curcumin. To estimate aggregation in an unbiased manner, a protocol was developed in which the images were captured automatically through a high-throughput cell-based screening microscope. The obtained images were processed automatically for aggregates within a defined dimension of 1-6 microm. Greater than 32% decrease in mutant alpha-synuclein aggregation was observed within 48 h subsequent to curcumin addition. Our data suggest that curcumin inhibits AS oligomerization into higher molecular weight aggregates and therefore should be further explored as a potential therapeutic compound for PD and related disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Neeraj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strider</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>William C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Sherry X</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG20764</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18189141</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0332-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18191617</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>135</EndPage><MedlinePgn>129-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(08)70001-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyloid-beta (Abeta) plaque formation is a hallmark of Alzheimer's disease (AD) and precedes the onset of dementia. Abeta imaging should allow earlier diagnosis, but clinical application is hindered by the short decay half-life of current Abeta-specific ligands. (18)F-BAY94-9172 is an Abeta ligand that, due to the half-life of (18)F, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">15 patients with mild AD, 15 healthy elderly controls, and five individuals with frontotemporal lobar degeneration (FTLD) were studied. (18)F-BAY94-9172 binding was quantified by use of the standardised uptake value ratio (SUVR), which was calculated for the neocortex by use of the cerebellum as reference region. SUVR images were visually rated as normal or AD.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">(18)F-BAY94-9172 binding matched the reported post-mortem distribution of Abeta plaques. All AD patients showed widespread neocortical binding, which was greater in the precuneus/posterior cingulate and frontal cortex than in the lateral temporal and parietal cortex. There was relative sparing of sensorimotor, occipital, and medial temporal cortex. Healthy controls and FTLD patients showed only white-matter binding, although three controls and one FTLD patient had mild uptake in frontal and precuneus cortex. At 90-120 min after injection, higher neocortical SUVR was observed in AD patients (2.0 [SD 0.3]) than in healthy controls (1.3 [SD 0.2]; p&lt;0.0001) or FTLD patients (1.2 [SD 0.2]; p=0.009). Visual interpretation was 100% sensitive and 90% specific for detection of AD.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">(18)F-BAY94-9172 PET discriminates between AD and FTLD or healthy controls and might facilitate integration of Abeta imaging into clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. christopher.rowe@austin.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackerman</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Browne</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Graeme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tochon-Danguy</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Berlangieri</LastName><ForeName>Salvatore U</ForeName><Initials>SU</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dickinson-Rowe</LastName><ForeName>Kerryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Hank P</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Mei Ping</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dyrks</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Holl</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Friebe</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lindemann</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dinkelborg</LastName><ForeName>Ludger M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>TLA7312TOI</RegistryNumber><NameOfSubstance UI="C527756">4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2008 Feb;7(2):114-5. doi: 10.1016/S1474-4422(08)70002-4.</RefSource><PMID Version="1">18191618</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="Y">Stilbenes</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70001-2</ArticleId><ArticleId IdType="pii">S1474-4422(08)70001-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18199773</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>748</EndPage><MedlinePgn>737-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2824-07.2008</ELocationID><Abstract><AbstractText>We describe two new transgenic mouse lines for studying pathological changes of Tau protein related to Alzheimer's disease. They are based on the regulatable expression of the four-repeat domain of human Tau carrying the FTDP17 (frontotemporal dementia and parkinsonism linked to chromosome 17) mutation deltaK280 (Tau(RD)/deltaK280), or the deltaK280 plus two proline mutations in the hexapeptide motifs (Tau(RD)/deltaK280/I277P/I308P). The deltaK280 mutation accelerates aggregation ("proaggregation mutant"), whereas the proline mutations inhibit Tau aggregation in vitro and in cell models ("antiaggregation mutant"). The inducible transgene expression was driven by the forebrain-specific CaMKIIalpha (calcium/calmodulin-dependent protein kinase IIalpha) promoter. The proaggregation mutant leads to Tau aggregates and tangles as early as 2-3 months after gene expression, even at low expression (70% of endogenous mouse Tau). The antiaggregation mutant does not aggregate even after 22 months of gene expression. Both mutants show missorting of Tau in the somatodendritic compartment and hyperphosphorylation in the repeat domain [KXGS motifs, targets of the kinase MARK (microtubule affinity regulating kinase)]. This indicates that these changes are related to Tau expression rather than aggregation. The proaggregation mutant causes astrogliosis, loss of synapses and neurons from 5 months of gene expression onward, arguing that Tau toxicity is related to aggregation. Remarkably, the human proaggregation mutant Tau(RD) coaggregates with mouse Tau, coupled with missorting and hyperphosphorylation at multiple sites. When expression of proaggregation Tau(RD) is switched off, soluble and aggregated exogenous Tau(RD) disappears within 1.5 months. However, tangles of mouse Tau, hyperphosphorylation, and missorting remain, suggesting an extended lifetime of aggregated wild-type Tau once a pathological conformation and aggregation is induced by a proaggregation Tau species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mocanu</LastName><ForeName>Maria-Magdalena</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Max Planck Unit for Structural Molecular Biology, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Eckermann</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Khlistunova</LastName><ForeName>Inna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Drexler</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Petrova</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xf6;nig</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bujard</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lepu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rune</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>632GS99618</RegistryNumber><NameOfSubstance UI="C025231">sarkosyl</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z711V88R5F</RegistryNumber><NameOfSubstance UI="D012521">Sarcosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012521" MajorTopicYN="N">Sarcosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18199773</ArticleId><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2824-07.2008</ArticleId><ArticleId IdType="pii">28/3/737</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Zheng-Fischhofer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron U, Freundlieb S, Gossen M, Bujard H. Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res. 1995;23:3605&#x2013;3606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307245</ArticleId><ArticleId IdType="pubmed">7567477</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 2005;1739:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615640</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta. 2005;1739:331&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615650</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol. 1988;132:86&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880629</ArticleId><ArticleId IdType="pubmed">2456021</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Sch&#xf6;nig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of Alzheimer tauopathy. J Biol Chem. 2007;282:31755&#x2013;31765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol. 2001;13:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis. 2006;9:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547&#x2013;5551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49329</ArticleId><ArticleId IdType="pubmed">1319065</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995;14:1304&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM. A decade of tau transgenic animal models and beyond. Brain Pathol. 2007;17:91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095624</ArticleId><ArticleId IdType="pubmed">17493043</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E. Global hairpin folding of tau in solution. Biochemistry. 2006;45:2283&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res. 1999;55:713&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Pangalos M, Geerts H, Wiech H, Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Lett. 1999;451:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10356980</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretz O, Fester L, Wehrenberg U, Zhou L, Brauckmann S, Zhao S, Prange-Kiel J, Naumann T, Jarry H, Frotscher M, Rune GM. Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci. 2004;24:5913&#x2013;5921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729232</ArticleId><ArticleId IdType="pubmed">15229239</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, von Bergen M, Mandelkow EM, Mandelkow E. Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis. J Biol Chem. 2002;277:41390&#x2013;41400.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198126</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson R, Bing G, Li X, Hunter T, Lu KP. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140191</ArticleId><ArticleId IdType="pubmed">11226152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E, von Bergen M, Biernat J, Mandelkow E-M. Structural principles of Tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007;17:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol. 2004;167:99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172520</ArticleId><ArticleId IdType="pubmed">15466480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006;22:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567017</ArticleId></ArticleIdList></Reference><Reference><Citation>Muly EC, Smith Y, Allen P, Greengard P. Subcellular distribution of spinophilin immunolabeling in primate prefrontal cortex: localization to and within dendritic spines. J Comp Neurol. 2004;469:185&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694533</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J Neurochem. 1996;67:1183&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Prange-Kiel J, Rune GM, Leranth C. Median raphe mediates estrogenic effects to the hippocampus in female rats. Eur J Neurosci. 2004;19:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">14725625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, Niermeijer MF, Hillebrand M, Ravid R, Oostra BA, Goedert M, van Duijn CM, Heutink P. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in The Netherlands. Am J Hum Genet. 1999;64:414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007;6:304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17396135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rune GM, Wehrenberg U, Prange-Kiel J, Zhou L, Adelmann G, Frotscher M. Estrogen up-regulates estrogen receptor alpha and synaptophysin in slice cultures of rat hippocampus. Neuroscience. 2002;113:167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">12123695</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999;38:3549&#x2013;3558.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ, Lee VM-Y. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem. 1995;270:18917&#x2013;18922.</Citation><ArticleIdList><ArticleId IdType="pubmed">7642549</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol. 1999;155:2153&#x2013;2165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002;156:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta. 2005;1739:280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem. 2002;50:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanemura K, Chui DH, Fukuda T, Murayama M, Park JM, Akagi T, Tatebayashi Y, Miyasaka T, Kimura T, Hashikawa T, Nakano Y, Kudo T, Takeda M, Takashima A. Formation of tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1) J Biol Chem. 2006;281:5037&#x2013;5041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16377636</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med. 2002;2:151&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428809</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem. 2005;280:3963&#x2013;3973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci USA. 2007;104:10252&#x2013;10257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891218</ArticleId><ArticleId IdType="pubmed">17535890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol. 1992;118:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18202749</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>118</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>671</StartPage><EndPage>682</EndPage><MedlinePgn>671-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI33622</ELocationID><Abstract><AbstractText>APOE genotype is a major genetic risk factor for late-onset Alzheimer disease (AD). ABCA1, a member of the ATP-binding cassette family of active transporters, lipidates apoE in the CNS. Abca1(-/-) mice have decreased lipid associated with apoE and increased amyloid deposition in several AD mouse models. We hypothesized that mice overexpressing ABCA1 in the brain would have increased lipidation of apoE-containing lipoproteins and decreased amyloid deposition. To address these hypotheses, we created PrP-mAbca1 Tg mice that overexpress mouse Abca1 throughout the brain under the control of the mouse prion promoter. We bred the PrP-mAbca1 mice to the PDAPP AD mouse model, a transgenic line overexpressing a mutant human amyloid precursor protein. PDAPP/Abca1 Tg mice developed a phenotype remarkably similar to that seen in PDAPP/Apoe(-/-) mice: there was significantly less amyloid beta-peptide (Abeta) deposition, a redistribution of Abeta to the hilus of the dentate gyrus in the hippocampus, and an almost complete absence of thioflavine S-positive amyloid plaques. Analyses of CSF from PrP-mAbca1 Tg mice and media conditioned by PrP-mAbca1 Tg primary astrocytes demonstrated increased lipidation of apoE-containing particles. These data support the conclusions that increased ABCA1-mediated lipidation of apoE in the CNS can reduce amyloid burden and that increasing ABCA1 function may have a therapeutic effect on AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wahrle</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aimin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Knoten</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hirsch-Reinshagen</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wellington</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 HD047396</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD047396</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK079333</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18202749</ArticleId><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="doi">10.1172/JCI33622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 1968;9:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">4868699</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eck M., Pennings M., Hoekstra M., Out R., Van Berkel T.J. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr. Opin. Lipidol. 2005;16:307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">15891392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.Y., Parks J.S. ATP-binding cassette transporter AI and its role in HDL formation. Curr. Opin. Lipidol. 2005;16:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650559</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer H.B., Jr., Remaley A.T., Neufeld E.B., Basso F., Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2004;24:1755&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin. Invest. 2007;117:2216&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924499</ArticleId><ArticleId IdType="pubmed">17657311</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks-Wilson A., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999;22:336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodzioch M., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 1999;22:347&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431237</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust S., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999;22:352&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431238</ArticleId></ArticleIdList></Reference><Reference><Citation>Remaley A.T., et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc. Natl. Acad. Sci. U. S. A. 1999;96:12685&#x2013;12690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23050</ArticleId><ArticleId IdType="pubmed">10535983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mott S., et al. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis. 2000;152:457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawn R.M., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 1999;104:R25&#x2013;R31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC481052</ArticleId><ArticleId IdType="pubmed">10525055</ArticleId></ArticleIdList></Reference><Reference><Citation>Brousseau M.E., et al. Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J. Lipid Res. 2000;41:1125&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884295</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer E.J., et al. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J. Lipid Res. 1981;22:217&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">6787156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer E.J., et al. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J. Med. 1978;299:905&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">211412</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce C.W., et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2002;99:407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117573</ArticleId><ArticleId IdType="pubmed">11752403</ArticleId></ArticleIdList></Reference><Reference><Citation>Singaraja R.R., et al. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 2002;110:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151034</ArticleId><ArticleId IdType="pubmed">12093886</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eck M., et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2006;26:929&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">16456089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S.E., et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 2004;279:41197&#x2013;41207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R., Staufenbiel M., Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 2005;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle, S.E., and Holtzman, D.M. 2007. Apolipoprotein E, amyloid beta-peptide and Alzheimer&#x2019;s disease. In Neurobiology of Alzheimer&#x2019;s disease. D. Dawbarn and S.J. Allen, editors. Oxford University Press. Oxford, United Kingdom. 161&#x2013;172.</Citation></Reference><Reference><Citation>Spires T.L., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S.E., et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Singaraja R.R., et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J. Biol. Chem. 2001;276:33969&#x2013;33979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., et al. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-beta peptide levels in vivo. J. Lipid Res. 2007;48:914&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">17235115</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisman B.L., et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 2001;108:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC203026</ArticleId><ArticleId IdType="pubmed">11457883</ArticleId></ArticleIdList></Reference><Reference><Citation>Selva D.M., et al. The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. J. Lipid Res. 2004;45:1040&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavelier L.B., et al. Regulation and activity of the human ABCA1 gene in transgenic mice. J. Biol. Chem. 2001;276:18046&#x2013;18051.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279093</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., et al. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development. 2004;131:5503&#x2013;5513.</Citation><ArticleIdList><ArticleId IdType="pubmed">15469971</ArticleId></ArticleIdList></Reference><Reference><Citation>Naughton C.K., Jain S., Strickland A.M., Gupta A., Milbrandt J. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol. Reprod. 2006;74:314&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K.R., et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K.R., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., et al. ApoE and clusterin cooperatively suppress abeta levels and deposition. Evidence that ApoE regulates extracellular abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M.C., et al. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol. (Berl.) 2000;100:451&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">11045665</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W.J., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel D.E., et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.M., Rebeck G.W., Vonsattel J.P., Gomez-Isla T., Hyman B.T. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995;38:254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">7654074</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W.J., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993;90:8098&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann. Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer J.D., et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 2003;23:7889&#x2013;7896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740607</ArticleId><ArticleId IdType="pubmed">12944519</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer&#x2019;s disease. J. Clin. Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M.A., et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2002;99:10843&#x2013;10848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R.D., et al. Transport pathways for clearance of human Alzheimer&#x2019;s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R., Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer&#x2019;s disease &#x2014; implications for a new therapeutic approach. Curr. Alzheimer Res. 2007;4:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430243</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G., Bales K.R., DeMattos R.B., Paul S.M. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer&#x2019;s disease therapeutics. Curr. Alzheimer Res. 2007;4:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y., et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 2004;88:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Yao J., Kim T.W., Tall A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 2003;278:27688&#x2013;27694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H., Deng A., Irizarry M.C., Fitzgerald M.L., Rebeck G.W. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 2002;277:48508&#x2013;48513.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384498</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R.P., et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 2003;278:13244&#x2013;13256.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N., et al. Attenuation of neuroinflammation and Alzheimer&#x2019;s disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U. S. A. 2007;104:10601&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M.P., et al. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 2006;98:792&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu M.J., et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 1994;269:23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu M.J., et al. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 1995;270:9039&#x2013;9042.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer&#x2019;s amyloid beta peptides. Biochem. J. 2000;348:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221074</ArticleId><ArticleId IdType="pubmed">10816430</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu M.J., et al. Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 1998;70:2070&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A.M., et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (&#x2013;/&#x2013;), and human apoE transgenic mice. J. Biol. Chem. 1999;274:30001&#x2013;30007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D.R., et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer&#x2019;s disease. J. Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington University Hybridoma Center protocols. 2007. http://pathology.wustl.edu/research/hybridoma.php</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18216194</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons.</ArticleTitle><Pagination><StartPage>862</StartPage><EndPage>867</EndPage><MedlinePgn>862-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3072-08.2008</ELocationID><Abstract><AbstractText>Accumulation of neurofibrillary tangles (NFTs) in Alzheimer's disease correlates with neuronal loss and cognitive decline, but the precise relationship between NFTs and neuronal death and downstream mechanisms of cell death remain unclear. Caspase cleaved products accumulate in tangles, implying that tangles may contribute to apoptotic neuronal death. To test this hypothesis, we developed methods using multiphoton imaging to detect both neurofibrillary pathology and caspase activation in the living mouse brain. We examined rTg4510 mice, a reversible mouse model of tauopathy that develops tangles and neuronal loss. Only a small percentage of imaged neurons were caspase activity positive, but the vast majority of the cells with active caspases contained NFTs. We next tested the hypothesis that caspase activation led to acute, apoptotic neuronal death. Caspase positive cell bodies did not degenerate over hours of imaging, despite the presence of activated executioner caspases. Suppression of the transgene, which stops ongoing death, did not suppress caspase activity. Finally, histochemical assessments revealed evidence of caspase-cleaved tau, but no TUNEL (terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling) positive or apoptotic nuclei. With the novel technique of observing NFTs and caspase activation in the living brain, we demonstrate that aggregated tau in neurons can be associated with caspase activation, but that caspase activation is not sufficient to cause acute neuronal death in this model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Calignon</LastName><ForeName>Alix</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zehr</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pitstick</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hai-Yan</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Osetek</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Phillip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jada</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG026252</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG26249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00277</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS46355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB00768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG26252</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18216194</ArticleId><ArticleId IdType="pmc">PMC6670992</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3072-08.2008</ArticleId><ArticleId IdType="pii">28/4/862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada P, Growdon J, Hedley-Whyte E, Hyman B. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG. From the cover: pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA. 2006;103:4246&#x2013;4251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449678</ArticleId><ArticleId IdType="pubmed">16537516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LK, Putcha GV, Deshmukh M, Johnson EM., Jr Mitochondrial involvement in the point of no return in neuronal apoptosis. Biochimie. 2002;84:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12022953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol. 2005;64:104&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 1998;4:1329&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang-Rollin ICJ, Rideout HJ, Noticewala M, Stefanis L. Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation. J Neurosci. 2003;23:11015&#x2013;11025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741034</ArticleId><ArticleId IdType="pubmed">14657158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q, Wang XC, Chen XQ, Yang Y, Zhang JY, Wang Q, Xu H, Liao FF, Wang JZ. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci USA. 2007;104:3591&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805527</ArticleId><ArticleId IdType="pubmed">17360687</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT. Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol. 2006;65:508&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Houseweart MK, Brown RH, Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97:13901&#x2013;13906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17673</ArticleId><ArticleId IdType="pubmed">11095709</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging. 2001;22:89&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164280</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, Cribbs DH. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol. 2001;158:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850275</ArticleId><ArticleId IdType="pubmed">11141492</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoch J, Hickey GA, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of amyloid-beta deposits in mouse brain with multiphoton microscopy. In: Sigurdsson EM, editor. Amyloid proteins: methods and protocols. Totowa, NJ: Humana; 2004. pp. 349&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980616</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol. 2006;168:1598&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606598</ArticleId><ArticleId IdType="pubmed">16651626</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol. 1981;10:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">7283403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Young C, Roth KA, Klocke BJ, West T, Holtzman DM, Labruyere J, Qin YQ, Dikranian K, Olney JW. Role of caspase-3 in ethanol-induced developmental neurodegeneration. Neurobiol Dis. 2005;20:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehr C, Lewis J, McGowan E, Crook J, Lin WL, Godwin K, Knight J, Dickson DW, Hutton M. Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice. Neurobiol Dis. 2004;15:553&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056463</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18216876</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>336</StartPage><EndPage>349</EndPage><MedlinePgn>336-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/sj.emboj.7601930</ELocationID><Abstract><AbstractText>The etiologies of neurodegenerative diseases may be diverse; however, a common pathological denominator is the formation of aberrant protein conformers and the occurrence of pathognomonic proteinaceous deposits. Different approaches coming from neuropathology, genetics, animal modeling and biophysics have established a crucial role of protein misfolding in the pathogenic process. However, there is an ongoing debate about the nature of the harmful proteinaceous species and how toxic conformers selectively damage neuronal populations. Increasing evidence indicates that soluble oligomers are associated with early pathological alterations, and strikingly, oligomeric assemblies of different disease-associated proteins may share common structural features. A major step towards the understanding of mechanisms implicated in neuronal degeneration is the identification of genes, which are responsible for familial variants of neurodegenerative diseases. Studies based on these disease-associated genes illuminated the two faces of protein misfolding in neurodegeneration: a gain of toxic function and a loss of physiological function, which can even occur in combination. Here, we summarize how these two faces of protein misfolding contribute to the pathomechanisms of Alzheimer's disease, frontotemporal lobar degeneration, Parkinson's disease and prion diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winklhofer</LastName><ForeName>Konstanze F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Neurobiochemisty, Department of Biochemistry, Adolf-Butenandt-Institute, Ludwig-Maximilians-University, Munich, Germany. konstanze.winklhofer@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatzelt</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18216876</ArticleId><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="doi">10.1038/sj.emboj.7601930</ArticleId><ArticleId IdType="pii">7601930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 104: 14807&#x2013;14812</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1976193</ArticleId><ArticleId IdType="pubmed">17766438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell 14: 4541&#x2013;4556</Citation><ArticleIdList><ArticleId IdType="pmc">PMC266771</ArticleId><ArticleId IdType="pubmed">12937272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Pagani F, Baralle FE (2006) TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett 580: 1339&#x2013;1344</Citation><ArticleIdList><ArticleId IdType="pubmed">16458894</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C et al. (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH, Heikenwalder M, Rulicke T, Burkle A, Aguzzi A (2007) Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 26: 538&#x2013;547</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783444</ArticleId><ArticleId IdType="pubmed">17245436</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C (1997) Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct 1: 149&#x2013;159</Citation><ArticleIdList><ArticleId IdType="pubmed">9680315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732&#x2013;742</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT (2005) Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 25: 3009&#x2013;3017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725136</ArticleId><ArticleId IdType="pubmed">15772361</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer K (2007) Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem Biophys 47: 285&#x2013;299</Citation><ArticleIdList><ArticleId IdType="pubmed">17652776</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Laferla FM (2006) Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 3: 437&#x2013;448</Citation><ArticleIdList><ArticleId IdType="pubmed">17168643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379: 339&#x2013;343</Citation><ArticleIdList><ArticleId IdType="pubmed">8552188</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20: 1774&#x2013;1784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL III, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A et al. (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171: 227&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19: 1377&#x2013;1379</Citation><ArticleIdList><ArticleId IdType="pubmed">15946991</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Baron GS (2006) Prions and their partners in crime. Nature 443: 803&#x2013;810</Citation><ArticleIdList><ArticleId IdType="pubmed">17051207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383&#x2013;396</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167&#x2013;1169</Citation><ArticleIdList><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435&#x2013;1439</Citation><ArticleIdList><ArticleId IdType="pubmed">15933194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiesa R, Piccardo P, Ghetti B, Harris DA (1998) Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 21: 1339&#x2013;1351</Citation><ArticleIdList><ArticleId IdType="pubmed">9883727</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises Parkin's protective function. Science 304: 1328&#x2013;1331</Citation><ArticleIdList><ArticleId IdType="pubmed">15105460</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162&#x2013;1166</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pubmed">11701929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet 12: 2957&#x2013;2965</Citation><ArticleIdList><ArticleId IdType="pubmed">14519684</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, van der Brug M (2007) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol; September 29 [E-pub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2231843</ArticleId><ArticleId IdType="pubmed">17603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324&#x2013;328</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP et al. (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292&#x2013;1295</Citation><ArticleIdList><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, Snowden JS, Mann DM (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (Berlin) 113: 521&#x2013;533</Citation><ArticleIdList><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 141&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Josephs KA, Amador-Ortiz C (2007) TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol (Berlin) 114: 71&#x2013;79</Citation><ArticleIdList><ArticleId IdType="pubmed">17569066</ArticleId></ArticleIdList></Reference><Reference><Citation>Doss-Pepe EW, Chen L, Madura K (2005) Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J Biol Chem 280: 16619&#x2013;16624</Citation><ArticleIdList><ArticleId IdType="pubmed">15718234</ArticleId></ArticleIdList></Reference><Reference><Citation>Duering M, Grimm MO, Grimm HS, Schroder J, Hartmann T (2005) Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging 26: 785&#x2013;788</Citation><ArticleIdList><ArticleId IdType="pubmed">15718035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumpitak C, Beekes M, Weinmann N, Metzger S, Winklhofer KF, Tatzelt J, Riesner D (2005) The polysaccharide scaffold of PrP 27-30 is a common compound of natural prions and consists of alpha-linked polyglucose. Biol Chem 386: 1149&#x2013;1155</Citation><ArticleIdList><ArticleId IdType="pubmed">16307480</ArticleId></ArticleIdList></Reference><Reference><Citation>Exner N, Treske B, Paquet D, Holmstr&#xf6;m K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken H-H, Gasser T, Kr&#xfc;ger R, Winklhofer KF, Vogel F, Reichert A, Auburger G, Kahle PJ, Schmid B, Haass C (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413&#x2013;12418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673250</ArticleId><ArticleId IdType="pubmed">17989306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T, Brice A, van Bergen En Henegouwen PM, Fon EA (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8: 834&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pubmed">16862145</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174&#x2013;179</Citation><ArticleIdList><ArticleId IdType="pubmed">14755720</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig E, Hegyi I, Leimeroth R, Zuniga A, Rossi D, Cozzio A, Schwarz P, Rulicke T, Gotz J, Aguzzi A, Weissmann C (2003) Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. EMBO J 22: 3095&#x2013;3101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162137</ArticleId><ArticleId IdType="pubmed">12805223</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig E, Weissmann C (2004) The role of PrP in health and disease. Curr Mol Med 4: 337&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pubmed">15354865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15: 223&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">16321986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorner K, Holtorf E, Odoy S, Nuscher B, Yamamoto A, Regula JT, Beyer K, Haass C, Kahle PJ (2004) Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1. J Biol Chem 279: 6943&#x2013;6951</Citation><ArticleIdList><ArticleId IdType="pubmed">14607841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorner K, Holtorf E, Waak J, Pham TT, Vogt-Weisenhorn DM, Wurst W, Haass C, Kahle PJ (2007) Structural determinants of the C-terminal helix&#x2013;kink&#x2013;helix motif essential for protein stability and survival promoting activity of DJ-1. J Biol Chem 282: 13680&#x2013;13691</Citation><ArticleIdList><ArticleId IdType="pubmed">17331951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277: 48984&#x2013;48992</Citation><ArticleIdList><ArticleId IdType="pubmed">12351643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491&#x2013;1495</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329&#x2013;341</Citation><ArticleIdList><ArticleId IdType="pubmed">16750377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu WJ, Corti O, Araujo F, Hampe C, Jacquier S, Lucking CB, Abbas N, Duyckaerts C, Rooney T, Pradier L, Ruberg M, Brice A (2003) The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol Dis 14: 357&#x2013;364</Citation><ArticleIdList><ArticleId IdType="pubmed">14678753</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5: 101&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C (2004) Take five-BACE and the g-secretase quartet conduct Alzheimer's amyloid b-peptide generation. EMBO J 23: 483&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund K, Dikic I (2005) Ubiquitylation and cell signaling. EMBO J 24: 3353&#x2013;3359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276169</ArticleId><ArticleId IdType="pubmed">16148945</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawani D, Latterich M (2006) p97: the cell's molecular purgatory? Mol Cell 22: 713&#x2013;717</Citation><ArticleIdList><ArticleId IdType="pubmed">16793541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O (2006) Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15: 2059&#x2013;2075</Citation><ArticleIdList><ArticleId IdType="pubmed">16714300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Ong CH, Halper J, Bateman A (2003) Progranulin is a mediator of the wound response. Nat Med 9: 225&#x2013;229</Citation><ArticleIdList><ArticleId IdType="pubmed">12524533</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279: 827&#x2013;834</Citation><ArticleIdList><ArticleId IdType="pubmed">9452375</ArticleId></ArticleIdList></Reference><Reference><Citation>Henn IH, Bouman L, Schlehe JS, Schlierf A, Schramm JE, Wegener E, Nakaso K, Culmsee C, Berninger B, Krappmann D, Tatzelt J, Winklhofer KF (2007) Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 27: 1868&#x2013;1878</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673568</ArticleId><ArticleId IdType="pubmed">17314283</ArticleId></ArticleIdList></Reference><Reference><Citation>Henn IH, Gostner JM, Tatzelt J, Winklhofer KF (2005) Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 92: 114&#x2013;122</Citation><ArticleIdList><ArticleId IdType="pubmed">15606901</ArticleId></ArticleIdList></Reference><Reference><Citation>Heske J, Heller U, Winklhofer KF, Tatzelt J (2004) The C-terminal domain of the prion protein is necessary and sufficient for import into the endoplasmic reticulum. J Biol Chem 279: 5435&#x2013;5443</Citation><ArticleIdList><ArticleId IdType="pubmed">14645231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter P (2006) Shedding a negative image. Research into their mechanism of infectivity reveals that prions might have important biological roles. EMBO Rep 7: 1196&#x2013;1198</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794699</ArticleId><ArticleId IdType="pubmed">17139293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J et al. (1998) Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169&#x2013;1171</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M (2007) Sept4, a component of presynaptic scaffold and lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53: 519&#x2013;533</Citation><ArticleIdList><ArticleId IdType="pubmed">17296554</ArticleId></ArticleIdList></Reference><Reference><Citation>Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM (2005) Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci USA 102: 9691&#x2013;9696</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1172235</ArticleId><ArticleId IdType="pubmed">15983381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal parkinsonism. Nature 392: 605&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM (2006) Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281: 16193&#x2013;16196</Citation><ArticleIdList><ArticleId IdType="pubmed">16672220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, Song H, Park BJ, Kim MJ, Kim S, Dawson VL, Dawson TM (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25: 7968&#x2013;7978</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725452</ArticleId><ArticleId IdType="pubmed">16135753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, van Leeuwen FW, Menendez-Benito V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 26: 175&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pubmed">17466621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106&#x2013;108</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Van Broeckhoven C (2007) Frontotemporal lobar degeneration: current concepts in the light of recent advances. Brain Pathol 17: 104&#x2013;114</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095552</ArticleId><ArticleId IdType="pubmed">17493044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, Saeki K, Matsumoto Y, Yokoyama T, Itohara S, Onodera T (1999) Prions prevent neuronal cell-line death. Nature 400: 225&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">10421360</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443: 774&#x2013;779</Citation><ArticleIdList><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG (2007) The effects of oxidative stress on parkin and other E3 ligases. J Neurochem; September 19 [E-pub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">17883392</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11: 1214&#x2013;1221</Citation><ArticleIdList><ArticleId IdType="pubmed">16227987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HG, Zhu X, Takeda A, Perry G, Smith MA (2006) Emerging evidence for the neuroprotective role of alpha-synuclein. Exp Neurol 200: 1&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">16780837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB (2007) ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol 17: 1561&#x2013;1567</Citation><ArticleIdList><ArticleId IdType="pubmed">17683935</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB (2004) Synthetic mammalian prions. Science 305: 673&#x2013;676</Citation><ArticleIdList><ArticleId IdType="pubmed">15286374</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Nguyen HO, Baskakov IV, Cohen FE, Dearmond SJ, Prusiner SB (2005) Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci USA 102: 2168&#x2013;2173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548557</ArticleId><ArticleId IdType="pubmed">15671162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I (1996) Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci USA 93: 14940&#x2013;14944</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26241</ArticleId><ArticleId IdType="pubmed">8962160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487&#x2013;1491</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA (2007) Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x2013;125. EMBO J 26: 548&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783448</ArticleId><ArticleId IdType="pubmed">17245437</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL (2004) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18: 962&#x2013;964</Citation><ArticleIdList><ArticleId IdType="pubmed">15059976</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, Tanaka Y, Smith W, Engelender S, Ross CA, Dawson VL, Dawson TM (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25: 2002&#x2013;2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726069</ArticleId><ArticleId IdType="pubmed">15728840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279: 12924&#x2013;12934</Citation><ArticleIdList><ArticleId IdType="pubmed">14711827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT (2004) Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 10: 1065&#x2013;1066</Citation><ArticleIdList><ArticleId IdType="pubmed">15448688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Lindquist S (2001) Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 98: 14955&#x2013;14960</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64965</ArticleId><ArticleId IdType="pubmed">11742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Wollmann R, Lindquist S (2002) Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298: 1781&#x2013;1785</Citation><ArticleIdList><ArticleId IdType="pubmed">12386337</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo MG, Anar B, Bronner IF, Cannella M, Squitieri F, Bonifati V, Hoogeveen A, Heutink P, Rizzu P (2003) The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet 12: 2807&#x2013;2816</Citation><ArticleIdList><ArticleId IdType="pubmed">12952867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VM, Trojanowski JQ (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61: 427&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R (2007) The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 8: 857&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">17805587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871&#x2013;874</Citation><ArticleIdList><ArticleId IdType="pubmed">14593181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E, von Bergen M, Biernat J, Mandelkow EM (2007) Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17: 83&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8: 425&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">9854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11: 721&#x2013;736</Citation><ArticleIdList><ArticleId IdType="pubmed">16786033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata IF, Lockhart PJ, Farrer MJ (2004) Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 13: R127&#x2013;R133</Citation><ArticleIdList><ArticleId IdType="pubmed">14976155</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda N, Kitami T, Suzuki T, Mizuno Y, Hattori N, Tanaka K (2006) Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281: 3204&#x2013;3209</Citation><ArticleIdList><ArticleId IdType="pubmed">16339143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26: 10068&#x2013;10078</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674486</ArticleId><ArticleId IdType="pubmed">17005870</ArticleId></ArticleIdList></Reference><Reference><Citation>McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE (2004) Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 165: 227&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618524</ArticleId><ArticleId IdType="pubmed">15215178</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C, Cookson MR (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 278: 36588&#x2013;36595</Citation><ArticleIdList><ArticleId IdType="pubmed">12851414</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitteregger G, Vosko M, Krebs B, Xiang W, Kohlmannsperger V, Nolting S, Hamann GF, Kretzschmar HA (2007) The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol 17: 174&#x2013;183</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1859984</ArticleId><ArticleId IdType="pubmed">17388948</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 99: 8025&#x2013;8030</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57&#x2013;87</Citation><ArticleIdList><ArticleId IdType="pubmed">16022590</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DJ, Zhang L, Dawson TM, Dawson VL (2003) A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem 87: 1558&#x2013;1567</Citation><ArticleIdList><ArticleId IdType="pubmed">14713311</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JS, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J, Levitch D, Taylor-Reinwald L, Gitcho M, Tu PH, Tenenholz Grinberg L, Liscic RM, Armendariz J, Morris JC, Goate AM (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 60: 314&#x2013;322</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803024</ArticleId><ArticleId IdType="pubmed">16983685</ArticleId></ArticleIdList></Reference><Reference><Citation>Muqit MM, Davidson SM, Payne Smith MD, MacCormac LP, Kahns S, Jensen PH, Wood NW, Latchman DS (2004) Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. Hum Mol Genet 13: 117&#x2013;135</Citation><ArticleIdList><ArticleId IdType="pubmed">14645198</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramoto T, DeArmond SJ, Scott M, Telling GC, Cohen FE, Prusiner SB (1997) Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix. Nat Med 3: 750&#x2013;755</Citation><ArticleIdList><ArticleId IdType="pubmed">9212101</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y, Kondoh G, Kudo T, Imaizumi K, Kato M, Miyazaki JI, Tohyama M, Takeda J, Takeda M (1999) Accumulation of murine amyloidbeta42 in a gene-dosage-dependent manner in PS1 &#x2018;knock-in' mice. Eur J Neurosci 11: 2577&#x2013;2581</Citation><ArticleIdList><ArticleId IdType="pubmed">10383647</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66: 152&#x2013;157</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280: 21212&#x2013;21219</Citation><ArticleIdList><ArticleId IdType="pubmed">15817478</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai Q, Ke H, Levey AI, Li L, Chin LS (2004) Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 279: 8506&#x2013;8515</Citation><ArticleIdList><ArticleId IdType="pubmed">14665635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69: 3584&#x2013;3596</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C (2007) Generation of Abeta 38 and Abeta 42 is independently and differentially affected by FAD-associated presenilin 1 mutations and gamma-secretase modulation. J Biol Chem; October 24 [E-pub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595&#x2013;600</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 1157&#x2013;1161</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36: 1007&#x2013;1019</Citation><ArticleIdList><ArticleId IdType="pubmed">12495618</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickart CM, Fushman D (2004) Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 8: 610&#x2013;616</Citation><ArticleIdList><ArticleId IdType="pubmed">15556404</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering-Brown SM (2007) Progranulin and frontotemporal lobar degeneration. Acta Neuropathol (Berlin) 114: 39&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">17572900</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270: 9564&#x2013;9570</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045&#x2013;2047</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136&#x2013;144</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Cruts M, Dermaut B, Sleegers K, Rosso SM, Van den Broeck M, Backhovens H, van Swieten J, van Duijn CM, Van Broeckhoven C (2002) Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval. Mol Psychiatry 7: 1064&#x2013;1074</Citation><ArticleIdList><ArticleId IdType="pubmed">12476321</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambold AS, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer KF, Tatzelt J (2006) Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell 17: 3356&#x2013;3368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525242</ArticleId><ArticleId IdType="pubmed">16707568</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel A, Burgaya F, Gavin R, Soriano E, Aguzzi A, Del Rio JA (2007) Enhanced susceptibility of Prnp-deficient mice to kainate-induced seizures, neuronal apoptosis, and death: role of AMPA/kainate receptors. J Neurosci Res 85: 2741&#x2013;2755</Citation><ArticleIdList><ArticleId IdType="pubmed">17304577</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer's disease. Science 314: 781&#x2013;784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roucou X, LeBlanc AC (2005) Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med 83: 3&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">15645198</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Kellings K, Serban A, Groth D, Cleaver JE, Prusiner SB, Riesner D (2005) Search for a prion-specific nucleic acid. J Virol 79: 10796&#x2013;10806</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182634</ArticleId><ArticleId IdType="pubmed">16051871</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick J, Yang Y, Andersen P, Vonsattel J, Greenway M, Momeni P, Elder J, Chio A, Restagno G, Robberecht W, Dahlberg C, Mukherjee O, Goate A, Graff-Radford N, Caselli R, Hutton M, Gass J, Cannon A, Rademakers R, Singleton A et al. (2007) Progranulin mutations and ALS or ALS-FTD phenotypes. J Neurol Neurosurg Psychiatry 78: 754&#x2013;756</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117704</ArticleId><ArticleId IdType="pubmed">17371905</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H, Jurgen Schelhaas H, Azmani A, Kusters B, Rosso S, Majoor-Krakauer D, de Rijik MC, Rizzu P, Brummelhuis MT, van Doorn PA, Kamphorst W, Willemsen R, van Swieten JC (2007) TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain 130: 1375&#x2013;1385</Citation><ArticleIdList><ArticleId IdType="pubmed">17360763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, Haass C (2007) TTLD-U linked progranulin missense mutations affect their secretion but transient knockdown is not sufficient to induce cytoplasmic TDP-43 depositon. J Biol Chem; November 5 [E-pub ahead of print]</Citation></Reference><Reference><Citation>Shmerling D, Hegyi I, Fischer M, Bl&#xe4;ttler T, Brandner S, G&#xf6;tz J, R&#xfc;licke T, Flechsig E, Cozzio A, von Mehring C, Hangartner C, Aguzzi A, Weissmann C (1998) Expression of animo-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203&#x2013;214</Citation><ArticleIdList><ArticleId IdType="pubmed">9568713</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyu A-B, Wilkinson MF, van Hoof A (2008) Messenger RNA regulation: to translate or to degrade. EMBO J (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2241649</ArticleId><ArticleId IdType="pubmed">18256698</ArticleId></ArticleIdList></Reference><Reference><Citation>Shyu WC, Lin SZ, Chiang MF, Ding DC, Li KW, Chen SF, Yang HI, Li H (2005) Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci 25: 8967&#x2013;8977</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725592</ArticleId><ArticleId IdType="pubmed">16192387</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20: 8717&#x2013;8726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773081</ArticleId><ArticleId IdType="pubmed">11102478</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, Brandner S, Brun A, Rossor MN, Gade A, Johannsen P, Sorensen SA, Gydesen S, Fisher EM, Collinge J (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37: 806&#x2013;808</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, Sawa A, Dawson VL, Dawson TM, Ross CA (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14: 3801&#x2013;3811</Citation><ArticleIdList><ArticleId IdType="pubmed">16239241</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231&#x2013;1233</Citation><ArticleIdList><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B (2003) Aggregated and monomeric alpha-synuclein bind to the S6&#x2032; proteasomal protein and inhibit proteasomal function. J Biol Chem 278: 11753&#x2013;11759</Citation><ArticleIdList><ArticleId IdType="pubmed">12551928</ArticleId></ArticleIdList></Reference><Reference><Citation>Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA (2004) Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303: 1514&#x2013;1516</Citation><ArticleIdList><ArticleId IdType="pubmed">14752167</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL, Hermann DM (2005) Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 20: 442&#x2013;449</Citation><ArticleIdList><ArticleId IdType="pubmed">15893468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, Dawson VL, Dawson TM (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 14: 2571&#x2013;2586</Citation><ArticleIdList><ArticleId IdType="pubmed">16049031</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21: 9549&#x2013;9560</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763041</ArticleId><ArticleId IdType="pubmed">11739566</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Volkening K, Hammond R, Yang W, Strong W, Leystra-Lantz C, Shoesmith C (2007) TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci 35: 320&#x2013;327</Citation><ArticleIdList><ArticleId IdType="pubmed">17481916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A, Nishizawa M, Kakita A, Takahashi H (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (Berlin) 113: 535&#x2013;542</Citation><ArticleIdList><ArticleId IdType="pubmed">17333220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson VL, Dawson TM, Ross CA (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10: 919&#x2013;926</Citation><ArticleIdList><ArticleId IdType="pubmed">11309365</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103: 17&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">17623039</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158&#x2013;1160</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Gijselinck I, Pirici D, Kumar-Singh S, Cruts M, Van Broeckhoven C (2007a) Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. Neurodegener Dis 4: 227&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">17596717</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M et al. (2007b) Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 28: 416.</Citation><ArticleIdList><ArticleId IdType="pubmed">17345602</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42: 7871&#x2013;7878</Citation><ArticleIdList><ArticleId IdType="pubmed">12834338</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812&#x2013;7819</Citation><ArticleIdList><ArticleId IdType="pubmed">11425308</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535&#x2013;539</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, Martins VR, Brentani RR (1999) Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia 40: 1679&#x2013;1682</Citation><ArticleIdList><ArticleId IdType="pubmed">10612329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, Lim KL (2005a) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14: 3885&#x2013;3897</Citation><ArticleIdList><ArticleId IdType="pubmed">16278233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Tan JM, Ho MW, Zaiden N, Wong SH, Chew CL, Eng PW, Lim TM, Dawson TM, Lim KL (2005b) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J Neurochem 93: 422&#x2013;431</Citation><ArticleIdList><ArticleId IdType="pubmed">15816865</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Song C, Li CC (2004) Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol 146: 44&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pubmed">15037236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang F, Arterburn L, Wollmann R, Ma J (2006) The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity. J Biol Chem 281: 13559&#x2013;13565</Citation><ArticleIdList><ArticleId IdType="pubmed">16537534</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36: 377&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Dalal S, Pestronk A, Hanson PI (2006) Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet 15: 189&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pubmed">16321991</ArticleId></ArticleIdList></Reference><Reference><Citation>Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, Zerr I, Bahr M (2006) Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke 37: 1296&#x2013;1300</Citation><ArticleIdList><ArticleId IdType="pubmed">16574930</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842&#x2013;16847</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283829</ArticleId><ArticleId IdType="pubmed">16269541</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 1772: 629&#x2013;644</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1986710</ArticleId><ArticleId IdType="pubmed">17451912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner RB (1994) (URE3) as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae (see comments). Science 264: 566&#x2013;569</Citation><ArticleIdList><ArticleId IdType="pubmed">7909170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118: 573&#x2013;584</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RL, Urbe S (2007) The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 8: 355&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">17450176</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer KF, Henn IH, Kay-Jackson P, Heller U, Tatzelt J (2003a) Inactivation of parkin by oxidative stress and C-terminal truncations; a protective role of molecular chaperones. J Biol Chem 278: 47199&#x2013;47208</Citation><ArticleIdList><ArticleId IdType="pubmed">12972428</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer KF, Heske J, Heller U, Reintjes A, Muranji W, Moarefi I, Tatzelt J (2003b) Determinants of the in vivo-folding of the prion protein: a bipartite function of helix 1 in folding and aggregation. J Biol Chem 278: 14961&#x2013;14970</Citation><ArticleIdList><ArticleId IdType="pubmed">12556465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 136&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796780</ArticleId><ArticleId IdType="pubmed">17268504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ES, Tan JM, Wang C, Zhang Z, Tay SP, Zaiden N, Ko HS, Dawson VL, Dawson TM, Lim KL (2007) Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J Biol Chem 282: 12310&#x2013;12318</Citation><ArticleIdList><ArticleId IdType="pubmed">17329252</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8: 600&#x2013;606</Citation><ArticleIdList><ArticleId IdType="pubmed">12042811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, Beal MF, Nishimura I, Wakamatsu K, Ito S, Takahashi R, Lu B (2005) Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102: 13670&#x2013;13675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224636</ArticleId><ArticleId IdType="pubmed">16155123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B (2006) Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103: 10793&#x2013;10798</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 101: 10810&#x2013;10814</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490016</ArticleId><ArticleId IdType="pubmed">15252205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J 20: 5383&#x2013;5391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125653</ArticleId><ArticleId IdType="pubmed">11574470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanocco-Marani T, Bateman A, Romano G, Valentinis B, He ZH, Baserga R (1999) Biological activities and signaling pathways of the granulin/epithelin precursor. Cancer Res 59: 5331&#x2013;5340</Citation><ArticleIdList><ArticleId IdType="pubmed">10537317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, Gambetti P, Singh N (1999) Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 274: 23396&#x2013;23404</Citation><ArticleIdList><ArticleId IdType="pubmed">10438517</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164&#x2013;173</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27: 10530&#x2013;10534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccato E, Buratti E, Stuani C, Baralle FE, Pagani F (2004) An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing. J Biol Chem 279: 16980&#x2013;16988</Citation><ArticleIdList><ArticleId IdType="pubmed">14966131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18230723</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The PINK1/Parkin pathway regulates mitochondrial morphology.</ArticleTitle><Pagination><StartPage>1638</StartPage><EndPage>1643</EndPage><MedlinePgn>1638-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0709336105</ELocationID><Abstract><AbstractText>Loss-of-function mutations in the PTEN-induced kinase 1 (PINK1) or parkin genes, which encode a mitochondrially localized serine/threonine kinase and a ubiquitin-protein ligase, respectively, result in recessive familial forms of Parkinsonism. Genetic studies in Drosophila indicate that PINK1 acts upstream of Parkin in a common pathway that influences mitochondrial integrity in a subset of tissues, including flight muscle and dopaminergic neurons. The mechanism by which PINK1 and Parkin influence mitochondrial integrity is currently unknown, although mutations in the PINK1 and parkin genes result in enlarged or swollen mitochondria, suggesting a possible regulatory role for the PINK1/Parkin pathway in mitochondrial morphology. To address this hypothesis, we examined the influence of genetic alterations affecting the machinery that governs mitochondrial morphology on the PINK1 and parkin mutant phenotypes. We report that heterozygous loss-of-function mutations of drp1, which encodes a key mitochondrial fission-promoting component, are largely lethal in a PINK1 or parkin mutant background. Conversely, the flight muscle degeneration and mitochondrial morphological alterations that result from mutations in PINK1 and parkin are strongly suppressed by increased drp1 gene dosage and by heterozygous loss-of-function mutations affecting the mitochondrial fusion-promoting factors OPA1 and Mfn2. Finally, we find that an eye phenotype associated with increased PINK1/Parkin pathway activity is suppressed by perturbations that reduce mitochondrial fission and enhanced by perturbations that reduce mitochondrial fusion. Our studies suggest that the PINK1/Parkin pathway promotes mitochondrial fission and that the loss of mitochondrial and tissue integrity in PINK1 and parkin mutants derives from reduced mitochondrial fission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Angela C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ruth E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Laurie A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Heidi M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Pallanck</LastName><ForeName>Leo J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5T32AG00057-28A</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-HD02774</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-4063</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS041780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000057</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS053762</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0713</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>1R21NS053762-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081987</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>1R01NS41780-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527117">Marf protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527116">OPA1 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C504426">DRP1 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.3.2.-</RegistryNumber><NameOfSubstance UI="C487430">park protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008933" MajorTopicYN="N">Mitochondrial Swelling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18230723</ArticleId><ArticleId IdType="pmc">PMC2234197</ArticleId><ArticleId IdType="doi">10.1073/pnas.0709336105</ArticleId><ArticleId IdType="pii">0709336105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherer TB, Betarbet R, Greenamyre JT. Neuroscientist. 2002;8:192&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove J, Prou D, Perier C, Przedborski S. NeuroRx. 2005;2:484&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1144492</ArticleId><ArticleId IdType="pubmed">16389312</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Cell Death Differ. 2007;14:1261&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17464321</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Sleiman PM, Muqit MM, Wood NW. Nat Rev Neurosci. 2006;7:207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495942</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A, Flint Beal M. J Neurochem. 2006;99:1062&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836655</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Soda M, Takahashi R. J Biol Chem. 2000;275:35661&#x2013;35664.</Citation><ArticleIdList><ArticleId IdType="pubmed">10973942</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Nat Genet. 2000;25:302&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Proc Natl Acad Sci USA. 2000;97:13354&#x2013;13359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27228</ArticleId><ArticleId IdType="pubmed">11078524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima A, Kataoka K, Hong M, Sakaguchi M, Huh NH. Cancer Lett. 2003;201:195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607334</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR. Proc Natl Acad Sci USA. 2005;102:5703&#x2013;5708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556294</ArticleId><ArticleId IdType="pubmed">15824318</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G. Hum Mol Genet. 2005;14:3477&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. Hum Mol Genet. 2006;15:3251&#x2013;3262.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000703</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, et al. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HQ, Takahashi R. Antioxid Redox Signal. 2007;9:553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">17465880</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J. Neuroscientist. 2006;12:469&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079513</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM. J Neural Transm Suppl. 2006:209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17017531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. Neuromol Med. 2003;3:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665672</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Min DS, Rhim H, Kim J, Paik SR, Chung KC. J Biol Chem. 2006;281:3595&#x2013;3603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16332688</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A. Nature. 2007;448:759&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">17700685</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Proc Natl Acad Sci USA. 2003;100:4078&#x2013;4083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153051</ArticleId><ArticleId IdType="pubmed">12642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G. Development. 2004;131:2183&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073152</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Nature. 2006;441:1162&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. Proc Natl Acad Sci USA. 2006;103:10793&#x2013;10798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Nature. 2006;441:1157&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan DC. Annu Rev Cell Dev Biol. 2006;22:79&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16704336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleazard W, McCaffery JM, King EJ, Bale S, Mozdy A, Tieu Q, Nunnari J, Shaw JM. Nat Cell Biol. 1999;1:298&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739991</ArticleId><ArticleId IdType="pubmed">10559943</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros F, Lombes A, Frachon P, Rojo M. Mol Biol Cell. 2002;13:4343&#x2013;4354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC138638</ArticleId><ArticleId IdType="pubmed">12475957</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Chan DC. Hum Mol Genet 14 Spec No. 2005;2:R283&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16244327</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL, Youle RJ. Dev Cell. 2001;1:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoppins S, Lackner L, Nunnari J. Annu Rev Biochem. 2007;76:751&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362197</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JC, Whitworth AJ, Andrews LA, Parker TJ, Pallanck LJ. Hum Mol Genet. 2005;14:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689351</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride HM, Neuspiel M, Wasiak S. Curr Biol. 2006;16:R551&#x2013;R560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16860735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, et al. J Biol Chem. 2005;280:42655&#x2013;42668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910375</ArticleId><ArticleId IdType="pubmed">16239214</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J. J Biol Chem. 2004;279:18614&#x2013;18622.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985362</ArticleId></ArticleIdList></Reference><Reference><Citation>Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H, Dalkara T, Ozer N. Mov Disord. 2004;19:544&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoepken HH, Gispert S, Morales B, Wingerter O, Del Turco D, Mulsch A, Nussbaum RL, Muller K, Drose S, Brandt U, et al. Neurobiol Dis. 2007;25:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">17141510</ArticleId></ArticleIdList></Reference><Reference><Citation>Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser T, et al. J Neurosci. 2007;27:12413&#x2013;12418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673250</ArticleId><ArticleId IdType="pubmed">17989306</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterham HR, Koster J, van Roermund CW, Mooyer PA, Wanders RJ, Leonard JV. N Engl J Med. 2007;356:1736&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460227</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. J Cell Biol. 2005;170:1067&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171517</ArticleId><ArticleId IdType="pubmed">16172208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Jeong SY, Lim WC, Kim S, Park YY, Sun X, Youle RJ, Cho H. J Biol Chem. 2007;282:22977&#x2013;22983.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545159</ArticleId></ArticleIdList></Reference><Reference><Citation>Benard G, Bellance N, James D, Parrone P, Fernandez H, Letellier T, Rossignol R. J Cell Sci. 2007;120:838&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, Rudka T, Bartoli D, Polishuck RS, Danial NN, De Strooper B, Scorrano L. Cell. 2006;126:177&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839885</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain M, Mathai JP, McBride HM, Shore GC. EMBO J. 2005;24:1546&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142564</ArticleId><ArticleId IdType="pubmed">15791210</ArticleId></ArticleIdList></Reference><Reference><Citation>Parone PA, James DI, Da Cruz S, Mattenberger Y, Donze O, Barja F, Martinou JC. Mol Cell Biol. 2006;26:7397&#x2013;7408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636857</ArticleId><ArticleId IdType="pubmed">17015472</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. J Biol Chem. 2007;282:11521&#x2013;11529.</Citation><ArticleIdList><ArticleId IdType="pubmed">17301055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CR, Blackstone C. J Biol Chem. 2007;282(30):21583&#x2013;21587.</Citation><ArticleIdList><ArticleId IdType="pubmed">17553808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM. J Cell Sci. 2007;120:1178&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasiak S, Zunino R, McBride HM. J Cell Biol. 2007;177:439&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064824</ArticleId><ArticleId IdType="pubmed">17470634</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder Z, Zunino R, McBride H. Curr Biol. 2004;14:340&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">14972687</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. EMBO Rep. 2006;7:1019&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618377</ArticleId><ArticleId IdType="pubmed">16936636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonashiro R, Ishido S, Kyo S, Fukuda T, Goto E, Matsuki Y, Ohmura-Hoshino M, Sada K, Hotta H, Yamamura H, et al. EMBO J. 2006;25:3618&#x2013;3626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538564</ArticleId><ArticleId IdType="pubmed">16874301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KL, Dawson VL, Dawson TM. Neurobiol Aging. 2006;27:524&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">16213628</ArticleId></ArticleIdList></Reference><Reference><Citation>Joch M, Ase AR, Chen CX, MacDonald PA, Kontogiannea M, Corera AT, Brice A, Seguela P, Fon EA. Mol Biol Cell. 2007;18:3105&#x2013;3118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949385</ArticleId><ArticleId IdType="pubmed">17553932</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ. Neuron. 2005;47:365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055061</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Neuron. 2003;37:911&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670421</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ. Proc Natl Acad Sci USA. 2005;102:8024&#x2013;8029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142368</ArticleId><ArticleId IdType="pubmed">15911761</ArticleId></ArticleIdList></Reference><Reference><Citation>Rikhy R, Kamat S, Ramagiri S, Sriram V, Krishnan KS. Genes Brain Behav. 2007;6:42&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17233640</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuibban GA, Lee JR, Zheng L, Juusola M, Freeman M. Curr Biol. 2006;16:982&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazelett DJ, Bourouis M, Walldorf U, Treisman JE. Development. 1998;125:3741&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pubmed">9716539</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman M. Cell. 1996;87:651&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">8929534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganayakulu G, Schulz RA, Olson EN. Dev Biol. 1996;176:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8654890</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18234899</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.</ArticleTitle><Pagination><StartPage>1213</StartPage><EndPage>1223</EndPage><MedlinePgn>1213-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5065-07.2008</ELocationID><Abstract><AbstractText>MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner. However, little is understood about the role(s) of miRNAs in Alzheimer's disease (AD). We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation. Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD. Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology. In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression. Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107. From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients. BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA. Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wang-Xia</ForeName><Initials>WX</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky 40536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajeev</LastName><ForeName>Bernard W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Stromberg</LastName><ForeName>Arnold J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Na</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Guiliang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Rigoutsos</LastName><ForeName>Isidore</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 RR016481</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AGO 28383</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS050110</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 RR16481</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18234899</ArticleId><ArticleId IdType="mid">NIHMS180027</ArticleId><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5065-07.2008</ArticleId><ArticleId IdType="pii">28/5/1213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ambros V. The functions of animal microRNAs. Nature. 2004;431:350&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372042</ArticleId></ArticleIdList></Reference><Reference><Citation>Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing microRNAs with microarrays: tissue specificity and functional inference. RNA. 2004;10:1813&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370668</ArticleId><ArticleId IdType="pubmed">15496526</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 2005;11:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370713</ArticleId><ArticleId IdType="pubmed">15701730</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D, Graham SL. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin Investig Drugs. 2005;14:1385&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">16255678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigl M, Apelt J, Luschekina EA, Lange-Dohna C, Rossner S, Schliebs R. Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. Neurosci Lett. 2000;292:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell. 2006a;24:157&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006b;5:2835&#x2013;2838.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334:1351&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">16039986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased rna oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res. 2006;31:705&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">16770743</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez DI, Hartmann D, De Strooper B. BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. Neurodegener Dis. 2004;1:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908986</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham TB, Shepherd TA. Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel. 2006;9:776&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117686</ArticleId></ArticleIdList></Reference><Reference><Citation>Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, Dean NM, Freier SM, Bennett CF, Lollo B, Griffey R. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279:52361&#x2013;52365.</Citation><ArticleIdList><ArticleId IdType="pubmed">15504739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67:2456&#x2013;2468.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Crino PB, Lee VM, Eberwine JH, Trojanowski JQ. Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol. 1997;41:200&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029069</ArticleId></ArticleIdList></Reference><Reference><Citation>Goff LA, Yang M, Bowers J, Getts RC, Padgett RW, Hart RP. Rational probe optimization and enhanced detection strategy for microRNAs using microarrays. RNA Biol. 2005;2:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114923</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol. 2006;342:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16957372</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800283</ArticleId><ArticleId IdType="pubmed">17612493</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Hobbs DW. Development of BACE1 inhibitors for Alzheimer's disease. Curr Med Chem. 2006;13:1811&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pubmed">16787223</ArticleId></ArticleIdList></Reference><Reference><Citation>Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, Katta V, Rogers G, Vassar R, Citron M. Characterization of Alzheimer's beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem. 2000;275:21099&#x2013;21106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science. 2007;317:1179&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761871</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem. 2005;280:20978&#x2013;20986.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs. 2006;66:2075&#x2013;2093.</Citation><ArticleIdList><ArticleId IdType="pubmed">17112302</ArticleId></ArticleIdList></Reference><Reference><Citation>John V. Human beta-secretase (BACE) and BACE inhibitors: progress report. Curr Top Med Chem. 2006;6:569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. A microRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317:1220&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782470</ArticleId><ArticleId IdType="pubmed">17761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004;18:1165&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC415641</ArticleId><ArticleId IdType="pubmed">15131085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Nelson P, Lamprinaki S, Sharma A, Mourelatos Z. Detection of microRNAs and assays to monitor microRNA activities in vivo and in vitro. Methods Mol Biol. 2005;309:295&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15990409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Tan GS, Lamprinakin S, De Plannell-Saguer M, Nelson PT, Mourelatos Z. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell. 2007;129:1141&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17524464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Krichevsky AM. The elegance of the microRNAs: a neuronal perspective. Neuron. 2005;47:779&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157272</ArticleId></ArticleIdList></Reference><Reference><Citation>Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15806104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. A microRNA signature of hypoxia. Mol Cell Biol. 2007;27:1859&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820461</ArticleId><ArticleId IdType="pubmed">17194750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Maloney B, Ge YW. BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation. J Mol Neurosci. 2006;28:193&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16679558</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi R, Zhang YM, Rock CO, Jackowski S. Coenzyme A: back in action. Prog Lipid Res. 2005;44:125&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129:147&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">17382377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou W, Tong Y, He G, Song W. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J. 2006;20:285&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. NeuroReport. 2007;18:297&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17314675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem. 2007;101:1265&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2080079</ArticleId><ArticleId IdType="pubmed">17629564</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Chevallier N, Ancolio K, Checler F. Post-transcriptional contribution of a cAMP-dependent pathway to the formation of alpha- and beta/gamma-secretases-derived products of beta APP maturation in human cells expressing wild-type and Swedish mutated beta APP. Mol Med. 1998;4:715&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230337</ArticleId><ArticleId IdType="pubmed">9932109</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 2006;66:10843&#x2013;10848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17108120</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihailovich M, Thermann R, Grohovaz F, Hentze MW, Zacchetti D. Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5&#x2032; untranslated region. Nucleic Acids Res. 2007;35:2975&#x2013;2985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888809</ArticleId><ArticleId IdType="pubmed">17439957</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126:1203&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990141</ArticleId></ArticleIdList></Reference><Reference><Citation>Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine-Paton M, Horvitz HR. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5:R68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522875</ArticleId><ArticleId IdType="pubmed">15345052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16:720&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155365</ArticleId><ArticleId IdType="pubmed">11914277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z. The microRNA world: small is mighty. Trends Biochem Sci. 2003;28:534&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Keller JN. RNA in brain disease: no longer just &#x201c;the messenger in the middle.&#x201d;. J Neuropathol Exp Neurol. 2007;66:461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">17549006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Hatzigeorgiou AG, Mourelatos Z. miRNP:mRNA association in polyribosomes in a human neuronal cell line. RNA. 2004;10:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370934</ArticleId><ArticleId IdType="pubmed">14970384</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RH, Mourelatos Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2006;12:187&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370897</ArticleId><ArticleId IdType="pubmed">16373485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu HL, Davis DG, Mendiondo MS, Abner E, Markesbery WR. Clinicopathological correlations in a large Alzheimer's disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M. Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. Rev Neurosci. 2006;17:429&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">17139843</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J, Hammond SM. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007;8:R27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852419</ArticleId><ArticleId IdType="pubmed">17326821</ArticleId></ArticleIdList></Reference><Reference><Citation>Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, Mudge AW, Jazin E, Cairns NJ. Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res Mol Brain Res. 2003;116:155&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941471</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677&#x2013;4684.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression&#x2014;implications for Alzheimer's disease. Prog Neurobiol. 2006;79:95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904810</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Habeck CG, Hilton J, Anderson KE, Flynn J, Park A, Stern Y. APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry. 2005;76:1440&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739360</ArticleId><ArticleId IdType="pubmed">16170092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. &#x201c;Preclinical&#x201d; AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55:370&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006;17:189&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679635</ArticleId><ArticleId IdType="pubmed">16518686</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SK. miRNAs: from neurogeneration to neurodegeneration. Pharmacogenomics. 2007;8:971&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716230</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans. 2007;35:574&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17511655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahiliani AG, Beinlich CJ. Pantothenic acid in health and disease. Vitam Horm. 1991;46:165&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">1746161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Gal J, Zhuang X, Wang W, Zhu H, Tang G. A simple array platform for microRNA analysis and its application in mouse tissues. RNA. 2007;13:1803&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1986807</ArticleId><ArticleId IdType="pubmed">17675362</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW, Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103:18255&#x2013;18260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838739</ArticleId><ArticleId IdType="pubmed">17108080</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang X. Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res. 2006;34:1646&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405822</ArticleId><ArticleId IdType="pubmed">16549876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilfred BR, Wang WX, Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab. 2007;91:209&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978064</ArticleId><ArticleId IdType="pubmed">17521938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying SY, Lin SL. Intronic microRNAs. Biochem Biophys Res Commun. 2005;326:515&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying SY, Lin SL. Current perspectives in intronic micro RNAs (miRNAs) J Biomed Sci. 2006;13:5&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16228283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying SY, Chang DC, Miller JD, Lin SL. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol. 2006;342:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16957363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18238903</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation.</ArticleTitle><Pagination><StartPage>2181</StartPage><EndPage>2186</EndPage><MedlinePgn>2181-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0706818105</ELocationID><Abstract><AbstractText>The neural underpinnings of age-related memory impairment remain to be fully elucidated. Using a subsequent memory face-name functional MRI (fMRI) paradigm, young and old adults showed a similar magnitude and extent of hippocampal activation during successful associative encoding. Young adults demonstrated greater deactivation (task-induced decrease in BOLD signal) in medial parietal regions during successful compared with failed encoding, whereas old adults as a group did not demonstrate a differential pattern of deactivation between trial types. The failure of deactivation was particularly evident in old adults who performed poorly on the memory task. These low-performing old adults demonstrated greater hippocampal and prefrontal activation to achieve successful encoding trials, possibly as a compensatory response. Findings suggest that successful encoding requires the coordination of neural activity in hippocampal, prefrontal, and parietal regions, and that age-related memory impairment may be primarily related to a loss of deactivation in medial parietal regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Saul L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celone</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>DePeau</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Eli</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pihlajam&#xe4;ki</LastName><ForeName>Maija</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18238903</ArticleId><ArticleId IdType="pmc">PMC2538895</ArticleId><ArticleId IdType="doi">10.1073/pnas.0706818105</ArticleId><ArticleId IdType="pii">0706818105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kirchhoff BA, Wagner AD, Maril A, Stern CE. J Neurosci. 2000;20:6173&#x2013;6180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772579</ArticleId><ArticleId IdType="pubmed">10934267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, Albert M. NeuroImage. 2003;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230827</ArticleId><ArticleId IdType="pubmed">14568509</ArticleId></ArticleIdList></Reference><Reference><Citation>Uncapher MR, Otten LJ, Rugg MD. Neuron. 2006;52:547&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1687210</ArticleId><ArticleId IdType="pubmed">17088219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Schacter DL, Rotte M, Koutstaal W, Maril A, Dale AM, Rosen BR, Buckner RL. Science. 1998;281:1188&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712582</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Veltman DJ, Rombouts SA, Lazeron RH, Raaijmakers JG, Jonker C. Brain. 2003;126:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12477696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutchess AH, Welsh RC, Hedden T, Bangert A, Minear M, Liu LL, Park DC. J Cognit Neurosci. 2005;17:84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701241</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcom AM, Good CD, Frackowiak RS, Rugg MD. Brain. 2003;126:213&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12477708</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand-Giovannetti E, Chua EF, Driscoll AE, Schacter DL, Albert MS, Sperling RA. Neurobiol Aging. 2006;27:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298252</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Prince SE, Cabeza R. NeuroImage. 2004;23:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Proc Natl Acad Sci USA. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BD, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe D, Blacker D, et al. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Proc Natl Acad Sci USA. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson J, Lustig C, Nelson JK, Reuter-Lorenz PA. J Cognit Neurosci. 2007;19:1021&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536972</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Fleck MS, Dobbins IG, Madden DJ, Cabeza R. Cereb Cortex. 2006;16:1771&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1810232</ArticleId><ArticleId IdType="pubmed">16421332</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Spring MV, Hongwanishkul D, McIntosh AR, Winocur G. J Cognit Neurosci. 2006;18:227&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16494683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, Anderson ND, Locantore JK, McIntosh AR. NeuroImage. 2002;17:1394&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, Daselaar SM, Dolcos F, Prince SE, Budde M, Nyberg L. Cereb Cortex. 2004;14:364&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15028641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis NA, Daselaar SM, Cabeza R. Neurobiol Aging. 2006;28:1749&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691865</ArticleId><ArticleId IdType="pubmed">16919850</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SW, Dennis NA, Daselaar SM, Fleck MS, Cabeza R. Cereb Cortex. 2007 Oct 8; (epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760260</ArticleId><ArticleId IdType="pubmed">17925295</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson J, Nyberg L, Lind J, Larsson A, Nilsson LG, Ingvar M, Buckner RL. Cereb Cortex. 2006;16:907&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">16162855</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat D, Greve D, Chua E, Rand-Giovannetti E, Rentz D, Bertram L, Mullin K, Tanzi R, Blacker D, et al. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan JM, Sanders AL, Snyder AZ, Morris JC, Buckner RL. Neuron. 2002;33:827&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Bates J, Chua E, Cocchiarella A, Schacter DL, Rosen B, Albert M. J Neurol Neurosurg Psychiatry. 2003;74:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738201</ArticleId><ArticleId IdType="pubmed">12486265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. Proc Natl Acad Sci USA. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelinski EM, Gilewski MJ. Psychopharmacol Bull. 1988;24:523&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">3074313</ArticleId></ArticleIdList></Reference><Reference><Citation>Handwerker DA, Gazzaley A, Inglis BA, D'Esposito M. Hum Brain Mapp. 2007;28:846&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871393</ArticleId><ArticleId IdType="pubmed">17094119</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson O, III, Shacter DL. NeuroImage. 2004;1:456&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeineh MM, Engel SA, Thompson PM, Bookheimer SY. Science. 2003;299:577&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543980</ArticleId></ArticleIdList></Reference><Reference><Citation>Otten LJ, Rugg MD. Curr Biol. 2001;11:1528&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Nat Rev Neurosci. 2001;2:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazoyer B, Zago L, Mellet E, Bricogne S, Etard O, Houde O, Crivello F, Joliot M, Petit L, Tzourio-Mazoyer N. Brain Res Bull. 2001;54:287&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Raichle ME, Petersen SE. J Cognit Neurosci. 1997;9:648&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanna AE, Trimble MR. Brain. 2006;129:564&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399806</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Gazes E, Hilton HJ, Stern Y. J Cognit Neurosci. in press.</Citation></Reference><Reference><Citation>Wheeler ME, Buckner RL. NeuroImage. 2004;21:1337&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050559</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua EF, Schacter DL, Rand-Giovannetti E, Sperling RA. NeuroImage. 2006;29:1150&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303318</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Wilder LS, Pipe JG, Heiserman JE, Prigatano GP. Brain. 2002;125:1808&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135971</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Menon V. J Cognit Neurosci. 2004;16:1481&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">15601513</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, et al. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. Neurology. 2005;65:1514&#x2013;1515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. N Engl J Med. 2000;17:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori CR, Buchmann A, Mustovic H, Schmidt CF, Boesiger P, Nitsch RM, Hock C, Streffer J, Henke K. Brain. 2006;129:2908&#x2013;29022.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18250315</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Lithium delays progression of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2052</StartPage><EndPage>2057</EndPage><MedlinePgn>2052-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0708022105</ELocationID><Abstract><AbstractText>ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time. In a parallel study on a genetic ALS animal model, the G93A mouse, we found a marked neuroprotection by lithium, which delayed disease onset and duration and augmented the life span. These effects were concomitant with activation of autophagy and an increase in the number of the mitochondria in motor neurons and suppressed reactive astrogliosis. Again, lithium reduced the slow necrosis characterized by mitochondrial vacuolization and increased the number of neurons counted in lamina VII that were severely affected in saline-treated G93A mice. After lithium administration in G93A mice, the number of these neurons was higher even when compared with saline-treated WT. All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fornai</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Human Morphology and Applied Biology, University of Pisa 56100 Pisa, Italy. f.fornai@med.unipi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longone</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cafaro</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kastsiuchenka</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Lazzeri</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Spalloni</LastName><ForeName>Alida</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bellio</LastName><ForeName>Natascia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Modugno</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Isidoro</LastName><ForeName>Ciro</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ruggieri</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Paparelli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16404-7</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):E17; author reply E18. doi: 10.1073/pnas.0801762105.</RefSource><PMID Version="1">18417448</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):E35; author reply E36. doi: 10.1073/pnas.0801837105.</RefSource><PMID Version="1">18550833</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18250315</ArticleId><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="doi">10.1073/pnas.0708022105</ArticleId><ArticleId IdType="pii">0708022105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Annu Rev Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. Neuron. 1995;14:1105&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boill&#xe9;e S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Nencini M, Casciati A, Cozzolino M, Angelini DF, Longone P, Spalloni A, Rotilio G, Carr&#xec; MT. FASEB J. 2004;11:1261&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">15208263</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Nat Neurosci. 2007;5:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Nat Neurosci. 2007;5:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, Golden WC. J Comp Neurol. 2007;500:20&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099894</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BM, Gordon JW, Ripps ME, Morrison JH. J Comp Neurol. 1996;373:619&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">8889947</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Logigian EL. Electromyogr Clin Neurophysiol. 1998;38:505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842486</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, Kanai H, Hough C, Hiroi T, Leeds P. Bipolar Disord. 2002;4:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryves JW, Dalton EC, Harwood AJ, Williams RS. Bipolar Disord. 2005;7:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1249491</ArticleId><ArticleId IdType="pubmed">15898963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio I, Calderone A, Busceti CL, Biagioni F, Pontarelli F, Bruno V, Storto M, Terstappen GT, Gaviraghi G, Fornai F, et al. J Neurosci. 2005;25:2647&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725177</ArticleId><ArticleId IdType="pubmed">15758175</ArticleId></ArticleIdList></Reference><Reference><Citation>Busceti CL, Biagioni F, Aronica E, Riozzi B, Storto M, Battaglia G, Giorgi FS, Gradini R, Fornai F, Caricasole A. Epilepsia. 2007;48:694&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">17437412</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ, Irvine RF. Nature. 1989;341:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">2550825</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ, Downes CP, Hanley MR. Cell. 1989;59:411&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. J Cell Biol. 2005;170:1101&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171537</ArticleId><ArticleId IdType="pubmed">16186256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, et al. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, et al. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Science. 2004;305:1292&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Ravikumar B, Acevedo-Arozena A, Imarisio S, O'Kane CJ, Brown SD. Autophagy. 2005;1:177&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimchinsky EA, Young WG, Yeung G, Shah RA, Gordon JW, Bloom FE, Morrison JH, Hof PR. J Comp Neurol. 2000;416:112&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">10578106</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenggeli C, Kato AC. Neurosci Lett. 2002;335:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12457737</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RC, Wilson VJ. Nature. 1965;206:211&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">4157758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Chang MY, Yu IT, Kim JH, Lee SH, Lee YS, Son H. J Neurochem. 2004;89:324&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Ke Y, Luo C, Li B, Gozal D, Kalyanaraman B, Liu R. Stem Cells. 2006;24:34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828038</ArticleId><ArticleId IdType="pubmed">16099995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, et al. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Nat Med. 1998;4:755&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662355</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. Neurobiol Dis. 2001;8:933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Struewing IT, Barnett CD, Tang T, Mao CD. FEBS J. 2007;274:2749&#x2013;2765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17451429</ArticleId></ArticleIdList></Reference><Reference><Citation>Munafo DB, Colombo MI. J Cell Sci. 2001;114:3619&#x2013;3629.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. EMBO J. 2000;19:5720&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyvik H, Gordon PB, Berg TO, Stramhaug PE, Seglen PO. J Cell Biol. 1991;113:1305&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289037</ArticleId><ArticleId IdType="pubmed">1904444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Trends Neurosci. 2006;29:528&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859759</ArticleId></ArticleIdList></Reference><Reference><Citation>Seglen PO, Gordon PB. Proc Natl Acad Sci USA. 1982;79:1889&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346086</ArticleId><ArticleId IdType="pubmed">6952238</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Albo F, Ferrari F, Mercuri N, Bernardi G, Zona C, Longone P. Neurobiol Dis. 2004;15:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006704</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, et al. Science. 2003;300:808&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O'Kane CJ, Brown SD, Rubinsztein DC. Nat Genet. 2005;37:771&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980862</ArticleId></ArticleIdList></Reference><Reference><Citation>La Monte BH, Wallace KE, Holloway BA, Shelly SS, Asca&#xf1;o J, Tokito M, Van Winkle T, Howland DS, Holzbaur EL. Neuron. 2002;34:715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, et al. Nat Genet. 2001;29:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabuta T, Suzuki Y, Wada K. J Biol Chem. 2006;281:30524&#x2013;30533.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920710</ArticleId></ArticleIdList></Reference><Reference><Citation>Criollo A, Maiuri MC, Tasdemir E, Vitale I, Fiebig AA, Andrews D, Molg&#xf3; J, D&#xed;az J, Lavandero S, Harper F, et al. Cell Death Differ. 2007;14:1029&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">17256008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC. Nature. 2006;443:780&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051204</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic; 2004.</Citation></Reference><Reference><Citation>Lin L, Georgievska B, Mattsson A, Isacson O. Proc Natl Acad Sci USA. 1999;96:12108&#x2013;12113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18420</ArticleId><ArticleId IdType="pubmed">10518584</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL World Federation of Neurology Research Group on Motor Neuron Diseases. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Cochrane Database Syst Rev 24. 2007;1:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17253460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. J Neurol Sci. 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash ML. J Neurol. 2002;249:178&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">11985383</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Cho S, Lim H, Lee J, Lee Y, Noh J, Joo I, Kim K, Gwag B. Mol Pharmacol. 2007;71:965&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">17105868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18256261</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging.</ArticleTitle><Pagination><StartPage>1410</StartPage><EndPage>1420</EndPage><MedlinePgn>1410-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4098-07.2008</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions of elderly individuals worldwide. Advances in the genetics of AD have led to new levels of understanding and treatment opportunities. Here, we used a systems biology approach based on weighted gene coexpression network analysis to determine transcriptional networks in AD. This method permits a higher order depiction of gene expression relationships and identifies modules of coexpressed genes that are functionally related, rather than producing massive gene lists. Using this framework, we characterized the transcriptional network in AD, identifying 12 distinct modules related to synaptic and metabolic processes, immune response, and white matter, nine of which were related to disease progression. We further examined the association of gene expression changes with progression of AD and normal aging, and were able to compare functional modules of genes defined in both conditions. Two biologically relevant modules were conserved between AD and aging, one related to mitochondrial processes such as energy metabolism, and the other related to synaptic plasticity. We also identified several genes that were central, or hub, genes in both aging and AD, including the highly abundant signaling molecule 14.3.3 zeta (YWHAZ), whose role in AD and aging is uncharacterized. Finally, we found that presenilin 1 (PSEN1) is highly coexpressed with canonical myelin proteins, suggesting a role for PSEN1 in aspects of glial-neuronal interactions related to neurodegenerative processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Neurobehavioral Genetics, University of California, Los Angeles, Los Angeles, California 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldham</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH073526</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG26938</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026938</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32MH073526-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG031649</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049490" MajorTopicYN="N">Systems Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18256261</ArticleId><ArticleId IdType="mid">NIHMS175627</ArticleId><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4098-07.2008</ArticleId><ArticleId IdType="pii">28/6/1410</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol. 2006;16:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678438</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. Neurobiol Aging. 2000;21:783&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124422</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Neurodegeneration and plasticity. Int J Dev Neurosci. 2004;22:507&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465280</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi P, Long A. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001;17:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">11395427</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi A, Oltvai Z. Network biology: understanding the cell's functional organization. Nat Rev Genet. 2004;5:101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging. 2004;25:5&#x2013;18. author reply 49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675724</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal M. Mitochondria take left stage in aging and neurodegeneration. Ann Neurol. 2005;58:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16178023</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E, Geddes J, Chen K, Porter N, Markesbery W, Landfield P. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Blass J, Gibson G, Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis. 2002;4:225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226541</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D, Thinakaran G, Eckman C, Lee M, Davenport F, Ratovitsky T, Prada C, Kim G, Seekins S, Yager D, Slunt H, Wang R, Seeger M, Levey A, Gandy S, Copeland N, Jenkins N, Price D, Younkin S, Sisodia S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol (Berl) 1996;92:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8841666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Leem J, Greenfield J, Wang P, Kim B, Wang R, Lopes K, Kim S, Zheng H, Greengard P, Sisodia S, Thinakaran G, Xu H. Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int. 2007;50:12&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973241</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Sharp B. Content-rich biological network constructed by mining PubMed abstracts. BMC Bioinformatics. 2004;5:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528731</ArticleId><ArticleId IdType="pubmed">15473905</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe S, Boutros M, Michelson A, Church G, Halfon M. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 2005;6:R16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551536</ArticleId><ArticleId IdType="pubmed">15693945</ArticleId></ArticleIdList></Reference><Reference><Citation>Colangelo V, Schurr J, Ball M, Pelaez R, Bazan N, Lukiw W. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002;70:462&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz J, Tsai L. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2004;10:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350898</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz J, Tseng H, Goldman J, Shih H, Tsai L. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz J, Kim D, Moy L, Dobbin M, Sun X, Bronson R, Tsai L. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman D. Aging of the brain, entropy, and Alzheimer disease. Neurology. 2006;67:1340&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060558</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson L, Saetre P, Jazin E. Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol Dis. 2006;21:618&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257224</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch C, Cohen D. Aging, metabolism, and Alzheimer disease: review and hypotheses. Exp Neurol. 1997;143:82&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000448</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind D. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron. 2003;40:457&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642270</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann F, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl D, Morrison J, Gold G, Hof P. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel PS. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA. 2006;103:17402&#x2013;17407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635024</ArticleId><ArticleId IdType="pubmed">17090670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosack D, Dennis G, Sherman B, Lane H, Lempicki R. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC328459</ArticleId><ArticleId IdType="pubmed">14519205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Mellor J, Wu J, DeLisi C. VisANT: an online visualization and analysis tool for biological interaction data. BMC Bioinformatics. 2004;5:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368431</ArticleId><ArticleId IdType="pubmed">15028117</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W, Irizarry R, Gentleman R, Carey VJ, Dudoit S. New York: Springer; 2005. Bioinformatics and computational biology solutions using R and bioconductor (statistics for biology and health)</Citation></Reference><Reference><Citation>Jeong H, Mason S, Barabasi A, Oltvai Z. Lethality and centrality in protein networks. Nature. 2001;411:41&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333967</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten S, Sang T, Gehman L, Chatterjee S, Liu J, Lawless G, Sengupta S, Berry R, Pomakian J, Oh H, Schulz C, Hui K, Wiedau-Pazos M, Vinters H, Binder L, Geschwind D, Jackson G. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron. 2006;51:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950154</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller J. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev. 2006;5:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">16084778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo W, Jenssen T, Butte A, Ohno-Machado L, Kohane I. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics. 2002;18:405&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">11934739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Hsu A, Sajdak J, Qin J, Pavlidis P. Coexpression analysis of human genes across many microarray data sets. Genome Res. 2004;14:1085&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419787</ArticleId><ArticleId IdType="pubmed">15173114</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, Horvath S. Network neighborhood analysis with the multi-node topological overlap measure. Bioinformatics. 2007;23:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M, Beal F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart D, Dong H, Byrne M, Follettie M, Gallo M, Chee M, Mittmann M, Wang C, Kobayashi M, Horton H, Brown E. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pubmed">9634850</ArticleId></ArticleIdList></Reference><Reference><Citation>Loring J, Wen X, Lee J, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 2001;20:683&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao S-Y, Li C, Kohane I, Chan J, Yankner B. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 1999;24:521&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci. 2004;7:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mischel P, Cloughesy T, Nelson S. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004;5:782&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton P, Martin L, Calhoun M, Dal Forno G, Price D. Cognitive decline strongly correlates with cortical atrophy in Alzheimer's dementia. Neurobiol Aging. 1998;19:371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj E, Jones P, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood C, Petersen R, Smith M. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487050</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham M, Horvath S, Geschwind D. Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proc Natl Acad Sci USA. 2006;103:17973&#x2013;17978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693857</ArticleId><ArticleId IdType="pubmed">17101986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak K, Chan S, Mattson M. Presenilin-1 mutation sensitizes oligo-dendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice. Neuromolecular Med. 2003;3:53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira A, Wu W, Small S. Imaging-guided microarray: isolating molecular profiles that dissociate Alzheimer's disease from normal aging. Ann NY Acad Sci. 2007;1097:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413025</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J, Morris J. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravasz E, Somera A, Mongru D, Oltvai Z, Barabasi A. Hierarchical organization of modularity in metabolic networks. Science. 2002;297:1551&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202830</ArticleId></ArticleIdList></Reference><Reference><Citation>Schena M, Shalon D, Davis R, Brown P. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569999</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim T-W. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Carney J, Starke-Reed P, Oliver C, Stadtman E, Floyd R, Markesbery W. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA. 1991;88:10540&#x2013;10543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52964</ArticleId><ArticleId IdType="pubmed">1683703</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter M, Crook J, Hyde T, Kleinman J, Weinberger D, Becker K, Freed W. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res. 2002;58:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12363385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernadakis A. The aging brain. Clin Geriatr Med. 1985;1:61&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">3006903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo B, Fountoulakis M, Cairns N, Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis. 2001;22:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">11197169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4 Article 17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005;33:W741&#x2013;W748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160236</ArticleId><ArticleId IdType="pubmed">15980575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18256671</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>451</Volume><Issue>7179</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>720</StartPage><EndPage>724</EndPage><MedlinePgn>720-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature06616</ELocationID><Abstract><AbstractText>Senile plaques accumulate over the course of decades in the brains of patients with Alzheimer's disease. A fundamental tenet of the amyloid hypothesis of Alzheimer's disease is that the deposition of amyloid-beta precedes and induces the neuronal abnormalities that underlie dementia. This idea has been challenged, however, by the suggestion that alterations in axonal trafficking and morphological abnormalities precede and lead to senile plaques. The role of microglia in accelerating or retarding these processes has been uncertain. To investigate the temporal relation between plaque formation and the changes in local neuritic architecture, we used longitudinal in vivo multiphoton microscopy to sequentially image young APPswe/PS1d9xYFP (B6C3-YFP) transgenic mice. Here we show that plaques form extraordinarily quickly, over 24 h. Within 1-2 days of a new plaque's appearance, microglia are activated and recruited to the site. Progressive neuritic changes ensue, leading to increasingly dysmorphic neurites over the next days to weeks. These data establish plaques as a critical mediator of neuritic pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Prada</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Alloza</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>de Calignon</LastName><ForeName>Alix</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rozkalne</LastName><ForeName>Anete</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Koenigsknecht-Talboo</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2008 Feb 7;451(7179):638-9. doi: 10.1038/451638a.</RefSource><PMID Version="1">18256653</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18256671</ArticleId><ArticleId IdType="mid">NIHMS347731</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pii">nature06616</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer&#x2019;s disease. Am. J. Pathol. 1990;137:1435&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877722</ArticleId><ArticleId IdType="pubmed">2260630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer&#x2019;s disease are centered on vessel walls. Am. J. Pathol. 2005;167:527&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603563</ArticleId><ArticleId IdType="pubmed">16049337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome) Proc. Natl Acad. Sci. USA. 1995;92:3586&#x2013;3590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42212</ArticleId><ArticleId IdType="pubmed">7724603</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Karlo JC, Kao SC, Landreth GE. &#x3b2;-Amyloid stimulation of microglia and monocytes results in TNF&#x3b1;-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 2001;21:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762255</ArticleId><ArticleId IdType="pubmed">11160388</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, et al. System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-&#x3b2; peptide 1&#x2013;40. J. Neurosci. 2006;26:3345&#x2013;3356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674113</ArticleId><ArticleId IdType="pubmed">16554485</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC. Contribution of glial cells to the development of amyloid plaques in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2004;25:663&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172746</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, et al. Imaging of amyloid-&#x3b2; deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 2001;7:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231639</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, et al. Aging renders the brain vulnerable to amyloid &#x3b2;-protein neurotoxicity. Nature Med. 1998;4:827&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662375</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 1999;96:5274&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Le R, et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 2001;60:753&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x2018;one-dimensional crystallization&#x2019;of amyloid: a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid-&#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging A&#x3b2; plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18272688</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice.</ArticleTitle><Pagination><StartPage>1682</StartPage><EndPage>1687</EndPage><MedlinePgn>1682-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5242-07.2008</ELocationID><Abstract><AbstractText>Elevated tau expression has been proposed as a possible basis for impaired axonal transport in Alzheimer's disease. To address this hypothesis, we analyzed the movement of pulse radiolabeled proteins in vivo along retinal ganglion cell (RGC) axons of mice that lack tau or overexpress human tau isoforms. Here, we show that the global axonal transport rates of slow and fast transport cargoes in axons are not significantly impaired when tau expression is eliminated or increased. In addition, markers of slow transport (neurofilament light subunit) and fast transport (snap25) do not accumulate in retinas and are distributed normally along optic axons in mice that lack or overexpress tau. Finally, ultrastructural analyses revealed no abnormal accumulations of vesicular organelles or neurofilaments in RGC perikarya or axons in mice overexpressing or lacking tau. These results suggest that tau is not essential for axonal transport and that transport rates in vivo are not significantly affected by substantial fluctuations in tau expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Aidong</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York 10962, USA. yuan@nki.rfmh.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Asok</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Peterhoff</LastName><ForeName>Corrinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01AG005604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050825">Synaptosomal-Associated Protein 25</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009900" MajorTopicYN="N">Optic Nerve</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050825" MajorTopicYN="N">Synaptosomal-Associated Protein 25</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18272688</ArticleId><ArticleId IdType="mid">NIHMS169155</ArticleId><ArticleId IdType="pmc">PMC2814454</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5242-07.2008</ArticleId><ArticleId IdType="pii">28/7/1682</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994;369:488&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">8202139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess DT, Slater TM, Wilson MC, Skene JH. The 25 kDa synaptosomal-associated protein SNAP-25 is the major methionine-rich polypeptide in rapid axonal transport and a major substrate for palmitoylation in adult CNS. J Neurosci. 1992;12:4634&#x2013;4641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575770</ArticleId><ArticleId IdType="pubmed">1281490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Takemura R. Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci. 2005;6:201&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">15711600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem. 1992;59:750&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">1629745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2:1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, Binder LI, Yen SH. Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. J Biol Chem. 1988;263:7948&#x2013;7953.</Citation><ArticleIdList><ArticleId IdType="pubmed">3131334</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Hoffman PN, Stirling W, Price DL, Lee MK. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J Neurochem. 2004;88:401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Fischer I, Kosik KS, Nixon RA. Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo. J Neurosci. 1995;15:8259&#x2013;8267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577949</ArticleId><ArticleId IdType="pubmed">8613759</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST. Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J Neurosci Res. 2007;85:2620&#x2013;2630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17265463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Paskevich PA, Sihag RK, Thayer CY. Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber. J Cell Biol. 1994;126:1031&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120120</ArticleId><ArticleId IdType="pubmed">7519617</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama F, Kotliarova S, Harada A, Ito M, Miyazaki H, Ueyama Y, Hirokawa N, Nukina N, Ihara Y. Gem GTPase and tau: morphological changes induced by gem GTPase in cho cells are antagonized by tau. J Biol Chem. 2004;279:27272&#x2013;27277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087445</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002;156:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Lees AJ, Miller CC, Anderton BH. The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J Neurosci. 2002;22:6394&#x2013;6400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758152</ArticleId><ArticleId IdType="pubmed">12151518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A. Neurofilament protein partnership, export, transport, phosphorylation and neurodegeneration. In: Arlen R, editor. New research on neurofilament proteins. New York: Nova Science; 2006. pp. 53&#x2013;79.</Citation></Reference><Reference><Citation>Yuan A, Rao MV, Kumar A, Julien JP, Nixon RA. Neurofilament transport in vivo minimally requires hetero-oligomer formation. J Neurosci. 2003;23:9452&#x2013;9458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740570</ArticleId><ArticleId IdType="pubmed">14561875</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Sasaki T, Chen Y, Kumar A, Veeranna, Liem RK, Eyer J, Peterson AC, Julien JP, Nixon RA. &#x3b1;-Internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J Neurosci. 2006;26:10006&#x2013;10019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674481</ArticleId><ArticleId IdType="pubmed">17005864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA. 2005;102:227&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544048</ArticleId><ArticleId IdType="pubmed">15615853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VM, Bruce J, Shuck T, Grossman M, Clark CM, Arnold SE, Masliah E, Galasko D, Trojanowski JQ, Lee VM. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol. 2001;49:165&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18278038</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>294</EndPage><MedlinePgn>283-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb1690</ELocationID><Abstract><AbstractText>The release of amyloid precursor protein (APP) intracellular domain (AICD) may be triggered by extracellular cues through gamma-secretase-dependent cleavage. AICD binds to Fe65, which may have a role in AICD-dependent signalling; however, the functional ligand has not been characterized. In this study, we have identified TAG1 as a functional ligand of APP. We found that, through an extracellular interaction with APP, TAG1 increased AICD release and triggered Fe65-dependent activity in a gamma-secretase-dependent manner. TAG1, APP and Fe65 colocalized in the neural stem cell niche of the fetal ventricular zone. Neural precursor cells from TAG1-/-, APP-/- and TAG1-/-;APP-/- mice had aberrantly enhanced neurogenesis, which was significantly reversed in TAG1-/- mice by TAG1 or AICD but not by AICD mutated at the Fe65 binding site. Notably, TAG1 reduced normal neurogenesis in Fe65+/+ mice. Abnormally enhanced neurogenesis also occurred in Fe65-/- mice but could not be reversed by TAG1. These results describe a TAG1-APP signalling pathway that negatively modulates neurogenesis through Fe65.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Quan-Hong</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Futagawa</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wu-Lin</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiao-Dan</ForeName><Initials>XD</Initials></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ru-Xiang</ForeName><Initials>RX</Initials></Author><Author ValidYN="Y"><LastName>Bagnard</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schachner</LastName><ForeName>Melitta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Furley</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Karagogeos</LastName><ForeName>Domna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Kazutada</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dawe</LastName><ForeName>Gavin S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Zhi-Cheng</ForeName><Initials>ZC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486243">Apbb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C548675">Cntn2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058969">Contactin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Cell Biol. 2008 Apr;10(4):497</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2008 Mar;10(3):249-50. doi: 10.1038/ncb0308-249.</RefSource><PMID Version="1">18311177</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058969" MajorTopicYN="N">Contactin 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18278038</ArticleId><ArticleId IdType="doi">10.1038/ncb1690</ArticleId><ArticleId IdType="pii">ncb1690</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18287270</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.</ArticleTitle><Pagination><StartPage>390</StartPage><EndPage>398</EndPage><MedlinePgn>390-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.107.045385</ELocationID><Abstract><AbstractText Label="UNLABELLED">This multicenter study examined (18)F-FDG PET measures in the differential diagnosis of Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) from normal aging and from each other and the relation of disease-specific patterns to mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the (18)F-FDG PET scans of 548 subjects, including 110 healthy elderly individuals ("normals" or NLs), 114 MCI, 199 AD, 98 FTD, and 27 DLB patients, collected at 7 participating centers. Individual PET scans were Z scored using automated voxel-based comparison with generation of disease-specific patterns of cortical and hippocampal (18)F-FDG uptake that were then applied to characterize MCI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Standardized disease-specific PET patterns were developed that correctly classified 95% AD, 92% DLB, 94% FTD, and 94% NL. MCI patients showed primarily posterior cingulate cortex and hippocampal hypometabolism (81%), whereas neocortical abnormalities varied according to neuropsychological profiles. An AD PET pattern was observed in 79% MCI with deficits in multiple cognitive domains and 31% amnesic MCI. (18)F-FDG PET heterogeneity in MCI with nonmemory deficits ranged from absent hypometabolism to FTD and DLB PET patterns.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Standardized automated analysis of (18)F-FDG PET scans may provide an objective and sensitive support to the clinical diagnosis in early dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosconi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Brain Health, New York University School of Medicine, New York, New York 10016, USA. lisa.mosconi@med.nyu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Wai H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Herholz</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pupi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lucignani</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Holthoff</LastName><ForeName>Vjera</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Kalbe</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Diehl-Schmid</LastName><ForeName>Janine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Perneczky</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Clerici</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Beuthien-Baumann</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Minoshima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01RR0096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18287270</ArticleId><ArticleId IdType="mid">NIHMS471249</ArticleId><ArticleId IdType="pmc">PMC3703818</ArticleId><ArticleId IdType="doi">10.2967/jnumed.107.045385</ArticleId><ArticleId IdType="pii">jnumed.107.045385</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DHS, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850493</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#x2019;s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39:1875&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829574</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong Y, Cho SS, Park JM, et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695781</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28:42&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448722</ArticleId></ArticleIdList></Reference><Reference><Citation>Albin RL, Minoshima S, DAmato CJ, Frey KA, Kuhl DE, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757021</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer&#x2019;s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11558792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer&#x2019;s disease and mild cognitive impairment. Ann Neurol. 2003;54:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953266</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET) Proc Natl Acad Sci USA. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer&#x2019;s disease: automated FDG-PET image analysis. Neurology. 2005;64:1860&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Li Y, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer&#x2019;s disease using FDG-PET. Eur J Nucl Med Imaging. 2006;33:210&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">16311757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer&#x2019;s disease. J Nucl Med. 2006;47:1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer&#x2019;s disease: a PET follow-up study. Eur J Nucl Med Imaging. 2003;30:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623696</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med. 2005;46:1625&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204712</ArticleId></ArticleIdList></Reference><Reference><Citation>Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286547</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wahlund L-O, Almkvist O, et al. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage. 2003;19:1137&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">12880839</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies&#x2014;report of the NINDS-AIRENS International Workshop. Neurology. 1993;43:250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM&#x2013;IV) 4th ed. Washington, D.C: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia. Ann Neurol. 2001;58:1803&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995.</Citation></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii K, Willoch F, Minoshima S, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer&#x2019;s disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42:548&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337540</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer&#x2019;s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System&#x2014;An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme Medical; 1988.</Citation></Reference><Reference><Citation>Mosconi L, Tsui WH, Pupi A, et al. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer&#x2019;s disease. J Nucl Med. 2007;48:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574982</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer&#x2019;s disease. Lancet. 1994;344:895.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2007 Jan 10; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871915</ArticleId><ArticleId IdType="pubmed">10912591</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropath-ological correlates in brains of dementia with Lewy bodies. Exp Neurol. 2000;162:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739631</ArticleId></ArticleIdList></Reference><Reference><Citation>Koeppe RA, Gilman S, Joshi A, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937303</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 1999;10:494&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559566</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18297066</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>308</EndPage><MedlinePgn>301-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn2058</ELocationID><Abstract><AbstractText>Pathogenic aggregates of alpha-synuclein are thought to contribute to the development of Parkinson's disease. Inclusion bodies containing alpha-synuclein are present in Parkinson's disease and other neurodegenerative diseases, including Alzheimer's disease. Moreover, alpha-synuclein mutations are found in cases of familial Parkinson's disease, and transgenic overexpression of alpha-synuclein causes neurodegeneration in mice. The molecular mechanisms involved, however, remain incompletely understood. Here we show that, in transgenic mice, alpha-synuclein induced neurodegeneration involves activation of the ubiquitin/proteasome system, a massive increase in apolipoprotein E (ApoE) levels and accumulation of insoluble mouse Abeta. ApoE was not protective, but was injurious, as deletion of ApoE delayed the neurodegeneration caused by alpha-synuclein and suppressed the accumulation of Abeta. Our data reveal a molecular link between central pathogenic mechanisms implicated in Parkinson's disease and Alzheimer's disease and suggest that intracellular alpha-synuclein is pathogenic, at least in part, by activation of extracellular signaling pathways involving ApoE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390-9111, USA. Gallardo@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schl&#xfc;ter</LastName><ForeName>Oliver M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH069585</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18297066</ArticleId><ArticleId IdType="doi">10.1038/nn2058</ArticleId><ArticleId IdType="pii">nn2058</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18297067</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory.</ArticleTitle><Pagination><StartPage>334</StartPage><EndPage>343</EndPage><MedlinePgn>334-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn2057</ELocationID><Abstract><AbstractText>Estrogens have long been implicated in influencing cognitive processes, yet the molecular mechanisms underlying these effects and the roles of the estrogen receptors alpha (ERalpha) and beta (ERbeta) remain unclear. Using pharmacological, biochemical and behavioral techniques, we demonstrate that the effects of estrogen on hippocampal synaptic plasticity and memory are mediated through ERbeta. Selective ERbeta agonists increased key synaptic proteins in vivo, including PSD-95, synaptophysin and the AMPA-receptor subunit GluR1. These effects were absent in ERbeta knockout mice. In hippocampal slices, ERbeta activation enhanced long-term potentiation, an effect that was absent in slices from ERbeta knockout mice. ERbeta activation induced morphological changes in hippocampal neurons in vivo, including increased dendritic branching and increased density of mushroom-type spines. An ERbeta agonist, but not an ERalpha agonist, also improved performance in hippocampus-dependent memory tasks. Our data suggest that activation of ERbeta can regulate hippocampal synaptic plasticity and improve hippocampus-dependent cognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Wyeth Research, Discovery Neuroscience, 865 Ridge Road, Monmouth Junction, New Jersey 08852, USA. liuf2@wyeth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mu&#xf1;iz</LastName><ForeName>Luis C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Bitran</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Arias</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Revilla-Sanchez</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Grauer</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guoming</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Cody</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pulito</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mervis</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Navarra</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hirst</LastName><ForeName>Warren D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Reinhart</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Marquis</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Pangalos</LastName><ForeName>Menelas N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Brandon</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS046478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048045</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS051195</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS056359</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS054900</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047629">Estrogen Receptor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047629" MajorTopicYN="N">Estrogen Receptor beta</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010052" MajorTopicYN="N">Ovariectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18297067</ArticleId><ArticleId IdType="doi">10.1038/nn2057</ArticleId><ArticleId IdType="pii">nn2057</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18298677</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1051-2284</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neuroimaging : official journal of the American Society of Neuroimaging</Title><ISOAbbreviation>J Neuroimaging</ISOAbbreviation></Journal><ArticleTitle>In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system.</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>129</EndPage><MedlinePgn>125-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1552-6569.2007.00179.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microscopic application of magnetic resonance imaging (MRI) has entered the era of clinical application. One of the most important targets is the visualization of pathological findings such as senile plaques (SP), in vivo, in patients with Alzheimer's disease (AD). Such an application provides not only the most accurate diagnostic tool for clinicians but also a solid basis for scientists for developing effective treatment and preventive strategies for AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Focused microscopic studies were performed on parietal association cortex at the level of the centrum semiovale identified on conventional axial slices using a system constructed based on General Electric Signa LX (Waukesha, WI) equipped with a 900-mm clear bore superconducting magnet operating at 7.0 T in 10 patients (67-83-year old, five males, five females) who fulfilled the NINCD and the SADRDA criteria for probable AD, 10 age-matched controls (71-85-year old, five males, five females), and 20 young adults (22-35-year old, 10 males, 10 females) using a susceptibility weighted imaging (SWI) algorithm.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SWI microscopy consistently provided images with SP-like pathology extending within the entire parietal cortex in all cases of AD and 2 out of 10 age-matched volunteers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the precise mechanisms leading to the higher susceptibility rendering SP-like pathology observable within the cortical mantle are not totally understood, the study unambiguously demonstrated that MR microscopy is capable of directly visualizing cortical pathology in AD patients in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakada</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata, Niigata, Japan. tnakada@bri.niigata-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuzawa</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Igarashi</LastName><ForeName>Hironaka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Yukihiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kwee</LastName><ForeName>Ingrid L</ForeName><Initials>IL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuroimaging</MedlineTA><NlmUniqueID>9102705</NlmUniqueID><ISSNLinking>1051-2284</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008853" MajorTopicYN="N">Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18298677</ArticleId><ArticleId IdType="doi">10.1111/j.1552-6569.2007.00179.x</ArticleId><ArticleId IdType="pii">JON179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18305152</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression.</ArticleTitle><Pagination><StartPage>3785</StartPage><EndPage>3789</EndPage><MedlinePgn>3785-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0800546105</ELocationID><Abstract><AbstractText>TDP-43 (for TAR DNA binding protein) is a highly conserved heterogeneous nuclear ribonucleoprotein (hnRNP) involved in specific pre-mRNA splicing and transcription events. TDP-43 recently has been identified as the main component of cytoplasmic inclusions in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), two neurodegenerative disorders. The cellular role of this protein remains to be identified. Here, we show that loss of TDP-43 results in dysmorphic nuclear shape, misregulation of the cell cycle, and apoptosis. Removal of TDP-43 in human cells significantly increases cyclin-dependent kinase 6 (Cdk6) protein and transcript levels. The control of Cdk6 expression mediated by TDP-43 involves GT repeats in the target gene sequence. Cdk6 up-regulation in TDP-43-depleted cells is accompanied by an increase in phosphorylation of two of its major targets, the retinoblastoma protein pRb and pRb-related protein pRb2/p130. TDP-43 silencing also is followed by changes in the expression levels of several factors that control cell proliferation. Morphological nuclear defects and increased apoptosis upon TDP-43 loss are mediated via the pRb pathway because pRb-negative cells (Saos-2) do not undergo programmed cell death or nuclear shape deformation upon TDP-43 removal. Our results identify a regulatory target of TDP-43 and show that TDP-43 depletion has important consequences in essential metabolic processes in human cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayala</LastName><ForeName>Youhna M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misteli</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Baralle</LastName><ForeName>Francisco E</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GGP06147</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050717">Retinoblastoma-Like Protein p130</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009685" MajorTopicYN="N">Nuclear Envelope</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016160" MajorTopicYN="N">Retinoblastoma Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050717" MajorTopicYN="N">Retinoblastoma-Like Protein p130</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18305152</ArticleId><ArticleId IdType="pmc">PMC2268791</ArticleId><ArticleId IdType="doi">10.1073/pnas.0800546105</ArticleId><ArticleId IdType="pii">0800546105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Pagani F, Baralle FE. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett. 2006;580:1339&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458894</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Pagani F, Baralle FE. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: A functional link with disease penetrance. Am J Hum Genet. 2004;74:1322&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182100</ArticleId><ArticleId IdType="pubmed">15195661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res. 2005;33:6000&#x2013;6010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1270946</ArticleId><ArticleId IdType="pubmed">16254078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Human, Drosophila, and C.elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348:575&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69:3584&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya KK, Govind CK, Shore AN, Stoler MH, Reddi PP. Cis-requirement for the maintenance of round spermatid-specific transcription. Dev Biol. 2006;295:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730344</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (Berl) 2007;113:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: Where cancer meets the cell cycle. Exp Biol Med (Maywood) 2006;231:1271&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem. 2002;71:133&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12045093</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JD, Kirk JA, Hunt T. Unmasking the S-phase-promoting potential of cyclin B1. Science. 2003;300:987&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738867</ArticleId></ArticleIdList></Reference><Reference><Citation>Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30:630&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rape M, Kirschner MW. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature. 2004;432:588&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15558010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell. 1995;82:915&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">7553852</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnaghi-Jaulin L, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998;391:601&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">9468140</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian YW, Lee EY. Dual retinoblastoma-binding proteins with properties related to a negative regulator of ras in yeast. J Biol Chem. 1995;270:25507&#x2013;25513.</Citation><ArticleIdList><ArticleId IdType="pubmed">7503932</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLellan WR, Xiao G, Abdellatif M, Schneider MD. A novel Rb- and p300-binding protein inhibits transactivation by MyoD. Mol Cell Biol. 2000;20:8903&#x2013;8915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86545</ArticleId><ArticleId IdType="pubmed">11073990</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake S, et al. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol. 2000;20:8889&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86544</ArticleId><ArticleId IdType="pubmed">11073989</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen J, et al. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription. Nucleic Acids Res. 2005;33:5458&#x2013;5470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1236722</ArticleId><ArticleId IdType="pubmed">16179649</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon HU, et al. Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. Biochem J. 1994;297:389&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137842</ArticleId><ArticleId IdType="pubmed">8297347</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbour JW, Dean DC. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev. 2000;14:2393&#x2013;2409.</Citation><ArticleIdList><ArticleId IdType="pubmed">11018009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewen ME. Where the cell cycle and histones meet. Genes Dev. 2000;14:2265&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995383</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14:2077&#x2013;2086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358568</ArticleId><ArticleId IdType="pubmed">8114739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojala PM, Yamamoto K, Castanos-Velez E, Biberfeld P, Korsmeyer SJ, Makela TP. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol. 2000;2:819&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">11056537</ArticleId></ArticleIdList></Reference><Reference><Citation>Godden-Kent D, et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997;71:4193&#x2013;4198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191633</ArticleId><ArticleId IdType="pubmed">9151805</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm SV, Reed SI. Regulation of G (1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063931</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossel MJ, Hinds PW. Beyond the cell cycle: A new role for Cdk6 in differentiation. J Cell Biochem. 2006;97:485&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">16294322</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Babapulle V, et al. Translocation t(2;7)(p12;q21&#x2013;22) with dysregulation of the CDK6 gene mapping to 7q21&#x2013;22 in a non-Hodgkin's lymphoma with leukemia. Haematologica. 2002;87:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940479</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcoran MM, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271&#x2013;6277.</Citation><ArticleIdList><ArticleId IdType="pubmed">10597225</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello JF, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 1997;57:1250&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9102208</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermann S, Hinds PW, Munger K. Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines. Cell Growth Differ. 1997;8:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">9101082</ArticleId></ArticleIdList></Reference><Reference><Citation>Munger K, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20:7888&#x2013;7898.</Citation><ArticleIdList><ArticleId IdType="pubmed">11753671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858&#x2013;5868.</Citation><ArticleIdList><ArticleId IdType="pubmed">9488723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24:2796&#x2013;2809.</Citation><ArticleIdList><ArticleId IdType="pubmed">15838516</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen KE, et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol. 2000;20:7751&#x2013;7763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86358</ArticleId><ArticleId IdType="pubmed">11003670</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese C, Trani D, Caputi M, Claudio PP. Cell cycle control and beyond: emerging roles for the retinoblastoma gene family. Oncogene. 2006;25:5201&#x2013;5209.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936738</ArticleId></ArticleIdList></Reference><Reference><Citation>Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem. 1996;271:10205&#x2013;10209.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakay M, et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain. 2006;129:996&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">16478798</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcon G, et al. Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet. 2006;15:637&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">16403804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530&#x2013;10534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18305170</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3587</StartPage><EndPage>3592</EndPage><MedlinePgn>3587-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0709788105</ELocationID><Abstract><AbstractText>Substantial evidence from epidemiological, pathological, and clinical reports suggests that vascular factors are critical in the pathogenesis of Alzheimer's disease (AD), and changes in blood flow are currently the most reliable indicators of the disease. We previously reported that older APP23 transgenic (tg) mice have significant blood flow alterations correlated with structural modifications of blood vessels. For the present study, our objective was to analyze the age-dependent morphological and architectural changes of the cerebral vasculature of APP23 tg mice. To visualize the 3D arrangement of the entire brain vasculature, we used vascular corrosion casts. Already at young ages, when typically parenchymal amyloid plaques are not yet present, APP23 tg mice had significant alterations, particularly of the microvasculature, often accompanied by small deposits attached to the vessels. In older animals, vasculature abruptly ended at amyloid plaques, resulting in holes. Often, small deposits were sitting near or at the end of truncated vessels. Between such holes, the surrounding vascular array appeared more dense and showed features typical for angiogenesis. We propose that small amyloid aggregates associated with the microvasculature lead to morphological and architectural alterations of the vasculature, resulting in altered local blood flow. The characteristic early onset of vascular alterations suggests that imaging blood flow and/or vasculature architecture could be used as a tool for early diagnosis of the disease and to monitor therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Eric P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Zoology, University of Z&#xfc;rich, Winterthurerstrasse 190, CH-8057 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulmann-Schuler</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Krucker</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016319" MajorTopicYN="N">Corrosion Casting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18305170</ArticleId><ArticleId IdType="pmc">PMC2265182</ArticleId><ArticleId IdType="doi">10.1073/pnas.0709788105</ArticleId><ArticleId IdType="pii">0709788105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Langui D, Ulrich J. Alzheimer's disease: A description of the structural lesions. Brain Pathol. 1991;1:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">1727015</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, KR, Bick KL, Sisodia SS. Alzheimer Disease. New York: Raven; 1994.</Citation></Reference><Reference><Citation>Prohovnik I, et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006;66:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401845</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging. 2000;21:357&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867221</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Esh C, Rahman A, Kokjohn TA, Beach TG. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke. 2004;35:2623&#x2013;2627.</Citation><ArticleIdList><ArticleId IdType="pubmed">15375298</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging. 2000;21:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867213</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman GA, Levi CR, Schofield P, Wang Y, Lovett EC. Quantitative measurement of cerebral haemodynamics in early vascular dementia and Alzheimer's disease. J Clin Neurosci. 2006;13:563&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">16540327</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res. 1993;15:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103579</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann N, et al. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci. 2003;23:8453&#x2013;8459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740368</ArticleId><ArticleId IdType="pubmed">13679413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueggler T, et al. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci. 2002;22:7218&#x2013;7224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757895</ArticleId><ArticleId IdType="pubmed">12177216</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, et al. A beta 1&#x2013;40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA. 2000;97:9735&#x2013;9740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16934</ArticleId><ArticleId IdType="pubmed">10944232</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, et al. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol. 2002;283:H315&#x2013;H323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12063304</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302999</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980533</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Krucker T, Lang A, Meyer EP. New polyurethane-based material for vascular corrosion casting with improved physical and imaging characteristics. Microsc Res Technol. 2006;69:138&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16456839</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofferson RH, Nilsson BO. Microvascular corrosion casting with analysis in the scanning electron microscope. Scanning. 1988;10:43&#x2013;63.</Citation></Reference><Reference><Citation>Miodonski AJ, Hodde KC, Bakker C. Scanning electron microscopy of plastic corrosion casts: The morphological distinction of arteries and veins. Beitr Elektronmikroskop Direktabb Oberfl. 1976:435&#x2013;442.</Citation></Reference><Reference><Citation>Heinzer S, et al. Hierarchical microimaging for multiscale analysis of large vascular networks. NeuroImage. 2006;32:626&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697665</ArticleId></ArticleIdList></Reference><Reference><Citation>Krucker T, Schuler A, Meyer EP, Staufenbiel M, Beckmann N. Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease. Neurol Res. 2004;26:507&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265268</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HM. Neovasculature and blood-brain barrier in ischemic brain infarct. Acta Neuropathol (Berl) 1988;75:422&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">3129898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassler O. Arterial deformities in senile brains. The occurrence of the deformities in a large autopsy series and some aspects of their functional significance. Acta Neuropathol (Berl) 1967;8:219&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">6032925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Barron E, Chui HC, Perlmutter LS. Vascular basement membrane pathology and Alzheimer's disease. Ann NY Acad Sci. 1997;826:147&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329687</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL. Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Rev. 1998;26:327&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651549</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzer S, et al. Novel three-dimensional analysis tool for vascular trees indicates complete micro-networks, not single capillaries, as the angiogenic endpoint in mice overexpressing human VEGF(165) in the brain. NeuroImage. 2007;39:1549&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18077185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lametschwandtner A, Lametschwandtner U, Weiger T. Scanning electron microscopy of vascular corrosion casts-technique and applications: updated review. Scan Microsc. 1990;4:889&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">2094009</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiger T, Lametschwandtner A, Stockmayer P. Technical parameters of plastics (Mercox CL-2B and various methylmethacrylates) used in scanning electron microscopy of vascular corrosion casts. Scan Electron Microsc. 1986:243&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">3738421</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouznetsova E, et al. Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci. 2006;24:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SP, et al. Coaccumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging. 2004;25:283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123332</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, et al. In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis. 2006;9:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16821113</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti HJ, et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol. 2000;156:965&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876841</ArticleId><ArticleId IdType="pubmed">10702412</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol. 2002;13:39&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11969370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke. 1996;27:1865&#x2013;1872. discussion 1872&#x2013;1863.</Citation><ArticleIdList><ArticleId IdType="pubmed">8841346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol. 1990;137:1435&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877722</ArticleId><ArticleId IdType="pubmed">2260630</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J Am Med Assoc. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CB, Vonsattel JP, Bell K, Honig LS. Dementia with cerebrovascular disease. Sci Aging Knowledge Environ. 2006 PMID 16807476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16807476</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbach GJ, et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging. 2007;28:202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16427722</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Sumiyoshi S, Murayama E, Deshimaru M. Ultrastructure of capillary plaque-like degeneration in senile dementia. Mechanism of amyloid production. Acta Neuropathol. 1974;29:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">4446949</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, et al. Beta-Amyloid-(1&#x2013;42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:10836&#x2013;10840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276:12991&#x2013;12998.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T. Amyloid beta40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knockout and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis. 2001;3:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004;89:807&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140180</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D, et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542676</ArticleId></ArticleIdList></Reference><Reference><Citation>Prut L, et al. Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze. Behav Brain Res. 2007;179:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324476</ArticleId></ArticleIdList></Reference><Reference><Citation>Krucker T, Siggins GR, Halpain S. Dynamic actin filaments are required for stable long-term potentiation (LTP) in area CA1 of the hippocampus. Proc Natl Acad Sci USA. 2000;97:6856&#x2013;6861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18765</ArticleId><ArticleId IdType="pubmed">10823894</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EP. Corrosion casts as a method for investigation of the insect tracheal system. Cell Tissue Res. 1989;256:1&#x2013;6.</Citation></Reference><Reference><Citation>Ravens JR. In: Three dimensional microanatomy of cells and tissue surfaces. Cervos-Navarro J, editor. New York: Raven; 1978. pp. 487&#x2013;501.</Citation></Reference><Reference><Citation>Tong XK, Nicolakakis N, Kocharyan A, Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci. 2005;25:11165&#x2013;11174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725645</ArticleId><ArticleId IdType="pubmed">16319316</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoeckli M, Staab D, Staufenbiel M, Wiederhold KH, Signor L. Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal Biochem. 2002;311:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">12441150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Staufenbiel M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann NY Acad Sci. 2000;920:134&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193142</ArticleId></ArticleIdList></Reference><Reference><Citation>Beskow J, Hassler O, Ottosson JO. Cerebral arterial deformities in relation to senile deterioration. Acta Psychiatr Scand Suppl. 1971;221:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">5286322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18309045</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>319</Volume><Issue>5870</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1668</StartPage><EndPage>1672</EndPage><MedlinePgn>1668-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1154584</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder characterized pathologically by ubiquitinated TAR DNA binding protein (TDP-43) inclusions. The function of TDP-43 in the nervous system is uncertain, and a mechanistic role in neurodegeneration remains speculative. We identified neighboring mutations in a highly conserved region of TARDBP in sporadic and familial ALS cases. TARDBPM337V segregated with disease within one kindred and a genome-wide scan confirmed that linkage was restricted to chromosome 1p36, which contains the TARDBP locus. Mutant forms of TDP-43 fragmented in vitro more readily than wild type and, in vivo, caused neural apoptosis and developmental delay in the chick embryo. Our evidence suggests a pathophysiological link between TDP-43 and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sreedharan</LastName><ForeName>Jemeen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, and Institute of Psychiatry, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian P</ForeName><Initials>IP</Initials></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Vineeta B</ForeName><Initials>VB</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rogelj</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ackerley</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Durnall</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Baralle</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>de Belleroche</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>J Douglas</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>P Nigel</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Garth</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0000749</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>076671</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501573</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002642" MajorTopicYN="N">Chick Embryo</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002878" MajorTopicYN="N">Chromosomes, Human, Pair 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047108" MajorTopicYN="N">Embryonic Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId><ArticleId IdType="mid">EMS110344</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pii">1154584</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shaw CE, Al-Chalabi A, Leigh N. Curr Neurol Neurosci Rep. 2001;1:69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11898502</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Nature. 1993;362:59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw CE, et al. Neurology. 1997;49:1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Science. 1994;264:1772.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, et al. Nat Genet. 2001;29:166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddy DM, et al. Am J Hum Genet. 2003;73:390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180376</ArticleId><ArticleId IdType="pubmed">12840784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp PC, et al. Am J Hum Genet. 2003;73:397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180377</ArticleId><ArticleId IdType="pubmed">12858291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosler BA, et al. JAMA. 2000;284:1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015796</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Brain. 2006;129:868.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, et al. Neurology. 2006;66:839.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, et al. Brain. 1991;114(Pt 2):775.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton AM, White CL, III, Bigio EH. Acta Neuropathol. 2004;108:379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351890</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Science. 2006;314:130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. Biochem Biophys Res Commun. 2006;351:602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>mador-Ortiz C, et al. Ann Neurol. 2007;61:435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Brain. 2007;130:1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, et al. Acta Neuropathol. 2007;114:221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP. J Neuropathol Exp Neurol. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">18091558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Ann Neurol. 2007;61:382.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469124</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge GD, et al. Neurobiol Dis. 2006;21:194.</Citation><ArticleIdList><ArticleId IdType="pubmed">16084730</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Front Biosci. 2008;13:867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, et al. J Biol Chem. 2005;280 37572.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, et al. Acta Neuropathol. 2007;114:81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569064</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhyankar MM, Urekar C, Reddi PP. J Biol Chem. 2007;282 36143.</Citation><ArticleIdList><ArticleId IdType="pubmed">17932037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollinson S, et al. Neurosci Lett. 2007;419:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">17434264</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher A, et al. Neurobiol Aging. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">16979267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, et al. Neurobiol Aging. 2007</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18310554</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>247</EndPage><MedlinePgn>240-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e318162992d</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the views of Alzheimer disease (AD) patients and their study partners on the ethics of proxy consent for clinical research.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional interview.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">At the 13 study sites of a randomized and placebo controlled study of simvastatin for the treatment of AD.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Patients with mild-to-moderate AD and their study partners enrolled in an Alzheimer's Disease Cooperative Study trial of simvastatin.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Interviews to assess how participants made the decision to enroll in a randomized controlled trial and their attitudes on proxy consent.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Study partners of patients judged not capable of providing informed consent reported the same degree of patient involvement in the decision to enroll as the study partners of patients capable of providing informed consent. Most study partners and patients supported proxy consent for this clinical trial and nearly all patients chose their study partner as their proxy. Study partners generally made research enrollment decisions based on what they thought would maximize the patient's well-being as opposed to a substituted judgment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients and their study partners who were enrolled in a clinical trial supported proxy consent both for themselves and as a matter of policy. Our findings suggest that policies that require substituted judgments may not accord with the views of the people currently participating in AD clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Alzheimer's Disease Center, Leonard Davis Institute for Health Economics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA. Jason.karlawish@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Scott Y H</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Bryan D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG00247</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001290" MajorTopicYN="Y">Attitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032984" MajorTopicYN="Y">Ethics, Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035842" MajorTopicYN="N">Research Subjects</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020458" MajorTopicYN="N">Third-Party Consent</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18310554</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318162992d</ArticleId><ArticleId IdType="pii">16/3/240</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18344992</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>422</EndPage><MedlinePgn>420-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn2073</ELocationID><Abstract><AbstractText>We report here that amyotrophic lateral sclerosis-linked superoxide dismutase 1 (SOD1) mutants with different biochemical characteristics disrupted the blood-spinal cord barrier in mice by reducing the levels of the tight junction proteins ZO-1, occludin and claudin-5 between endothelial cells. This resulted in microhemorrhages with release of neurotoxic hemoglobin-derived products, reductions in microcirculation and hypoperfusion. SOD1 mutant-mediated endothelial damage accumulated before motor neuron degeneration and the neurovascular inflammatory response occurred, indicating that it was a central contributor to disease initiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders and Department of Neurosurgery, University of Rochester Medical Center, Kornberg Medical Research Bldg., 601 Elmwood Avenue, Box 670, Rochester, New York 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Zarina</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shapovalov</LastName><ForeName>Yuriy</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>O'Banion</LastName><ForeName>M Kerry</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Stojanovic</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Boillee</LastName><ForeName>Severine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL63290</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS27036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL063290</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062507">Claudin-5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491511">Cldn5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568985">OCLN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062793">Occludin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568986">Ocln protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569042">TJP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569043">Tjp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062826">Zonula Occludens-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Amyotroph Lateral Scler. 2008 Dec;9(6):375-6. doi: 10.1080/17482960802160990.</RefSource><PMID Version="1">18608097</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062507" MajorTopicYN="N">Claudin-5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062793" MajorTopicYN="N">Occludin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019108" MajorTopicYN="N">Tight Junctions</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062826" MajorTopicYN="N">Zonula Occludens-1 Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18344992</ArticleId><ArticleId IdType="mid">NIHMS207961</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pii">nn2073</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boill&#xe9;e S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2:e1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, et al. Selective vulnerability and pruning of phasic motorneuron axons in motorneuron disease alleviated by CNTF. Nat Neurosci. 2006;9:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger C, et al. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA. 2007;104:7319&#x2013;7326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1863491</ArticleId><ArticleId IdType="pubmed">17463094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer&#x2019;s neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan S, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. GLIA. 2005;51:241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15846792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall E, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. GLIA. 1998;23:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosthuyse B, et al. Deletion of the hypoxia-response element in the vascular endothelial groh factor promoter causes motor neuron degeneration. Nat Genet. 2001;28:131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847526</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan RF, Guo Y. Toxic effect of hemoglobin on spinal cord neurons in culture. J Neurotrauma. 1998;15:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, Brown RH., Jr Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper&#x2013;zinc superoxide dismutase. Proc Natl Acad Sci USA. 1998;95:15763&#x2013;15768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28118</ArticleId><ArticleId IdType="pubmed">9861044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, S&#xfc;ssmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurol. 2006;66:852&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18375754</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>13</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation.</ArticleTitle><Pagination><StartPage>5099</StartPage><EndPage>5104</EndPage><MedlinePgn>5099-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0711731105</ELocationID><Abstract><AbstractText>According to the amyloid hypothesis, the pathogenesis of Alzheimer's disease is triggered by the oligomerization and aggregation of the amyloid-beta (Abeta) peptide into protein plaques. Formation of the potentially toxic oligomeric and fibrillar Abeta assemblies is accompanied by a conformational change toward a high content of beta-structure. Here, we report the solution structure of Abeta(1-40) in complex with the phage-display selected affibody protein Z(Abeta3), a binding protein of nanomolar affinity. Bound Abeta(1-40) features a beta-hairpin comprising residues 17-36, providing the first high-resolution structure of Abeta in beta conformation. The positions of the secondary structure elements strongly resemble those observed for fibrillar Abeta. Z(Abeta3) stabilizes the beta-sheet by extending it intermolecularly and by burying both of the mostly nonpolar faces of the Abeta hairpin within a large hydrophobic tunnel-like cavity. Consequently, Z(Abeta3) acts as a stoichiometric inhibitor of Abeta fibrillation. The selected Abeta conformation allows us to suggest a structural mechanism for amyloid formation based on soluble oligomeric hairpin intermediates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoyer</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Swedish Nuclear Magnetic Resonance Center, University of Gothenburg, Box 440, SE-405 30 G&#xf6;teborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf6;nwall</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>St&#xe5;hl</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>H&#xe4;rd</LastName><ForeName>Torleif</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2OTK</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004220">Disulfides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004220" MajorTopicYN="N">Disulfides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017186" MajorTopicYN="N">Titrimetry</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: A.J. is an employee of Affibody AB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18375754</ArticleId><ArticleId IdType="pmc">PMC2278213</ArticleId><ArticleId IdType="doi">10.1073/pnas.0711731105</ArticleId><ArticleId IdType="pii">0711731105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A&#x3b2; Oligomers&#x2014;a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004;5:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322526</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6:404&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Balass M, Katchalski-Katzir E, Solomon B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of &#x3b2;-amyloid peptide is essential for modulation of fibrillar aggregation. J Neuroimmunol. 1999;95:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229123</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer &#x3b2;-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997;94:4109&#x2013;4112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20576</ArticleId><ArticleId IdType="pubmed">9108113</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciarretta KL, Gordon DJ, Meredith SC. Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 2006;413:273&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046402</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, et al. &#x3b2;-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998;4:822&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjernberg LO, et al. Arrest of &#x3b2;-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271:8545&#x2013;8548.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardberg AS, et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:15659&#x2013;15664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994138</ArticleId><ArticleId IdType="pubmed">17895381</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to &#x3b2;-amyloid. J Neurosci. 2003;23:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742136</ArticleId><ArticleId IdType="pubmed">12514198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf6;nwall C, et al. Selection and characterization of affibody ligands binding to Alzheimer amyloid &#x3b2; peptides. J Biotechnol. 2007;128:162&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088007</ArticleId></ArticleIdList></Reference><Reference><Citation>Binz HK, Amstutz P, Pl&#xfc;ckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol. 2005;23:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16211069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nord K, et al. Binding proteins selected from combinatorial libraries of an &#x3b1;-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">9255793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolmachev V, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773&#x2013;2782.</Citation><ArticleIdList><ArticleId IdType="pubmed">17363599</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-&#x212b; resolution. Biochemistry. 1981;20:2361&#x2013;2370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7236608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendel C, Dogan J, H&#xe4;rd T. Structural basis for molecular recognition in an affibody:affibody complex. J Mol Biol. 2006;359:1293&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlberg E, et al. An affibody in complex with a target protein: structure and coupled folding. Proc Natl Acad Sci USA. 2003;100:3185&#x2013;3190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152267</ArticleId><ArticleId IdType="pubmed">12594333</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TJ, Stains CI, Meyer SC, Ghosh I. Inhibition of &#x3b2;-amyloid fibrillization by directed evolution of a &#x3b2;-sheet presenting miniature protein. J Am Chem Soc. 2006;128:14456&#x2013;14457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17090018</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hrs T, et al. 3D structure of Alzheimer's amyloid-&#x3b2;(1&#x2013;42) fibrils. Proc Natl Acad Sci USA. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson A, Sauer-Eriksson AE, &#xd6;hman A. The solvent protection of Alzheimer amyloid-&#x3b2;-(1&#x2013;42) fibrils as determined by solution NMR spectroscopy. J Biol Chem. 2006;281:477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">16215229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel R, Shivaprasad S, Williams AD. Plasticity of amyloid fibrils. Biochemistry. 2007;46:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526019</ArticleId><ArticleId IdType="pubmed">17198370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, et al. Solution NMR studies of the A&#x3b2;(1&#x2013;40) and A&#x3b2;(1&#x2013;42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc. 2004;126:1992&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">14971932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Habicht G, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A&#x3b2; protofibrils. Proc Natl Acad Sci USA. 2007;104:19232&#x2013;19237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148273</ArticleId><ArticleId IdType="pubmed">18042730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Lansbury PT., Jr Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys. 2006;39:167&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16978447</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart AC, Borzilleri KA, Withka JM, Palmer AG. Compensating for variations in 1H&#x2013;13C scalar coupling constants in isotope-filtered NMR experiments. J Am Chem Soc. 1999;121:5346&#x2013;5347.</Citation></Reference><Reference><Citation>Cornilescu G, Delaglio F, Bax A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR. 1999;13:289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">10212987</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM. The Xplor-NIH NMR molecular structure determination package. J Magn Reson. 2003;160:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuszewski J, Gronenborn AM, Clore GM. Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J Am Chem Soc. 1999;121:2337&#x2013;2338.</Citation></Reference><Reference><Citation>Kuszewski J, Gronenborn AM, Clore GM. Improvements and extensions in the conformational database potential for the refinement of NMR and X-ray structures of proteins and nucleic acids. J Magn Reson. 1997;125:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18385314</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>14</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.</ArticleTitle><Pagination><StartPage>3555</StartPage><EndPage>3566</EndPage><MedlinePgn>3555-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0208-08.2008</ELocationID><Abstract><AbstractText>Aged canines (dogs) accumulate human-type beta-amyloid (Abeta) in diffuse plaques in the brain with parallel declines in cognitive function. We hypothesized that reducing Abeta in a therapeutic treatment study of aged dogs with preexisting Abeta pathology and cognitive deficits would lead to cognitive improvements. To test this hypothesis, we immunized aged beagles (8.4-12.4 years) with fibrillar Abeta(1-42) formulated with aluminum salt (Alum) for 2.4 years (25 vaccinations). Cognitive testing during this time revealed no improvement in measures of learning, spatial attention, or spatial memory. After extended treatment (22 vaccinations), we observed maintenance of prefrontal-dependent reversal learning ability. In the brain, levels of soluble and insoluble Abeta(1-40) and Abeta(1-42) and the extent of diffuse plaque accumulation was significantly decreased in several cortical regions, with preferential reductions in the prefrontal cortex, which is associated with a maintenance of cognition. However, the amount of soluble oligomers remained unchanged. The extent of prefrontal Abeta was correlated with frontal function and serum anti-Abeta antibody titers. Thus, reducing total Abeta may be of limited therapeutic benefit to recovery of cognitive decline in a higher mammalian model of human brain aging and disease. Immunizing animals before extensive Abeta deposition and cognitive decline to prevent oligomeric or fibrillar Abeta formation may have a greater impact on cognition and also more directly evaluate the role of Abeta on cognition in canines. Alternatively, clearing preexisting Abeta from the brain in a treatment study may be more efficacious for cognition if combined with a second intervention that restores neuron health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Brain Aging and Dementia, and Department of Neurology, University of California, Irvine, Irvine, California 92697, USA. ehead@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pop</LastName><ForeName>Viorela</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Vasilevko</LastName><ForeName>Vitaly</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saing</LastName><ForeName>Tommy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sarsoza</LastName><ForeName>Floyd</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nistor</LastName><ForeName>Michaela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>Lori-Ann</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Milton</LastName><ForeName>Saskia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG20241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20242</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020242</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020241</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS50895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="N">Discrimination Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="Y">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18385314</ArticleId><ArticleId IdType="pmc">PMC6671080</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0208-08.2008</ArticleId><ArticleId IdType="pii">28/14/3555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci. 2006;24:2530&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779823</ArticleId><ArticleId IdType="pubmed">17100841</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, Lott IT, Cotman CW. Molecular dating of senile plaques in aged Down's syndrome and canine brains. Exp Neurol. 2000;163:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AD, Nippak PM, Murphey H, Ikeda-Douglas CJ, Muggenburg B, Head E, Cotman CW, Milgram NW. Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Behav Neurosci. 2002;116:443&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12049325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res. 2007;85:451&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086547</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Kobayashi D, Barbour R, Motter R, Games D, Martin SJ, Morris RG. Active &#x3b2;-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of &#x3b2;-amyloid. J Neurosci. 2007;27:2654&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672499</ArticleId><ArticleId IdType="pubmed">17344403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging. 2002;23:809&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483061</ArticleId><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Head E, Ruehl WW, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiol Aging. 1996a;17:259&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem. 1996b;66:11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">8661247</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1&#x2013;42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705631</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-&#x3b2; immunization effectively reduces amyloid deposition in FcR&#x3b3;&#x2212;/&#x2212; knock-out mice. J Neurosci. 2003;23:8532&#x2013;8538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740360</ArticleId><ArticleId IdType="pubmed">13679422</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Head E, Velasquez P, Cotman CW, Tenner AJ. The presence of isoaspartic acid in b-amyloid plaques indicates plaque age. Exp Neurol. 1999;157:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo JM. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-&#x3b2; antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:6213&#x2013;6220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725066</ArticleId><ArticleId IdType="pubmed">15987951</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Mehta R, Hartley J, Kameka AM, Cummings BJ, Cotman CW, Ruehl WW, Milgram NW. Spatial learning and memory as a function of age in the dog. Behav Neurosci. 1995;109:851&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">8554710</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging. 1998;19:415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880044</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging. 2000;21:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794853</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Ab and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001;8:792&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592849</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, Glabe CC, Kayed R, Milton S, Vasilevko V, Milgram NW, Agadjanyan MG, Cribbs DH, Cotman CW. Immunization with fibrillar Abeta(1&#x2013;42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine. 2006;24:2824&#x2013;2834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8:1270&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res. 1991;10:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B, Mishkin M. Limbic lesions and the problem of stimulus-reinforcement associations. Exp Neurol. 1972;36:362&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">4626489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002;41:922&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest. 1987;57:230&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">2441141</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82:497&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Head E, Weiner E, Thomas E. Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav Neurosci. 1994;108:57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">8192851</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Adams B, Callahan H, Head E, Mackay W, Thirlwell C, Cotman CW. Landmark discrimination learning in the dog. Learn Mem. 1999;6:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311280</ArticleId><ArticleId IdType="pubmed">10355524</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas C, Cotman CW. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging. 2002a;23:737&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392778</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Head E, Muggenburg BA, Holowachuk D, Murphey H, Estrada J, Ikeda-Douglas CJ, Zicker SC, Cotman CW. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified diet, and cognitive strategy. Neurosci Biobehav Rev. 2002b;26:679&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">12479842</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Head E, Zicker SC, Ikeda-Douglas C, Murphey H, Muggenberg BA, Siwak CT, Dwight Tapp P, Lowry SR, Cotman CW. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp Gerontol. 2004;39:753&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130670</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging. 2005;26:77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Farr SA, Flood JF. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem. 2002;78:125&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll J. Potential mechanisms of Abeta plaque clearance in patients immunized with Abeta. In: Fisher A, Hanin I, Poewe W, Windisch M, editors. Alzheimer's and Parkinson's diseases: progress and new perspectives; 8th International Conference AD/PD; Salzburg, Austria: Karger; 2007. p. 14.</Citation></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281:39413&#x2013;39423.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pop V, Head E, Nistor M, Milgram NW, Muggenburg BA, Cotman CW. Reduced Ab deposition with long-term antioxidant diet treatment in aged canines. Soc Neurosci Abstr. 2003;29:525&#x2013;4.</Citation></Reference><Reference><Citation>Price JL. Aging, preclinical Alzheimer disease, and early detection. Alzheimer Dis Assoc Disord. 2003;17(Suppl 2):S60&#x2013;S62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12813212</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandervert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-b attentuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996;271:18295&#x2013;18298.</Citation><ArticleIdList><ArticleId IdType="pubmed">8756120</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science. 1987;235:873&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">3544219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-&#x3b2; derivatives. J Neurosci. 2004;24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwak CT, Tapp PD, Head E, Zicker SC, Murphey HL, Muggenburg BA, Ikeda-Douglas CJ, Cotman CW, Milgram NW. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15795055</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging. 2008;29:39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198929</ArticleId><ArticleId IdType="pubmed">17092609</ArticleId></ArticleIdList></Reference><Reference><Citation>Studzinski CM, Christie LA, Araujo JA, Burnham WM, Head E, Cotman CW, Milgram NW. Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Neurobiol Learn Mem. 2006;86:197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616528</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapp PD, Siwak CT, Estrada J, Holowachuk D, Milgram NW. Effects of age on measures of complex working memory span in the beagle dog (Canis familiaris) using two versions of a spatial list learning paradigm. Learn Mem. 2003a;10:148&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196663</ArticleId><ArticleId IdType="pubmed">12663753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapp PD, Siwak CT, Estrada J, Muggenburg BA, Head E, Cotman CW, Milgram NW. Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem. 2003b;10:64&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196651</ArticleId><ArticleId IdType="pubmed">12551965</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapp PD, Siwak CT, Gao FQ, Chiou JY, Black SE, Head E, Muggenburg BA, Cotman CW, Milgram NW, Su MY. Frontal lobe volume, function, and &#x3b2;-amyloid pathology in a canine model of aging. J Neurosci. 2004;24:8205&#x2013;8213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729694</ArticleId><ArticleId IdType="pubmed">15385603</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002;30:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004a;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004b;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Tenner AJ. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation. 2005;2:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326209</ArticleId><ArticleId IdType="pubmed">16332263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18385378</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>14</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.</ArticleTitle><Pagination><StartPage>5585</StartPage><EndPage>5590</EndPage><MedlinePgn>5585-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0710373105</ELocationID><Abstract><AbstractText>beta-Site APP-cleaving enzyme 1 (BACE1) is required for the penultimate cleavage of the amyloid-beta precursor protein (APP) leading to the generation of amyloid-beta peptides that is central to the pathogenesis of Alzheimer's disease. In addition to its role in endoproteolysis of APP, BACE1 participates in the proteolytic processing of neuregulin 1 (NRG1) and influences the myelination of central and peripheral axons. Although NRG1 has been genetically linked to schizophrenia and NRG1(+/-) mice exhibit a number of schizophrenia-like behavioral traits, it is not known whether altered BACE1-dependent NRG1 signaling can cause similar behavioral abnormalities. To test this hypothesis, we analyze the behaviors considered to be rodent analogs of clinical features of schizophrenia in BACE1(-/-) mice with impaired processing of NRG1. We demonstrate that BACE1(-/-) mice exhibit deficits in prepulse inhibition, novelty-induced hyperactivity, hypersensitivity to a glutamatergic psychostimulant (MK-801), cognitive impairments, and deficits in social recognition. Importantly, some of these manifestations were responsive to treatment with clozapine, an atypical antipsychotic drug. Moreover, although the total amount of ErbB4, a receptor for NRG1 was not changed, binding of ErbB4 with postsynaptic density protein 95 (PSD95) was significantly reduced in the brains of BACE1(-/-) mice. Consistent with the role of ErbB4 in spine morphology and synaptic function, BACE1(-/-) mice displayed reduced spine density in hippocampal pyramidal neurons. Collectively, our findings suggest that alterations in BACE1-dependent NRG1/ErbB4 signaling may participate in the pathogenesis of schizophrenia and related psychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savonenko</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Neurology, and Neuroscience, Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melnikova</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Laird</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>K-A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS41438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS047308</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C587690">Erbb4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066247">Receptor, ErbB-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066247" MajorTopicYN="N">Receptor, ErbB-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18385378</ArticleId><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="doi">10.1073/pnas.0710373105</ArticleId><ArticleId IdType="pii">0710373105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004;5:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322526</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, et al. BACE1, a major determinant of selective vulnerability of the brain to A&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, et al. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailov GV, et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044753</ArticleId></ArticleIdList></Reference><Reference><Citation>Falls DL. Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648463</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378543</ArticleId><ArticleId IdType="pubmed">12145742</ArticleId></ArticleIdList></Reference><Reference><Citation>Law AJ, et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5&#x2032; SNPs associated with the disease. Proc Natl Acad Sci USA. 2006;103:6747&#x2013;6752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458952</ArticleId><ArticleId IdType="pubmed">16618933</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">16442083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci. 2006;9:1477&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlai R, Pisacane P, Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res. 2000;109:219&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762692</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Woo RS, Mei L, Malinow R. The neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity. Neuron. 2007;54:583&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2031848</ArticleId><ArticleId IdType="pubmed">17521571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn CG, et al. Altered neuregulin 1-ErbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767099</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo RS, et al. Neuregulin-1 enhances depolarization-induced GABA release. Neuron. 2007;54:599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521572</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26:365&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11881825</ArticleId><ArticleId IdType="pubmed">16773445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arguello PA, Gogos JA. Modeling madness in mice: One piece at a time. Neuron. 2006;52:179&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015235</ArticleId></ArticleIdList></Reference><Reference><Citation>Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry. 2002;52:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. Neuregulin 1&#x2013;ErbB signaling is necessary for normal myelination and sensory function. J Neurosci. 2006;26:3079&#x2013;3086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674097</ArticleId><ArticleId IdType="pubmed">16554459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson JN, Young LJ, Insel TR. The neuroendocrine basis of social recognition. Front Neuroendocrinol. 2002;23:200&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950245</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra AK, et al. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry. 1997;42:664&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">9325559</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425138</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol. 2001;11:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerecke KM, Wyss JM, Karavanova I, Buonanno A, Carroll SL. ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J Comp Neurol. 2001;433:86&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283951</ArticleId></ArticleIdList></Reference><Reference><Citation>Losonczy A, Magee JC. Integrative properties of radial oblique dendrites in hippocampal CA1 pyramidal neurons. Neuron. 2006;50:291&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630839</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simoni A, Edwards FA. Pathway specificity of dendritic spine morphology in identified synapses onto rat hippocampal CA1 neurons in organotypic slices. Hippocampus. 2006;16:1111&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron. 2006;52:139&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Lipska BK, Weinberger DR. Genetic mouse models of schizophrenia: From hypothesis-based to susceptibility gene-based models. Biol Psychiatry. 2006;59:1180&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631133</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Tuathaigh CM, et al. Phenotypic characterization of spatial cognition and social behavior in mice with &#x201c;knockout&#x201d; of the schizophrenia risk gene neuregulin 1. Neuroscience. 2007;147:18&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512671</ArticleId></ArticleIdList></Reference><Reference><Citation>Corfas G, Roy K, Buxbaum JD. Neuregulin 1&#x2013;ErbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci. 2004;7:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15162166</ArticleId></ArticleIdList></Reference><Reference><Citation>Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr Res. 2004;67:269&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">14984887</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, et al. Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. J Biol Chem. 2007;282:24343&#x2013;24351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17565985</ArticleId></ArticleIdList></Reference><Reference><Citation>Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 2007;16:129&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">17164265</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, et al. Regulation of neuregulin signaling by PSD95 interacting with ErbB4 at CNS synapses. Neuron. 2000;26:443&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">10839362</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbach GD. NRG1 and synaptic function in the CNS. Neuron. 2007;54:495&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjarnadottir M, et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: Differential synaptic function in NRG1+/&#x2212; knockouts compared with wild-type mice. J Neurosci. 2007;27:4519&#x2013;4529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672983</ArticleId><ArticleId IdType="pubmed">17460065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study. Synapse. 2005;57:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15858835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, et al. BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Maatta JA, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell. 2006;17:67&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345647</ArticleId><ArticleId IdType="pubmed">16251361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18391196</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>15</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.</ArticleTitle><Pagination><StartPage>5856</StartPage><EndPage>5861</EndPage><MedlinePgn>5856-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0801677105</ELocationID><Abstract><AbstractText>The long-term goal of nuclear transfer or alternative reprogramming approaches is to create patient-specific donor cells for transplantation therapy, avoiding immunorejection, a major complication in current transplantation medicine. It was recently shown that the four transcription factors Oct4, Sox2, Klf4, and c-Myc induce pluripotency in mouse fibroblasts. However, the therapeutic potential of induced pluripotent stem (iPS) cells for neural cell replacement strategies remained unexplored. Here, we show that iPS cells can be efficiently differentiated into neural precursor cells, giving rise to neuronal and glial cell types in culture. Upon transplantation into the fetal mouse brain, the cells migrate into various brain regions and differentiate into glia and neurons, including glutamatergic, GABAergic, and catecholaminergic subtypes. Electrophysiological recordings and morphological analysis demonstrated that the grafted neurons had mature neuronal activity and were functionally integrated in the host brain. Furthermore, iPS cells were induced to differentiate into dopamine neurons of midbrain character and were able to improve behavior in a rat model of Parkinson's disease upon transplantation into the adult brain. We minimized the risk of tumor formation from the grafted cells by separating contaminating pluripotent cells and committed neural cells using fluorescence-activated cell sorting. Our results demonstrate the therapeutic potential of directly reprogrammed fibroblasts for neuronal cell replacement in the animal model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wernig</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jian-Ping</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Pruszak</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hedlund</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Dongdong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Soldner</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Broccoli</LastName><ForeName>Vania</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Constantine-Paton</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Isacson</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Jaenisch</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-CA087869</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GGP07181</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><GrantID>R37-CA084198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HD0445022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 CA084198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA087869</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS39793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090062" MajorTopicYN="N">Kruppel-Like Factor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391196</ArticleId><ArticleId IdType="pmc">PMC2311361</ArticleId><ArticleId IdType="doi">10.1073/pnas.0801677105</ArticleId><ArticleId IdType="pii">0801677105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev. 2005;19:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. N Engl J Med. 2003;349:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaenisch R. Human cloning: The science and ethics of nuclear transplantation. N Engl J Med. 2004;351:2787&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pubmed">15625328</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman IL. Medicine: Politic stem cells. Nature. 2006;439:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407938</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideout WM, III, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002;109:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakayama T, et al. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science. 2001;292:740&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11326103</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberi T, et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol. 2003;21:1200&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502203</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Maherali N, et al. Global epigenetic remodeling in directly reprogrammed fibroblasts Cell. Stem Cell. 2007;1:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371336</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">17554338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernig M, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">17554336</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 2007;25:1177&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna J, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441:1094&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810245</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: How can we make it work? Trends Neurosci. 2005;28:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15667931</ArticleId></ArticleIdList></Reference><Reference><Citation>Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol. 2003;2:417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849120</ArticleId></ArticleIdList></Reference><Reference><Citation>Parish CL, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest. 2008;118:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2104477</ArticleId><ArticleId IdType="pubmed">18060047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund LM, Isacson O. Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res. 2002;138:411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">12432781</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed CR, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini P, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 1999;2:1137&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain. 2000;123:1365&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez I, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128:1498&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610438</ArticleId><ArticleId IdType="pubmed">15872020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12077607</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS, et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med. 2006;12:1259&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17057709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells. 2008;26:55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707927</ArticleId><ArticleId IdType="pubmed">17951220</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe S, Forsberg-Nilsson K, Spiro AC, Segal M, McKay RD. Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech Dev. 1996;59:89&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18:675&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">10835609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295:868&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786607</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17(Suppl 2):S32&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9358193</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain. 1991;114:2283&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakkenberg B, M&#xf8;ller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54:30&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014294</ArticleId><ArticleId IdType="pubmed">2010756</ArticleId></ArticleIdList></Reference><Reference><Citation>German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol. 1989;26:507&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">2817827</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdo F, et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab. 2003;23:780&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedlund E, et al. Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells. 2007;25:1126&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614084</ArticleId><ArticleId IdType="pubmed">17234989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells. 2007;25:2257&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238728</ArticleId><ArticleId IdType="pubmed">17588935</ArticleId></ArticleIdList></Reference><Reference><Citation>Brustle O, Maskos U, McKay RD. Host-guided migration allows targeted introduction of neurons into the embryonic brain. Neuron. 1995;15:1275&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">8845152</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiano N, Fishell G. Transplantation as a tool to study progenitors within the vertebrate nervous system. J Neurobiol. 1998;36:152&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernig M, et al. Functional integration of embryonic stem cell-derived neurons in vivo. J Neurosci. 2004;24:5258&#x2013;5268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729190</ArticleId><ArticleId IdType="pubmed">15175396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund LM, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002;99:2344&#x2013;2349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122367</ArticleId><ArticleId IdType="pubmed">11782534</ArticleId></ArticleIdList></Reference><Reference><Citation>Brustle O, et al. In vitro-generated neural precursors participate in mammalian brain development. Proc Natl Acad Sci USA. 1997;94:14809&#x2013;14814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25119</ArticleId><ArticleId IdType="pubmed">9405695</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR, Nakashima K, Toni N, Sandler VM, Gage FH. Development of functional human embryonic stem cell-derived neurons in mouse brain. Proc Natl Acad Sci USA. 2005;102:18644&#x2013;18648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317971</ArticleId><ArticleId IdType="pubmed">16352714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18391946</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism.</ArticleTitle><Pagination><StartPage>547</StartPage><EndPage>554</EndPage><MedlinePgn>547-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2100</ELocationID><Abstract><AbstractText>Synaptic dysfunction caused by oligomeric assemblies of amyloid-beta peptide (Abeta) has been linked to cognitive deficits in Alzheimer's disease. Here we found that incubation of primary cortical neurons with oligomeric Abeta decreases the level of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), a phospholipid that regulates key aspects of neuronal function. The destabilizing effect of Abeta on PtdIns(4,5)P2 metabolism was Ca2+-dependent and was not observed in neurons that were derived from mice that are haploinsufficient for Synj1. This gene encodes synaptojanin 1, the main PtdIns(4,5)P2 phosphatase in the brain and at the synapses. We also found that the inhibitory effect of Abeta on hippocampal long-term potentiation was strongly suppressed in slices from Synj1+/- mice, suggesting that Abeta-induced synaptic dysfunction can be ameliorated by treatments that maintain the normal PtdIns(4,5)P2 balance in the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Diego E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'Armi</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Voronov</LastName><ForeName>Sergey V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>McIntire</LastName><ForeName>Laura Beth J</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ann Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Staniszewski</LastName><ForeName>Agniezka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Wan</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS043467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS056049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AT002643</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AT002643</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD047733</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD047733</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019269">Phosphatidylinositol 4,5-Diphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C097702">synaptojanin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.-</RegistryNumber><NameOfSubstance UI="D010738">Type C Phospholipases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008818" MajorTopicYN="N">Mice, Neurologic Mutants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019269" MajorTopicYN="N">Phosphatidylinositol 4,5-Diphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010738" MajorTopicYN="N">Type C Phospholipases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391946</ArticleId><ArticleId IdType="mid">NIHMS57722</ArticleId><ArticleId IdType="pmc">PMC2532986</ArticleId><ArticleId IdType="doi">10.1038/nn.2100</ArticleId><ArticleId IdType="pii">nn.2100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid-&#x3b2; peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjaux E, Hartmann D, De Strooper B. Presenilins inmemory, Alzheimer's disease and therapy. Neuron. 2004;42:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15091335</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat. Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004;279:46363&#x2013;46366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolov Y, et al. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 2006;128:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2151594</ArticleId><ArticleId IdType="pubmed">17101816</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Diaz JC, Simakova O. A&#x3b2; ion channels. Prospects for treating Alzheimer's disease with A&#x3b2; channel blockers. Biochim. Biophys. Acta. 2007;1768:1952&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">17490607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DH, Lee RC, Davis CB, Shank RP. Amyloid peptide A&#x3b2; (1&#x2013;42) bindsselectively and with picomolar affinity to &#x3b1;7 nicotinic acetylcholine receptors. J. Neurochem. 2000;75:1155&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936198</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035995</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HL, Janmey PA. Phosphoinositide regulation of the actin cytoskeleton. Annu. Rev. Physiol. 2003;65:761&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471164</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. Curr. Opin. Neurobiol. 2005;15:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgemann DW, Feng S, Nasuhoglu C. The complex and intriguing lives of PIP2 with ion channels and transporters. Sci. STKE. 2001;29:RE19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734659</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J. Neurochem. 1987;48:1018&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029323</ArticleId></ArticleIdList></Reference><Reference><Citation>Landman N, et al. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl. Acad. Sci. USA. 2006;103:19524&#x2013;19529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748258</ArticleId><ArticleId IdType="pubmed">17158800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasuhoglu C, et al. Nonradioactive analysis of phosphatidylinositides and other anionic phospholipids by anion-exchange high-performance liquid chromatography with suppressed conductivity detection. Anal. Biochem. 2002;301:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814295</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-&#x3b2; oligomers. Ann. Neurol. 2006;60:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192927</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid &#x3b2; peptide and inhibit abeta -induced toxicity. J. Biol. Chem. 2000;275:18495&#x2013;18502.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764800</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor&#x2013;dependent signaling pathway. J. Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid-&#x3b2; protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. (Lond.) 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, et al. A&#x3b2; oligomers induce neuronal oxidative stress through an N-methyld-aspartate receptor&#x2013;dependent mechanism that is blocked by the Alzheimer drugmemantine. J. Biol. Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley JH, Meyer T. Subcellular targeting by membrane lipids. Curr. Opin. Cell Biol. 2001;13:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11248547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremona O, et al. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell. 1999;99:179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10535736</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid-&#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A&#x3b2; oligomers&#x2014;a decade of discovery. J. Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, et al. Ubiquitin hydrolase Uch-L1 rescues &#x3b2;-amyloid&#x2013;induced decreases in synaptic function and contextual memory. Cell. 2006;126:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WT, et al. Delayed reentry of recycling vesicles into the fusion-competent synaptic vesicle pool in synaptojanin 1 knockout mice. Proc. Natl. Acad. Sci. USA. 2002;99:17143&#x2013;17148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139283</ArticleId><ArticleId IdType="pubmed">12481038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani M, et al. The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. Neuron. 2007;56:1004&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653591</ArticleId><ArticleId IdType="pubmed">18093523</ArticleId></ArticleIdList></Reference><Reference><Citation>Irie F, Okuno M, Pasquale EB, Yamaguchi Y. EphrinB-EphB signaling regulates clathrin-mediated endocytosis through tyrosine phosphorylation of synaptojanin 1. Nat. Cell Biol. 2005;7:501&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473167</ArticleId><ArticleId IdType="pubmed">15821731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid beta protein immunotherapy neutralizes A&#x3b2; oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. Use-dependent effects of amyloidogenic fragments of (&#x3b2;)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 2001;21:1327&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762223</ArticleId><ArticleId IdType="pubmed">11160403</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney MT, Bamburg JR. Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. Mol. Neurobiol. 2007;35:21&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17519504</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks B, McMahon HT. Calcium triggers calcineurin-dependent synaptic vesicle recycling in mammalian nerve terminals. Curr. Biol. 1998;8:740&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauerfeind R, Takei K, De Camilli P. Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals. J. Biol. Chem. 1997;272:30984&#x2013;30992.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Wenk MR, Kim Y, Nairn AC, De Camilli P. Regulation of synaptojanin 1by cyclin-dependent kinase 5 at synapses. Proc. Natl. Acad. Sci. USA. 2004;101:546&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327184</ArticleId><ArticleId IdType="pubmed">14704270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001;7:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553933</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA. 1976;73:2424&#x2013;2428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC430592</ArticleId><ArticleId IdType="pubmed">1065897</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker GA, Goslin K. Culturing Nerve Cells. MIT Press, Cambridge; Massachusetts: 1991.</Citation></Reference><Reference><Citation>Dahlgren KN, et al. Oligomeric and fibrillar species of amyloid-&#x3b2; peptides differentially affect neuronal viability. J. Biol. Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;&#x3b2;-secretase&#x201d; site occurs in the golgi apparatus. J. Biol. Chem. 1996;271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, et al. Amyloid-&#x3b2; peptide inhibits activation of the nitric oxide/cGMP/cAMPresponsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 2005;25:6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG. Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-d-aspartate receptor antagonist AP5. J. Neurosci. 1989;9:3040&#x2013;3057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569656</ArticleId><ArticleId IdType="pubmed">2552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 2004;114:1624&#x2013;1634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529285</ArticleId><ArticleId IdType="pubmed">15578094</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18391961</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.</ArticleTitle><Pagination><StartPage>507</StartPage><EndPage>509</EndPage><MedlinePgn>507-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm1752</ELocationID><Abstract><AbstractText>Postmortem analysis of five subjects with Parkinson's disease 9-14 years after transplantation of fetal midbrain cell suspensions revealed surviving grafts that included dopamine and serotonin neurons without pathology. These findings are important for the understanding of the etiopathogenesis of midbrain dopamine neuron degeneration and future use of cell replacement therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Ivar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dalhousie University and Queen Elizabeth II Health Sciences Centre, Division of Neurosurgery and Department of Anatomy &amp; Neurobiology, 1976 Summer Street, Halifax, Nova Scotia B3H 3A7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vi&#xf1;uela</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Astradsson</LastName><ForeName>Arnar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mukhida</LastName><ForeName>Karim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hallett</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Harold</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tierney</LastName><ForeName>Travis</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Holness</LastName><ForeName>Renn</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dagher</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Isacson</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS039793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS 39793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2008 May;14(5):483-5. doi: 10.1038/nm0508-483.</RefSource><PMID Version="1">18463652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016380" MajorTopicYN="N">Brain Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391961</ArticleId><ArticleId IdType="mid">NIHMS82029</ArticleId><ArticleId IdType="pmc">PMC2656682</ArticleId><ArticleId IdType="doi">10.1038/nm1752</ArticleId><ArticleId IdType="pii">nm1752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Isacson O, Bjorklund LM, Schumacher JM. Ann. Neurol. 2003;53 Suppl 3:S135&#x2013;S148.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy F. Dtsch. Z. Nervenheilkd. 1913;50:50&#x2013;55.</Citation></Reference><Reference><Citation>Eriksen JL, Wszolek Z, Petrucelli L. Arch. Neurol. 2005;62:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767499</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Wakabayashi K. Neuropathology. 2001;21:315&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez I, et al. Brain. 2005;128:1498&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610438</ArticleId><ArticleId IdType="pubmed">15872020</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, et al. Am. J. Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusisto E, Parkkinen L, Alafuzoff I. J. Neuropathol. Exp. Neurol. 2003;62:1241&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692700</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Schuck TM, Lee VM, Trojanowski JQ. Exp. Neurol. 2001;168:347&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259122</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. J. Neurosci. 2007;27:8011&#x2013;8022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672736</ArticleId><ArticleId IdType="pubmed">17652591</ArticleId></ArticleIdList></Reference><Reference><Citation>Carta M, Carlsson T, Kirik D, Bjorklund A. Brain. 2007;130:1819&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452372</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Stem Cells. 2007;25:2257&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238728</ArticleId><ArticleId IdType="pubmed">17588935</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed CR, et al. N. Engl. J. Med. 2001;344:710&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, et al. Ann. Neurol. 2003;54:403&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953276</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrier AL, et al. Proc. Natl. Acad. Sci. USA. 2004;101:12543&#x2013;12548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515094</ArticleId><ArticleId IdType="pubmed">15310843</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS, et al. Nat. Med. 2006;12:1259&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17057709</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18391962</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.</ArticleTitle><Pagination><StartPage>504</StartPage><EndPage>506</EndPage><MedlinePgn>504-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm1747</ELocationID><Abstract><AbstractText>Fourteen years after transplantation into the striatum of an individual with Parkinson's disease, grafted nigral neurons were found to have Lewy body-like inclusions that stained positively for alpha-synuclein and ubiquitin and to have reduced immunostaining for dopamine transporter. These pathological changes suggest that Parkinson's disease is an ongoing process that can affect grafted cells in the striatum in a manner similar to host dopamine neurons in the substantia nigra. These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kordower</LastName><ForeName>Jeffrey H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA. jkordowe@rush.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2008 May;14(5):483-5. doi: 10.1038/nm0508-483.</RefSource><PMID Version="1">18463652</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Oct 26;538(7626):S13-S16. doi: 10.1038/538S13a.</RefSource><PMID Version="1">27783578</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016380" MajorTopicYN="N">Brain Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId><ArticleId IdType="doi">10.1038/nm1747</ArticleId><ArticleId IdType="pii">nm1747</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18391963</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.</ArticleTitle><Pagination><StartPage>501</StartPage><EndPage>503</EndPage><MedlinePgn>501-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm1746</ELocationID><Abstract><AbstractText>Two subjects with Parkinson's disease who had long-term survival of transplanted fetal mesencephalic dopaminergic neurons (11-16 years) developed alpha-synuclein-positive Lewy bodies in grafted neurons. Our observation has key implications for understanding Parkinson's pathogenesis by providing the first evidence, to our knowledge, that the disease can propagate from host to graft cells. However, available data suggest that the majority of grafted cells are functionally unimpaired after a decade, and recipients can still experience long-term symptomatic relief.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia-Yi</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, 221 84 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Soulet</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hagell</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Niall P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Rehncrona</LastName><ForeName>Stig</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bj&#xf6;rklund</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Widner</LastName><ForeName>H&#xe5;kan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lindvall</LastName><ForeName>Olle</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>Patrik</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G-4062</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2008 May;14(5):483-5. doi: 10.1038/nm0508-483.</RefSource><PMID Version="1">18463652</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Oct 26;538(7626):S13-S16. doi: 10.1038/538S13a.</RefSource><PMID Version="1">27783578</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016380" MajorTopicYN="N">Brain Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId><ArticleId IdType="doi">10.1038/nm1746</ArticleId><ArticleId IdType="pii">nm1746</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18400162</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>51</EndPage><MedlinePgn>42-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.02.003</ELocationID><Abstract><AbstractText>Aggregation of amyloid-beta (Abeta) peptide into soluble and insoluble forms within the brain extracellular space is central to the pathogenesis of Alzheimer's disease. Full-length amyloid precursor protein (APP) is endocytosed from the cell surface into endosomes where it is cleaved to produce Abeta. Abeta is subsequently released into the brain interstitial fluid (ISF). We hypothesized that synaptic transmission results in more APP endocytosis, thereby increasing Abeta generation and release into the ISF. We found that inhibition of clathrin-mediated endocytosis immediately lowers ISF Abeta levels in vivo. Two distinct methods that increased synaptic transmission resulted in an elevation of ISF Abeta levels. Inhibition of endocytosis, however, prevented the activity-dependent increase in Abeta. We estimate that approximately 70% of ISF Abeta arises from endocytosis-associated mechanisms, with the vast majority of this pool also dependent on synaptic activity. These findings have implications for AD pathogenesis and may provide insights into therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. cirritoj@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jae-Eun</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jiyeon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Verges</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Silverio</LastName><ForeName>Luz M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mennerick</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS054174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA07261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH78823</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH078823</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS54174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="Y">Endocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18400162</ArticleId><ArticleId IdType="mid">NIHMS46988</ArticleId><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.02.003</ArticleId><ArticleId IdType="pii">S0896-6273(08)00124-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993;90:2092&#x2013;2096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46027</ArticleId><ArticleId IdType="pubmed">8446635</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem. 2004;279:29639&#x2013;29646.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cam JA, Zerbinatti CV, Li Y, Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J Biol Chem. 2005;280:15464&#x2013;15470.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705569</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC cell biology. 2005;6:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208872</ArticleId><ArticleId IdType="pubmed">16095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic Activity Regulates Interstitial Fluid Amyloid-beta Levels In Vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. The American journal of psychiatry. 2006;163:2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson SM, Brasnjo G, Hayashi M, Wolfel M, Collesi C, Giovedi S, Raimondi A, Gong LW, Ariel P, Paradise S, et al. A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science. 2007;316:570&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S. Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. Ann Neurol. 1997;41:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuser JE, Reese TS. Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction. The Journal of cell biology. 1973;57:315&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108984</ArticleId><ArticleId IdType="pubmed">4348786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Youkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikin AF, Annaert WG, Takei K, De Camilli P, Jahn R, Greengard P, Buxbaum JD. Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5-containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway. J Biol Chem. 1996;271:31783&#x2013;31786.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP Processing and Synaptic Function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673&#x2013;10678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL, Selkoe DJ, Koo CH. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci . 1996;109(Pt 5):991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743946</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Levey AI. Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments. Mol Cell Neurosci. 2000;16:111&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, Plotkine M, Marchand-Verrecchia C, Vivien D, Buisson A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci. 2005;25:9367&#x2013;9377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725703</ArticleId><ArticleId IdType="pubmed">16221845</ArticleId></ArticleIdList></Reference><Reference><Citation>Losonczy A, Somogyi P, Nusser Z. Reduction of excitatory postsynaptic responses by persistently active metabotropic glutamate receptors in the hippocampus. J Neurophysiol. 2003;89:1910&#x2013;1919.</Citation><ArticleIdList><ArticleId IdType="pubmed">12686572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol (Berl) 1994;87:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059603</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks B, McMahon HT. Calcium triggers calcineurin-dependent synaptic vesicle recycling in mammalian nerve terminals. Curr Biol. 1998;8:740&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651678</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez-Sterling NR, Lo AC, Sisodia SS, Koo EH. Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci. 1997;17:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793693</ArticleId><ArticleId IdType="pubmed">8987743</ArticleId></ArticleIdList></Reference><Reference><Citation>Maycox PR, Link E, Reetz A, Morris SA, Jahn R. Clathrin-coated vesicles in nervous tissue are involved primarily in synaptic vesicle recycling. The Journal of cell biology. 1992;118:1379&#x2013;1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289614</ArticleId><ArticleId IdType="pubmed">1325974</ArticleId></ArticleIdList></Reference><Reference><Citation>McNaughton BL. Evidence for two physiologically distinct perforant pathways to the fascia dentata. Brain Res. 1980;199:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">7407615</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton AJ, Kirchhausen T, Murthy VN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc Natl Acad Sci U S A. 2006;103:17955&#x2013;17960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693854</ArticleId><ArticleId IdType="pubmed">17093049</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48:913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P. Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J Biol Chem. 1993;268:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci. 2002;22:9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta-secretase&#x201d; site occurs in the golgi apparatus. J Biol Chem. 1996;271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JT, Kelley BG, Lambert TJ, Cook DG, Sullivan JM. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci U S A. 2007;104:353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765464</ArticleId><ArticleId IdType="pubmed">17185415</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. The Journal of cell biology. 1993;123:1107&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119875</ArticleId><ArticleId IdType="pubmed">8245121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk MR, Pellegrini L, Klenchin VA, Di Paolo G, Chang S, Daniell L, Arioka M, Martin TF, De Camilli P. PIP kinase Igamma is the major PI(4,5)P(2) synthesizing enzyme at the synapse. Neuron. 2001;32:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Bennett DA, Li Y, Bienias JL, Mendes de Leon CF, Evans DA. Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology. 2005;64:380&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology. 2003;61:1479&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci. 2006;26:10939&#x2013;10948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674654</ArticleId><ArticleId IdType="pubmed">17065436</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18410407</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Cerebral amyloid angiopathy and parenchymal amyloid deposition in transgenic mice expressing the Danish mutant form of human BRI2.</ArticleTitle><Pagination><StartPage>58</StartPage><EndPage>68</EndPage><MedlinePgn>58-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1750-3639.2008.00164.x</ELocationID><Abstract><AbstractText>Familial Danish dementia (FDD) is an autosomal dominant neurodegenerative disease clinically characterized by the presence of cataracts, hearing impairment, cerebellar ataxia and dementia. Neuropathologically, FDD is characterized by the presence of widespread cerebral amyloid angiopathy (CAA), parenchymal amyloid deposition and neurofibrillary tangles. FDD is caused by a 10-nucleotide duplication-insertion in the BRI(2) gene that generates a larger-than-normal precursor protein, of which the Danish amyloid subunit (ADan) comprises the last 34 amino acids. Here, we describe a transgenic mouse model for FDD (Tg-FDD) in which the mouse Prnp (prion protein) promoter drives the expression of the Danish mutant form of human BRI(2). The main neuropathological findings in Tg-FDD mice are the presence of widespread CAA and parenchymal deposition of ADan. In addition, we observe the presence of amyloid-associated gliosis, an inflammatory response and deposition of oligomeric ADan. As the animals aged, they showed abnormal grooming behavior, an arched back, and walked with a wide-based gait and shorter steps. This mouse model may give insights on the pathogenesis of FDD and will prove useful for the development of therapeutics. Moreover, the study of Tg-FDD mice may offer new insights into the role of amyloid in neurodegeneration in other disorders, including Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. rvidal@iupui.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbeito</LastName><ForeName>Ana G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Miravalle</LastName><ForeName>Leticia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS050227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120083">ITM2B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072002">Prion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512657">Prnp protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006120" MajorTopicYN="N">Grooming</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072002" MajorTopicYN="N">Prion Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18410407</ArticleId><ArticleId IdType="mid">NIHMS46779</ArticleId><ArticleId IdType="pmc">PMC2605177</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00164.x</ArticleId><ArticleId IdType="pii">BPA164</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K et&#x2003;al (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human p301s tau protein. J Neurosci 22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T et&#x2003;al (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O, Giaccone G, Verga L, Pollo B, Frangione B, Farlow MR et&#x2003;al (1993) Beta PP participates in PrP&#x2010;amyloid plaques of Gerstmann&#x2010;Str&#xe4;ussler&#x2010;Scheinker disease, Indiana kindred. J Neuropathol Exp Neurol 52:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093899</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SI, Vidal R, Frangione B, Levy E (2004) Axonal transport of British and Danish amyloid peptides via secretory vesicles. FASEB J 18:373&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656991</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie R, Yamada M, Moskowitz M, Hyman B (2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158:1065&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850363</ArticleId><ArticleId IdType="pubmed">11238054</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomaraswamy J, Herzig MC, Kaeser SA, Ghiso J, Jucker M (2006) Transgenic mouse models of familial British and Danish dementias. Alzheimer's &amp; Dementia 2:S116.</Citation></Reference><Reference><Citation>Deleersnijder W, Hong G, Cortvrindt R, Poirier C, Tylzanowski P, Pittois K et&#x2003;al (1996) Isolation of markers for chondro&#x2010;osteogenic differentiation using cDNA library subtraction. Molecular cloning and characterization of a gene belonging to a novel multigene family of integral membrane proteins. J Biol Chem 271:19475&#x2013;19482.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702637</ArticleId></ArticleIdList></Reference><Reference><Citation>Domnitz SB, Robbins EM, Hoang AW, Garcia&#x2010;Alloza M, Hyman BT, Rebeck GW et&#x2003;al (2005) Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J Neuropathol Exp Neurol 64:588&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042310</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Janus CG (2007) Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet 37:79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G, Gunasekera N, Lee M, Lelyveld V, El&#x2010;Agnaf OM, Wright A, Austen B (2004) Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. J Neurochem 88:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW et&#x2003;al (2002) Time course of the development of Alzheimer&#x2010;like pathology in the doubly transgenic PS1&#x2003;+&#x2003;APP mouse. Exp Neurol 173:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkness KA, Coles A, Pohl U, Xuereb JH, Baron JC, Lennox GG (2004) Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy. Eur J Neurol 11:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692890</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD et&#x2003;al (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, Ghiso J, Lashley T, Rostagno A, Guerin CJ, Gibb G et&#x2003;al (2001) Regional distribution of amyloid&#x2010;Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol 158:515&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850296</ArticleId><ArticleId IdType="pubmed">11159188</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin CJ et&#x2003;al (2002) Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid&#x2010;Dan and amyloid&#x2010;beta. J Neuropathol Exp Neurol 61:254&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Wang R, Gordon DJ, Bass J, Steiner DF, Lynn DG et&#x2003;al (1999) Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci 2:984&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Creemers JW, Chu S, Thinakaran G, Sisodia SS (2002) Proteolytic processing of familial British dementia&#x2010;associated BRI variants: evidence for enhanced intracellular accumulation of amyloidogenic peptides. J Biol Chem 277:1872&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709554</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Fluhrer R, Reiss K, Kremmer E, Saftig P, Haass C (2008) Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/b. J Biol Chem 283:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965014</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C et&#x2003;al (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J, Vitek MP, Xu F, Previti ML, Davis J, Van Nostrand WE (2005) Reducing cerebral microvascular amyloid&#x2010;beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci 25:6271&#x2013;6277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725284</ArticleId><ArticleId IdType="pubmed">16000616</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J, Xu F, Davis J, Otte&#x2010;H&#xf6;ller I, Verbeek MM, Van Nostrand WE (2005) Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol 167:505&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603574</ArticleId><ArticleId IdType="pubmed">16049335</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama K (1997) Furin: a mammalian subtilisin/Kex2p&#x2010;like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 327:625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218878</ArticleId><ArticleId IdType="pubmed">9599222</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS (2004) Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 62:494&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">14872042</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant GT, Esiri MM (1977) Familial cerebral amyloid angiopathies. In: The Neuropathology of Dementia. Esiri MM, Morris JH (eds), pp. 260&#x2013;276. University Press: Cambridge.</Citation></Reference><Reference><Citation>Rensink AA, De Waal RM, Kremer B, Verbeek MM (2003) Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43:207&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostagno A, Revesz T, Lashley T, Tomidokoro Y, Magnotti L, Braendgaard H et&#x2003;al (2002) Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem 277:49782&#x2013;49790.</Citation><ArticleIdList><ArticleId IdType="pubmed">12388551</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf6;mgren E (1981) Heredopathia ophthalmo&#x2010;oto&#x2010;encephalica. In: Handbook of Clinical Neurology. Vinken PJ, Bruyn GW (eds), pp. 150&#x2013;152. North&#x2010;Holland Publishing Company: Amsterdam.</Citation></Reference><Reference><Citation>Str&#xf6;mgren E, Dalby A, Dalby MA, Ranheim B (1970) Cataract, deafness, cerebellar ataxia, psychosis and dementia: a new syndrome. Acta Neurol Scand 46(Suppl. 43):261&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">5457846</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C et&#x2003;al (2000) Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol 157:1283&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850171</ArticleId><ArticleId IdType="pubmed">11021833</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Frangione B, Rostagno A, Mead S, R&#xe9;v&#xe9;sz T, Plant G, Ghiso J (1999) A stop&#x2010;codon mutation in the BRI gene associated with familial British dementia. Nature 399:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Revesz T, Rostagno A, Kim E, Holton JL, Bek T et&#x2003;al (2000) A decamer duplication in the 3&#x2019; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA 97:4920&#x2013;4925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Delisle MB, Ghetti B (2004) Neurodegeneration caused by proteins with an aberrant carboxyl&#x2010;terminus. J Neuropathol Exp Neurol 63:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15330334</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV (1987) Cerebral amyloid angiopathy a critical review. Stroke 18:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV, Secor DL, Pardridge WM, Gray F (1990) Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread Alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy. Ann Neurol 28:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2197973</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE (1998) Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 153:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18413480</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.</ArticleTitle><Pagination><StartPage>540</StartPage><EndPage>544</EndPage><MedlinePgn>540-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.65.4.540</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate amyloid accumulation by carbon 11-labeled Pittsburgh Compound B (11C-PiB) in hereditary cerebral amyloid angiopathy and APP locus duplication.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">Positron emission tomography with 11C-PiB and magnetic resonance imaging were performed for 2 patients, 49-year-old and 60-year-old siblings with APP locus duplication, with hereditary Alzheimer disease and cerebral amyloid angiopathy.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Change in 11C-PiB uptake.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Uptake of 11C-PiB was increased especially in the striatum (caudate nucleus to 225% and 280% of the control mean and putamen to 166% and 185% of the control mean) and in the posterior cingulate (to 168% and 198% of the control mean), and it was marginally increased in other cortical brain areas. The pattern of increased 11C-PiB uptake was different from that seen in sporadic Alzheimer disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Amyloid imaging with 11C-PiB positron emission tomography is a useful tool for detecting in vivo amyloid accumulation in patients with hereditary cerebral amyloid angiopathy. However, the pattern of 11C-PiB accumulation differs between patients with typical AD and patients with APP locus duplication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Oulu University Hospital, University of Oulu, Oulu, Finland. anne.remes@oulu.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laru</LastName><ForeName>Lauri</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tuominen</LastName><ForeName>Hannu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Aalto</LastName><ForeName>Sargo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kemppainen</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mononen</LastName><ForeName>Helin&#xe4;</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>N&#xe5;gren</LastName><ForeName>Kjell</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Parkkola</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="Y">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028243" MajorTopicYN="N">Cerebral Amyloid Angiopathy, Familial</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="N">Gene Duplication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18413480</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.4.540</ArticleId><ArticleId IdType="pii">65/4/540</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18417702</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>16</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.</ArticleTitle><Pagination><StartPage>4231</StartPage><EndPage>4237</EndPage><MedlinePgn>4231-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5161-07.2008</ELocationID><Abstract><AbstractText>The current development of immunotherapy for Alzheimer's disease is based on the assumption that human-derived amyloid beta protein (Abeta) can be targeted in a similar manner to animal cell-derived or synthetic Abeta. Because the structure of Abeta depends on its source and the presence of cofactors, it is of great interest to determine whether human-derived oligomeric Abeta species impair brain function and, if so, whether or not their disruptive effects can be prevented using antibodies. We report that untreated ex vivo human CSF that contains Abeta dimers rapidly inhibits hippocampal long-term potentiation in vivo and that acute systemic infusion of an anti-Abeta monoclonal antibody can prevent this disruption of synaptic plasticity. Abeta monomer isolated from human CSF did not affect long-term potentiation. These results strongly support a strategy of passive immunization against soluble Abeta oligomers in early Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klyubin</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>Vicki</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Welzel</LastName><ForeName>Alfred T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>William K</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Anwyl</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG020245</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>067660</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG20245</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18417702</ArticleId><ArticleId IdType="mid">NIHMS60594</ArticleId><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5161-07.2008</ArticleId><ArticleId IdType="pii">28/16/4231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association. Ed 3. Arlington, VA: American Psychiatric Association; 1987. Diagnostic and statistical manual of mental disorders.</Citation></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta- peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1&#x2013;42) and tau levels in CSF. Neurology. 1999;52:1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, St., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Morris JH, Selkoe DJ, Kosik KS. Tau epitopes are incorporated into a range of lesions in Alzheimer's disease. J Neuropathol Exp Neurol. 1987;46:611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">2443617</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small A&#x3b2; oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang LY, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging. 2002;23:991&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer's disease A&#x3b2; vaccine reduces central nervous system A&#x3b2; levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618542</ArticleId><ArticleId IdType="pubmed">15215183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, O'Carroll C. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Phil Trans Roy Soc Lond B Biol Sci. 2003;358:773&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693159</ArticleId><ArticleId IdType="pubmed">12744273</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. Immunization with amyloid-beta attenuates Alzheimer disease- like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther. 2007;9:79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17330405</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar G, Mehta T, Walsh D, Selkoe D. Effects of secreted oligomers of amyloid {beta}-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (Lond) 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid beta-peptide (A beta) fibrillogenesis block oligomerization of natural A beta and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725159</ArticleId><ArticleId IdType="pubmed">15758153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QW, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18417708</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>16</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.</ArticleTitle><Pagination><StartPage>4283</StartPage><EndPage>4292</EndPage><MedlinePgn>4283-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4814-07.2008</ELocationID><Abstract><AbstractText>Microglial cells aggregate around amyloid plaques in Alzheimer's disease, but, despite their therapeutic potential, various aspects of their reactive kinetics and role in plaque pathogenesis remain hypothetical. Through use of in vivo imaging and quantitative morphological measures in transgenic mice, we demonstrate that local resident microglia rapidly react to plaque formation by extending processes and subsequently migrating toward plaques, in which individual transformed microglia somata remain spatially stable for weeks. The number of plaque-associated microglia increased at a rate of almost three per plaque per month, independent of plaque volume. Larger plaques were surrounded by larger microglia, and a subset of plaques changed in size over time, with an increase or decrease related to the volume of associated microglia. Far from adopting a more static role, plaque-associated microglia retained rapid process and membrane movement at the plaque/glia interface. Microglia internalized systemically injected amyloid-binding dye at a much higher rate in the vicinity of plaques. These results indicate a role for microglia in plaque maintenance and provide a model with multiple targets for therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haiss</LastName><ForeName>Florent</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Eicke</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Radde</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Calhoun</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG0011039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18417708</ArticleId><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4814-07.2008</ArticleId><ArticleId IdType="pii">28/16/4283</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andra K, Abramowski D, Duke M, Probst A, Wiederhold KH, Burki K, Goedert M, Sommer B, Staufenbiel M. Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging. 1996;17:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Hyman BT. Alzheimer's disease: what multiphoton microscopy teaches us. The Neuroscientist. 2002;8:386&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW. Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of &#x201c;malactivation&#x201d; of microglia enough? J Neuroinflammation. 2005;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545943</ArticleId><ArticleId IdType="pubmed">15644140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 1999;96:14088&#x2013;14093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci. 2001;21:858&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762315</ArticleId><ArticleId IdType="pubmed">11157072</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging. 2004;25:675&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172747</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak J, Potempska A, LeVine H, Haske T, Dickson D, Mazur-Kolecka B. Extracellular deposits of A beta produced in cultures of Alzheimer disease brain vascular smooth muscle cells. J Neuropathol Exp Neurol. 2005;64:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715088</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. EMBO J. 1987;6:3627&#x2013;3632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553830</ArticleId><ArticleId IdType="pubmed">3322812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirasawa T, Ohsawa K, Imai Y, Ondo Y, Akazawa C, Uchino S, Kohsaka S. Visualization of microglia in living tissues using Iba1-EGFP transgenic mice. J Neurosci Res. 2005;81:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948177</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Science. 2003;302:834&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593170</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005;64:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganetti PA, Lis M, Klafki HW, Staufenbiel M. Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. J Neurosci Res. 1996;46:283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8933367</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, K&#xe4;ser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. A&#x3b2;42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002;40:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379913</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 2001;22:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Nikolic V, Tan J. The microglial &#x201c;activation&#x201d; continuum: from innate to adaptive responses. J Neuroinflammation. 2005;2:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1298325</ArticleId><ArticleId IdType="pubmed">16259628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol (Berl) 1990;81:116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18434538</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>17</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.</ArticleTitle><Pagination><StartPage>6439</StartPage><EndPage>6444</EndPage><MedlinePgn>6439-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0802082105</ELocationID><Abstract><AbstractText>Protein misfolding is intimately associated with devastating human neurodegenerative diseases, including Alzheimer's, Huntington's, and Parkinson's. Although disparate in their pathophysiology, many of these disorders share a common theme, manifested in the accumulation of insoluble protein aggregates in the brain. Recently, the major disease protein found in the pathological inclusions of two of these diseases, amyotrophic lateral sclerosis (ALS) and frontal temporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U), was identified as the 43-kDa TAR-DNA-binding protein (TDP-43), providing a molecular link between them. TDP-43 is a ubiquitously expressed nuclear protein that undergoes a pathological conversion to an aggregated cytoplasmic localization in affected regions of the nervous system. Whether TDP-43 itself can convey toxicity and whether its abnormal aggregation is a cause or consequence of pathogenesis remain unknown. We report a yeast model to define mechanisms governing TDP-43 subcellular localization and aggregation. Remarkably, this simple model recapitulates several salient features of human TDP-43 proteinopathies, including conversion from nuclear localization to cytoplasmic aggregation. We establish a connection between this aggregation and toxicity. The pathological features of TDP-43 are distinct from those of yeast models of other protein-misfolding diseases, such as polyglutamine. This suggests that the yeast model reveals specific aspects of the underlying biology of the disease protein rather than general cellular stresses associated with accumulating misfolded proteins. This work provides a mechanistic framework for investigating the toxicity of TDP-43 aggregation relevant to human disease and establishes a manipulable, high-throughput model for discovering potential therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Brian S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaffery</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023454</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR022588</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR021023</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR019409</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: S.L. is a cofounder of and owns stock in FoldRx Pharmaceuticals, a company developing therapies for diseases of protein misfolding. S.L. and A.D.G. are inventors on patents and patent applications that have been licensed to FoldRx Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18434538</ArticleId><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId><ArticleId IdType="pii">0802082105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dobson CM. Protein folding and misfolding. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Balin BJ, Otvos L, Jr, Trojanowski JQ. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991;251:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell. 1983;35:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">6414721</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004;56:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">15349867</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, et al. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol. 2006;59:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Jones AG, Dickson DW. Hippocampal sclerosis and ubiquitin-positive inclusions in dementia lacking distinctive histopathology. Dementia Geriatr Cognit Disorders. 2004;17:342&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, et al. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69:3584&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35:320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Pagani F, Baralle FE. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett. 2006;580:1339&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Reddy NM, Shen CK. Higher-order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci USA. 2002;99:13583&#x2013;13588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129717</ArticleId><ArticleId IdType="pubmed">12361981</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. TDP-43 in amyotrophic lateral sclerosis: Pathophysiology or patho-babel? Ann Neurol. 2007;61:382&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models, Science. 2006;313:324&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology Science. 2003;302:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780172</ArticleId><ArticleId IdType="pubmed">14657500</ArticleId></ArticleIdList></Reference><Reference><Citation>Duennwald ML, et al. A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci USA. 2006;103:11051&#x2013;11056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544172</ArticleId><ArticleId IdType="pubmed">16832049</ArticleId></ArticleIdList></Reference><Reference><Citation>Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA. 2006;103:11045&#x2013;11050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544171</ArticleId><ArticleId IdType="pubmed">16832050</ArticleId></ArticleIdList></Reference><Reference><Citation>Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA. 2000;97:1589&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26479</ArticleId><ArticleId IdType="pubmed">10677504</ArticleId></ArticleIdList></Reference><Reference><Citation>Meriin AB, et al. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol. 2002;157:997&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174031</ArticleId><ArticleId IdType="pubmed">12058016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagriantsev S, Liebman S. Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol. 2006;4:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1594584</ArticleId><ArticleId IdType="pubmed">17002801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Lindquist S. De novo generation of a PrPSc-like conformation in living cells. Nat Cell Biol. 1999;1:358&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD. Beer and bread to brains and beyond: Can yeast cells teach us about neurodegenerative disease? NeuroSignals. 2008;16:52&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097160</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. TDP-43: A novel neurodegenerative proteinopathy. Curr Opin Neurobiol. 2007;17:548&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678676</ArticleId><ArticleId IdType="pubmed">17936612</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, et al. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol. 2003;163:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868149</ArticleId><ArticleId IdType="pubmed">12819014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Willingham S, et al. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science. 2003;302:1769&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pubmed">14657499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(Suppl):S10&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagriantsev SN, Kushnirov VV, Liebman SW. Analysis of amyloid aggregates using agarose gel electrophoresis. Methods Enzymol. 2006;412:33&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA. 2008;105:145&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530&#x2013;10534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008 doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgini F, et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet. 2005;37:526&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449881</ArticleId><ArticleId IdType="pubmed">15806102</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie C, Fink GR. Methods in Ezymology: Guide to Yeast Genetics and Molecular Biology. New York: Academic; 2002. p. 169.</Citation></Reference><Reference><Citation>Ito H, Fukuda Y, Murata K, Kimura A. Transformation of intact yeast cells treated with alkali cations. J Bacteriol. 1983;153:163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC217353</ArticleId><ArticleId IdType="pubmed">6336730</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchowski PJ, et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA. 2000;97:7841&#x2013;7846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16632</ArticleId><ArticleId IdType="pubmed">10859365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18436784</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>320</Volume><Issue>5875</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.</ArticleTitle><Pagination><StartPage>520</StartPage><EndPage>523</EndPage><MedlinePgn>520-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1156609</ELocationID><Abstract><AbstractText>beta-Secretase plays a critical role in beta-amyloid formation and thus provides a therapeutic target for Alzheimer's disease. Inhibitor design has usually focused on active-site binding, neglecting the subcellular localization of active enzyme. We have addressed this issue by synthesizing a membrane-anchored version of a beta-secretase transition-state inhibitor by linking it to a sterol moiety. Thus, we targeted the inhibitor to active beta-secretase found in endosomes and also reduced the dimensionality of the inhibitor, increasing its local membrane concentration. This inhibitor reduced enzyme activity much more efficiently than did the free inhibitor in cultured cells and in vivo. In addition to effectively targeting beta-secretase, this strategy could also be used in designing potent drugs against other membrane protein targets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstr. 108, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schlechtingen</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Weidlich</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ries</LastName><ForeName>Jonas</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Braxmeier</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Schwille</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>J&#xf6;rg B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kn&#xf6;lker</LastName><ForeName>Hans-Joachim</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013261">Sterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021962" MajorTopicYN="N">Membrane Microdomains</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013261" MajorTopicYN="Y">Sterols</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId><ArticleId IdType="doi">10.1126/science.1156609</ArticleId><ArticleId IdType="pii">320/5875/520</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18439297</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2350</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2008</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC medical genetics</Title><ISOAbbreviation>BMC Med Genet</ISOAbbreviation></Journal><ArticleTitle>A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele.</ArticleTitle><Pagination><StartPage>37</StartPage><MedlinePgn>37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2350-9-37</ELocationID><Abstract><AbstractText>Genetic and biochemical studies support the apolipoprotein E (APOE) epsilon4 allele as a major risk factor for late-onset Alzheimer's disease (AD), though ~50% of AD patients do not carry the allele. APOE transports cholesterol for luteinizing hormone (LH)-regulated steroidogenesis, and both LH and neurosteroids have been implicated in the etiology of AD. Since polymorphisms of LH beta-subunit (LHB) and its receptor (LHCGR) have not been tested for their association with AD, we scored AD and age-matched control samples for APOE genotype and 14 polymorphisms of LHB and LHCGR. Thirteen gene-gene interactions between the loci of LHB, LHCGR, and APOE were associated with AD. The most strongly supported of these interactions was between an LHCGR intronic polymorphism (rs4073366; lhcgr2) and APOE in males, which was detected using all three interaction analyses: linkage disequilibrium, multi-dimensionality reduction, and logistic regression. While the APOE epsilon4 allele carried significant risk of AD in males [p = 0.007, odds ratio (OR) = 3.08(95%confidence interval: 1.37, 6.91)], epsilon4-positive males carrying 1 or 2 C-alleles at lhcgr2 exhibited significantly decreased risk of AD [OR = 0.06(0.01, 0.38); p = 0.003]. This suggests that the lhcgr2 C-allele or a closely linked locus greatly reduces the risk of AD in males carrying an APOE epsilon4 allele. The reversal of risk embodied in this interaction powerfully supports the importance of considering the role gene-gene interactions play in the etiology of complex biological diseases and demonstrates the importance of using multiple analytic methods to detect well-supported gene-gene interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haasl</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Section of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA. haasl@wisc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>M Reza</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Meethal</LastName><ForeName>Sivan Vadakkadath</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Gleason</LastName><ForeName>Carey E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Genet</MedlineTA><NlmUniqueID>100968552</NlmUniqueID><ISSNLinking>1471-2350</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037101">Luteinizing Hormone, beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011974">Receptors, LH</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037101" MajorTopicYN="N">Luteinizing Hormone, beta Subunit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011974" MajorTopicYN="N">Receptors, LH</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18439297</ArticleId><ArticleId IdType="pmc">PMC2396156</ArticleId><ArticleId IdType="doi">10.1186/1471-2350-9-37</ArticleId><ArticleId IdType="pii">1471-2350-9-37</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, Tanzi RE. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res. 2004;50:385&#x2013;396. doi: 10.1016/j.phrs.2003.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2003.11.018</ArticleId><ArticleId IdType="pubmed">15304236</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278:1349&#x2013;1356. doi: 10.1001/jama.278.16.1349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.278.16.1349</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses A, Devlin B, Conneally P, Small G, Saunders A, Pritchard M. Measuring the genetic contribution of APOE in late-onset Alzheimer disease. Am J Hum Genet. 1995;57:A202.</Citation></Reference><Reference><Citation>Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000;66:196&#x2013;204. doi: 10.1086/302710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302710</ArticleId><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="pubmed">10631151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Tian J, Shi J, Bensemain F, Cottel D, Lendon C, Amouyel P, Mann D, Lambert JC. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol Aging. 2006;27:1212&#x2013;1215. doi: 10.1016/j.neurobiolaging.2005.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.07.013</ArticleId><ArticleId IdType="pubmed">16154235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk A, DeKosky ST, Kamboh MI. Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease. Neurosci Lett. 2006;406:265&#x2013;269. doi: 10.1016/j.neulet.2006.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.07.054</ArticleId><ArticleId IdType="pubmed">16914266</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, Chartier-Harlin MC, Hayes A, Thaker U, Iwatsubo T, Mann DM, Lendon C. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett. 2005;382:221&#x2013;226. doi: 10.1016/j.neulet.2005.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.03.016</ArticleId><ArticleId IdType="pubmed">15925094</ArticleId></ArticleIdList></Reference><Reference><Citation>Monastero R, Cefalu AB, Camarda C, Noto D, Camarda LK, Caldarella R, Imbornone E, Averna MR, Camarda R. Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study. J Alzheimers Dis. 2006;9:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirskanen M, Hiltunen M, Mannermaa A, Helisalmi S, Lehtovirta M, Hanninen T, Soininen H. Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet. 2005;13:1000&#x2013;1006. doi: 10.1038/sj.ejhg.5201447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201447</ArticleId><ArticleId IdType="pubmed">15944651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol. 2000;12:351&#x2013;354. doi: 10.1046/j.1365-2826.2000.00461.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2826.2000.00461.x</ArticleId><ArticleId IdType="pubmed">10718932</ArticleId></ArticleIdList></Reference><Reference><Citation>Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76:906&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">11560301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004;39:1633&#x2013;1639. doi: 10.1016/j.exger.2004.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2004.06.019</ArticleId><ArticleId IdType="pubmed">15582279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs H, Hiatt ES, Lei ZM, Rao CV. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm Behav. 1995;29:42&#x2013;58. doi: 10.1006/hbeh.1995.1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/hbeh.1995.1004</ArticleId><ArticleId IdType="pubmed">7782062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei ZM, Rao CV. Novel presence of luteinizing hormone/human chorionic gonadotropin (hCG) receptors and the down-regulating action of hCG on gonadotropin-releasing hormone gene expression in immortalized hypothalamic GT1-7 neurons. Mol Endocrinol. 1994;8:1111&#x2013;1121. doi: 10.1210/me.8.8.1111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.8.8.1111</ArticleId><ArticleId IdType="pubmed">7997235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004;279:20539&#x2013;20545. doi: 10.1074/jbc.M311993200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311993200</ArticleId><ArticleId IdType="pubmed">14871891</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadesus G, Atwood CS, Bowen RL, Smith MA. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP tansgenic mice. Biochem Biophys Acta. 2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503402</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Wimalasena J, Bowen RL, Atwood CS. Luteinizing hormone receptor mediates neuronal pregnenolone production via up-regulation of steroidogenic acute regulatory protein expression. J Neurochem. 2007;100:1329&#x2013;1339. doi: 10.1111/j.1471-4159.2006.04307.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04307.x</ArticleId><ArticleId IdType="pubmed">17241129</ArticleId></ArticleIdList></Reference><Reference><Citation>Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, Schumacher M, Delacourte A, Baulieu EE, Akwa Y. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab. 2002;87:5138&#x2013;5143. doi: 10.1210/jc.2002-020878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2002-020878</ArticleId><ArticleId IdType="pubmed">12414884</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpkins JW, Yang SH, Wen Y, Singh M. Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci. 2005;62:271&#x2013;280. doi: 10.1007/s00018-004-4382-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-004-4382-2</ArticleId><ArticleId IdType="pmc">PMC11924488</ArticleId><ArticleId IdType="pubmed">15723163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630. doi: 10.1126/science.3283935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3283935</ArticleId><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Willnow TE. Lipoprotein receptors in Alzheimer's disease. Trends Neurosci. 2006;29:687&#x2013;694. doi: 10.1016/j.tins.2006.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2006.09.002</ArticleId><ArticleId IdType="pubmed">17000013</ArticleId></ArticleIdList></Reference><Reference><Citation>Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev. 2000;21:551&#x2013;583. doi: 10.1210/er.21.5.551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.21.5.551</ArticleId><ArticleId IdType="pubmed">11041448</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhtaniemi IT, Themmen AP. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine. 2005;26:207&#x2013;217. doi: 10.1385/ENDO:26:3:207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/ENDO:26:3:207</ArticleId><ArticleId IdType="pubmed">16034174</ArticleId></ArticleIdList></Reference><Reference><Citation>Furui K, Suganuma N, Tsukahara S, Asada Y, Kikkawa F, Tanaka M, Ozawa T, Tomoda Y. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab. 1994;78:107&#x2013;113. doi: 10.1210/jc.78.1.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.78.1.107</ArticleId><ArticleId IdType="pubmed">7904610</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Kurioka H, Ozaki T, Kanasaki H, Miyazaki K, Karino K. Pituitary response to luteinizing hormone-releasing hormone in women with variant luteinizing hormone. Eur J Endocrinol. 2000;143:375&#x2013;381. doi: 10.1530/eje.0.1430375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje.0.1430375</ArticleId><ArticleId IdType="pubmed">11022180</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller T, Gromoll J, Simoni M. Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action. J Clin Endocrinol Metab. 2003;88:2242&#x2013;2249. doi: 10.1210/jc.2002-021946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2002-021946</ArticleId><ArticleId IdType="pubmed">12727981</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter-Unruh A, Martens JW, Verhoef-Post M, Wessels HT, Kors WA, Sinnecker GH, Boehmer A, Drop SL, Toledo SP, Brunner HG, Themmen AP. Leydig cell hypoplasia: cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol (Oxf) 2002;56:103&#x2013;112. doi: 10.1046/j.0300-0664.2001.01437.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0300-0664.2001.01437.x</ArticleId><ArticleId IdType="pubmed">11849253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley-Koch AE, Mei H, Jaworski J, Ma DQ, Ritchie MD, Menold MM, Delong GR, Abramson RK, Wright HH, Hussman JP, Cuccaro ML, Gilbert JR, Martin ER, Pericak-Vance MA. An analysis paradigm for investigating multi-locus effects in complex disease: examination of three GABA receptor subunit genes on 15q11-q13 as risk factors for autistic disorder. Ann Hum Genet. 2006;70:281&#x2013;292. doi: 10.1111/j.1469-1809.2006.00253.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-1809.2006.00253.x</ArticleId><ArticleId IdType="pubmed">16674551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Thal DR, Rub U, Ohm TG, Braak E, Braak H. Gender and age modify the association between APOE and AD-related neuropathology. Neurology. 2001;56:1696&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425936</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet. 1996;58:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914663</ArticleId><ArticleId IdType="pubmed">8644745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, Butler HT, Warden DR, Combrinck M, King E, Nicoll JA, Budge MM, de Jager CA, Hogervorst E, Esiri MM, Ragoussis J, Smith AD. Association of the androgen receptor CAG repeat polymorphism with Alzheimer's disease in men. Neurosci Lett. 2003;340:87&#x2013;90. doi: 10.1016/S0304-3940(03)00069-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00069-7</ArticleId><ArticleId IdType="pubmed">12668243</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Perry G, Atwood CS, Bowen RL. Estrogen replacement and risk of Alzheimer disease. Jama. 2003;289:1100; author reply 1101&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12622570</ArticleId></ArticleIdList></Reference><Reference><Citation>Meethal SV, Smith MA, Bowen RL, Atwood CS. The gonadotropin connection in Alzheimer's disease. Endocrine. 2005;26:317&#x2013;326. doi: 10.1385/ENDO:26:3:317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/ENDO:26:3:317</ArticleId><ArticleId IdType="pubmed">16034187</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:8098&#x2013;8102. doi: 10.1073/pnas.90.17.8098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.17.8098</ArticleId><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S. The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci. 2006;245:35&#x2013;39. doi: 10.1016/j.jns.2005.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.08.018</ArticleId><ArticleId IdType="pubmed">16631796</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Curtiss LK, Wade RL, Dyer CA. An apolipoprotein E synthetic peptide selectively modulates the transcription of the gene for rat ovarian theca and interstitial cell P450 17alpha-hydroxylase, C17-20 lyase. J Lipid Res. 1998;39:2406&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">9831628</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JD, Strauss JF, 3rd, Paavola LG. Cellular events involved in hormonal control of receptor-mediated endocytosis: regulation occurs at multiple sites in the low density lipoprotein pathway, including steps beyond the receptor. Endocrinology. 1993;132:337&#x2013;350. doi: 10.1210/en.132.1.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.132.1.337</ArticleId><ArticleId IdType="pubmed">8419131</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne RL, Ribas G, Gonzalez-Neira A, Fagerholm R, Salas A, Gonzalez E, Dopazo J, Nevanlinna H, Robledo M, Benitez J. ERCC4 Associated with Breast Cancer Risk: A Two-Stage Case-Control Study Using High-throughput Genotyping. Cancer Res. 2006;66:9420&#x2013;9427. doi: 10.1158/0008-5472.CAN-06-1418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-1418</ArticleId><ArticleId IdType="pubmed">17018596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Panhuysen C, Kranzler HR, Hesselbrock V, Rounsaville B, Weiss R, Brady K, Farrer LA, Gelernter J. Intronic variants in the dopa decarboxylase (DDC) gene are associated with smoking behavior in European-Americans and African-Americans. Hum Mol Genet. 2006;15:2192&#x2013;2199. doi: 10.1093/hmg/ddl144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl144</ArticleId><ArticleId IdType="pubmed">16740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SL, Miller JD, Ying SY. Intronic MicroRNA (miRNA) J Biomed Biotechnol. 2006;2006:26818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559912</ArticleId><ArticleId IdType="pubmed">17057362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessagowit V, Nalla VK, Rogan PK, McGrath JA. Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases. J Dermatol Sci. 2005;40:73&#x2013;84. doi: 10.1016/j.jdermsci.2005.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2005.05.006</ArticleId><ArticleId IdType="pmc">PMC1351063</ArticleId><ArticleId IdType="pubmed">16054339</ArticleId></ArticleIdList></Reference><Reference><Citation>Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6:386&#x2013;398. doi: 10.1038/nrm1645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1645</ArticleId><ArticleId IdType="pubmed">15956978</ArticleId></ArticleIdList></Reference><Reference><Citation>Churbanov A, Rogozin IB, Deogun JS, Ali H. Method of predicting splice sites based on signal interactions. Biol Direct. 2006;1:10. doi: 10.1186/1745-6150-1-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6150-1-10</ArticleId><ArticleId IdType="pmc">PMC1526722</ArticleId><ArticleId IdType="pubmed">16584568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis P, Zaykin D. Computer program for the analysis of allelic data. Version 1.0(d16c). . 2007. </Citation></Reference><Reference><Citation>Minitab Minitab v 14.0 State College, PA</Citation></Reference><Reference><Citation>Lancaster A, Nelson MP, Meyer D, Thomson G, Single RM. PyPop: a software framework for population genomics: analyzing large-scale multi-locus genotype data. Pac Symp Biocomput. 2003:514&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891851</ArticleId><ArticleId IdType="pubmed">12603054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003;19:376&#x2013;382. doi: 10.1093/bioinformatics/btf869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btf869</ArticleId><ArticleId IdType="pubmed">12584123</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet. 2004;20:640&#x2013;647. doi: 10.1016/j.tig.2004.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2004.09.007</ArticleId><ArticleId IdType="pubmed">15522460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373&#x2013;1379. doi: 10.1016/S0895-4356(96)00236-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(96)00236-3</ArticleId><ArticleId IdType="pubmed">8970487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001;69:138&#x2013;147. doi: 10.1086/321276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/321276</ArticleId><ArticleId IdType="pmc">PMC1226028</ArticleId><ArticleId IdType="pubmed">11404819</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered. 2003;56:73&#x2013;82. doi: 10.1159/000073735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000073735</ArticleId><ArticleId IdType="pubmed">14614241</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, Brown NJ, Vaughan DE, Moore JH. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics. 2004;5:49. doi: 10.1186/1471-2105-5-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-5-49</ArticleId><ArticleId IdType="pmc">PMC419697</ArticleId><ArticleId IdType="pubmed">15119966</ArticleId></ArticleIdList></Reference><Reference><Citation>Motsinger AA, Ritchie MD. The effect of reduction in cross-validation intervals on the performance of multifactor dimensionality reduction. Genet Epidemiol. 2006;30:546&#x2013;555. doi: 10.1002/gepi.20166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.20166</ArticleId><ArticleId IdType="pubmed">16800004</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med. 2002;34:88&#x2013;95. doi: 10.1080/07853890252953473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890252953473</ArticleId><ArticleId IdType="pubmed">12108579</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SM, Addy JH, Phillips JA, 3rd, Dai M, Kpodonu J, Afful J, Jackson H, Joseph K, Eason F, Murray MM, Epperson P, Aduonum A, Wong LJ, Jose PA, Felder RA. Combinations of variations in multiple genes are associated with hypertension. Hypertension. 2000;36:2&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10904004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Lamminen T, Pakarinen P, Hellman J, Manna P, Herrera RJ, Huhtaniemi I. A novel Ala(-3)Thr mutation in the signal peptide of human luteinizing hormone beta-subunit: potentiation of the inositol phosphate signalling pathway and attenuation of the adenylate cyclase pathway by recombinant variant hormone. Mol Hum Reprod. 2002;8:201&#x2013;212. doi: 10.1093/molehr/8.3.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/8.3.201</ArticleId><ArticleId IdType="pubmed">11870227</ArticleId></ArticleIdList></Reference><Reference><Citation>Atger M, Misrahi M, Sar S, Le Flem L, Dessen P, Milgrom E. Structure of the human luteinizing hormone-choriogonadotropin receptor gene: unusual promoter and 5' non-coding regions. Mol Cell Endocrinol. 1995;111:113&#x2013;123. doi: 10.1016/0303-7207(95)03557-N.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0303-7207(95)03557-N</ArticleId><ArticleId IdType="pubmed">7556872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer H, Martens JW, van Reen M, Verhoef-Post M, Wit JM, Otten BJ, Drop SL, Delemarre-van de Waal HA, Pombo-Arias M, De Luca F, Potau N, Buckler JM, Jansen M, Parks JS, Latif HA, Moll GW, Epping W, Saggese G, Mariman EC, Themmen AP, Brunner HG. A limited repertoire of mutations of the luteinizing hormone (LH) receptor gene in familial and sporadic patients with male LH-independent precocious puberty. J Clin Endocrinol Metab. 1999;84:1136&#x2013;1140. doi: 10.1210/jc.84.3.1136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.84.3.1136</ArticleId><ArticleId IdType="pubmed">10084607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18443288</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>19</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery.</ArticleTitle><Pagination><StartPage>7070</StartPage><EndPage>7075</EndPage><MedlinePgn>7070-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0711845105</ELocationID><Abstract><AbstractText>Mitochondria form dynamic tubular networks that undergo frequent morphological changes through fission and fusion, the imbalance of which can affect cell survival in general and impact synaptic transmission and plasticity in neurons in particular. Some core components of the mitochondrial fission/fusion machinery, including the dynamin-like GTPases Drp1, Mitofusin, Opa1, and the Drp1-interacting protein Fis1, have been identified. How the fission and fusion processes are regulated under normal conditions and the extent to which defects in mitochondrial fission/fusion are involved in various disease conditions are poorly understood. Mitochondrial malfunction tends to cause diseases with brain and skeletal muscle manifestations and has been implicated in neurodegenerative diseases such as Parkinson's disease (PD). Whether abnormal mitochondrial fission or fusion plays a role in PD pathogenesis has not been shown. Here, we show that Pink1, a mitochondria-targeted Ser/Thr kinase linked to familial PD, genetically interacts with the mitochondrial fission/fusion machinery and modulates mitochondrial dynamics. Genetic manipulations that promote mitochondrial fission suppress Drosophila Pink1 mutant phenotypes in indirect flight muscle and dopamine neurons, whereas decreased fission has opposite effects. In Drosophila and mammalian cells, overexpression of Pink1 promotes mitochondrial fission, whereas inhibition of Pink1 leads to excessive fusion. Our genetic interaction results suggest that Fis1 may act in-between Pink1 and Drp1 in controlling mitochondrial fission. These results reveal a cell biological role for Pink1 and establish mitochondrial fission/fusion as a paradigm for PD research. Compounds that modulate mitochondrial fission/fusion could have therapeutic value in PD intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yufeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Yingshi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lichuan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Beal</LastName><ForeName>M Flint</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>McQuibban</LastName><ForeName>Angus</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Hannes</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bingwei</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR054926</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AR054926</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C504426">DRP1 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17585</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017344" MajorTopicYN="N">Genes, Insect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18443288</ArticleId><ArticleId IdType="pmc">PMC2383971</ArticleId><ArticleId IdType="doi">10.1073/pnas.0711845105</ArticleId><ArticleId IdType="pii">0711845105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 1999;399:A32&#x2013;A39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392578</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli-Avella AM, Oostra BA, Heutink P. Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet. 2004;114:413&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Hum Mol Genet. 2005;14:2063&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944198</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Darios F, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet. 2003;12:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588799</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon H, et al. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci. 2002;18:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12059041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA. 2006;103:10793&#x2013;10798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441:1157&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci USA. 2006;103:13520&#x2013;13525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569195</ArticleId><ArticleId IdType="pubmed">16938835</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Shaw JM. Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. Annu Rev Genet. 2005;39:503&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">16285870</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, et al. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron. 2005;47:365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055061</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuibban GA, Lee JR, Zheng L, Juusola M, Freeman M. Normal mitochondrial dynamics requires rhomboid-7 and affects Drosophila lifespan and neuronal function. Curr Biol. 2006;16:982&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA. 2005;102:13670&#x2013;13675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224636</ArticleId><ArticleId IdType="pubmed">16155123</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole AC, et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA. 2008;105:1638&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234197</ArticleId><ArticleId IdType="pubmed">18230723</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovski D, Koutsopoulos OS, Okamoto K, Ryan MT. Levels of human Fis1 at the mitochondrial outer membrane regulate mitochondrial morphology. J Cell Sci. 2004;117:1201&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pubmed">14996942</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon Y, Krueger EW, Oswald BJ, McNiven MA. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. Mol Cell Biol. 2003;23:5409&#x2013;5420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165727</ArticleId><ArticleId IdType="pubmed">12861026</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander C, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kijima K, et al. Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum Genet. 2005;116:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15549395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozdy AD, McCaffery JM, Shaw JM. Dnm1p GTPase-mediated mitochondrial fission is a multi-step process requiring the novel integral membrane component Fis1p. J Cell Biol. 2000;151:367&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192649</ArticleId><ArticleId IdType="pubmed">11038183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tieu Q, Okreglak V, Naylor K, Nunnari J. The WD repeat protein, Mdv1p, functions as a molecular adaptor by interacting with Dnm1p and Fis1p during mitochondrial fission. J Cell Biol. 2002;158:445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173813</ArticleId><ArticleId IdType="pubmed">12163467</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri L, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet. 2005;14:3477&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207731</ArticleId></ArticleIdList></Reference><Reference><Citation>Exner N, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci. 2007;27:12413&#x2013;12418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673250</ArticleId><ArticleId IdType="pubmed">17989306</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagasia R, Grote P, Westermann B, Conradt B. DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C. elegans. Nature. 2005;433:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716954</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelwahid E, et al. Mitochondrial disruption in Drosophila apoptosis. Dev Cell. 2007;12:793&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130:548&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugioka R, Shimizu S, Tsujimoto Y. Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis. J Biol Chem. 2004;279:52726&#x2013;52734.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459195</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabadkai G, et al. Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca2+ waves and protects against Ca2+-mediated apoptosis. Mol Cell. 2004;16:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15469822</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 2004;119:873&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA. 2007;104:11441&#x2013;11446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890561</ArticleId><ArticleId IdType="pubmed">17563363</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesah Y, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development. 2004;131:2183&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073152</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnova E, Shurland DL, Ryazantsev SN, van der Bliek AM. A human dynamin-related protein controls the distribution of mitochondria. J Cell Biol. 1998;143:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132828</ArticleId><ArticleId IdType="pubmed">9786947</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 2003;37:911&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18448652</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>18</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>4756</StartPage><EndPage>4766</EndPage><MedlinePgn>4756-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0141-08.2008</ELocationID><Abstract><AbstractText>Recent research on Alzheimer's disease (AD) has shown that cognitive and memory decline in this disease is accompanied by disrupted changes in the coordination of large-scale brain functional networks. However, alterations in coordinated patterns of structural brain networks in AD are still poorly understood. Here, we used cortical thickness measurement from magnetic resonance imaging to investigate large-scale structural brain networks in 92 AD patients and 97 normal controls. Brain networks were constructed by thresholding cortical thickness correlation matrices of 54 regions and analyzed using graph theoretical approaches. Compared with controls, AD patients showed decreased cortical thickness intercorrelations between the bilateral parietal regions and increased intercorrelations in several selective regions involving the lateral temporal and parietal cortex as well as the cingulate and medial frontal cortex regions. Specially, AD patients showed abnormal small-world architecture in the structural cortical networks (increased clustering and shortest paths linking individual regions), implying a less optimal topological organization in AD. Moreover, AD patients were associated with reduced nodal centrality predominantly in the temporal and parietal heteromodal association cortex regions and increased nodal centrality in the occipital cortex regions. Finally, the brain networks of AD were about equally as robust to random failures as those of controls, but more vulnerable against targeted attacks, presumably because of the effects of pathological topological organization. Our findings suggest that the coordinated patterns of cortical morphology are widely altered in AD patients, thus providing structural evidence for disrupted integrity in large-scale brain networks that underlie cognition. This work has implications for our understanding of how functional deficits in patients are associated with their underlying structural (morphological) basis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01MHO52176-11</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2008 Aug 13;28(33):8148-9. doi: 10.1523/JNEUROSCI.2433-08.2008.</RefSource><PMID Version="1">18701676</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016571" MajorTopicYN="N">Neural Networks, Computer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013238" MajorTopicYN="N">Stereotaxic Techniques</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18448652</ArticleId><ArticleId IdType="pmc">PMC6670444</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0141-08.2008</ArticleId><ArticleId IdType="pii">28/18/4756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol. 2007;3:e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794324</ArticleId><ArticleId IdType="pubmed">17274684</ArticleId></ArticleIdList></Reference><Reference><Citation>Achard S, Salvador R, Whitcher B, Suckling J, Bullmore E. A resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci. 2006;26:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674299</ArticleId><ArticleId IdType="pubmed">16399673</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406:378&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935628</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews TJ, Halpern SD, Purves D. Correlated size variations in human visual cortex, lateral geniculate nucleus, and optic tract. J Neurosci. 1997;17:2859&#x2013;2868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573115</ArticleId><ArticleId IdType="pubmed">9092607</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman L, Almkvist O, Nyberg L, Andersson J. Functional changes in brain activity during priming in Alzheimer's disease. J Cogn Neurosci. 2000;12:134&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769311</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat A, Barthelemy M, Pastor-Satorras R, Vespignani A. The architecture of complex weighted networks. Proc Natl Acad Sci USA. 2004;101:3747&#x2013;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374315</ArticleId><ArticleId IdType="pubmed">15007165</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton RA, Harvey PH. Mosaic evolution of brain structure in mammals. Nature. 2000;405:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10890446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Bullmore E. Small-world brain networks. Neuroscientist. 2006;12:512&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Meyer-Lindenberg A, Achard S, Duke T, Bullmore E. Adaptive reconfiguration of fractal small-world human brain functional networks. Proc Natl Acad Sci USA. 2006;103:19518&#x2013;19523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838565</ArticleId><ArticleId IdType="pubmed">17159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohbot VD, Lerch J, Thorndycraft B, Iaria G, Zijdenbos AP. Gray matter differences correlate with spontaneous strategies in a human virtual navigation task. J Neurosci. 2007;27:10078&#x2013;10083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672675</ArticleId><ArticleId IdType="pubmed">17881514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokde AL, Lopez-Bayo P, Meindl T, Pechler S, Born C, Faltraco F, Teipel SJ, Moller HJ, Hampel H. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain. 2006;129:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520329</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore ET, Woodruff PW, Wright IC, Rabe-Hesketh S, Howard RJ, Shuriquie N, Murray RM. Does dysplasia cause anatomical dysconnectivity in schizophrenia? Schizophr Res. 1998;30:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">9549775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging. 1999;18:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DA, Mitra PP, Wang SS. Scalable architecture in mammalian brains. Nature. 2001;411:189&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">11346794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, Cohen P. Applied multiple regression/correlation analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum; 1983.</Citation></Reference><Reference><Citation>Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126267</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Holmes CJ, Peters TM, Evans AC. Automatic 3-D model-based neuroanatomical segmentation. Hum Brain Mapp. 1995;3:190&#x2013;208.</Citation></Reference><Reference><Citation>Delbeuck X, Van der Linden M, Collette F. Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Blanco R, Carulla M, Condom M, Alcantara S, Olive M, Planas A. Transforming growth factor-alpha immunoreactivity in the developing and adult brain. Neuroscience. 1995;66:189&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">7637868</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman LC. A set of measures of centrality based upon betweenness. Sociometry. 1977;40:35&#x2013;41.</Citation></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Girvan M, Newman ME. Community structure in social and biological networks. Proc Natl Acad Sci USA. 2002;99:7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122977</ArticleId><ArticleId IdType="pubmed">12060727</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology. 1986;36:1390&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">3762951</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol. 1988;10:576&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">3265710</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Furey ML, Pietrini P, Horwitz B, Rapoport SI. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain. 2001;124:739&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287374</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003;23:986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741917</ArticleId><ArticleId IdType="pubmed">12574428</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Kurant M, Gigandet X, Thiran P, Wedeen VJ, Meuli R, Thiran JP. Mapping human whole-brain structural networks with diffusion MRI. PLoS ONE. 2007;2:e597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895920</ArticleId><ArticleId IdType="pubmed">17611629</ArticleId></ArticleIdList></Reference><Reference><Citation>Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">2357155</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Wang L, Zang Y, Tian L, Zhang X, Li K, Jiang T. Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study. NeuroImage. 2007a;35:488&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254803</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Chen ZJ, Evans AC. Small-world anatomical networks in the human brain revealed by cortical thickness from MRI. Cereb Cortex. 2007b;17:2407&#x2013;2419.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgetag CC, Burns GA, O'Neill MA, Scannell JW, Young MP. Anatomical connectivity defines the organization of clusters of cortical areas in the macaque monkey and the cat. Philos Trans R Soc Lond B Biol Sci. 2000;355:91&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692723</ArticleId><ArticleId IdType="pubmed">10703046</ArticleId></ArticleIdList></Reference><Reference><Citation>Honey CJ, Kotter R, Breakspear M, Sporns O. Network structure of cerebral cortex shapes functional connectivity on multiple time scales. Proc Natl Acad Sci USA. 2007;104:10240&#x2013;10245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891224</ArticleId><ArticleId IdType="pubmed">17548818</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz B, Grady CL, Schlageter NL, Duara R, Rapoport SI. Intercorrelations of regional cerebral glucose metabolic rates in Alzheimer's disease. Brain Res. 1987;407:294&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">3494486</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz B, McIntosh AR, Haxby JV, Furey M, Salerno JA, Schapiro MB, Rapoport SI, Grady CL. Network analysis of PET-mapped visual pathways in Alzheimer type dementia. NeuroReport. 1995;6:2287&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8747138</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Zhang J, Jiang H, Wakana S, Poetscher L, Miller MI, van Zijl PC, Hillis AE, Wytik R, Mori S. DTI tractography based parcellation of white matter: application to the mid-sagittal morphology of corpus callosum. NeuroImage. 2005;26:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, He Y, Zang Y, Weng X. Modulation of functional connectivity during the resting state and the motor task. Hum Brain Mapp. 2004;22:63&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871844</ArticleId><ArticleId IdType="pubmed">15083527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabani N, Le Goualher G, MacDonald D, Evans AC. Measurement of cortical thickness using an automated 3-D algorithm: a validation study. NeuroImage. 2001;13:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser M, Hilgetag CC. Edge vulnerability in neural and metabolic networks. Biol Cybern. 2004;90:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">15221391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser M, Hilgetag CC. Nonoptimal component placement, but short processing paths, due to long-distance projections in neural systems. PLoS Comput Biol. 2006;2:e95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513269</ArticleId><ArticleId IdType="pubmed">16848638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Singh V, Lee JK, Lerch J, Ad-Dab'bagh Y, MacDonald D, Lee JM, Kim SI, Evans AC. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. NeuroImage. 2005;27:210&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896981</ArticleId></ArticleIdList></Reference><Reference><Citation>Latora V, Marchiori M. Efficient behavior of small-world networks. Phys Rev Lett. 2001;87:198701.</Citation><ArticleIdList><ArticleId IdType="pubmed">11690461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JK, Lee JM, Kim JS, Kim IY, Evans AC, Kim SI. A novel quantitative cross-validation of different cortical surface reconstruction algorithms using MRI phantom. NeuroImage. 2006;31:572&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. NeuroImage. 2005;24:163&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex. 2005;15:995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerch JP, Worsley K, Shaw WP, Greenstein DK, Lenroot RK, Giedd J, Evans AC. Mapping anatomical correlations across cerebral cortex (MACACC) using cortical thickness from MRI. NeuroImage. 2006;31:993&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624590</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald D, Kabani N, Avis D, Evans AC. Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. NeuroImage. 2000;12:340&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">10944416</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Gadian DG, Johnsrude IS, Good CD, Ashburner J, Frackowiak RS, Frith CD. Navigation-related structural change in the hippocampi of taxi drivers. Proc Natl Acad Sci USA. 2000;97:4398&#x2013;4403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18253</ArticleId><ArticleId IdType="pubmed">10716738</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL. Open access series of imaging studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci. 2007;19:1498&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">17714011</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science. 2002;296:910&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988575</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlonan GM, Cheung V, Cheung C, Suckling J, Lam GY, Tai KS, Yip L, Murphy DG, Chua SE. Mapping the brain in autism. A voxel-based MRI study of volumetric differences and intercorrelations in autism. Brain. 2005;128:268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A, Friston KJ, Frackowiak RS, Price CJ. Structural covariance in the human cortex. J Neurosci. 2005;25:8303&#x2013;8310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725541</ArticleId><ArticleId IdType="pubmed">16148238</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina D, DeToledo-Morrell L, Urresta F, Gabrieli JD, Moseley M, Fleischman D, Bennett DA, Leurgans S, Turner DA, Stebbins GT. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol Aging. 2006;27:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentis MJ, Horwitz B, Grady CL, Alexander GE, VanMeter JW, Maisog JM, Pietrini P, Schapiro MB, Rapoport SI. Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded &#x201c;stress test&#x201d; during PET. Am J Psychiatry. 1996;153:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8540589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. From sensation to cognition. Brain. 1998;121:1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitelman SA, Buchsbaum MS, Brickman AM, Shihabuddin L. Cortical intercorrelations of frontal area volumes in schizophrenia. NeuroImage. 2005;27:753&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">15990338</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman MEJ. The structure and function of complex networks. SIAM Rev Soc Ind Appl Math. 2003;45:167&#x2013;256.</Citation></Reference><Reference><Citation>Pandya DN. Anatomy of the auditory cortex. Rev Neurol (Paris) 1995;151:486&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">8578069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantel J, Schroder J, Jauss M, Essig M, Minakaran R, Schonknecht P, Schneider G, Schad LR, Knopp MV. Topography of callosal atrophy reflects distribution of regional cerebral volume reduction in Alzheimer's disease. Psychiatry Res. 1999;90:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">10466737</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent A, Carpenter MB. Human neuroanatomy. Baltimore: Williams and Wilkins; 1995.</Citation></Reference><Reference><Citation>Prvulovic D, Hubl D, Sack AT, Melillo L, Maurer K, Frolich L, Lanfermann H, Zanella FE, Goebel R, Linden DE, Dierks T. Functional imaging of visuospatial processing in Alzheimer's disease. NeuroImage. 2002;17:1403&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414280</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujol J, Soriano-Mas C, Alonso P, Cardoner N, Menchon JM, Deus J, Vallejo J. Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry. 2004;61:720&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15237084</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins S, Evans AC, Collins DL, Whitesides S. Tuning and comparing spatial normalization methods. Med Image Anal. 2004;8:311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450225</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose SE, Chen F, Chalk JB, Zelaya FO, Strugnell WE, Benson M, Semple J, Doddrell DM. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry. 2000;69:528&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737121</ArticleId><ArticleId IdType="pubmed">10990518</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador R, Suckling J, Coleman MR, Pickard JD, Menon D, Bullmore E. Neurophysiological architecture of functional magnetic resonance images of human brain. Cereb Cortex. 2005;15:1332&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635061</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltzer B, Pandya DN. The distribution of posterior parietal fibers in the corpus callosum of the rhesus monkey. Exp Brain Res. 1983;49:147&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">6861933</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltzer B, Pandya DN. Parietal, temporal, and occipital projections to cortex of the superior temporal sulcus in the rhesus monkey: a retrograde tracer study. J Comp Neurol. 1994;343:445&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">8027452</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006;129:2885&#x2013;2893.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Zwi JD. The small world of the cerebral cortex. Neuroinformatics. 2004;2:145&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, Edelman GM. Theoretical neuroanatomy: relating anatomical and functional connectivity in graphs and cortical connection matrices. Cereb Cortex. 2000;10:127&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Chialvo DR, Kaiser M, Hilgetag CC. Organization, development and function of complex brain networks. Trends Cogn Sci. 2004;8:418&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350243</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JP, de Munck JC, van Dijk BW, Berendse HW, Scheltens P. Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. NeuroImage. 2006;32:1335&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815039</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Jones BF, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex. 2007;17:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452642</ArticleId></ArticleIdList></Reference><Reference><Citation>Strogatz SH. Exploring complex networks. Nature. 2001;410:268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11258382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydykova D, Stahl R, Dietrich O, Ewers M, Reiser MF, Schoenberg SO, Moller HJ, Hampel H, Teipel SJ. Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. Cereb Cortex. 2007;17:2276&#x2013;2282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17164468</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach T, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988.</Citation></Reference><Reference><Citation>Vincent JL, Patel GH, Fox MD, Snyder AZ, Baker JT, Van Essen DC, Zempel JM, Snyder LH, Corbetta M, Raichle ME. Intrinsic functional architecture in the anaesthetized monkey brain. Nature. 2007;447:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada Y, Nanbu Y, Koshino Y, Yamaguchi N, Hashimoto T. Reduced interhemispheric EEG coherence in Alzheimer disease: analysis during rest and photic stimulation. Alzheimer Dis Assoc Disord. 1998;12:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">9772020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, Wu T, Jiang T, Li K. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. NeuroImage. 2006;31:496&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts DJ, Strogatz SH. Collective dynamics of &#x201c;small-world&#x201d; networks. Nature. 1998;393:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright IC, Sharma T, Ellison ZR, McGuire PK, Friston KJ, Brammer MJ, Murray RM, Bullmore ET. Supra-regional brain systems and the neuropathology of schizophrenia. Cereb Cortex. 1999;9:366&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10426416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijdenbos AP, Forghani R, Evans AC. Automatic &#x201c;pipeline&#x201d; analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2002;21:1280&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12585710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18454144</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Single-neuron labeling with inducible Cre-mediated knockout in transgenic mice.</ArticleTitle><Pagination><StartPage>721</StartPage><EndPage>728</EndPage><MedlinePgn>721-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2118</ELocationID><Abstract><AbstractText>To facilitate a functional analysis of neuronal connectivity in a mammalian nervous system that is tightly packed with billions of cells, we developed a new technique that uses inducible genetic manipulations in fluorescently labeled single neurons in mice. Our technique, single-neuron labeling with inducible Cre-mediated knockout (SLICK), is achieved by coexpressing a drug-inducible form of Cre recombinase and a fluorescent protein in a small subsets of neurons, thus combining the powerful Cre recombinase system for conditional genetic manipulation with fluorescent labeling of single neurons for imaging. Here, we demonstrate efficient inducible genetic manipulation in several types of neurons using SLICK. Furthermore, we applied SLICK to eliminate synaptic transmission in a small subset of neuromuscular junctions. Our results provide evidence for the long-term stability of inactive neuromuscular synapses in adult animals and demonstrate a Cre-loxP compatible system for dissecting gene functions in single identifiable neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Duke University Medical Center, Research Drive, Durham, North Carolina 27710, USA. p.young@ucc.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongqing</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shengli</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Guoping</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 MH073121</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004965">Estrogen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518649">Kcnt2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081033">Potassium Channels, Sodium-Activated</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019426">Integrases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004965" MajorTopicYN="N">Estrogen Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081033" MajorTopicYN="N">Potassium Channels, Sodium-Activated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18454144</ArticleId><ArticleId IdType="mid">NIHMS276529</ArticleId><ArticleId IdType="pmc">PMC3062628</ArticleId><ArticleId IdType="doi">10.1038/nn.2118</ArticleId><ArticleId IdType="pii">nn.2118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collins FS, Rossant J. A mouse for all reasons. Cell. 2007;128:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17218247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht M, et al. Novel approaches to monitor and manipulate single neurons in vivo. J Neurosci. 2004;24:9223&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730093</ArticleId><ArticleId IdType="pubmed">15496655</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway EM. A molecular and genetic arsenal for systems neuroscience. Trends Neurosci. 2005;28:196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808354</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, et al. Next-generation optical technologies for illuminating genetically targeted brain circuits. J Neurosci. 2006;26:10380&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820367</ArticleId><ArticleId IdType="pubmed">17035522</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek KW, Davis GW. Controlling the active properties of excitable cells. Curr Opin Neurobiol. 2003;13:607&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630226</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesenbock G. Genetic methods for illuminating the function of neural circuits. Curr Opin Neurobiol. 2004;14:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194122</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyawaki A. Fluorescence imaging of physiological activity in complex systems using GFP-based probes. Curr Opin Neurobiol. 2003;13:591&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630223</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Callaway EM, Svoboda K. Genetic dissection of neural circuits. Neuron. 2008;57:634&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628815</ArticleId><ArticleId IdType="pubmed">18341986</ArticleId></ArticleIdList></Reference><Reference><Citation>Young P, Feng G. Labeling neurons in vivo for morphological and functional studies. Curr Opin Neurobiol. 2004;14:642&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong H, Espinosa JS, Su HH, Muzumdar MD, Luo L. Mosaic analysis with double markers in mice. Cell. 2005;121:479&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882628</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Kasthuri N, Gan WB. Long-term dendritic spine stability in the adult cortex. Nature. 2002;420:812&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasthuri N, Lichtman JW. Structural dynamics of synapses in living animals. Curr Opin Neurobiol. 2004;14:105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15018945</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420:788&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi A, Katz LC. Dendritic stability in the adult olfactory bulb. Nat Neurosci. 2003;6:1201&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14528309</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun. 1997;237:752&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299439</ArticleId></ArticleIdList></Reference><Reference><Citation>Branda CS, Dymecki SM. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell. 2004;6:7&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">14723844</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzger D, Chambon P. Site- and time-specific gene targeting in the mouse. Methods. 2001;24:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327805</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916792</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrone J, Murthy VN. Synaptic gain control and homeostasis. Curr Opin Neurobiol. 2003;13:560&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua JY, Smith SJ. Neural activity and the dynamics of central nervous system development. Nat Neurosci. 2004;7:327&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048120</ArticleId></ArticleIdList></Reference><Reference><Citation>Misgeld T, et al. Roles of neurotransmitter in synapse formation: development of neuromuscular junctions lacking choline acetyltransferase. Neuron. 2002;36:635&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12441053</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandon EP, et al. Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. J Neurosci. 2003;23:539&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741871</ArticleId><ArticleId IdType="pubmed">12533614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Tonegawa S. Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu Rev Neurosci. 1997;20:157&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Luo L. Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. Neuron. 1999;22:451&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Prolongation of evoked and spontaneous synaptic currents at the neuromuscular junction after activity blockade is caused by the upregulation of fetal acetylcholine receptors. J Neurosci. 2006;26:8983&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675328</ArticleId><ArticleId IdType="pubmed">16943554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Activity-dependent presynaptic regulation of quantal size at the mammalian neuromuscular junction in vivo. J Neurosci. 2005;25:343&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725499</ArticleId><ArticleId IdType="pubmed">15647477</ArticleId></ArticleIdList></Reference><Reference><Citation>Son YJ, Thompson WJ. Nerve sprouting in muscle is induced and guided by processes extended by Schwann cells. Neuron. 1995;14:133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826631</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns DC, Marx R, Mains RE, O'Rourke B, Marban E. Inducible genetic suppression of neuronal excitability. J Neurosci. 1999;19:1691&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782162</ArticleId><ArticleId IdType="pubmed">10024355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney ST, Broadie K, Keane J, Niemann H, O'Kane CJ. Targeted expression of tetanus toxin light chain in Drosophila specifically eliminates synaptic transmission and causes behavioral defects. Neuron. 1995;14:341&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857643</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenkiel BR, et al. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. Neuron. 2007;54:205&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634585</ArticleId><ArticleId IdType="pubmed">17442243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc Natl Acad Sci U S A. 2007 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876585</ArticleId><ArticleId IdType="pubmed">17483470</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaner NC, et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22:1567&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15558047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet. 2001;2:743&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods. 1998;14:381&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9608509</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroni P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods. 1997;71:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan B, Constantini F, Lacey E. Production of transgenic mice. In: Hogan B, Constantini F, Lacey E, editors. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 1994. pp. 217&#x2013;252.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18454154</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-7105</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature methods</Title><ISOAbbreviation>Nat Methods</ISOAbbreviation></Journal><ArticleTitle>Improving the photostability of bright monomeric orange and red fluorescent proteins.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>551</EndPage><MedlinePgn>545-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nmeth.1209</ELocationID><Abstract><AbstractText>All organic fluorophores undergo irreversible photobleaching during prolonged illumination. Although fluorescent proteins typically bleach at a substantially slower rate than many small-molecule dyes, in many cases the lack of sufficient photostability remains an important limiting factor for experiments requiring large numbers of images of single cells. Screening methods focusing solely on brightness or wavelength are highly effective in optimizing both properties, but the absence of selective pressure for photostability in such screens leads to unpredictable photobleaching behavior in the resulting fluorescent proteins. Here we describe an assay for screening libraries of fluorescent proteins for enhanced photostability. With this assay, we developed highly photostable variants of mOrange (a wavelength-shifted monomeric derivative of DsRed from Discosoma sp.) and TagRFP (a monomeric derivative of eqFP578 from Entacmaea quadricolor) that maintain most of the beneficial qualities of the original proteins and perform as reliably as Aequorea victoria GFP derivatives in fusion constructs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaner</LastName><ForeName>Nathan C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Michael Z</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>McKeown</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Steinbach</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Hazelwood</LastName><ForeName>Kristin L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Tsien</LastName><ForeName>Roger Y</ForeName><Initials>RY</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>DQ336159</AccessionNumber><AccessionNumber>DQ336160</AccessionNumber><AccessionNumber>EU582019</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM072033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS27177</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027177</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM72033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS027177</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Methods</MedlineTA><NlmUniqueID>101215604</NlmUniqueID><ISSNLinking>1548-7091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Methods. 2008 Jun;5(6):472-3. doi: 10.1038/nmeth0608-472.</RefSource><PMID Version="1">18511915</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055095" MajorTopicYN="N">Optics and Photonics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038761" MajorTopicYN="N">Photobleaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010777" MajorTopicYN="N">Photochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097573" MajorTopicYN="N">Red Fluorescent Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18454154</ArticleId><ArticleId IdType="mid">NIHMS180998</ArticleId><ArticleId IdType="pmc">PMC2853173</ArticleId><ArticleId IdType="doi">10.1038/nmeth.1209</ArticleId><ArticleId IdType="pii">nmeth.1209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Campbell RE, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A. 2002;99:7877&#x2013;7882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122988</ArticleId><ArticleId IdType="pubmed">12060735</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaner NC, et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22:1567&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15558047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudakov DM, et al. Photoswitchable cyan fluorescent protein for protein tracking. Nat Biotechnol. 2004;22:1435&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502815</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesbeck O, Baird GS, Campbell RE, Zacharias DA, Tsien RY. Reducing the environmental sensitivity of yellow fluorescent protein. Mechanism and applications. J Biol Chem. 2001;276:29188&#x2013;29194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387331</ArticleId></ArticleIdList></Reference><Reference><Citation>Habuchi S, et al. Reversible single-molecule photoswitching in the GFP-like fluorescent protein Dronpa. Proc Natl Acad Sci U S A. 2005;102:9511&#x2013;9516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157093</ArticleId><ArticleId IdType="pubmed">15972810</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa S, Araki T, Nagai T, Mizuno H, Miyawaki A. Cyan-emitting and orange-emitting fluorescent proteins as a donor/acceptor pair for fluorescence resonance energy transfer. Biochem J. 2004;381:307&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133789</ArticleId><ArticleId IdType="pubmed">15065984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, et al. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol. 2002;20:87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AW, Daugherty PS. Evolutionary optimization of fluorescent proteins for intracellular FRET. Nat Biotechnol. 2005;23:355&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15696158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo MA, Springer GH, Granada B, Piston DW. An improved cyan fluorescent protein variant useful for FRET. Nat Biotechnol. 2004;22:445&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">14990965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedenmann J, et al. EosFP, a fluorescent marker protein with UV-inducible green-to-red fluorescence conversion. Proc Natl Acad Sci U S A. 2004;101:15905&#x2013;15910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528746</ArticleId><ArticleId IdType="pubmed">15505211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapata-Hommer O, Griesbeck O. Efficiently folding and circularly permuted variants of the Sapphire mutant of GFP. BMC Biotechnol. 2003;3:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161811</ArticleId><ArticleId IdType="pubmed">12769828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai HW, Henderson JN, Remington SJ, Campbell RE. Directed evolution of a monomeric, bright and photostable version of Clavularia cyan fluorescent protein: structural characterization and applications in fluorescence imaging. Biochem J. 2006;400:531&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698604</ArticleId><ArticleId IdType="pubmed">16859491</ArticleId></ArticleIdList></Reference><Reference><Citation>Merzlyak EM, et al. Bright monomeric red fluorescent protein with an extended fluorescence lifetime. Nat Methods. 2007;4:555&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572680</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz MV, et al. Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol. 1999;17:969&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">10504696</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen J, et al. The 2.0-A crystal structure of eqFP611, a far red fluorescent protein from the sea anemone Entacmaea quadricolor. J Biol Chem. 2003;278:44626&#x2013;44631.</Citation><ArticleIdList><ArticleId IdType="pubmed">12909624</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nat Methods. 2005;2:905&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16299475</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesenbock G, De Angelis DA, Rothman JE. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature. 1998;394:192&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnecker D, Voigt P, Hellwig N, Schaefer M. Reversible photobleaching of enhanced green fluorescent proteins. Biochemistry. 2005;44:7085&#x2013;7094.</Citation><ArticleIdList><ArticleId IdType="pubmed">15865453</ArticleId></ArticleIdList></Reference><Reference><Citation>Habuchi S, et al. Evidence for the isomerization and decarboxylation in the photoconversion of the red fluorescent protein DsRed. J Am Chem Soc. 2005;127:8977&#x2013;8984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15969574</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudakov DM, Feofanov AV, Mudrik NN, Lukyanov S, Lukyanov KA. Chromophore environment provides clue to &#x201c;kindling fluorescent protein&#x201d; riddle. J Biol Chem. 2003;278:7215&#x2013;7219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12496281</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen M, et al. Structure and mechanism of the reversible photoswitch of a fluorescent protein. Proc Natl Acad Sci U S A. 2005;102:13070&#x2013;13074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201575</ArticleId><ArticleId IdType="pubmed">16135569</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen M, et al. Structural basis for reversible photoswitching in Dronpa. Proc Natl Acad Sci U S A. 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941826</ArticleId><ArticleId IdType="pubmed">17646653</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson JN, Ai HW, Campbell RE, Remington SJ. Structural basis for reversible photobleaching of a green fluorescent protein homologue. Proc Natl Acad Sci U S A. 2007;104:6672&#x2013;6677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1871844</ArticleId><ArticleId IdType="pubmed">17420458</ArticleId></ArticleIdList></Reference><Reference><Citation>van Thor JJ, Gensch T, Hellingwerf KJ, Johnson LN. Phototransformation of green fluorescent protein with UV and visible light leads to decarboxylation of glutamate 222. Nat Struct Biol. 2002;9:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell AF, Stoner-Ma D, Wachter RM, Tonge PJ. Light-driven decarboxylation of wild-type green fluorescent protein. J Am Chem Soc. 2003;125:6919&#x2013;6926.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783544</ArticleId></ArticleIdList></Reference><Reference><Citation>van Thor JJ, Georgiev GY, Towrie M, Sage JT. Ultrafast and low barrier motions in the photoreactions of the green fluorescent protein. J Biol Chem. 2005;280:33652&#x2013;33659.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033764</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhusha VV, Sorkin A. Conversion of the monomeric red fluorescent protein into a photoactivatable probe. Chem Biol. 2005;12:279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando R, Hama H, Yamamoto-Hino M, Mizuno H, Miyawaki A. An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein. Proc Natl Acad Sci U S A. 2002;99:12651&#x2013;12656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130515</ArticleId><ArticleId IdType="pubmed">12271129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukyanov KA, Chudakov DM, Lukyanov S, Verkhusha VV. Innovation: Photoactivatable fluorescent proteins. Nat Rev Mol Cell Biol. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16167053</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson GH, Lippincott-Schwartz J. Selective photolabeling of proteins using photoactivatable GFP. Methods. 2004;32:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsui H, Karasawa S, Shimizu H, Nukina N, Miyawaki A. Semi-rational engineering of a coral fluorescent protein into an efficient highlighter. EMBO Rep. 2005;6:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299271</ArticleId><ArticleId IdType="pubmed">15731765</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird GS, Zacharias DA, Tsien RY. Circular permutation and receptor insertion within green fluorescent proteins. Proc Natl Acad Sci U S A. 1999;96:11241&#x2013;11246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18018</ArticleId><ArticleId IdType="pubmed">10500161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18458226</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>19</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Protective effects of NSAIDs on the development of Alzheimer disease.</ArticleTitle><Pagination><StartPage>1672</StartPage><EndPage>1677</EndPage><MedlinePgn>1672-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000311269.57716.63</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer disease (AD), but observational studies and trials have offered contradictory results. Prior studies have also been relatively short and small. We examined the effects on AD risk of NSAID use for &gt;5 years and of NSAIDs that suppress formation of A beta (1-42) amyloid in a large health care database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cases were veterans aged 55 years and older with incident AD using the US Veterans Affairs Health Care system. Matched controls were drawn from the same population. NSAID exposure was categorized into seven time periods: no use, &lt;or=1 year, &gt;1 but &lt;or=2 years, and so on. Using conditional logistic regression, adjusted for race and comorbidities, we tested the association between AD development and the use of 1) any NSAID, 2) any NSAID excluding nonacetylated salicylates, 3) each NSAID class, 4) each individual NSAID, and 5) A beta (1-42)-suppressing NSAIDs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 49,349 cases and 196,850 controls. Compared with no NSAID use, the adjusted odds ratios for AD among NSAID users decreased from 0.98 for &lt;or=1 year of use (95% CI 0.95-1.00) to 0.76 for &gt;5 years of use (0.68-0.85). For users of ibuprofen, it decreased from 1.03 (1.00-1.06) to 0.56 (0.42-0.75). Effects of other NSAID classes and individual NSAIDs were inconsistent. There was no difference between a group of A beta (1-42)-suppressing NSAIDs and others.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Long-term nonsteroidal anti-inflammatory drug (NSAID) use was protective against Alzheimer disease. Findings were clearest for ibuprofen. A beta (1-42)-suppressing NSAIDs did not differ from others.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vlad</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Clinical Epidemiology Research and Training Unit, 650 Albany St., Suite X200, Boston, MA 02118, USA. svlad@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Felson</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AR47785</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR007598</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AR047785</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR07598</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><i>Disclosure:</i> The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18458226</ArticleId><ArticleId IdType="mid">NIHMS140887</ArticleId><ArticleId IdType="pmc">PMC2758242</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000311269.57716.63</ArticleId><ArticleId IdType="pii">70/19/1672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37:289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474976</ArticleId></ArticleIdList></Reference><Reference><Citation>de Craen AJM, Gussekloo J, Vrijsen B, Westendorp RGJ. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005;161:114&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632261</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718699</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408559</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002;58:1050&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Ongini E, Wenk G. Non-steroidal antiinflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem. 2004;91:521&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485484</ArticleId></ArticleIdList></Reference><Reference><Citation>Morihara T, Teter B, Yang F, et al. Ibuprofen suppresses interleukin-1&#x3b2; induction of pro-amyloidogenic &#x3b1;1-antichymotrypsin to ameliorate &#x3b2;-amyloid (A&#x3b2;) pathology in Alzheimer's models. Neuropsychopharmacology. 2005;30:1111&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flurbiprofen and chemically related antiinflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev. 2005;48:400&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850679</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid1-42 secretion. J Med Chem. 2005;48:5705&#x2013;5720.</Citation><ArticleIdList><ArticleId IdType="pubmed">16134939</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower A&#x3b2; 42 in vivo. J Clin Invest. 2003;112:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(suppl 2):B10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano F, Mitchell JA, Warner TD. Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. J Pharmacol Exp Ther. 2001;299:894&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">11714873</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, Larrieu S, Barberger-Gateau P. Alcohol and tobacco consumption as risk factors of dementia: a review of epidemiological studies. Biomed Pharmacother. 2004;58:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18463254</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>19</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>5007</StartPage><EndPage>5017</EndPage><MedlinePgn>5007-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0590-08.2008</ELocationID><Abstract><AbstractText>The enkephalin signaling pathway regulates various neural functions and can be altered by neurodegenerative disorders. In Alzheimer's disease (AD), elevated enkephalin levels may reflect compensatory processes or contribute to cognitive impairments. To differentiate between these possibilities, we studied transgenic mice that express human amyloid precursor protein (hAPP) and amyloid-beta (Abeta) peptides in neurons and exhibit key aspects of AD. Met-enkephalin levels in neuronal projections from the entorhinal cortex and dentate gyrus (brain regions important for memory that are affected in early stages of AD) were increased in hAPP mice, as were preproenkephalin mRNA levels. Genetic manipulations that exacerbate or prevent excitotoxicity also exacerbated or prevented the enkephalin alterations. In human AD brains, enkephalin levels in the dentate gyrus were also increased. In hAPP mice, enkephalin elevations correlated with the extent of Abeta-dependent neuronal and behavioral alterations, and memory deficits were reduced by irreversible blockade of mu-opioid receptors with the antagonist beta-funaltrexamine. We conclude that enkephalin elevations may contribute to cognitive impairments in hAPP mice and possibly in humans with AD. The therapeutic potential of reducing enkephalin production or signaling merits further exploration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004745">Enkephalins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>58569-55-4</RegistryNumber><NameOfSubstance UI="D004744">Enkephalin, Methionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>93443-35-7</RegistryNumber><NameOfSubstance UI="C033660">preproenkephalin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004744" MajorTopicYN="N">Enkephalin, Methionine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004745" MajorTopicYN="N">Enkephalins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18463254</ArticleId><ArticleId IdType="mid">NIHMS87738</ArticleId><ArticleId IdType="pmc">PMC3315282</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0590-08.2008</ArticleId><ArticleId IdType="pii">28/19/5007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ, Loh HH, Law PY, Wessendorf MW, Elde R. Distribution and targeting of a &#x3bc;-opioid receptor (MOR1) in brain and spinal cord. J Neurosci. 1995;15:3328&#x2013;3341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578209</ArticleId><ArticleId IdType="pubmed">7751913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A&#x3b2; antibody. J Clin Invest. 2006;116:825&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1378188</ArticleId><ArticleId IdType="pubmed">16498501</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar RJ, Klein GE. Endogenous opiates and behavior: 2004. Peptides. 2005;26:2629&#x2013;2711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16039752</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, &#x3b2;-funaltrexamine, and &#x3b2;-chlornaltrexamine. J Pharmacol Exp Ther. 2000;294:933&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">10945843</ArticleId></ArticleIdList></Reference><Reference><Citation>Canli T, Cook RG, Miczek KA. Opiate antagonists enhance the working memory of rats in the radial maze. Pharmacol Biochem Behav. 1990;36:521&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">2377653</ArticleId></ArticleIdList></Reference><Reference><Citation>Caudle RM, Wagner JJ, Chavkin C. Endogenous opioids released from perforant path modulate norepinephrine actions and inhibitory postsynaptic potentials in guinea pig CA3 pyramidal cells. J Pharmacol Exp Ther. 1991;258:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2072294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng I, Scearce-Levie K, Legleiter J, Palop J, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe K, Muchowski P, Mucke L. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker MW, Introini-Collison IB, McGaugh JL. Effects of naloxone on Morris water maze learning in the rat: Enhanced acquisition with pretraining but not posttraining administration. Psychobiology. 1989;17:270&#x2013;275.</Citation></Reference><Reference><Citation>deIpolyi A, Fang S, Wang F, Mucke L. Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging. 2008;29:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126954</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, Annaert W, Van Broeckhoven C, De Strooper B. Pathogenic APP mutations near the &#x3b3;-secretase cleavage site differentially affect A&#x3b2; secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10:1665&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004;367:164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331144</ArticleId></ArticleIdList></Reference><Reference><Citation>Derrick BE, Rodriguez SB, Lieberman DN, Martinez JL., Jr Mu opioid receptors are associated with the induction of hippocampal mossy fiber long-term potentiation. J Pharmacol Exp Ther. 1992;263:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">1359112</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Koistinaho J, Kahn K, Games D, H&#xf6;kfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein&#x2014;initial observations. Neuroscience. 2000;100:259&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">11008166</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, Hokfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing &#x3b2;-amyloid precursor protein (APP) with the Swedish double mutation (APP23) Neurobiol Dis. 2003;14:579&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding YQ, Kaneko T, Nomura S, Mizuno N. Immunohistochemical localization of &#x3bc;-opioid receptors in the central nervous system of the rat. J Comp Neurol. 1996;367:375&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">8698899</ArticleId></ArticleIdList></Reference><Reference><Citation>Do VH, Martinez CO, Martinez JL, Jr, Derrick BE. Long-term potentiation in direct perforant path projections to the hippocampal CA3 region in vivo. J Neurophysiol. 2002;87:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826036</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake CT, Milner TA. &#x3bc; opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation. Brain Res. 1999;849:203&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10592303</ArticleId></ArticleIdList></Reference><Reference><Citation>Duka T, Wuster M, Schubert P, Stoiber R, Herz A. Selective localization of different types of opiate receptors in hippocampus as revealed by in vitro autoradiography. Brain Res. 1981;205:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">6258708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischknecht HR, Siegfried B, Riggio G, Waser PG. Inhibition of morphine-induced analgesia and locomotor activity in strains of mice: a comparison of long-acting opiate antagonists. Pharmacol Biochem Behav. 1983;19:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6657726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gall C. Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci. 1988;8:1852&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569340</ArticleId><ArticleId IdType="pubmed">2898512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gall C, Brecha N, Karten HJ, Chang KJ. Localization of enkephalin-like immunoreactivity to identified axonal and neuronal populations of the rat hippocampus. J Comp Neurol. 1981;198:335&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">6263955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M. Naloxone enhancement of memory processes: effects of other opiate antagonists. Behav Neural Biol. 1982;35:375&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">6299265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M. Effect of &#x3b2;-funaltrexamine on retention of passive-avoidance conditioning. Behav Neural Biol. 1985;44:499&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">3002317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M, King RA, Young NB. Opiate antagonists improve spatial memory. Science. 1983;221:975&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">6879198</ArticleId></ArticleIdList></Reference><Reference><Citation>Godsil BP, Stefanacci L, Fanselow MS. Bright light suppresses hyperactivity induced by excitotoxic dorsal hippocampus lesions in the rat. Behav Neurosci. 2005;119:1339&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton DA, Rosenfelt CS, Whishaw IQ. Sequential control of navigation by locale and taxon cues in the Morris water task. Behav Brain Res. 2004;154:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM. Mutations in APP have independent effects on A&#x3b2; and CTF&#x3b3; generation. Neurobiol Dis. 2004;17:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong JS, McGinty JF, Grimes L, Kanamatsu T, Obie J, Mitchell CL. Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizure-related behaviors. NIDA Res Monogr. 1988;82:48&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo I. Effect of naloxone and morphine on various forms of memory in the rat: possible role of endogenous opiate mechanisms in memory consolidation. Psychopharmacology (Berl) 1979;66:199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">119264</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo I, Dias RD. Retrograde amnesia caused by Met-, Leu- and des-Try-Met-enkephalin in the rat and its reversal by naloxone. Neurosci Lett. 1981;22:189&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">7194992</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo I, Graudenz M. Memory facilitation by naloxone is due to release of dopaminergic and &#x3b2;-adrenergic systems from tonic inhibition. Psychopharmacology. 1980;67:265&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">6247739</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo I, Paiva AC, Elisabetsky E. Post-training intraperitoneal administration of leu-enkephalin and &#x3b2;-endorphin causes retrograde amnesia for two different tasks in rats. Behav Neural Biol. 1980;28:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">7362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors&#x2014;an autoradiographic study. Neuroscience. 1990;39:613&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">1965859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyuzhny AE, Wessendorf MW. Relationship of &#x3bc;- and &#x3b4;-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. J Comp Neurol. 1998;392:528&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">9514515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanamatsu T, Obie J, Grimes L, McGinty JF, Yoshikawa K, Sabol S, Hong JS. Kainic acid alters the metabolism of Met5-enkephalin and the level of dynorphin A in the rat hippocampus. J Neurosci. 1986;6:3094&#x2013;3102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568791</ArticleId><ArticleId IdType="pubmed">2876067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kergoat H, Kergoat MJ, Justino L, Chertkow H, Robillard A, Bergman H. Visual retinocortical function in dementia of the Alzheimer type. Gerontology. 2002;48:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyosawa M, Bosley TM, Chawluk J, Jamieson D, Schatz NJ, Savino PJ, Sergott RC, Reivich M, Alavi A. Alzheimer's disease with prominent visual symptoms. Clinical and metabolic evaluation. Ophthalmology. 1989;96:1077&#x2013;1085. discussion 1085&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">2788851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005;4:173&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Wang J, Mansuy IM, Grant SGN, Mayford M, Kandel ER. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci USA. 1997;94:4761&#x2013;4765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20798</ArticleId><ArticleId IdType="pubmed">9114065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Ishibashi H, Obata K, Kandel ER. Higher seizure susceptibility and enhanced tyrosine phosphorylation on N-methyl-d-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem. 1998;5:429&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311255</ArticleId><ArticleId IdType="pubmed">10489260</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Gao HM, Zhang WQ, Tang YY, Song HS. Effects of chronic administration of PL017 and &#x3b2;-funaltrexamine hydrochloride on susceptibility of kainic acid-induced seizures in rats. Sheng Li Xue Bao. 2004;56:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:513&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409164</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison DV, Nicoll RA. Enkephalin hyperpolarizes interneurones in the rat hippocampus. J Physiol (Lond) 1988;398:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1191763</ArticleId><ArticleId IdType="pubmed">3392667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci. 1995;18:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">7535487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Steffenella TM, Duffy CJ. A visuospatial variant of mild cognitive impairment: getting lost between aging and AD. Neurology. 2003;60:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629237</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez JL, Jr, Conner P, Dana RC. Central versus peripheral actions of Leu-enkephalin on acquisition of a one-way active avoidance response in rats. Brain Res. 1985;327:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">3986516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. &#x3bc;-, &#x3b4;- and &#x3ba;-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 2001;893:121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11223000</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara RK, Skelton RW. Pretraining morphine impairs acquisition and performance in the Morris water maze: motivation reduction rather than amnesia. Psychobiology. 1991;19:313&#x2013;322.</Citation></Reference><Reference><Citation>Mendez MF, Cherrier MM. Agnosia for scenes in topographagnosia. Neuropsychologia. 2003;41:1387&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757910</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing RB, Jensen RA, Martinez JL, Jr, Spiehler VR, Vasquez BJ, Soumireu-Mourat B, Liang KC, McGaugh JL. Naloxone enhancement of memory. Behav Neural Biol. 1979;27:266&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">518457</ArticleId></ArticleIdList></Reference><Reference><Citation>Moneta ME, H&#xf6;llt V. Perforant path kindling induces differential alterations in the mRNA levels coding for prodynorphin and proenkephalin in the rat hippocampus. Neurosci Lett. 1990;110:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325899</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris BJ, Feasey KJ, Ten Bruggencate G, Herz A, H&#xf6;llt V. Electrical stimulation in vivo increases the expression of proenkephalin mRNA and decreases the expression of prodynorphin mRNA in rat hippocampal granule cells. Proc Natl Acad Sci USA. 1988;85:3226&#x2013;3230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280177</ArticleId><ArticleId IdType="pubmed">3362871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA, Alger BE, Jahr CE. Enkephalin blocks inhibitory pathways in the vertebrate CNS. Nature. 1980;287:22&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">6251377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto MM, Guen SL, Kieffer BL, Roques BP, Noble F. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the &#x394; opioid receptors. Neuroscience. 2005;135:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">16112476</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien HL, Tetewsky SJ, Avery LM, Cushman LA, Makous W, Duffy CJ. Visual mechanisms of spatial disorientation in Alzheimer's disease. Cereb Cortex. 2001;11:1083&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590117</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu G-Q, Mucke L. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci. 2005;25:9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara N, Roberts R, Rhiew HB, Stanley M, Gershon S. Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease. Neurobiol Aging. 1985;6:233&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">3903533</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Ferris SH, Anand R, Mir P, Geibel V, De Leon MJ, Roberts E. Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med. 1983;308:721&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">6338389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, L&#xf6;nnberg P, Marjam&#xe4;ki P, M&#xf6;ls&#xe4; P, S&#xe4;k&#xf6; E, Palj&#xe4;rvi L. Brain methionine- and leucine-enkephalin receptors in patients with dementia. Neurosci Lett. 1993;161:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255552</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, McConlogue L, Tan H, Gordon M, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid &#x3b2; protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease. J Biol Chem. 1995;270:28257&#x2013;28267.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Serby M, Resnick R, Jordan B, Adler J, Corwin J, Rotrosen JP. Naltrexone and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:587&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">3541052</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons ML, Chavkin C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol. 1996;39:145&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">8894847</ArticleId></ArticleIdList></Reference><Reference><Citation>Snead OC, III, Bearden LJ. Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin. Science. 1980;210:1031&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">6254150</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengaard-Pedersen K. Comparative mapping of opioid receptors and enkephalin immunoreactive nerve terminals in the rat hippocampus. A radiohistochemical and immunocytochemical study. Histochemistry. 1983;79:311&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">6317617</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumm RK, Zhou C, Schulz S, Hollt V. Neuronal types expressing &#x3bc; and &#x3b4;-opioid receptor mRNA in the rat hippocampal formation. J Comp Neurol. 2004;469:107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689476</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda KR, Lupica CR. Opioid inhibition of hippocampal interneurons via modulation of potassium and hyperpolarization-activated cation (Ih) currents. J Neurosci. 1998;18:7084&#x2013;7098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793245</ArticleId><ArticleId IdType="pubmed">9736632</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemori AE, Larson DL, Portoghese PS. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol. 1981;70:445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">6263637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Sunderland T, Murphy DL, Cohen MR, Welkowitz JA, Weingartner H, Newhouse PA, Cohen RM. Design and interpretation of opiate antagonist trials in dementia. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:611&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">3025928</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortella FC, Robles L, Mosberg HI. Evidence for &#x3bc; opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J Pharmacol Exp Ther. 1987;240:571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">3027318</ArticleId></ArticleIdList></Reference><Reference><Citation>von Zastrow M, Svingos A, Haberstock-Debic H, Evans C. Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr Opin Neurobiol. 2003;13:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850220</ArticleId></ArticleIdList></Reference><Reference><Citation>Whishaw IQ, Cassel JC, Jarrad LE. Rats with fimbria-fornix lesions display a place response in a swimming pool: a dissociation between getting there and knowing where. J Neurosci. 1995;15:5779&#x2013;5788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577651</ArticleId><ArticleId IdType="pubmed">7643218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. Familial Alzheimer's disease mutations inhibit &#x3b3;-secretase-mediated liberation of &#x3b2;-amyloid precursor protein carboxy-terminal fragment. J Neurochem. 2005;94:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992373</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 2001;81:299&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152760</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SH, Johnston D. Actions of endogenous opioids on NMDA receptor-independent long-term potentiation in area CA3 of the hippocampus. J Neurosci. 1996;16:3652&#x2013;3660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578829</ArticleId><ArticleId IdType="pubmed">8642409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18463291</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>19</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6813</StartPage><EndPage>6818</EndPage><MedlinePgn>6813-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0800712105</ELocationID><Abstract><AbstractText>Amelyoid-beta peptide (Abeta) is a major causative agent responsible for Alzheimer's disease (AD). Abeta contains a high affinity metal binding site that modulates peptide aggregation and toxicity. Therefore, identifying molecules targeting this site represents a valid therapeutic strategy. To test this hypothesis, a range of L-PtCl(2) (L = 1,10-phenanthroline derivatives) complexes were examined and shown to bind to Abeta, inhibit neurotoxicity and rescue Abeta-induced synaptotoxicity in mouse hippocampal slices. Coordination of the complexes to Abeta altered the chemical properties of the peptide inhibiting amyloid formation and the generation of reactive oxygen species. In comparison, the classic anticancer drug cisplatin did not affect any of the biochemical and cellular effects of Abeta. This implies that the planar aromatic 1,10-phenanthroline ligands L confer some specificity for Abeta onto the platinum complexes. The potent effect of the L-PtCl(2) complexes identifies this class of compounds as therapeutic agents for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Melbourne, Parkville, Victoria, 3010, Australia. kbarnham@unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenche</LastName><ForeName>Vijaya B</ForeName><Initials>VB</Initials></Author><Author ValidYN="Y"><LastName>Ciccotosto</LastName><ForeName>Giuseppe D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Tew</LastName><ForeName>Deborah J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Keyla</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cranston</LastName><ForeName>Greg A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Johanssen</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Volitakis</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jeffrey P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Cherny</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WT069851MA</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>49DFR088MY</RegistryNumber><NameOfSubstance UI="D010984">Platinum</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010984" MajorTopicYN="N">Platinum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017356" MajorTopicYN="N">Synchrotrons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: K.J.B., A.I.B., C.L.M., R.A.C., and R.C. are consultants to Prana Biotechnology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18463291</ArticleId><ArticleId IdType="pmc">PMC2383936</ArticleId><ArticleId IdType="doi">10.1073/pnas.0800712105</ArticleId><ArticleId IdType="pii">0800712105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappai R, Barnham KJ. Molecular determinants of Alzheimer's disease Abeta peptide neurotoxicity. Future Neurol. 2007;2:397&#x2013;409.</Citation></Reference><Reference><Citation>Tickler AK, et al. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem. 2005;280:13355&#x2013;13363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668252</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DP, et al. Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem. 2006;281:15145&#x2013;15154.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595673</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtain CC, et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 2001;276:20466&#x2013;20473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274207</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995;377:649&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566180</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, et al. Characterization of copper interactions with Alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1&#x2013;42. J Neurochem. 2000;75:1219&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao S, Cherny RA, Bush AI, Masters CL, Barnham KJ. Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloid beta-peptide by NMR. J Pept Sci. 2004;10:210&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">15119593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug-interactions with DNA. Chem Rev. 1987;87:1153&#x2013;1181.</Citation></Reference><Reference><Citation>Lee JP, et al. 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry. 1995;34:5191&#x2013;5200.</Citation><ArticleIdList><ArticleId IdType="pubmed">7711039</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons LK, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994;45:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">8145724</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Opazo C, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem. 2002;277:40302&#x2013;40308.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192006</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 2004;18:1427&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15231727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J. Long-term potentiation: Outstanding questions and attempted synthesis. Philos Trans R Soc Lond B. 2003;358:829&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693147</ArticleId><ArticleId IdType="pubmed">12740130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsodyks M. Spike-timing-dependent synaptic plasticity&#x2014;the long road towards understanding neuronal mechanisms of learning and memory. Trends Neurosci. 2002;25:599&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446119</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DW, et al. Naturally secreted oliogmers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106355</ArticleId></ArticleIdList></Reference><Reference><Citation>Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des. 2006;67:27&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16492146</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A&#x3b2;(1-42) and A&#x3b2;(25-35) J Am Chem Soc. 2001;123:5625&#x2013;5631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403592</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, et al. Neurotoxic, redox-competent Alzheimer's &#x3b2;-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003;278:42959&#x2013;42965.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanizzi FP, et al. Steric crowding and redox reactivity in platinum(II) and platinum(IV) complexes containing substituted 1,10-phenanthrolines. Inorg Chem. 1996;35:3173&#x2013;3182.</Citation><ArticleIdList><ArticleId IdType="pubmed">11666514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccotosto GD, et al. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem. 2004;279:42528&#x2013;42534.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18467692</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.</ArticleTitle><Pagination><StartPage>1683</StartPage><EndPage>1692</EndPage><MedlinePgn>1683-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2353/ajpath.2008.070829</ELocationID><Abstract><AbstractText>The amyloid cascade hypothesis proposes that amyloid beta (Abeta) pathology precedes and induces tau pathology, but the neuropathological connection between these two lesions has not been demonstrated. We examined the regional distribution and co-localization of Abeta and phosphorylated tau (p-tau) in synaptic terminals of Alzheimer's disease brains. To quantitatively examine large populations of individual synaptic terminals, flow cytometry was used to analyze synaptosomes prepared from cryopreserved Alzheimer's disease tissue. An average 68.4% of synaptic terminals in the Alzheimer's disease cohort (n = 11) were positive for Abeta, and 32.3% were positive for p-tau; Abeta and p-tau fluorescence was lowest in cerebellum. In contrast to synaptic p-tau, which was highest in the entorhinal cortex and hippocampus (P = 0.004), synaptic Abeta fluorescence was significantly lower in the entorhinal cortex and hippocampus relative to neocortical regions (P = 0.0003). Synaptic Abeta and p-tau fluorescence was significantly correlated (r = 0.683, P &lt; 0.004), and dual-labeling experiments demonstrated that 24.1% of Abeta-positive terminals were also positive for p-tau, with the highest fraction of dual labeling (39.3%) in the earliest affected region, the entorhinal cortex. Western blotting experiments show a significant correlation between synaptic Abeta levels measured by flow cytometry and oligomeric Abeta species (P &lt; 0.0001). These results showing overlapping Abeta and tau pathology are consistent with a model in which both synaptic loss and dysfunction are linked to a synaptic amyloid cascade within the synaptic compartment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fein</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>School of Nursing, University of California at Los Angeles School of Medicine, Sepulveda Veterans Administration Medical Center, Los Angeles, California 90095-6919, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolow</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fusheng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Gylys</LastName><ForeName>Karen Hoppens</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043946</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>050 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 28697</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS43946</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018879</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016042</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI028697</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA 16042</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18879</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18467692</ArticleId><ArticleId IdType="pmc">PMC2408427</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2008.070829</ArticleId><ArticleId IdType="pii">S0002-9440(10)61926-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer&#x2019;s disease. Arch Neurol. 1995;52:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826280</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40. N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, Xia W, Nicholson LK, Lu KP. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-[beta] production. Nature. 2006;440:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554819</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer&#x2019;s disease. Neurobiol Aging. 2005;26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006;168:184&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer&#x2019;s and Parkinson&#x2019;s disease patients. Neurosci Lett. 1993;162:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121624</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993;33:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62:1984&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184601</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. From the cover: nMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA. 2006;103:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413822</ArticleId><ArticleId IdType="pubmed">16477009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci USA. 2007;104:10252&#x2013;10257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891218</ArticleId><ArticleId IdType="pubmed">17535890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer&#x2019;s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging. 2007, Mar 31 [Epub ahead of press]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Synaptic changes in Alzheimer&#x2019;s disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol. 2004;165:1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618663</ArticleId><ArticleId IdType="pubmed">15509549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci. 2002;22:9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res. 1994;667:138&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Tan AM, Cole GM. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem. 2003;84:1442&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614344</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid I, Uittenbogaart CH, Giorgi JV. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry. 1991;12:279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">1709845</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliner JA, Morgan GA, Harmon RJ. Single-factor repeated-measures designs: analysis and interpretation. J Am Acad Child Adolesc Psychiatry. 2002;41:1014&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Yang F, Miller CA, Cole GM. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer&#x2019;s disease cortex. Neurobiol Aging. 2007;28:8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16332401</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Yang F, Cole GM. Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex. Cytometry A. 2004;60:90&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem. 1998;252:542&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546672</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack J, Schneider A, Mandelkow EM, Hyman B. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol (Berl) 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:2853&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287017</ArticleId><ArticleId IdType="pubmed">2649895</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2006;103:1953&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413647</ArticleId><ArticleId IdType="pubmed">16446437</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095864</ArticleId><ArticleId IdType="pubmed">12146796</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002;9:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci. 1998;18:9629&#x2013;9637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793291</ArticleId><ArticleId IdType="pubmed">9822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2004;24:3801&#x2013;3809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729359</ArticleId><ArticleId IdType="pubmed">15084661</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima N, Morishima-Kawashima M, Yamaguchi H, Yoshimura M, Sugihara S, Khan K, Games D, Schenk D, Ihara Y. Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. Am J Pathol. 2001;158:2209&#x2013;2218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891992</ArticleId><ArticleId IdType="pubmed">11395399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakio A, Nishimoto Si, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem. 2001;276:24985&#x2013;24990.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342534</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson TJ, Alkon DL. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans. 2005;33:1033&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufour F, Liu QY, Gusev P, Alkon D, Atzori M. Cholesterol-enriched diet affects spatial learning and synaptic function in hippocampal synapses. Brain Res. 2006;1103:88&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer&#x2019;s-related amyloid beta oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer&#x2019;s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol. 2006;175:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064590</ArticleId><ArticleId IdType="pubmed">17101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C. Looking for the link between plaques and tangles. Neurobiol Aging. 2004;25:735&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165696</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonheit B, Zarski R, Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging. 2004;25:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18468996</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>283</Volume><Issue>27</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Promotion of BACE1 mRNA alternative splicing reduces amyloid beta-peptide production.</ArticleTitle><Pagination><StartPage>18694</StartPage><EndPage>18701</EndPage><MedlinePgn>18694-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M801322200</ELocationID><Abstract><AbstractText>Production of the amyloid beta-peptide (Abeta) via sequential proteolytic cleavage of the amyloid precursor protein by beta- and gamma-secretases is strongly implicated in the pathogenesis of Alzheimer disease. The beta-secretase that executes the first cleavage event is a transmembrane aspartyl protease known as beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). BACE1 pre-mRNA is alternatively spliced through the use of alternative splice sites in exons 3 and 4, although the significance of these splicing events is unclear. Here, we quantitatively measured relative levels of BACE1 transcripts and identified a novel splice variant of BACE1. We found a subtle but significant difference in BACE1 splicing between brain and pancreas, indicating the cellular environment can affect BACE1 alternative splicing. Furthermore, we have shown that BACE1 proteins translated from alternatively spliced transcripts have dramatically reduced beta-secretase activity and promotion of BACE1 alternative splicing reduces Abeta production. These findings illustrate the importance of BACE1 alternative splicing in affecting the level of Abeta produced in cells and suggest that targeting regulation of BACE1 alternative splicing is a potential therapeutic strategy for lowering beta-secretase activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mowrer</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="Y">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18468996</ArticleId><ArticleId IdType="doi">10.1074/jbc.M801322200</ArticleId><ArticleId IdType="pii">S0021-9258(20)81470-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18474729</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.</ArticleTitle><Pagination><StartPage>896</StartPage><EndPage>905</EndPage><MedlinePgn>896-905</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.2008.65.7.nct70006</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, double-masked chemoprevention trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Six US memory clinics.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Seven tests of cognitive function and a global summary score measured annually.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>ADAPT Research Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Barbara K</ForeName><Initials>BK</Initials></Author><Author ValidYN="Y"><LastName>Szekely</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Piantadosi</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John C S</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mullan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00007189</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG015477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG15477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>57Y76R9ATQ</RegistryNumber><NameOfSubstance UI="D009288">Naproxen</NameOfSubstance></Chemical><Chemical><RegistryNumber>JCX84Q7J1L</RegistryNumber><NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2009 Apr;66(4):539-40; author reply 540. doi: 10.1001/archneurol.2009.52.</RefSource><PMID Version="1">19364945</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009288" MajorTopicYN="N">Naproxen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Breitner</LastName></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName></Investigator><Investigator ValidYN="Y"><LastName>Meinert</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullan</LastName></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>Saleem</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName></Investigator><Investigator ValidYN="Y"><LastName>Piantadosi</LastName></Investigator><Investigator ValidYN="Y"><LastName>Negele</LastName><ForeName>Janette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montero</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piantadosi</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dassopoulos</LastName><ForeName>Themistocles</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whelton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breitner</LastName></Investigator><Investigator ValidYN="Y"><LastName>Negele</LastName></Investigator><Investigator ValidYN="Y"><LastName>Montero</LastName></Investigator><Investigator ValidYN="Y"><LastName>Aigbe</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorje</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholerton</LastName><ForeName>Brenna</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meinert</LastName></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName></Investigator><Investigator ValidYN="Y"><LastName>Piantadosi</LastName></Investigator><Investigator ValidYN="Y"><LastName>Casper</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donithan</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Hsu-Tai</ForeName><Initials>HT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piantadosi</LastName></Investigator><Investigator ValidYN="Y"><LastName>Shanklin</LastName><ForeName>Anne V</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Julia J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergey</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dassopoulos</LastName><ForeName>Themos</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieter</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gogel</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson-Sturdivant</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoritomo</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName></Investigator><Investigator ValidYN="Y"><LastName>Auerbach</LastName><ForeName>Sanford</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyle</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cisewski</LastName><ForeName>Dawn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mwicigi</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Mary-Tara</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brickley</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Compton</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanna</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lambrechts</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nafissi</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packard</LastName><ForeName>Andreja</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakuria</LastName><ForeName>Mayuri</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>Saleem</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson-Logan</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallum</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decker</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jakimovick</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pustalka</LastName><ForeName>Arlene</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salem-Spencer</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widman</LastName><ForeName>Asa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName></Investigator><Investigator ValidYN="Y"><LastName>Fishel</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahl</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigda</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biro</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boucher</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dasher</LastName><ForeName>Nickolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVita</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrett</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamm</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindsey</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sissons-Ross</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liebsack</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciemo</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hicksenhiser</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson-Traver</LastName><ForeName>Sherry</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolody</LastName><ForeName>Healther</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royer</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tweedy</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullan</LastName></Investigator><Investigator ValidYN="Y"><LastName>Luis</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrish</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Laila</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chea</LastName><ForeName>Theavy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Creamer</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayne</LastName><ForeName>Melody Brooks</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>Summer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zolton</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>C Morton</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>High</LastName><ForeName>Dallas M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schnitzer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName></Investigator><Investigator ValidYN="Y"><LastName>Meinert</LastName></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18474729</ArticleId><ArticleId IdType="mid">NIHMS226281</ArticleId><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="doi">10.1001/archneur.2008.65.7.nct70006</ArticleId><ArticleId IdType="pii">2008.65.7.nct70006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23(4):159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15279021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozzini R, Ferrucci L, Losonczy K, et al. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc. 1996;44(9):1025&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">8790225</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? an analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology. 1998;50(2):374&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982;25(8):1013&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">7115443</ArticleId></ArticleIdList></Reference><Reference><Citation>Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect? Drug Saf. 1998;19(6):427&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880087</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BK, Meinert CL. Breitner JCS for the ADAPT Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials. 2002;23(1):93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">11852171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials. 1995;16(6):395&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">8720017</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>Statement from the Steering Committee of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee.   http://www.jhucct.com/adapt/pdf%20documents/FDA%20ADAPT %20STATEMENT_web%20posting.pdf. Published February 18, 2005. Accessed December 22, 2005.</Citation></Reference><Reference><Citation>ADAPT Research Group Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) PLoS Clin Trials. 2006;1(7):e33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851724</ArticleId><ArticleId IdType="pubmed">17111043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43(8):1609&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53(1):197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408559</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002;58(7):1050&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940691</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease; Presented at: The Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy; Stockholm, Sweden. April 5-8, 2000.</Citation></Reference><Reference><Citation>Black SE, Wilcock G, Haworth J, et al. A placebo-controlled, double-blind trial of the selective A 42-lowering agent Flurizan in patients with mild to moderate Alzheimer's disease: efficacy, safety, and follow-on study results [program No. 585.6]; Presented at: the 35th Annual Meeting of the Society for Neuroscience; Washington, DC. November 15, 2005.</Citation></Reference><Reference><Citation>Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15742005</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials registration for &#x201c;Anti-inflammatory treatment for age-associated memory impairment: a double-blind placebo-controlled trial&#x201d; [NCT00009230]   http://clinicaltrials.gov/ct2/show/NCT00009230?term=NCT00009230&amp;rank=1. Accessed March 22, 2006.</Citation></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease: a double-edged sword. Neuron. 2002;35(3):419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic A&#x3b2;42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59(6):880&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18474740</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>641</EndPage><MedlinePgn>636-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.65.5.636</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pathological 43-kDa transactivating responsive sequence DNA-binding protein (TDP-43) has been identified recently as the major disease protein in amyotrophic lateral sclerosis (ALS), and in frontotemporal lobar degeneration with ubiquitinated inclusions, with or without motor neuron disease, but the distribution of TDP-43 pathology in ALS may be more widespread than previously described.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the extent of TDP-43 pathology in the central nervous systems of patients with clinically confirmed and autopsy confirmed diagnoses of ALS.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Performance of an immunohistochemical whole-central nervous system scan for evidence of pathological TDP-43 in ALS patients.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">An academic medical center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">We included 31 patients with clinically and pathologically confirmed ALS and 8 control participants.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Immunohistochemistry and double-labeling immunofluorescence to assess the frequency and severity of TDP-43 pathology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In addition to the stereotypical involvement of upper and lower motor neurons, neuronal and glial TDP-43 pathology was present in multiple areas of the central nervous systems of ALS patients, including in the nigro-striatal system, the neocortical and allocortical areas, and the cerebellum, but not in those of the controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that ALS does not selectively affect only the pyramidal motor system, but rather is a multisystem neurodegenerative TDP-43 proteinopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geser</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer's Disease Core Center, Institute on Aging, Philadelphia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandmeir</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Martinez-Lage</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Sharon X</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.5.636</ArticleId><ArticleId IdType="pii">65/5/636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18479180</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Communicating the results of clinical research to participants: attitudes, practices, and future directions.</ArticleTitle><Pagination><StartPage>e91</StartPage><MedlinePgn>e91</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e91</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.0050091</ELocationID><Abstract><AbstractText>The authors discuss the available data on the effects of communicating aggregate and individual research results on participants, investigators, and the research enterprise.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shalowitz</LastName><ForeName>David I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Bioethics Program, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. dshalowi@med.umich</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Franklin G</ForeName><Initials>FG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001290" MajorTopicYN="N">Attitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030881" MajorTopicYN="N">Disclosure</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028744" MajorTopicYN="N">Ethics Committees, Research</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004991" MajorTopicYN="Y">Ethics, Institutional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032984" MajorTopicYN="Y">Ethics, Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016134" MajorTopicYN="Y">Organizational Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="Y">Patient Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests:</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18479180</ArticleId><ArticleId IdType="pmc">PMC2375946</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.0050091</ArticleId><ArticleId IdType="pii">07-PLME-GG-1895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fernandez CV, Kodish E, Weijer C. Informing study participants of research results: An ethical imperative. IRB. 2003;25:12&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14569989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalowitz DI, Miller FG. Disclosing individual results of clinical research: Implications of respect for participants. JAMA. 2005;294:737&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">16091577</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: International perspectives. Eur J Hum Genet. 2006;14:1170&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">16868560</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia J. Sharing research results with patients: The views of care-givers involved in a randomized controlled trial. J Reprod Infant Psychol. 1987;5:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11659937</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon C, Garcia J, Elbourne D. Reactions of participants to the results of a randomised controlled trial: Exploratory study. BMJ. 1998;317:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28597</ArticleId><ArticleId IdType="pubmed">9651262</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbourne D. Subjects' views about participation in a randomized controlled trial. J Reprod Infant Psychol. 1987;5:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11659936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormondroyd E, Moynihan C, Watson M, Foster C, Davolls, S, et al. Disclosure of genetics research results after the death of the patient participant: A qualitative study of the impact on relatives. J Genet Couns. 2007;16:527&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492498</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon-Woods M, Jackson C, Windridge KC, Kenyon S. Receiving a summary of the results of a trial: Qualitative study of participants' views. BMJ. 2006;332:206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352050</ArticleId><ArticleId IdType="pubmed">16401631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormond KE, Smith ME, Cirino AL, Chisholm RL, Wolf WA. &#x201c;Duty&#x201d; to recontact participants in a population based genetic database: The NUgene experience. 2004. American College of Medical Genetics Annual Conference; 6 March 2004; Kissimmee, Florida, United States.</Citation></Reference><Reference><Citation>Bunin GR, Kazak AE, Mitelman O. Informing subjects of epidemiologic study results. Children's Cancer Group. Pediatrics. 1996;97:486&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632933</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards MP, Ponder M, Pharoah P, Everest S, Mackay J. Issues of consent and feedback in a genetic epidemiological study of women with breast cancer. J Med Ethics. 2003;29:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1733695</ArticleId><ArticleId IdType="pubmed">12672889</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez CV, Kodish E, Shurin S, Weijer C. Offering to return results to research participants: Attitudes and needs of principal investigators in the Children's Oncology Group. J Pediatr Hematol Oncol. 2003;25:704&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972805</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez CV, Kodish E, Taweel S, Shurin S, Weijer C. Disclosure of the right of research participants to receive research results: An analysis of consent forms in the Children's Oncology Group. Cancer. 2003;97:2904&#x2013;2909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez CV, Santor D, Weijer C, Strahlendorf C, Moghrabi A, et al. The return of research results to participants: Pilot questionnaire of adolescents and parents of children with cancer. Pediatr Blood Cancer. 2007;48:441&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16425279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez CV, Taweel S, Kodish E, Weijer C. Disclosure of research results to research participants: A pilot study of the needs and attitudes of adolescents and parents. Paediatr Child Health. 2005;10:332&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722972</ArticleId><ArticleId IdType="pubmed">19675841</ArticleId></ArticleIdList></Reference><Reference><Citation>Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results. J Natl Cancer Inst. 2003;95:491&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644548</ArticleId></ArticleIdList></Reference><Reference><Citation>Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, et al. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004;96:629&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100341</ArticleId></ArticleIdList></Reference><Reference><Citation>Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, et al. Offering participants results of a clinical trial: Sharing results of a negative study. Lancet. 2005;365:963&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz CJ, Riddle MP, Valdimirsdottir HB, Abramson DH, Sklar CA. Impact on survivors of retinoblastoma when informed of study results on risk of second cancers. Med Pediatr Oncol. 2003;41:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764741</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler D, Pentz R. How does the collection of genetic test results affect research participants. Am J Med Genet A. 2007;143:1733&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pubmed">17618487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong M, Braun KL, Chang RM. Native Hawaiian preferences for informed consent and disclosure of results from research using stored biological specimens. Pac Health Dialog. 2004;11:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16281693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeyer K, Olofsson BO, Mjorndal T, Lynoe N. Informed consent and biobanks: A population-based study of attitudes towards tissue donation for genetic research. Scand J Public Health. 2004;32:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204184</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutel G, Duchange N, Raffi F, Sharara LI, Theodorou I, et al. Communication of pharmacogenetic research results to HIV-infected treated patients: Standpoints of professionals and patients. Eur J Hum Genet. 2005;13:1055&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868604</ArticleId><ArticleId IdType="pubmed">15957002</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald H, Fitch LL, Matts JP, Johnson JW, Hansen BJ, et al. Perception of quality of life before and after disclosure of trial results: A report from the Program on the Surgical Control of the Hyperlipidemias (POSCH) Control Clin Trials. 1993;14:500&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8119065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler D, Prasad K, Wilfond B. Does the current consent process minimize the risks of genetics research. Am J Med Genet. 2002;113:258&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">12439893</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Blasi Z, Kaptchuk TJ, Weinman J, Kleijnen J. Informing participants of allocation to placebo at trial closure: Postal survey. BMJ. 2002;325:1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137805</ArticleId><ArticleId IdType="pubmed">12468480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnett EM, Mungall MM, Gordon C, Ronald ES, Gaw A. Offering results to research participants. BMJ. 2006;332:549&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1388168</ArticleId><ArticleId IdType="pubmed">16513719</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnett EM, Mungall MM, Kent JA, Ronald ES, McIntyre KE, et al. Unblinding of trial participants to their treatment allocation: Lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Clin Trials. 2005;2:254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279148</ArticleId></ArticleIdList></Reference><Reference><Citation>Macneil SD, Fernandez CV. Informing research participants of research results: Analysis of Canadian university based research ethics board policies. J Med Ethics. 2006;32:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563276</ArticleId><ArticleId IdType="pubmed">16373524</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNeil SD, Fernandez CV. Attitudes of research ethics board chairs towards disclosure of research results to participants: Results of a national survey. J Med Ethics. 2007;33:549&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2598188</ArticleId><ArticleId IdType="pubmed">17761827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigby H, Fernandez CV. Providing research results to study participants: Support versus practice of researchers presenting at the American Society of Hematology annual meeting. Blood. 2005;106:1199&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">15878983</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler D, Emanuel E. The debate over research on stored biological samples: What do sources think. Arch Intern Med. 2002;162:1457&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">12090881</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer R. Notifying workers at risk: The politics of the right-to-know. Am J Public Health. 1986;76:1352&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1646744</ArticleId><ArticleId IdType="pubmed">3766840</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte PA, Boal WL, Friedland JM, Walker JT, Connally LB, et al. Methodologic issues in risk communications to workers. Am J Ind Med. 1993;23:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringen K. The case for worker notification. Ann N Y Acad Sci. 1989;572:133&#x2013;141. discussion 142&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">2627071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood FB. Letter submitted to NIOSH by Westinghouse Electric Corporation as part of a panel of experts' analysis regarding interim report. HETA. 1990. pp. 89&#x2013;116.</Citation></Reference><Reference><Citation>Hornsby JL, Sappington JT, Mongan P, Gullen WH, Bono SF, et al. Risk for bladder cancer. Psychological impact of notification. JAMA. 1985;253:1899&#x2013;1902.</Citation><ArticleIdList><ArticleId IdType="pubmed">3974078</ArticleId></ArticleIdList></Reference><Reference><Citation>Houts PS, McDougall V. Effects of informing workers of their health risks from exposure to toxic materials. Am J Ind Med. 1988;13:271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">3354579</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz BE, Sullivan CD, Premeau CL. Reactions of asbestos-exposed workers to notification and screening. Am J Ind Med. 1989;15:463&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">2729288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzuckelli LF, Schulte PA. Notification of workers about an excess of malignant melanoma: A case study. Am J Ind Med. 1993;23:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumekawa ES, Lash AA, Becker CE. Challenges of worker notification in neurotoxic studies of the central nervous system. Environ Res. 1992;59:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">1425502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash AA, Kumekawa ES, Becker CE. Evaluating the clarity of research reports written for research subjects. Am J Ind Med. 1993;23:211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422053</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz BE. Assessing quality of life when planning and evaluating worker notification programs: Two case examples. Am J Ind Med. 1993;23:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422054</ArticleId></ArticleIdList></Reference><Reference><Citation>Needleman C. Social aspects of high-risk notification among chromium-exposed workers. Am J Ind Med. 1993;23:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422041</ArticleId></ArticleIdList></Reference><Reference><Citation>Needleman C. Worker notification: Lessons from the past. Am J Ind Med. 1993;23:11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph L. Issues in notification: Reflections of a public health worker. Am J Ind Med. 1993;23:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422060</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: A systematic review. Eur J Hum Genet. 2000;8:731&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">11039571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: Psychological aspects and implications. J Consult Clin Psychol. 2002;70:784&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">12090383</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol. 2004;61:875&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210524</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001;58:1828&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorval M, Gauthier G, Maunsell E, Dugas MJ, Rouleau I, et al. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev. 2005;14:2862&#x2013;2867.</Citation><ArticleIdList><ArticleId IdType="pubmed">16365001</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossaert CH, Boer H, Seydel ER. Does mammographic screening and a negative result affect attitudes towards future breast screening. J Med Screen. 2001;8:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11743037</ArticleId></ArticleIdList></Reference><Reference><Citation>Marteau TM, Kinmonth AL, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: A problem of false reassurance? British Family Heart Study Group. Br J Gen Pract. 1996;46:577&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239781</ArticleId><ArticleId IdType="pubmed">8945794</ArticleId></ArticleIdList></Reference><Reference><Citation>Marteau TM, Roberts S, LaRusse S, Green RC. Predictive genetic testing for Alzheimer's disease: Impact upon risk perception. Risk Anal. 2005;25:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15876213</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk S, Otten W, Timmermans DR, van Asperen CJ, Meijers-Heijboer H, et al. What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med. 2005;7:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834241</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Trimbath JD, Petersen GM, Griffin CA, Giardiello FM. Impact of genetic counseling and testing on colorectal cancer screening behavior. Genet Test. 2002;6:303&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12537654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman C, Marshall J, Audrain J, Gomez-Caminero A. Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. Int J Cancer. 1996;69:58&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600064</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen H, Brandt NJ, Schwartz M, Flemming S. Psychological impact of carrier screening for cystic fibrosis among pregnant women. Eur J Hum Genet. 1996;4:120&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18480253</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>20</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation.</ArticleTitle><Pagination><StartPage>7327</StartPage><EndPage>7332</EndPage><MedlinePgn>7327-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0802545105</ELocationID><Abstract><AbstractText>Although deficiencies in the retromer sorting pathway have been linked to late-onset Alzheimer's disease, whether these deficiencies underlie the disease remains unknown. Here we characterized two genetically modified animal models to test separate but related questions about the effects that retromer deficiency has on the brain. First, testing for cognitive defects, we investigated retromer-deficient mice and found that they develop hippocampal-dependent memory and synaptic dysfunction, which was associated with elevations in endogenous Abeta peptide. Second, testing for neurodegeneration and amyloid deposits, we investigated retromer-deficient flies expressing human wild-type amyloid precursor protein (APP) and human beta-site APP-cleaving enzyme (BACE) and found that they develop neuronal loss and human Abeta aggregates. By recapitulating features of the disease, these animal models suggest that retromer deficiency observed in late-onset Alzheimer's disease can contribute to disease pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Alim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Staniszewski</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Planel</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Lingling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kreber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Ganetzky</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS015390</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS48447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG172116</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS015390</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18480253</ArticleId><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802545105</ArticleId><ArticleId IdType="pii">0802545105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087184</ArticleId><ArticleId IdType="pubmed">15864339</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Gandy W. Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, et al. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Haft CR, et al. Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: Assembly into multimeric complexes. Mol Biol Cell. 2000;11:4105&#x2013;4116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15060</ArticleId><ArticleId IdType="pubmed">11102511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampe W, et al. The genes for the human VPS10 domain-containing receptors are large and contain many small exons. Hum Genet. 2001;108:529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11499680</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. J Cell Biol. 2004;165:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172078</ArticleId><ArticleId IdType="pubmed">15078902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, et al. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 1996;271:31894&#x2013;31902.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs DM, et al. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology. 1995;45:957&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">7746414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, et al. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain. 1998;121:1631&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, et al. Identification and characterization of a novel, evolutionarily conserved gene disrupted by the murine H beta 58 embryonic lethal transgene insertion. Development. 1992;115:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">1638986</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges M, et al. The mammalian retromer regulates transcytosis of the polymeric immunoglobulin receptor. Nat Cell Biol. 2004;6:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant'Angelo A, Trinchese F, Arancio O. Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. Neurochem Res. 2003;28:1009&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">12737525</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett. 1994;174:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7970158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, et al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans. 2005;33:1096&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol. 2005;168:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899&#x2013;3906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729409</ArticleId><ArticleId IdType="pubmed">15102905</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, et al. Alzheimer's disease: Genetic studies and transgenic models. Annu Rev Genet. 1998;32:461&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9928488</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K. Transgenic mouse models of Alzheimer's disease: Phenotype and mechanisms of pathogenesis. Biochem Soc Symp. 2001;67:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447835</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton S. Retromer retrieves wntless. Dev Cell. 2008;14:4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18194646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, et al. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: Implications for beta-catenin activation in tumorigenesis. Cell. 2002;110:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297048</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:9434&#x2013;9439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890512</ArticleId><ArticleId IdType="pubmed">17517621</ArticleId></ArticleIdList></Reference><Reference><Citation>Solodkin A, Van Hoesen GW. Entorhinal cortex modules of the human brain. J Comp Neurol. 1996;365:610&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742306</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins CP. New York: Columbia University; 1993. Further characterization of the murine embryonic lethal mutant Hb58, and its role in the visceral yolk sac. PhD dissertation.</Citation></Reference><Reference><Citation>Petrone A, et al. Receptor protein tyrosine phosphatase alpha is essential for hippocampal neuronal migration and long-term potentiation. EMBO J. 2003;22:4121&#x2013;4131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC175789</ArticleId><ArticleId IdType="pubmed">12912911</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990&#x2013;6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci. 2004;24:2401&#x2013;2411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729502</ArticleId><ArticleId IdType="pubmed">15014115</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci. 2003;23:5645&#x2013;5649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741250</ArticleId><ArticleId IdType="pubmed">12843267</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Nixon RA, Mathews PM. ELISA method for measurement of amyloid-beta levels. Methods Mol Biol. 2005;299:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18481275</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9861</ISSN><JournalIssue CitedMedium="Internet"><Volume>509</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of comparative neurology</Title><ISOAbbreviation>J Comp Neurol</ISOAbbreviation></Journal><ArticleTitle>Tauopathy with paired helical filaments in an aged chimpanzee.</ArticleTitle><Pagination><StartPage>259</StartPage><EndPage>270</EndPage><MedlinePgn>259-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cne.21744</ELocationID><Abstract><AbstractText>An enigmatic feature of age-related neurodegenerative diseases is that they seldom, if ever, are fully manifested in nonhuman species under natural conditions. The neurodegenerative tauopathies are typified by the intracellular aggregation of hyperphosphorylated microtubule-associated protein tau (MAPT) and the dysfunction and death of affected neurons. We document the first case of tauopathy with paired helical filaments in an aged chimpanzee (Pan troglodytes). Pathologic forms of tau in neuronal somata, neuropil threads, and plaque-like clusters of neurites were histologically identified throughout the neocortex and, to a lesser degree, in allocortical and subcortical structures. Ultrastructurally, the neurofibrillary tangles consisted of tau-immunoreactive paired helical filaments with a diameter and helical periodicity indistinguishable from those seen in Alzheimer's disease. A moderate degree of Abeta deposition was present in the cerebral vasculature and, less frequently, in senile plaques. Sequencing of the exons and flanking intronic regions in the genomic MAPT locus disclosed no mutations that are associated with the known human hereditary tauopathies, nor any polymorphisms of obvious functional significance. Although the lesion profile in this chimpanzee differed somewhat from that in Alzheimer's disease, the copresence of paired helical filaments and Abeta-amyloidosis indicates that the molecular mechanisms for the pathogenesis of the two canonical Alzheimer lesions--neurofibrillary tangles and senile plaques--are present in aged chimpanzees.</AbstractText><CopyrightInformation>Copyright 2008 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farberg</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dooyema</LastName><ForeName>Jeromy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Davis-Turak</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Par&#xe9;</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Timothy Q</ForeName><Initials>TQ</Initials></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>William D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Preuss</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG026423</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045879</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026423</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Comp Neurol</MedlineTA><NlmUniqueID>0406041</NlmUniqueID><ISSNLinking>0021-9967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019600" MajorTopicYN="N">Neuropil Threads</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002679" MajorTopicYN="Y">Pan troglodytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18481275</ArticleId><ArticleId IdType="mid">NIHMS70746</ArticleId><ArticleId IdType="pmc">PMC2573460</ArticleId><ArticleId IdType="doi">10.1002/cne.21744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer&#x2019;s disease. Neurology. 1992;42(9):1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey P, von Bonin G, McCulloch W. The Isocortex of the Chimpanzee. Univ. of Illinois Press; Urbana, Illinois: 1950.</Citation></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom GS, Ren K, Glabe CG. Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid. Biochim Biophys Acta. 2005;1739(2-3):116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615631</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkowski R, Taylor TG, Rush J. Cerebral infarction and myocardial fibrosis in a white-handed gibbon (Hylobates lar) J Zoo Wildl Med. 2000;31(1):65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884127</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Morphological criteria for the recognition of Alzheimer&#x2019;s disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging. 1994;15(3):355&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7936061</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodmann K. Neue Ergebnisse uber die vergleichende histologische Lokalisation der Grosshirnrinde mit besonderer Berucksichtigung des Stirnhirns. Anat. Anz. Suppl. 1912;41:157&#x2013;216.</Citation></Reference><Reference><Citation>Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer&#x2019;s disease. Curr Top Med Chem. 2006;6(6):597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervenakova L, Brown P, Goldfarb LG, Nagle J, Pettrone K, Rubenstein R, Dubnick M, Gibbs CJ, Jr., Gajdusek DC. Infectious amyloid precursor gene sequences in primates used for experimental transmission of human spongiform encephalopathy. Proc Natl Acad Sci U S A. 1994;91(25):12159&#x2013;12162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45396</ArticleId><ArticleId IdType="pubmed">7991600</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Vianna C, Schultz C, Thal DR, Ghebremedhin E, Lenz J, Braak H, Davies P. Molecular evolution and genetics of the Saitohin gene and tau haplotype in Alzheimer&#x2019;s disease and argyrophilic grain disease. J Neurochem. 2004;89(1):179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">15030402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL. Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol. 1988;47(6):629&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">3171607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cork LC, Walker LC. Age-related lesions, nervous system. In: Jones TC, Mohr U, Hunt RD, editors. Monographs on Pathology of Laboratory Animals Nonhuman Primates II. Springer-Verlag; Berlin: 1993. pp. 173&#x2013;183.</Citation></Reference><Reference><Citation>Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci U S A. 1991;88(6):2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer&#x2019;s disease. Neurology. 1988;38(11):1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7(2):87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Colle MA, Dessi F, Piette F, Hauw JJ. Progression of Alzheimer histopathological changes. Acta Neurol Belg. 1998;98(2):180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">9686277</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfenbein HA, Rosen RF, Stephens SL, Switzer RC, Smith Y, Pare J, Mehta PD, Warzok R, Walker LC. Cerebral beta-amyloid angiopathy in aged squirrel monkeys. Histol Histopathol. 2007;22(2):155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17149688</ArticleId></ArticleIdList></Reference><Reference><Citation>Erwin JM, Nimchinsky EA, Gannon PJ, Perl DP, Hof PR. The Study of Brain Aging in Great Apes. In: Hof PR, Mobbs CV, editors. Functional Neurobiology of Aging. Academic Press; 2000. pp. 447&#x2013;456.</Citation></Reference><Reference><Citation>Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998;8(3):186&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 1998;8(3):175&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521921</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish PH, Carpenter JW, Kraft S. Diagnosis and treatment of a cerebral infarct in a chimpanzee (Pan troglodytes) J Zoo Wildl Med. 2004;35(2):203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15305516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS. Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91(20):9382&#x2013;9386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44816</ArticleId><ArticleId IdType="pubmed">7937774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing M, Tigges J, Mori H, Mirra SS. Abeta40 is a major form of beta-amyloid in nonhuman primates. Neurobiol Aging. 1996;17(6):903&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing M, Tigges J, Mori H, Mirra SS. beta-Amyloid (Abeta) deposition in the brains of aged orangutans. Neurobiol Aging. 1997;18(2):139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258890</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Nagykery N, Wu CK. Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol (Berl) 2002;103(1):48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837747</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Gold G, Kovari E, von Gunten A, Imhof A, Bouras C, Hof PR. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol (Berl) 2007;113(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17036244</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004;15(1):45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036206</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739(2-3):240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189(3):167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267(1):564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Orr H. The genetics of neurodegenerative diseases. J Neurochem. 2006;97(6):1690&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Pittman A, Myers A, Fung HC, de Silva R, Duckworth J. Tangle diseases and the tau haplotypes. Alzheimer Dis Assoc Disord. 2006;20(1):60&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartig W, Bruckner G, Schmidt C, Brauer K, Bodewitz G, Turner JD, Bigl V. Co-localization of beta-amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. Brain Res. 1997;751(2):315&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">9099821</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon JG, Tigges J, Anderson DC, Klumpp SA, McClure HM. Brain weight throughout the life span of the chimpanzee. J Comp Neurol. 1999;409(4):567&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10376740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer M, Craxton M, Jakes R, Arendt T, Goedert M. Tau gene (MAPT) sequence variation among primates. Gene. 2004;341:313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474313</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Ibata I, Ito D, Oshawa K, Kohsaka S. A novel gene Iba1 in the major histocompatibility complex class III region encoding and EF hand protein expressed in a monocyte lineage. Biochem and Biophys Res Comm. 224:855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48(2):128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer&#x2019;s Disease. J Neurosci. 1999;19(17):7486&#x2013;7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. The role of cerebral ischemia in Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21(2):321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867217</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Kawas C. The epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer Disease. 2nd edition Lippincott Williams &amp; Wilkins; Philadelphia: 1999. pp. 95&#x2013;116.</Citation></Reference><Reference><Citation>Kiatipattanasakul W, Nakayama H, Yongsiri S, Chotiapisitkul S, Nakamura S, Kojima H, Doi K. Abnormal neuronal and glial argyrophilic fibrillary structures in the brain of an aged albino cynomolgus monkey (Macaca fascicularis) Acta Neuropathol (Berl) 2000;100(5):580&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">11045682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27(3):627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun. 1988;2:121&#x2013;130.</Citation></Reference><Reference><Citation>Kimura N, Tanemura K, Nakamura S, Takashima A, Ono F, Sakakibara I, Ishii Y, Kyuwa S, Yoshikawa Y. Age-related changes of Alzheimer&#x2019;s disease-associated proteins in cynomolgus monkey brains. Biochem Biophys Res Commun. 2003;310(2):303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521910</ArticleId></ArticleIdList></Reference><Reference><Citation>Komori T, Arai N, Oda M, Nakayama H, Mori H, Yagishita S, Takahashi T, Amano N, Murayama S, Murakami S, Shibata N, Kobayashi M, Sasaki S, Iwata M. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 1998;96(4):401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">9797005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM-Y, Goedert M, Trojanowski JQ. Neurodegenerative Tauopathies. Ann Rev Neurosci. 2001;24(1):1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer&#x2019;s disease. Brain Pathol. 2007;17(1):83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47(2):191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre-Frances N, Keller E, Calenda A, Barelli H, Checler F, Bons N. Immunohistochemical analysis of cerebral cortical and vascular lesions in the primate Microcebus murinus reveal distinct amyloid beta1-42 and beta1-40 immunoreactivity profiles. Neurobiol Dis. 2000;7(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671318</ArticleId></ArticleIdList></Reference><Reference><Citation>Metuzals J. Neurofilaments and paired helical filaments. In: Metuzals J, editor. Electron Microscopy and Alzheimer&#x2019;s Disease. San Francisco Press, Inc.; San Francisco: 1986. pp. 34&#x2013;37.</Citation></Reference><Reference><Citation>Nakamura S, Kiatipattanasakul W, Nakayama H, Ono F, Sakakibara I, Yoshikawa Y, Goto N, Doi K. Immunohistochemical characteristics of the constituents of senile plaques and amyloid angiopathy in aged cynomolgus monkeys. J Med Primatol. 1996;25(4):294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">8906609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Tamaoka A, Sawamura N, Kiatipattanasakul W, Nakayama H, Shoji S, Yoshikawa Y, Doi K. Deposition of amyloid beta protein (Abeta) subtypes [A beta 40 and A beta 42(43)] in canine senile plaques and cerebral amyloid angiopathy. Acta Neuropathol (Berl) 1997;94(4):323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341932</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Greenberg SG, Saper CB. Neurofibrillary tangles in the cerebral cortex of sheep. Neurosci Lett. 1994;170(1):187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8041504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Marton L, Saper CB. Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study. Brain Res. 1993;600(2):285&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094642</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Saper CB. Ultrastructure of neurofibrillary tangles in the cerebral cortex of sheep. Neurobiol Aging. 1995;16(3):315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566341</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Stefansson K, Gulcher J, Saper CB. Molecular evolution of tau protein: implications for Alzheimer&#x2019;s disease. J Neurochem. 1996;67(4):1622&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Meske V. Cholesterol, statins and tau. Acta Neurol Scand Suppl. 2006;185:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866917</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39(6):669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccardo P, Mirra SS, Young K, Gearing M, Dlouhy SR, Ghetti B. [alpha]-Synuclein accumulation in Gerstmann-Straussler-Schenker disease (GSS) with prion protein gene (PRNP) F198S. Neurobiol Aging. 1998;19:S724.</Citation></Reference><Reference><Citation>Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42(11):837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduri A, Gearing M, Rebeck GW, Mirra SS, Tigges J, Hyman BT. Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys. Am J Pathol. 1994;144(6):1183&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887468</ArticleId><ArticleId IdType="pubmed">8203459</ArticleId></ArticleIdList></Reference><Reference><Citation>Popa-Wagner A, Schroder E, Walker LC, Kessler C. beta-Amyloid precursor protein and beta-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age. Stroke. 1998;29(10):2196&#x2013;2202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756603</ArticleId></ArticleIdList></Reference><Reference><Citation>Potempska A, Mack K, Mehta P, Kim KS, Miller DL. Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides. Amyloid. 1999;6(1):14&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211407</ArticleId></ArticleIdList></Reference><Reference><Citation>Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Emmerling MR. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. J Neurochem. 1998;71(6):2505&#x2013;2509.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832149</ArticleId></ArticleIdList></Reference><Reference><Citation>Roertgen KE, Parisi JE, Clark HB, Barnes DL, O&#x2019;Brien TD, Johnson KH. Abeta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (Gulo gulo) Neurobiol Aging. 1996;17(2):243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744405</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz C, Hubbard GB, Tredici KD, Braak E, Braak H. Tau pathology in neurons and glial cells of aged baboons. Adv Exp Med Biol. 2001;487:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403166</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Cork LC. The Neurobiology of Aging in Nonhuman Primates. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer Disease. 2nd edition Lippincott Williams &amp; Wilkins; Philadelphia: 1999. pp. 223&#x2013;243.</Citation></Reference><Reference><Citation>Walker LC, Masters C, Beyreuther K, Price DL. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathol (Berl) 1990;80(4):381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">2239150</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Abeta oligomers - a decade of discovery. J Neurochem. 2007;101(5):1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Yang SH, Liu R, Perez EJ, Brun-Zinkernagel AM, Koulen P, Simpkins JW. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta. 2007;1772(4):473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56(2-3):343&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7175555</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J. 2006;36(10):652&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16958643</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18486992</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>367</EndPage><MedlinePgn>357-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2008.03.027</ELocationID><Abstract><AbstractText>Numerous studies have shown a marked decrease of beta-amyloid(42) (Abeta(42)) in the cerebrospinal fluid (CSF) of patients with incipient Alzheimer's disease (AD). However, studies on Abeta in plasma are contradictory, and show very marginal differences between patients and controls. Here, we analyzed plasma samples using a new multiplex immunoassay for simultaneous analysis of Abeta(1-40), Abeta(n-40), Abeta(1-42), and Abeta(n-42). The plasma samples were obtained at baseline from two independent cohorts of patients with mild cognitive impairment (MCI) and age-matched controls. In the first cohort, 41% of the 117 MCI cases converted to AD during a clinical follow-up period of 4-7 years. In the second cohort, 14% of the 110 MCI subjects developed AD during a clinical follow-up period of 2-4 years. None of the plasma Abeta isoforms differed between MCI patients that subsequently developed AD and healthy controls or stable MCI patients. The Cox proportional hazards model did not reveal any differences in the probability of progression from MCI to AD related to plasma Abeta levels. In contrast, low levels of Abeta(1-42) in CSF were strongly associated with increased risk of future AD. The absence of a change in plasma Abeta in incipient AD, despite the marked change in CSF, may be explained by the lack of a correlation between the levels of Abeta(1-42) in CSF and plasma. In conclusion, the results show that CSF biomarkers are better predictors of progression to AD than plasma Abeta isoforms.</AbstractText><CopyrightInformation>Copyright 2008 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Sweden. oskar.hansson@med.lu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vanderstichele</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2010 Apr;31(4):539-40; author reply 541. doi: 10.1016/j.neurobiolaging.2008.07.024.</RefSource><PMID Version="1">18963255</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004435" MajorTopicYN="N">Eating</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18486992</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.03.027</ArticleId><ArticleId IdType="pii">S0197-4580(08)00131-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18488016</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>453</Volume><Issue>7197</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Towards a transgenic model of Huntington's disease in a non-human primate.</ArticleTitle><Pagination><StartPage>921</StartPage><EndPage>924</EndPage><MedlinePgn>921-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature06975</ELocationID><Abstract><AbstractText>Non-human primates are valuable for modelling human disorders and for developing therapeutic strategies; however, little work has been reported in establishing transgenic non-human primate models of human diseases. Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor impairment, cognitive deterioration and psychiatric disturbances followed by death within 10-15 years of the onset of the symptoms. HD is caused by the expansion of cytosine-adenine-guanine (CAG, translated into glutamine) trinucleotide repeats in the first exon of the human huntingtin (HTT) gene. Mutant HTT with expanded polyglutamine (polyQ) is widely expressed in the brain and peripheral tissues, but causes selective neurodegeneration that is most prominent in the striatum and cortex of the brain. Although rodent models of HD have been developed, these models do not satisfactorily parallel the brain changes and behavioural features observed in HD patients. Because of the close physiological, neurological and genetic similarities between humans and higher primates, monkeys can serve as very useful models for understanding human physiology and diseases. Here we report our progress in developing a transgenic model of HD in a rhesus macaque that expresses polyglutamine-expanded HTT. Hallmark features of HD, including nuclear inclusions and neuropil aggregates, were observed in the brains of the HD transgenic monkeys. Additionally, the transgenic monkeys showed important clinical features of HD, including dystonia and chorea. A transgenic HD monkey model may open the way to understanding the underlying biology of HD better, and to the development of potential therapies. Moreover, our data suggest that it will be feasible to generate valuable non-human primate models of HD and possibly other human genetic diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shang-Hsun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Pei-Hsun</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Banta</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Piotrowska-Nitsche</LastName><ForeName>Karolina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jin-Jing</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Eric C H</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Brooke</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Orkin</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Zhi-Hui</ForeName><Initials>ZH</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Yoland</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bachevalier</LastName><ForeName>Jocelyne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zola</LastName><ForeName>Stuart M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shi-Hua</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Jiang</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Anthony W S</ForeName><Initials>AW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036232</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041669</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 OD010930</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2008 Jun 12;453(7197):863-4. doi: 10.1038/nature06365.</RefSource><PMID Version="1">18488017</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002819" MajorTopicYN="N">Chorea</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18488016</ArticleId><ArticleId IdType="mid">NIHMS74948</ArticleId><ArticleId IdType="pmc">PMC2652570</ArticleId><ArticleId IdType="doi">10.1038/nature06975</ArticleId><ArticleId IdType="pii">nature06975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings CJ, Zoghbi HY. Trinucleotide repeats: mechanisms and pathophysiology. Annu. Rev. Genomics Hum. Genet. 2000;1:281&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701632</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies S, Ramsden DB. Huntington's disease. Mol. Pathol. 2001;54:409&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187131</ArticleId><ArticleId IdType="pubmed">11724916</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers RH, Marans KS, MacDonald ME. In: Huntington's Disease in Genetic Instabilities and Hereditary Neurological Diseases. Wells RD, Warren ST, editors. Academic; San Diego: 1998. pp. 301&#x2013;324.</Citation></Reference><Reference><Citation>Rubinsztein DC. Lessons from animal models of Hungtington's disease. Trends Genet. 2002;18:202&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932021</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald ME, et al. HD research collaborative groups. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntintgton's disease chromosome. Cell. 1993;72:971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp AH, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 1995;14:1065&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">7748554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane MA. Nonhuman primate models in biogerontology. Exp. Gerontol. 2000;35:533&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978676</ArticleId></ArticleIdList></Reference><Reference><Citation>King MC, Wilson AC. Evolution at two levels in humans and chimpanzees. Science. 1975;188:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1090005</ArticleId></ArticleIdList></Reference><Reference><Citation>McConkey EH, Varki A. A primate genome project deserves high priority. Science. 2000;289:1295&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">10979852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AWS, Chong KY, Martinovich C, Simerly C, Schatten G. Transgenic monkeys produced by retroviral gene transfer into mature oocytes. Science. 2001;291:309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">11209082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AWS, Chong KY, Schatten G. In: Transgenic Animal Technology: A Laboratory Handbook. Pinkert CA, editor. Academic; San Diego: 2002.</Citation></Reference><Reference><Citation>Zhou H, et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J. Cell Biol. 2003;163:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173440</ArticleId><ArticleId IdType="pubmed">14557250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutekunst CA, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999;19:2522&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786077</ArticleId><ArticleId IdType="pubmed">10087066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates GP, Mangiarini L, Wanker EE, Davies SW. Polyglutamine expansion and Huntington's disease. Biochem. Soc. Trans. 1998;26:471&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9765898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001;10:137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152661</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 1999;8:1227&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369868</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 2001;21:8473&#x2013;8481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762783</ArticleId><ArticleId IdType="pubmed">11606636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ZX, et al. Mutant Huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 2003;23:2193&#x2013;2202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742008</ArticleId><ArticleId IdType="pubmed">12657678</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies SW, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267033</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain. Science. 1997;277:1990&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SH, et al. Enhanced transgenesis by intracytoplasmic injection of envelope-free lentivirus. Genesis. 2007;45:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4381737</ArticleId><ArticleId IdType="pubmed">17417786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18492803</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>21</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice.</ArticleTitle><Pagination><StartPage>7594</StartPage><EndPage>7599</EndPage><MedlinePgn>7594-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0802556105</ELocationID><Abstract><AbstractText>Dominant mutations in ubiquitously expressed superoxide dismutase (SOD1) cause familial ALS by provoking premature death of adult motor neurons. To test whether mutant damage to cell types beyond motor neurons is required for the onset of motor neuron disease, we generated chimeric mice in which all motor neurons and oligodendrocytes expressed mutant SOD1 at a level sufficient to cause fatal, early-onset motor neuron disease when expressed ubiquitously, but did so in a cellular environment containing variable numbers of non-mutant, non-motor neurons. Despite high-level mutant expression within 100% of motor neurons and oligodendrocytes, in most of these chimeras, the presence of WT non-motor neurons substantially delayed onset of motor neuron degeneration, increasing disease-free life by 50%. Disease onset is therefore non-cell autonomous, and mutant SOD1 damage within cell types other than motor neurons and oligodendrocytes is a central contributor to initiation of motor neuron degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research and Department of Medicine and Neuroscience, University of California at San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boillee</LastName><ForeName>Severine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>McAlonis-Downes</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mikse</LastName><ForeName>Oliver R</ForeName><Initials>OR</Initials></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NSO47101</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 27036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS047101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18492803</ArticleId><ArticleId IdType="pmc">PMC2396671</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802556105</ArticleId><ArticleId IdType="pii">0802556105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001;21:3369&#x2013;3374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762496</ArticleId><ArticleId IdType="pubmed">11331366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci. 2002;22:4825&#x2013;4832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757755</ArticleId><ArticleId IdType="pubmed">12077179</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D, et al. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci. 2008;28:2075&#x2013;2088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671838</ArticleId><ArticleId IdType="pubmed">18305242</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006;103:16021&#x2013;16026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci USA. 2002;99:1604&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci USA. 2007;104:14825&#x2013;14830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1976195</ArticleId><ArticleId IdType="pubmed">17804792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Misawa H, et al. VAChT-Cre.Fast and VAChT-Cre.Slow: Postnatal expression of Cre recombinase in somatomotor neurons with different onset. Genesis. 2003;37:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong YH, et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci. 2000;20:660&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772423</ArticleId><ArticleId IdType="pubmed">10632595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell. 2002;109:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QR, et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell. 2002;109:75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955448</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebayashi H, et al. The basic helix&#x2013;loop&#x2013;helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr Biol. 2002;12:1157&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger CS, Garcia ML, Ward CM, Cleveland DW. Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci USA. 2005;102:10351&#x2013;10356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177385</ArticleId><ArticleId IdType="pubmed">16002469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Progressive spinal axonal degeneration and slowness in ALS2-deficient mice. Ann Neurol. 2006;60:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Xu Z. Peripheral axotomy slows motoneuron degeneration in a transgenic mouse line expressing mutant SOD1 G93A. J Comp Neurol. 1999;412:373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441762</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006;103:19546&#x2013;19551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748262</ArticleId><ArticleId IdType="pubmed">17164329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, et al. ALS-causing SOD1 mutants generate blood-spinal cord barrier breakdown and reductions in microcirculation prior to motor neuron degeneration. Nat Neurosci. 2008;11:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo CA, et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA. 1995;92:954&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42615</ArticleId><ArticleId IdType="pubmed">7862672</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18505838</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>22</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model.</ArticleTitle><Pagination><StartPage>7863</StartPage><EndPage>7868</EndPage><MedlinePgn>7863-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0802908105</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with progressive memory decline. Hippocampal place cells are a well understood candidate for the neural basis of one type of memory in rodents; these cells identify the animal's location in an environment and are crucial for spatial memory and navigation. We have recorded place cells in the Tg2576 mouse model of AD, and we report that aged (16 mo) but not young (3 mo) transgenic mice show degraded neuronal representations of the environment. The level of place cell degradation correlates with the animals' (poorer) spatial memory as tested in a forced-choice spatial alternation T-maze task and with hippocampal, but not neocortical, amyloid plaque burden. Place cell recording provides a sensitive assay for measuring the amount and rate of functional deterioration in animal models of dementia as well as providing a quantifiable physiological indication of the beneficial effects of potential therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cacucci</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, University College London, London WC1E 6BT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18505838</ArticleId><ArticleId IdType="pmc">PMC2396558</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802908105</ArticleId><ArticleId IdType="pii">0802908105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes P, Hale G, Good M. Intramaze and extramaze cue processing in adult APPSWE Tg2576 transgenic mice. Behav Neurosci. 2004;118:1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, et al. A learning deficit related to age and &#x3b2;-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000;408:975&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, et al. Correlation between cognitive deficits and A&#x3b2; deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001;22:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378242</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, et al. Correlation between elevated levels of amyloid &#x3b2;-peptide in the brain and cognitive decline. J Am Med Assoc. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, et al. Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm T, et al. &#x3b2;-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or &#x3b2;-amyloid deposits. Proc Natl Acad Sci USA. 2006;103:8852&#x2013;8857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482667</ArticleId><ArticleId IdType="pubmed">16723396</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Dostrovsky J. The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res. 1971;34:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Nadel L. The Hippocampus as a Cognitive Map. Oxford: Oxford Univ Press; 1978.</Citation></Reference><Reference><Citation>Deacon RM, Bannerman DM, Kirby BP, Croucher A, Rawlins JN. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res. 2002;133:57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">12048174</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Speakman A. Single unit activity in the rat hippocampus during a spatial memory task. Exp Brain Res. 1987;68:1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">3691688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenck-Santini PP, Save E, Poucet B. Evidence for a relationship between place-cell spatial firing and spatial memory performance. Hippocampus. 2001;11:377&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">11530842</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl. 1998;54:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Martin MV, Chambers S, Csernansky JG. Spatial relationship between synapse loss and &#x3b2;-amyloid deposition in Tg2576 mice. J Comp Neurol. 2007;500:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1661843</ArticleId><ArticleId IdType="pubmed">17111375</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda-Saita K, et al. Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer's disease. Acta Neuropathol (Berlin) 2004;108:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, et al. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacucci F, Wills TJ, Lever C, Giese K, O'Keefe J. Experience-dependent increase in CA1 place cell spatial information, but not spatial reproducibility, is dependent on the autophosphorylation of &#x3b1;CaMKII. J Neurosci. 2007;27:7854&#x2013;7859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680063</ArticleId><ArticleId IdType="pubmed">17634379</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaggs WE, McNaughton BL, Gothard KM, Markus EJ. An information-theoretic approach to deciphering the hippocampal code. Adv Neural Inf Process Syst. 1993;5:1030&#x2013;1037.</Citation></Reference><Reference><Citation>Johnson-Wood K, et al. Amyloid precursor protein processing and A &#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JD, et al. Quantitative measurement of changes in amyloid-&#x3b2;(40) in the rat brain and cerebrospinal fluid following treatment with the &#x3b3;-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide] J Pharmacol Exp Ther. 2005;313:902&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">15743924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18509095</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Biochemical markers in persons with preclinical familial Alzheimer disease.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>92</EndPage><MedlinePgn>85-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000303973.71803.81</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-one subjects at risk for presenilin-1 (n = 17) or amyloid precursor protein (n = 4) mutations underwent evaluation with the Clinical Dementia Rating (CDR) scale. We obtained plasma from all subjects and CSF from 11. Plasma (Abeta(40), Abeta(42), F(2)-isoprostanes) and CSF (F(2)-isoprostanes, t-tau, p-tau(181), Abeta(40), Abeta(42), and Abeta(42)/Abeta(40) ratio) levels were compared between FAD mutation carriers (MCs) and noncarriers (NCs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma Abeta(42) levels (25.1 pM vs 15.5 pM, p = 0.031) and the ratio of Abeta(42)/Abeta(40) (0.16 vs 0.11, p = 0.045) were higher in presymptomatic MCs. Among MCs, those with CDR scores of 0.5 had lower plasma Abeta(42) levels than those with CDR scores of 0 (14.1 pM vs 25.1, p = 0.02). The ratio of Abeta(42) to Abeta(40) was also reduced in the CSF (0.08 vs 0.15, p = 0.046) of nondemented MCs compared to NCs. Total CSF tau and p-tau(181) levels were elevated in presymptomatic FAD MCs. CSF levels of F(2)-isoprostanes were also elevated in MCs (n = 7, 48.6 pg/mL) compared to NCs (n = 4, 21.6 pg/mL, p = 0.031).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data indicate that Abeta(42) is elevated in plasma in familial Alzheimer disease (FAD) mutation carriers (MCs) and suggests that this level may decrease with disease progression prior to the development of overt dementia. We also demonstrated that the ratio of Abeta(42) to Abeta(40) was reduced in the CSF of nondemented MCs and that elevations of t-tau and p-tau(181) are sensitive indicators of presymptomatic disease. Our finding of elevated F(2)-isoprostane levels in the CSF of preclinical FAD MCs suggests that oxidative stress occurs downstream to mismetabolism of amyloid precursor protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>UCLA Department of Neurology, Alzheimer Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095-7226, USA. jringman@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Pratico</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Seltzer</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>D H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez-Agudelo</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fein</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sokolow</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Gylys</LastName><ForeName>K H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Varpetian</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG022228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489697">APLP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028421">Isoprostanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2008 Jul 8;71(2):78-9. doi: 10.1212/01.wnl.0000316808.21277.69.</RefSource><PMID Version="1">18606962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028421" MajorTopicYN="N">Isoprostanes</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000303973.71803.81</ArticleId><ArticleId IdType="pii">01.wnl.0000303973.71803.81</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18511691</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>320</Volume><Issue>5880</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>MeCP2, a key contributor to neurological disease, activates and represses transcription.</ArticleTitle><Pagination><StartPage>1224</StartPage><EndPage>1229</EndPage><MedlinePgn>1224-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1153252</ELocationID><Abstract><AbstractText>Mutations in the gene encoding the transcriptional repressor methyl-CpG binding protein 2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome. Loss of function as well as increased dosage of the MECP2 gene cause a host of neuropsychiatric disorders. To explore the molecular mechanism(s) underlying these disorders, we examined gene expression patterns in the hypothalamus of mice that either lack or overexpress MeCP2. In both models, MeCP2 dysfunction induced changes in the expression levels of thousands of genes, but unexpectedly the majority of genes (approximately 85%) appeared to be activated by MeCP2. We selected six genes and confirmed that MeCP2 binds to their promoters. Furthermore, we showed that MeCP2 associates with the transcriptional activator CREB1 at the promoter of an activated target but not a repressed target. These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chahrour</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sung Yun</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Stephen T C</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Huda Y</ForeName><Initials>HY</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE11150</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>NS057819</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057819</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492004">Creb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497393">Mecp2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 May 30;320(5880):1172-3. doi: 10.1126/science.1159146.</RefSource><PMID Version="1">18511680</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007027" MajorTopicYN="N">Hypothalamic Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015518" MajorTopicYN="N">Rett Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HHMIMS51376</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18511691</ArticleId><ArticleId IdType="mid">NIHMS51376</ArticleId><ArticleId IdType="pmc">PMC2443785</ArticleId><ArticleId IdType="doi">10.1126/science.1153252</ArticleId><ArticleId IdType="pii">320/5880/1224</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amir RE, et al. Nat Genet. 1999;23:185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti P, Zoghbi HY. Curr Opin Genet Dev. 2006;16:276.</Citation><ArticleIdList><ArticleId IdType="pubmed">16647848</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy J, Hendrich B, Holmes M, Martin JE, Bird A. Nat Genet. 2001;27:322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242117</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins AL, et al. Hum Mol Genet. 2004;13:2679.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan X, et al. Nature. 1998;393:386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones PL, et al. Nat Genet. 1998;19:187.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao H, Zoghbi HY, Rosenmund C. Neuron. 2007;56:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198899</ArticleId><ArticleId IdType="pubmed">17920015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor M, Akbarian S, Chen RZ, Jaenisch R. Proc Natl Acad Sci U S A. 2002;99:15536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137752</ArticleId><ArticleId IdType="pubmed">12432090</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod FB, Chelimsky GG, Weese-Mayer DE. Pediatrics. 2006;118:309.</Citation><ArticleIdList><ArticleId IdType="pubmed">16818580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardina PJ, et al. BMC Genomics. 2006;7:325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769375</ArticleId><ArticleId IdType="pubmed">17192196</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, et al. Methods. 2005;37:345.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. Neuron. 2006;52:255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962021</ArticleId><ArticleId IdType="pubmed">17046689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla K, et al. J Hum Genet. 2004;49:308.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148587</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin CL, et al. Am J Med Genet B Neuropsychiatr Genet. 2007;144:869.</Citation><ArticleIdList><ArticleId IdType="pubmed">17503474</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldeira Araujo H, et al. Am J Med Genet A. 2005;133:122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15651030</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbruggen KT, et al. Eur J Pediatr. 2007;166:921.</Citation><ArticleIdList><ArticleId IdType="pubmed">17186272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykut-Cegielska J, Gradowska W, Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S. Acta Biochim Pol. 2004;51:875.</Citation><ArticleIdList><ArticleId IdType="pubmed">15625559</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ME, et al. Nat Neurosci. 2007;10:1513.</Citation><ArticleIdList><ArticleId IdType="pubmed">17994015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasui DH, et al. Proc Natl Acad Sci U S A. 2007;104:19416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148304</ArticleId><ArticleId IdType="pubmed">18042715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WG, et al. Science. 2003;302:885.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593183</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinowich K, et al. Science. 2003;302:890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. Neuron. 2006;49:341.</Citation><ArticleIdList><ArticleId IdType="pubmed">16446138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18511942</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.</ArticleTitle><Pagination><StartPage>558</StartPage><EndPage>566</EndPage><MedlinePgn>558-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.1437</ELocationID><Abstract><AbstractText>The accumulation of beta-sheet-rich amyloid fibrils or aggregates is a complex, multistep process that is associated with cellular toxicity in a number of human protein misfolding disorders, including Parkinson's and Alzheimer's diseases. It involves the formation of various transient and intransient, on- and off-pathway aggregate species, whose structure, size and cellular toxicity are largely unclear. Here we demonstrate redirection of amyloid fibril formation through the action of a small molecule, resulting in off-pathway, highly stable oligomers. The polyphenol (-)-epigallocatechin gallate efficiently inhibits the fibrillogenesis of both alpha-synuclein and amyloid-beta by directly binding to the natively unfolded polypeptides and preventing their conversion into toxic, on-pathway aggregation intermediates. Instead of beta-sheet-rich amyloid, the formation of unstructured, nontoxic alpha-synuclein and amyloid-beta oligomers of a new type is promoted, suggesting a generic effect on aggregation pathways in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ehrnhoefer</LastName><ForeName>Dagmar E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Max Delbrueck Center for Molecular Medicine, AG Neuroproteomics, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieschke</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boeddrich</LastName><ForeName>Annett</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Masino</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lurz</LastName><ForeName>Rudi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Engemann</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pastore</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wanker</LastName><ForeName>Erich E</ForeName><Initials>EE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U117533887</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U117584256</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C444321">amyloid beta-protein (1-34)</NameOfSubstance></Chemical><Chemical><RegistryNumber>8R1V1STN48</RegistryNumber><NameOfSubstance UI="D002392">Catechin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BQM438CTEL</RegistryNumber><NameOfSubstance UI="C045651">epigallocatechin gallate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Struct Mol Biol. 2008 Jun;15(6):537. doi: 10.1038/nsmb0608-537.</RefSource><PMID Version="1">18523460</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Struct Mol Biol. 2008 Jun;15(6):544-6. doi: 10.1038/nsmb0608-544.</RefSource><PMID Version="1">18523464</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017772" MajorTopicYN="N">Amyloid Neuropathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002392" MajorTopicYN="N">Catechin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18511942</ArticleId><ArticleId IdType="doi">10.1038/nsmb.1437</ArticleId><ArticleId IdType="pii">nsmb.1437</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18516051</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>687</EndPage><MedlinePgn>681-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm1781</ELocationID><Abstract><AbstractText>Alzheimer's disease is the most common dementia and is pathologically characterized by deposition of amyloid-beta peptide (Abeta) into beta-amyloid plaques, neuronal injury and low-level, chronic activation of brain immunity. Transforming growth factor-betas (TGF-betas) are pleiotropic cytokines that have key roles in immune cell activation, inflammation and repair after injury. We genetically interrupted TGF-beta and downstream Smad2/3 signaling (TGF-beta-Smad2/3) in innate immune cells by inducing expression of CD11c promoter-driven dominant-negative TGF-beta receptor type II in C57BL/6 mice (CD11c-DNR), crossed these mice with mice overexpressing mutant human amyloid precursor protein, the Tg2576 Alzheimer's disease mouse model, and evaluated Alzheimer's disease-like pathology. Aged double-transgenic mice showed complete mitigation of Tg2576-associated hyperactivity and partial mitigation of defective spatial working memory. Brain parenchymal and cerebrovascular beta-amyloid deposits and Abeta abundance were markedly (up to 90%) attenuated in Tg2576-CD11c-DNR mice. This was associated with increased infiltration of Abeta-containing peripheral macrophages around cerebral vessels and beta-amyloid plaques. In vitro, cultures of peripheral macrophages, but not microglia, from CD11c-DNR mice showed blockade of classical TGF-beta-activated Smad2/3 but also showed hyperactivation of alternative bone morphogenic protein-activated Smad1/5/8 signaling and increased Abeta phagocytosis. Similar effects were noted after pharmacological inhibition of activin-like kinase-5, a type I TGF-beta receptor. Taken together, our results suggest that blockade of TGF-beta-Smad2/3 signaling in peripheral macrophages represents a new therapeutic target for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Town</LastName><ForeName>Terrence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale University School of Medicine, 300 Cedar Street, New Haven, Connecticut 06520-8011, USA. terrence.town@cshs.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laouar</LastName><ForeName>Yasmina</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Pittenger</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Szekely</LastName><ForeName>Christine A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Duman</LastName><ForeName>Ronald S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Flavell</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>4R00AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS048335</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K99AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051899">Smad2 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497783">Smad2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051900">Smad3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497791">Smad3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051899" MajorTopicYN="N">Smad2 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051900" MajorTopicYN="N">Smad3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18516051</ArticleId><ArticleId IdType="mid">NIHMS95394</ArticleId><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="doi">10.1038/nm1781</ArticleId><ArticleId IdType="pii">nm1781</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-&#x3b2; regulation of immune responses. Annu. Rev. Immunol. 2006;24:99&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551245</ArticleId></ArticleIdList></Reference><Reference><Citation>Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-&#x3b2; controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 2005;6:600&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach B. Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can. J. Neurol. Sci. 1989;16:535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553231</ArticleId></ArticleIdList></Reference><Reference><Citation>Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGF-&#x3b2;1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 2003;40:1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-&#x3b2;1 by astrocytes promotes Alzheimer's disease&#x2013;like microvascular degeneration in transgenic mice. Am. J. Pathol. 2000;156:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868631</ArticleId><ArticleId IdType="pubmed">10623661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. Amyloidogenic role of cytokine TGF-&#x3b2;1 in transgenic mice and in Alzheimer's disease. Nature. 1997;389:603&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">9335500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. TGF-&#x3b2;1 promotes microglial amyloid-&#x3b2; clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, et al. Deficiency in neuronal TGF-&#x3b2; signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 2006;116:3060&#x2013;3069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626127</ArticleId><ArticleId IdType="pubmed">17080199</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>King DL, et al. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 1999;103:145&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10513583</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A&#x3b2; deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, et al. Augmented senile plaque load in aged female &#x3b2;-amyloid precursor protein&#x2013;transgenic mice. Am. J. Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 1996;46:1592&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins EM, et al. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J. Neurosci. 2006;26:365&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674403</ArticleId><ArticleId IdType="pubmed">16407531</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-&#x3b2; efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, et al. Nasal A&#x3b2; treatment induces anti-A&#x3b2; antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 2000;920:328&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871640</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, et al. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat. Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Nikolic V, Tan J. The microglial &#x201c;activation&#x201d; continuum: from innate to adaptive responses. J. Neuroinflammation. 2005;2:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1298325</ArticleId><ArticleId IdType="pubmed">16259628</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow&#x2013;derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 2002;5:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18523548</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism.</ArticleTitle><Pagination><StartPage>e2334</StartPage><MedlinePgn>e2334</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2334</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0002334</ELocationID><Abstract><AbstractText>ALS8 is caused by a dominant mutation in an evolutionarily conserved protein, VAPB (vesicle-associated membrane protein (VAMP)-associated membrane protein B)/ALS8). We have established a fly model of ALS8 using the corresponding mutation in Drosophila VAPB (dVAP33A) and examined the effects of this mutation on VAP function using genetic and morphological analyses. By simultaneously assessing the effects of VAP(wt) and VAP(P58S) on synaptic morphology and structure, we demonstrate that the phenotypes produced by neuronal expression of VAP(P58S) resemble VAP loss of function mutants and are opposite those of VAP overexpression, suggesting that VAP(P58S) may function as a dominant negative. This is brought about by aggregation of VAP(P58S) and recruitment of wild type VAP into these aggregates. Importantly, we also demonstrate that the ALS8 mutation in dVAP33A interferes with BMP signaling pathways at the neuromuscular junction, identifying a new mechanism underlying pathogenesis of ALS8. Furthermore, we show that mutant dVAP33A can serve as a powerful tool to identify genetic modifiers of VAPB. This new fly model of ALS, with its robust pathological phenotypes, should for the first time allow the power of unbiased screens in Drosophila to be applied to study of motor neuron diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratnaparkhi</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawless</LastName><ForeName>George M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Schweizer</LastName><ForeName>Felix E</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Golshani</LastName><ForeName>Peyman</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>George R</ForeName><Initials>GR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS046489</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS046489</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491921">Vap33 protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019485" MajorTopicYN="N">Bone Morphogenetic Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="Y">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18523548</ArticleId><ArticleId IdType="pmc">PMC2390852</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0002334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques VD, Barreira AA, Davis MB, Abou-Sleiman PM, Silva WA, Jr, et al. Expanding the phenotypes of the Pro56Ser VAPB mutation: proximal SMA with dysautonomia. Muscle Nerve. 2006;34:731&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Hayashi M, Inada H, Tanaka T. Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem Biophys Res Commun. 1999;254:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9920726</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir ML, Klip A, Trimble WS. Identification of a human homologue of the vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (VAP-33): a broadly expressed protein that binds to VAMP. Biochem J. 1998;333 (Pt 2):247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1219579</ArticleId><ArticleId IdType="pubmed">9657962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, et al. Structural basis of FFAT motif-mediated ER targeting. Structure. 2005;13:1035&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">16004875</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiano JE, Jr, Stewart M, Roberts TM. How the assembly dynamics of the nematode major sperm protein generate amoeboid cell motility. Int Rev Cytol. 2001;202:1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11061562</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarilio R, Ramachandran S, Sabanay H, Lev S. Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction. J Biol Chem. 2005;280:5934&#x2013;5944.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545272</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster LJ, Weir ML, Lim DY, Liu Z, Trimble WS, et al. A functional role for VAP-33 in insulin-stimulated GLUT4 traffic. Traffic. 2000;1:512&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208137</ArticleId></ArticleIdList></Reference><Reference><Citation>Skehel PA, Martin KC, Kandel ER, Bartsch D. A VAMP-binding protein from Aplysia required for neurotransmitter release. Science. 1995;269:1580&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">7667638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagiwada S, Hosaka K, Murata M, Nikawa J, Takatsuki A. The Saccharomyces cerevisiae SCS2 gene product, a homolog of a synaptobrevin-associated protein, is an integral membrane protein of the endoplasmic reticulum and is required for inositol metabolism. J Bacteriol. 1998;180:1700&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC107080</ArticleId><ArticleId IdType="pubmed">9537365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennetta G, Hiesinger PR, Fabian-Fine R, Meinertzhagen IA, Bellen HJ. Drosophila VAP-33A directs bouton formation at neuromuscular junctions in a dosage-dependent manner. Neuron. 2002;35:291&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Nishimoto I, Aiso S, Matsuoka M. Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem. 2006;281:30223&#x2013;30233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16891305</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, et al. Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci. 2007;27:9801&#x2013;9815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672975</ArticleId><ArticleId IdType="pubmed">17804640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberle H, Haghighi AP, Fetter RD, McCabe BD, Magalhaes TR, et al. wishful thinking encodes a BMP type II receptor that regulates synaptic growth in Drosophila. Neuron. 2002;33:545&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">11856529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, et al. The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell. 2005;122:633&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122429</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci. 2006;31:150&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473510</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004;14:703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">15564047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol. 2004;204:438&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011821</ArticleId><ArticleId IdType="pubmed">15495240</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard JF, Cote F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature. 1995;375:61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">7536898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology. 1996;47:535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757033</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Krukkert K, Roos J, Davis G, Klambt C. Drosophila Futsch/22C10 is a MAP1B-like protein required for dendritic and axonal development. Neuron. 2000;26:357&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">10839355</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos J, Hummel T, Ng N, Klambt C, Davis GW. Drosophila Futsch regulates synaptic microtubule organization and is necessary for synaptic growth. Neuron. 2000;26:371&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10839356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood NT, Sun Q, Xue M, Zhang B, Zinn K. Drosophila spastin regulates synaptic microtubule networks and is required for normal motor function. PLoS Biol. 2004;2:e429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC532392</ArticleId><ArticleId IdType="pubmed">15562320</ArticleId></ArticleIdList></Reference><Reference><Citation>Packard M, Koo ES, Gorczyca M, Sharpe J, Cumberledge S, et al. The Drosophila Wnt, wingless, provides an essential signal for pre- and postsynaptic differentiation. Cell. 2002;111:319&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499980</ArticleId><ArticleId IdType="pubmed">12419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagh DA, Rasse TM, Asan E, Hofbauer A, Schwenkert I, et al. Bruchpilot, a protein with homology to ELKS/CAST, is required for structural integrity and function of synaptic active zones in Drosophila. Neuron. 2006;49:833&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16543132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittel RJ, Wichmann C, Rasse TM, Fouquet W, Schmidt M, et al. Bruchpilot promotes active zone assembly, Ca2+ channel clustering, and vesicle release. Science. 2006;312:1051&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">16614170</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D, Schneider C, Xu L, Borg J, Spooren W, et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci. 2000;20:2534&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006;9:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai A, Withers J, Koh YH, Parry K, Bao H, et al. hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction. Hum Mol Genet. 2008;17:266&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516386</ArticleId><ArticleId IdType="pubmed">17947296</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe BD, Marques G, Haghighi AP, Fetter RD, Crotty ML, et al. The BMP homolog Gbb provides a retrograde signal that regulates synaptic growth at the Drosophila neuromuscular junction. Neuron. 2003;39:241&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873382</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe BD, Hom S, Aberle H, Fetter RD, Marques G, et al. Highwire regulates presynaptic BMP signaling essential for synaptic growth. Neuron. 2004;41:891&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">15046722</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques G, Haerry TE, Crotty ML, Xue M, Zhang B, et al. Retrograde Gbb signaling through the Bmp type 2 receptor wishful thinking regulates systemic FMRFa expression in Drosophila. Development. 2003;130:5457&#x2013;5470.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507784</ArticleId></ArticleIdList></Reference><Reference><Citation>Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996;85:947&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">8674122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Gurdon JB. A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Proc Natl Acad Sci U S A. 1999;96:6791&#x2013;6796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21994</ArticleId><ArticleId IdType="pubmed">10359791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimoto H, Itoh S, ten Dijke P, Tabata T. Hedgehog creates a gradient of DPP activity in Drosophila wing imaginal discs. Mol Cell. 2000;5:59&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudu V, Bittig T, Entchev E, Kicheva A, Julicher F, et al. Postsynaptic mad signaling at the Drosophila neuromuscular junction. Curr Biol. 2006;16:625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, Zou K, Esposito L, Bard F, Berber E, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest. 2006;116:3060&#x2013;3069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626127</ArticleId><ArticleId IdType="pubmed">17080199</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerry TE, Khalsa O, O'Connor MB, Wharton KA. Synergistic signaling by two BMP ligands through the SAX and TKV receptors controls wing growth and patterning in Drosophila. Development. 1998;125:3977&#x2013;3987.</Citation><ArticleIdList><ArticleId IdType="pubmed">9735359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang B, Chiba A. Single-cell analysis of Drosophila larval neuromuscular synapses. Dev Biol. 2001;229:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11133154</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson U, Izumi H, Souchelnytskyi S, Itoh S, Grimsby S, et al. The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 1998;434:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">9738456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang TK, Chang HY, Lawless GM, Ratnaparkhi A, Mee L, et al. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J Neurosci. 2007;27:981&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673194</ArticleId><ArticleId IdType="pubmed">17267552</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18524908</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>23</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>BRI2 (ITM2b) inhibits Abeta deposition in vivo.</ArticleTitle><Pagination><StartPage>6030</StartPage><EndPage>6036</EndPage><MedlinePgn>6030-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0891-08.2008</ELocationID><Abstract><AbstractText>Analyses of the biologic effects of mutations in the BRI2 (ITM2b) and the amyloid beta precursor protein (APP) genes support the hypothesis that cerebral accumulation of amyloidogenic peptides in familial British and familial Danish dementias and Alzheimer's disease (AD) is associated with neurodegeneration. We have used somatic brain transgenic technology to express the BRI2 and BRI2-Abeta1-40 transgenes in APP mouse models. Expression of BRI2-Abeta1-40 mimics the suppressive effect previously observed using conventional transgenic methods, further validating the somatic brain transgenic methodology. Unexpectedly, we also find that expression of wild-type human BRI2 reduces cerebral Abeta deposition in an AD mouse model. Additional data indicate that the 23 aa peptide, Bri23, released from BRI2 by normal processing, is present in human CSF, inhibits Abeta aggregation in vitro and mediates its anti-amyloidogenic effect in vivo. These studies demonstrate that BRI2 is a novel mediator of Abeta deposition in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Levites</LastName><ForeName>Yona</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Karen Jansen</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Zwizinski</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Brenda D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Troendle</LastName><ForeName>Fredrick J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Bann</LastName><ForeName>Maralyssa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Verbeeck</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Smithson</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sonoda</LastName><ForeName>Leilani</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wagg</LastName><ForeName>Kayleigh</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rangachari</LastName><ForeName>Vijayaraghavan</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Fanggeng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rosenberry</LastName><ForeName>Terrone</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG025531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120083">ITM2B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18524908</ArticleId><ArticleId IdType="mid">NIHMS67733</ArticleId><ArticleId IdType="pmc">PMC2586000</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0891-08.2008</ArticleId><ArticleId IdType="pii">28/23/6030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Kondo H, Arai T, Ikeda K, Kato M, Iseki E, Schwab C, McGeer PL. Expression of BRI, the normal precursor of the amyloid protein of familial Br dementia, in human brain. Acta Neuropathol (Berl) 2004;107:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">14586629</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience. 2006;138:501&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SI, Vidal R, Frangione B, Levy E. Axonal transport of Br and Danish amyloid peptides via secretory vesicles. FASEB J. 2004;18:373&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656991</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1&#x2013;42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705631</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem. 2006;281:30471&#x2013;30478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16912050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotinopoulou A, Tsachaki M, Vlavaki M, Poulopoulos A, Rostagno A, Frangione B, Ghiso J, Efthimiopoulos S. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem. 2005;280:30768&#x2013;30772.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Rostagno A, Tomidokoro Y, Lashley T, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Lal R, Revesz T, Frangione B. Genetic alterations of the BRI2 gene: familial Br and Danish dementias. Brain Pathol. 2006;16:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095812</ArticleId><ArticleId IdType="pubmed">16612984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G, El-Agnaf OM, Anwar Z, Sidera C, Isbister A, Austen BM. Structure and neurotoxicity of novel amyloids derived from the BRI gene. Biochem Soc Trans. 2005;33:1111&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246057</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest. 2003;111:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151845</ArticleId><ArticleId IdType="pubmed">12511580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments] Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. A&#x3b2;40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-H, Wang R, Gordon D, Bass J, Steiner D, Lynn D, Thinakarn G, Meredith S, Sisodia S. Furin mediates enhanced production of fibrillogenic ABri peptides in familial Br dementia. Nat Neurosci. 1999;2:984&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526337</ArticleId></ArticleIdList></Reference><Reference><Citation>Klug GM, Losic D, Subasinghe SS, Aguilar MI, Martin LL, Small DH. Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem. 2003;270:4282&#x2013;4293.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622293</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006a;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid &#x3b2;, amyloid &#x3b2;40, and amyloid &#x3b2;42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006b;26:11923&#x2013;11928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674861</ArticleId><ArticleId IdType="pubmed">17108166</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Crocker E, Zhang W, Elliott JI, Luy B, Li H, Aimoto S, Smith SO. Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. Biochemistry. 2005;44:3591&#x2013;3597.</Citation><ArticleIdList><ArticleId IdType="pubmed">15736968</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Fluhrer R, Reiss K, Kremmer E, Saftig P, Haass C. Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/b. J Biol Chem. 2007;283:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965014</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem. 2005;280:28912&#x2013;28916.</Citation><ArticleIdList><ArticleId IdType="pubmed">15983050</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols MR, Moss MA, Reed DK, Cratic-McDaniel S, Hoh JH, Rosenberry TL. Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J Biol Chem. 2005;280:2471&#x2013;2480.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528204</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol. 2003;77:7034&#x2013;7040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156185</ArticleId><ArticleId IdType="pubmed">12768022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangachari V, Reed DK, Moore BD, Rosenberry TL. Secondary structure and interfacial aggregation of amyloid-beta(1&#x2013;40) on sodium dodecyl sulfate micelles. Biochemistry. 2006;45:8639&#x2013;8648.</Citation><ArticleIdList><ArticleId IdType="pubmed">16834338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pulido L, Devos D, Valencia A. BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem Sci. 2002;27:329&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">12114016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry. 2006;45:5503&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593882</ArticleId><ArticleId IdType="pubmed">16634632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomidokoro Y, Lashley T, Rostagno A, Neubert TA, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Frangione B, Revesz T, Ghiso J. Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. J Biol Chem. 2005;280:36883&#x2013;36894.</Citation><ArticleIdList><ArticleId IdType="pubmed">16091362</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J. A stop-codon mutation in the BRI gene associated with familial Br dementia. Nature. 1999;399:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Revesz T, Rostagno A, Kim E, Holton JL, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Ghiso J, Frangione B. A decamer duplication in the 3&#x2032; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA. 2000;97:4920&#x2013;4925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Calero M, Revesz T, Plant G, Ghiso J, Frangione B. Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family. Gene. 2001;266:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11290423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham L, Benjannet S, Marcinkiewicz E, Chretien M, Seidah NG. Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. J Neurochem. 2005;92:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15606899</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18525029</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>209</EndPage><MedlinePgn>202-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000316197.04157.6f</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer disease (AD) has been associated with abnormal cerebral clearance of macromolecules, such as amyloid and microtubule-associated-protein tau (MAP-tau). We hypothesized that improving clearance of macromolecules from the CNS might slow the progression of dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This prospective, randomized, double-blinded, placebo-controlled trial evaluated the safety and effectiveness of a surgically implanted shunt in subjects with probable AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 215 subjects with probable AD by National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria received either a low-flow ventriculoperitoneal shunt or a sham (occluded) shunt for 9 months. Longitudinal CSF sampling was performed in both active and control subjects. Primary outcome measures were the Mattis Dementia Rating Scale and the Global Deterioration Scale. CSF Abeta((1-42)) and MAP-tau also were assayed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After a planned interim analysis, the study was halted for futility. Using the intent-to-treat population, no between-group differences were observed in the primary outcome measures. The surgical procedure and device were associated with 12 CNS infections, some temporally associated with CSF sampling. All were treated successfully.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found no benefit to low-flow CSF shunting in subjects with mild to severe Alzheimer disease. CSF infections, while treatable, occurred more frequently than expected, in some cases likely related to CSF sampling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silverberg</LastName><ForeName>G D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Warren Alpert School of Medicine, Brown University, Providence, RI, USA. geralds@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saul</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fellmann</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002557" MajorTopicYN="N">Cerebrospinal Fluid Shunts</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18525029</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000316197.04157.6f</ArticleId><ArticleId IdType="pii">01.wnl.0000316197.04157.6f</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18541914</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>23</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.</ArticleTitle><Pagination><StartPage>8050</StartPage><EndPage>8054</EndPage><MedlinePgn>8050-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0801227105</ELocationID><Abstract><AbstractText>There is substantial evidence that cerebrospinal fluid (CSF) levels of both Abeta42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Abeta and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Abeta42 levels were used to stratify the sample into those with and without likely Abeta deposition in the brain the association was only observed in individuals with evidence of Abeta deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain Abeta deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Abeta deposition) interaction that places changes in CSF tau after Abeta deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bertelsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 TL1 RR024995-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014677</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024994</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH14677</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 UL1 RR024992-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 RR024995</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 KL2 RR 024994-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18541914</ArticleId><ArticleId IdType="pmc">PMC2430357</ArticleId><ArticleId IdType="doi">10.1073/pnas.0801227105</ArticleId><ArticleId IdType="pii">0801227105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet. 2007;8:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1800865</ArticleId><ArticleId IdType="pubmed">17266761</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet. 2005;14:2399&#x2013;2404.</Citation><ArticleIdList><ArticleId IdType="pubmed">16000317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Hampel H, Takeda M, Putnam KT, Cohen RM. Biomarkers in the diagnosis of Alzheimer's disease: Are we ready? J Geriatr Psychiatry Neurol. 2006;19:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880359</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007;6:464&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">17541419</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005;14:3281&#x2013;3292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195395</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet. 2004;13:1267&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115761</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws SM, et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Molecular Psychiatry. 2007;12:510&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179995</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, McKeel DW, Jr, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg. 2005;107:165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823670</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002;32:1372&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074169</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18544724</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>299</Volume><Issue>22</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>2642</StartPage><EndPage>2655</EndPage><MedlinePgn>2642-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.299.22.2642</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Cognitive decline, mood, behavioral and sleep disturbances, and limitations of activities of daily living commonly burden elderly patients with dementia and their caregivers. Circadian rhythm disturbances have been associated with these symptoms.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether the progression of cognitive and noncognitive symptoms may be ameliorated by individual or combined long-term application of the 2 major synchronizers of the circadian timing system: bright light and melatonin.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A long-term, double-blind, placebo-controlled, 2 x 2 factorial randomized trial performed from 1999 to 2004 with 189 residents of 12 group care facilities in the Netherlands; mean (SD) age, 85.8 (5.5) years; 90% were female and 87% had dementia.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Random assignment by facility to long-term daily treatment with whole-day bright (+/- 1000 lux) or dim (+/- 300 lux) light and by participant to evening melatonin (2.5 mg) or placebo for a mean (SD) of 15 (12) months (maximum period of 3.5 years).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Standardized scales for cognitive and noncognitive symptoms, limitations of activities of daily living, and adverse effects assessed every 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Light attenuated cognitive deterioration by a mean of 0.9 points (95% confidence interval [CI], 0.04-1.71) on the Mini-Mental State Examination or a relative 5%. Light also ameliorated depressive symptoms by 1.5 points (95% CI, 0.24-2.70) on the Cornell Scale for Depression in Dementia or a relative 19%, and attenuated the increase in functional limitations over time by 1.8 points per year (95% CI, 0.61-2.92) on the nurse-informant activities of daily living scale or a relative 53% difference. Melatonin shortened sleep onset latency by 8.2 minutes (95% CI, 1.08-15.38) or 19% and increased sleep duration by 27 minutes (95% CI, 9-46) or 6%. However, melatonin adversely affected scores on the Philadelphia Geriatric Centre Affect Rating Scale, both for positive affect (-0.5 points; 95% CI, -0.10 to -1.00) and negative affect (0.8 points; 95% CI, 0.20-1.44). Melatonin also increased withdrawn behavior by 1.02 points (95% CI, 0.18-1.86) on the Multi Observational Scale for Elderly Subjects scale, although this effect was not seen if given in combination with light. Combined treatment also attenuated aggressive behavior by 3.9 points (95% CI, 0.88-6.92) on the Cohen-Mansfield Agitation Index or 9%, increased sleep efficiency by 3.5% (95% CI, 0.8%-6.1%), and improved nocturnal restlessness by 1.00 minute per hour each year (95% CI, 0.26-1.78) or 9% (treatment x time effect).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Light has a modest benefit in improving some cognitive and noncognitive symptoms of dementia. To counteract the adverse effect of melatonin on mood, it is recommended only in combination with light.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">controlled-trials.com/isrctn Identifier: ISRCTN93133646.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riemersma-van der Lek</LastName><ForeName>Rixt F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaab</LastName><ForeName>Dick F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Twisk</LastName><ForeName>Jos</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hol</LastName><ForeName>Elly M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Hoogendijk</LastName><ForeName>Witte J G</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Van Someren</LastName><ForeName>Eus J W</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN93133646</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008029" MajorTopicYN="N">Lighting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="Y">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18544724</ArticleId><ArticleId IdType="doi">10.1001/jama.299.22.2642</ArticleId><ArticleId IdType="pii">299/22/2642</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18548070</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>453</Volume><Issue>7197</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Substrate-targeting gamma-secretase modulators.</ArticleTitle><Pagination><StartPage>925</StartPage><EndPage>929</EndPage><MedlinePgn>925-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature07055</ELocationID><Abstract><AbstractText>Selective lowering of Abeta42 levels (the 42-residue isoform of the amyloid-beta peptide) with small-molecule gamma-secretase modulators (GSMs), such as some non-steroidal anti-inflammatory drugs, is a promising therapeutic approach for Alzheimer's disease. To identify the target of these agents we developed biotinylated photoactivatable GSMs. GSM photoprobes did not label the core proteins of the gamma-secretase complex, but instead labelled the beta-amyloid precursor protein (APP), APP carboxy-terminal fragments and amyloid-beta peptide in human neuroglioma H4 cells. Substrate labelling was competed by other GSMs, and labelling of an APP gamma-secretase substrate was more efficient than a Notch substrate. GSM interaction was localized to residues 28-36 of amyloid-beta, a region critical for aggregation. We also demonstrate that compounds known to interact with this region of amyloid-beta act as GSMs, and some GSMs alter the production of cell-derived amyloid-beta oligomers. Furthermore, mutation of the GSM binding site in the APP alters the sensitivity of the substrate to GSMs. These findings indicate that substrate targeting by GSMs mechanistically links two therapeutic actions: alteration in Abeta42 production and inhibition of amyloid-beta aggregation, which may synergistically reduce amyloid-beta deposition in Alzheimer's disease. These data also demonstrate the existence and feasibility of 'substrate targeting' by small-molecule effectors of proteolytic enzymes, which if generally applicable may significantly broaden the current notion of 'druggable' targets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kukar</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA. kukar.thomas@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladd</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Bann</LastName><ForeName>Maralyssa A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Fraering</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Narlawar</LastName><ForeName>Rajeshwar</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Maharvi</LastName><ForeName>Ghulam M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>Brent</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Welzel</LastName><ForeName>Alfred T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rangachari</LastName><ForeName>Vijayaraghavan</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Cusack</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Eriksen</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Verbeeck</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yager</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Sagi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cottrell</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Torpey</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosenberry</LastName><ForeName>Terrone L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Fauq</LastName><ForeName>Abdul</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG020206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041355</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2008 Jun 12;453(7197):861-2. doi: 10.1038/453861a.</RefSource><PMID Version="1">18548057</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18548070</ArticleId><ArticleId IdType="mid">NIHMS107276</ArticleId><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="doi">10.1038/nature07055</ArticleId><ArticleId IdType="pii">nature07055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate &#x3b3;-secretase cleavage. Curr Top Med Chem. 2008;8:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740624</ArticleId><ArticleId IdType="pubmed">18220932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodadek T. Inhibition of proteolysis and other posttranslational modifications with substrate-targeted inhibitors. Biopolymers. 2002;66:134&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325163</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, et al. NSAIDs and enantiomers of flurbiprofen target &#x3b3;-secretase and lower A&#x3b2; 42 in vivo. J Clin Invest. 2003;112:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. A subset of NSAIDs lower amyloidogenic A&#x3b2;42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DD. Changing the course of Alzheimer&#x2019;s disease: anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry. 2007;9:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1894844</ArticleId><ArticleId IdType="pubmed">17599166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007;8:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1948891</ArticleId><ArticleId IdType="pubmed">17650315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A&#x3b2;42 production. Nature Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Narlawar R, Baumann K, Czech C, Schmidt B. Conversionof the LXR-agonist TO-901317&#x2013;From inverse to normal modulation of &#x3b3;-secretase by addition of a carboxylic acid and a lipophilic anchor. Bioorg Med Chem Lett. 2007;17:5428&#x2013;5431.</Citation><ArticleIdList><ArticleId IdType="pubmed">17723298</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchtenberger S, et al. Inhibitors of Rho-kinase modulate amyloid-&#x3b2; (A&#x3b2;) secretion but lack selectivity for A&#x3b2;42. J Neurochem. 2006;96:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300630</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid &#x3b2;42 production by direct modulation of &#x3b3;-secretase activity. J Biol Chem. 2003;278:31831&#x2013;31837.</Citation><ArticleIdList><ArticleId IdType="pubmed">12805356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorman G, Prestwich GD. Benzophenone photophores in biochemistry. Biochemistry. 1994;33:5661&#x2013;5673.</Citation><ArticleIdList><ArticleId IdType="pubmed">8180191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, et al. Purification and characterization of the human &#x3b3;-secretase complex. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Narlawar R, et al. Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer &#x3b3;-secretase modulators. J Med Chem. 2006;49:7588&#x2013;7591.</Citation><ArticleIdList><ArticleId IdType="pubmed">17181139</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, et al. Secretion of the Notch-1 A&#x3b2;-like peptide during Notch signaling. J Biol Chem. 2006;281:7890&#x2013;7898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagi SA, et al. NSAIDs Show Specificity for APP &#x3b3;-Secretase Cleavage over Notch and CD44. Society for Neuroscience, Program no. 264.10, Abstract Viewer/Itinerary Planner; Washington DC: 2004.</Citation></Reference><Reference><Citation>Grziwa B, et al. The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J Biol Chem. 2003;278:6803&#x2013;6808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12454010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of A&#x3b2;40 and A&#x3b2;42. Biochemistry. 2006;45:5503&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593882</ArticleId><ArticleId IdType="pubmed">16634632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YR, Glabe CG. Distinct early folding and aggregation properties of Alzheimer amyloid-&#x3b2; peptides A&#x3b2;40 and A&#x3b2;42. J Biol Chem. 2006;281:24414&#x2013;24422.</Citation><ArticleIdList><ArticleId IdType="pubmed">16809342</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, et al. &#x3b3;-secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid &#x3b2; peptides of varying length. J Biol Chem. 1999;274:11914&#x2013;11923.</Citation><ArticleIdList><ArticleId IdType="pubmed">10207012</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of A&#x3b2;42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer&#x2019;s &#x3b2;-amyloid fibrils in vitro. Neuropharmacology. 2005;49:1088&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125740</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, et al. Oligomerization of endogenous and synthetic amyloid &#x3b2;-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry. 1998;37:3602&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrao-Gonzales AD, et al. Controlling &#x3b2;-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species. J Biol Chem. 2005;280:34747&#x2013;34754.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041062</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese B, et al. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-&#x3b2; protein. Mol Cell Neurosci. 2007;35:183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268524</ArticleId><ArticleId IdType="pubmed">17368908</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, et al. Enhanced production and oligomerization of the 42-residue amyloid &#x3b2;-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272:7977&#x2013;7982.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065468</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomeriation of amyloid &#x3b2; protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, et al. Nonsteroidal anti-inflammatory drugs lower A&#x3b2;42 and change presenilin 1 conformation. Nature Med. 2004;10:1065&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448688</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target &#x3b3;-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem. 2004;279:43419&#x2013;43426.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304503</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong DL, Liu R, Sherlock R, Wigler MH, Nestler HP. Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus. Chem Biol. 1999;6:133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10074468</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Mallender WD, Inestrosa NC, Rosenberry TL. Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation Sites. J Biol Chem. 2001;276:23282&#x2013;23287.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313335</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JL, Cusack B, Davies MP, Fauq A, Rosenberry TL. Unmasking tandem site interaction in human acetylcholinesterase. Substrate activation with a cationic acetanilide substrate. Biochemistry. 2003;42:5438&#x2013;5452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12731886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18549781</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>ApoE promotes the proteolytic degradation of Abeta.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>693</EndPage><MedlinePgn>681-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.04.010</ELocationID><Abstract><AbstractText>Apolipoprotein E is associated with age-related risk for Alzheimer's disease and plays critical roles in Abeta homeostasis. We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. The endolytic degradation of Abeta peptides within microglia by neprilysin and related enzymes is dramatically enhanced by ApoE. Similarly, Abeta degradation extracellularly by insulin-degrading enzyme is facilitated by ApoE. The capacity of ApoE to promote Abeta degradation is dependent upon the ApoE isoform and its lipidation status. The enhanced expression of lipidated ApoE, through the activation of liver X receptors, stimulates Abeta degradation. Indeed, aged Tg2576 mice treated with the LXR agonist GW3965 exhibited a dramatic reduction in brain Abeta load. GW3965 treatment also reversed contextual memory deficits. These data demonstrate a mechanism through which ApoE facilitates the clearance of Abeta from the brain and suggest that LXR agonists may represent a novel therapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qingguang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Y Daniel</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Mandrekar</LastName><ForeName>Shweta</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Brandy</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zelcer</LastName><ForeName>Noam</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Willson</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Jon L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Jill C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Comery</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Tontonoz</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HL66088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL066082</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020202</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL066088</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL30568</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AG24031</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG024031</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL030568</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG020202</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C473027">GW 3965</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18549781</ArticleId><ArticleId IdType="mid">NIHMS55457</ArticleId><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.04.010</ArticleId><ArticleId IdType="pii">S0896-6273(08)00328-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med. 2006;57:313&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem. 2006;98:792&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J., Jr. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1) J Biol Chem. 2004;279:7384&#x2013;7394.</Citation><ArticleIdList><ArticleId IdType="pubmed">14660648</ArticleId></ArticleIdList></Reference><Reference><Citation>Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochim Biophys Acta. 2000;1484:14&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">10685027</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolev I, Michaelson DM. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci U S A. 2004;101:13909&#x2013;13914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC518852</ArticleId><ArticleId IdType="pubmed">15365176</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (&#x2212;/ &#x2212;), and human apoE transgenic mice. J Biol Chem. 1999;274:30001&#x2013;30007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="pubmed">17591969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher CA, Ryan RO. Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E. J Lipid Res. 1999;40:93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem. 2002;277:48508&#x2013;48513.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem. 1996;66:2429&#x2013;2435.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007;4:e262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952204</ArticleId><ArticleId IdType="pubmed">17760499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004;279:41197&#x2013;41207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci. 2001;17:147&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816788</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci. 2004;23:247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang XC, Beyer TP, Li Z, Liu J, Quan W, Schmidt RJ, Zhang Y, Bensch WR, Eacho PI, Cao G. Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression. J Biol Chem. 2003;278:49072&#x2013;49078.</Citation><ArticleIdList><ArticleId IdType="pubmed">12947111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001;42:1143&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441143</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005a;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003;278:13244&#x2013;13256.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry. 2001;40:3553&#x2013;3560.</Citation><ArticleIdList><ArticleId IdType="pubmed">11297421</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005b;280:4079&#x2013;4088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurochkin IV, Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 1994;345:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8194595</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995;270:9039&#x2013;9042.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladu MJ, Stine WB, Jr., Narita M, Getz GS, Reardon CA, Bu G. Self-Assembly of HEK Cell-Secreted ApoE Particles Resembles ApoE Enrichment of Lipoproteins as a Ligand for the LDL Receptor-Related Protein. Biochemistry. 2006;45:381&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564845</ArticleId><ArticleId IdType="pubmed">16401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol. 2005;16:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007;2:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="pubmed">17953774</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, et al. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiol Dis. 2005;19:66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837562</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27:190&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399206</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002;40:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379913</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 1996;47:387&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Saunders AM, Corder EH, Pericak-Vance MA, Han SH, Einstein G, Hulette C, Schmechel DE, Holsti M, Huang D, et al. Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease. Arzneimittelforschung. 1995;45:413&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">7763336</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller JK, Zaccheo D, Gambetti P, Tabaton M. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci U S A. 1998;95:15598&#x2013;15602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28089</ArticleId><ArticleId IdType="pubmed">9861015</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen CL, Murphy RM. Solvent effects on self-assembly of beta-amyloid peptide. Biophys J. 1995;69:640&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1236289</ArticleId><ArticleId IdType="pubmed">8527678</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JD, Le Goff W, Settle M, Brubaker G, Waelde C, Horwitz A, Oda MN. ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res. 2004;45:635&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">14703508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Yao J, Kim TW, Tall AR. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003;278:27688&#x2013;27694.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R, Moir R, Wagner S. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J. 2000;348(Pt 2):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221074</ArticleId><ArticleId IdType="pubmed">10816430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A. 2002;99:13878&#x2013;13883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129791</ArticleId><ArticleId IdType="pubmed">12368482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276:23742&#x2013;23747.</Citation><ArticleIdList><ArticleId IdType="pubmed">11309399</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Li Y, Cyras C, Sanan DA, Cordell B. Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J Biol Chem. 2000;275:31770&#x2013;31777.</Citation><ArticleIdList><ArticleId IdType="pubmed">10918055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J, Heneka MT. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem. 2002;81:1052&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A. 2007;104:10601&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006;116:607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386115</ArticleId><ArticleId IdType="pubmed">16511593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 2005;15:78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095816</ArticleId><ArticleId IdType="pubmed">15779240</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18555774</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors.</ArticleTitle><Pagination><StartPage>963</StartPage><EndPage>977</EndPage><MedlinePgn>963-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2008.04.039</ELocationID><Abstract><AbstractText>VAP proteins (human VAPB/ALS8, Drosophila VAP33, and C. elegans VPR-1) are homologous proteins with an amino-terminal major sperm protein (MSP) domain and a transmembrane domain. The MSP domain is named for its similarity to the C. elegans MSP protein, a sperm-derived hormone that binds to the Eph receptor and induces oocyte maturation. A point mutation (P56S) in the MSP domain of human VAPB is associated with Amyotrophic lateral sclerosis (ALS), but the mechanisms underlying the pathogenesis are poorly understood. Here we show that the MSP domains of VAP proteins are cleaved and secreted ligands for Eph receptors. The P58S mutation in VAP33 leads to a failure to secrete the MSP domain as well as ubiquitination, accumulation of inclusions in the endoplasmic reticulum, and an unfolded protein response. We propose that VAP MSP domains are secreted and act as diffusible hormones for Eph receptors. This work provides insight into mechanisms that may impact the pathogenesis of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuda</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Sung Min</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Youfeng</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong Qi</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Kriti</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Haueter</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Harati</LastName><ForeName>Yadollah</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Bellen</LastName><ForeName>Hugo J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496748">VAPB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C529738">VPR-1 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2008 Jun 13;133(6):949-51. doi: 10.1016/j.cell.2008.05.028.</RefSource><PMID Version="1">18555770</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036081" MajorTopicYN="N">Receptors, Eph Family</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HHMIMS56072</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18555774</ArticleId><ArticleId IdType="mid">NIHMS56072</ArticleId><ArticleId IdType="pmc">PMC2494862</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2008.04.039</ArticleId><ArticleId IdType="pii">S0092-8674(08)00613-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amarilio R, Ramachandran S, Sabanay H, Lev S. Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction. The Journal of biological chemistry. 2005;280:5934&#x2013;5944.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545272</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, et al. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. The Journal of biological chemistry. 2006;281:30152&#x2013;30165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847061</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker AM, Roberts TM, Stewart M. 2.6 A resolution crystal structure of helices of the motile major sperm protein (MSP) of Caenorhabditis elegans. J Mol Biol. 2002;319:491&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">12051923</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M, Massignan T, Samengo G, Cheroni C, De Biasi S, Salmona M, Bendotti C, Bonetto V. Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. The Journal of biological chemistry. 2006;281:33325&#x2013;33335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16943203</ArticleId></ArticleIdList></Reference><Reference><Citation>Blelloch R, Anna-Arriola SS, Gao D, Li Y, Hodgkin J, Kimble J. The gon-1 gene is required for gonadal morphogenesis in Caenorhabditis elegans. Dev Biol. 1999;216:382&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588887</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottino D, Mogilner A, Roberts T, Stewart M, Oster G. How nematode sperm crawl. Journal of cell science. 2002;115:367&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839788</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle M, Nighorn A, Thomas JB. Drosophila Eph receptor guides specific axon branches of mushroom body neurons. Development (Cambridge, England) 2006;133:1845&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794001</ArticleId><ArticleId IdType="pubmed">16613832</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickner JH, Walter P. Gene recruitment of the activated INO1 locus to the nuclear membrane. PLoS Biol. 2004;2:e342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC519002</ArticleId><ArticleId IdType="pubmed">15455074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai A, Withers J, Koh YH, Parry K, Bao H, Zhang B, Budnik V, Pennetta G. hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the Neuromuscular Junction. Hum Mol Genet. 2008;17:266&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516386</ArticleId><ArticleId IdType="pubmed">17947296</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin-Sang ID, George SE, Ding M, Moseley SL, Lynch AS, Chisholm AD. The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C. elegans. Cell. 1999;99:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">10619431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin-Sang ID, Moseley SL, Ding M, Harrington RJ, George SE, Chisholm AD. The divergent C. elegans ephrin EFN-4 functions inembryonic morphogenesis in a pathway independent of the VAB-1 Eph receptor. Development (Cambridge, England) 2002;129:5499&#x2013;5510.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403719</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan C, Subramanian R, Miller MA. Eph and NMDA receptors control Ca2+/calmodulin-dependent protein kinase II activation during C. elegans oocyte meiotic maturation. Development (Cambridge, England) 2005;132:5225&#x2013;5237.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267094</ArticleId></ArticleIdList></Reference><Reference><Citation>Culi J, Mann RS. Boca, an endoplasmic reticulum protein required for wingless signaling and trafficking of LDL receptor family members in Drosophila. Cell. 2003;112:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell. 2000;103:945&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136979</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Progress in neurobiology. 2004;74:249&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearborn R, Jr, He Q, Kunes S, Dai Y. Eph receptor tyrosine kinase-mediated formation of a topographic map in the Drosophila visual system. J Neurosci. 2002;22:1338&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757577</ArticleId><ArticleId IdType="pubmed">11850461</ArticleId></ArticleIdList></Reference><Reference><Citation>Elefant F, Palter KB. Tissue-specific expression of dominant negative mutant Drosophila HSC70 causes developmental defects and lethality. Molecular biology of the cell. 1999;10:2101&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25422</ArticleId><ArticleId IdType="pubmed">10397752</ArticleId></ArticleIdList></Reference><Reference><Citation>George SE, Simokat K, Hardin J, Chisholm AD. The VAB-1 Eph receptor tyrosine kinase functions in neural and epithelial morphogenesis in C. elegans. Cell. 1998;92:633&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506518</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindan JA, Cheng H, Harris JE, Greenstein D. Galphao/i and Galphas signaling function in parallel with the MSP/Eph receptor to control meiotic diapause in C. elegans. Curr Biol. 2006;16:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">16824915</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JE, Govindan JA, Yamamoto I, Schwartz J, Kaverina I, Greenstein D. Major sperm protein signaling promotes oocyte microtubule reorganization prior to fertilization in Caenorhabditis elegans. Dev Biol. 2006;299:105&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919258</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpers B, Rabouille C. mRNA localization and ER-based protein sorting mechanisms dictate the use of transitional endoplasmic reticulum-golgi units involved in gurken transport in Drosophila oocytes. Molecular biology of the cell. 2004;15:5306&#x2013;5317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC532012</ArticleId><ArticleId IdType="pubmed">15385627</ArticleId></ArticleIdList></Reference><Reference><Citation>Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327877</ArticleId><ArticleId IdType="pubmed">17928214</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamasa H, Ohta K, Yamada T, Ushijima K, Terasaki H, Tanaka H. Expression of Eph receptor tyrosine kinases and their ligands in chick embryonic motor neurons and hindlimb muscles. Dev Growth Differ. 1999;41:685&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">10646798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagiwada S, Hosaka K, Murata M, Nikawa J, Takatsuki A. The Saccharomyces cerevisiae SCS2 gene product, a homolog of a synaptobrevin-associated protein, is an integral membrane protein of the endoplasmic reticulum and is required for inositol metabolism. J Bacteriol. 1998;180:1700&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC107080</ArticleId><ArticleId IdType="pubmed">9537365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagiwada S, Zen R. Role of the yeast VAP homolog, Scs2p, in INO1 expression and phospholipid metabolism. J Biochem (Tokyo) 2003;133:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, Brunger AT. Structural basis of FFAT motif-mediated ER targeting. Structure. 2005;13:1035&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">16004875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi H, Almer G, Yamashita S, Guegan C, Nagai M, Xu Z, Sosunov AA, McKhann GM, 2nd, Przedborski S. Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:6025&#x2013;6030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458691</ArticleId><ArticleId IdType="pubmed">16595634</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol. 2004;16:580&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosinski M, McDonald K, Schwartz J, Yamamoto I, Greenstein D. C. elegans sperm bud vesicles to deliver a meiotic maturation signal to distant oocytes. Development (Cambridge, England) 2005;132:3357&#x2013;3369.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by Eph-ephrin interactions. Trends in cardiovascular medicine. 2007;17:145&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai KO, Ip FC, Cheung J, Fu AK, Ip NY. Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction. Mol Cell Neurosci. 2001;17:1034&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414792</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewen CJ, Levine TP. A highly conserved binding site in vesicle-associated membrane protein-associated protein (VAP) for the FFAT motif of lipid-binding proteins. The Journal of biological chemistry. 2005;280:14097&#x2013;14104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668246</ArticleId></ArticleIdList></Reference><Reference><Citation>Magal E, Holash JA, Toso RJ, Chang D, Lindberg RA, Pasquale EB. B61, a ligand for the Eck receptor protein-tyrosine kinase, exhibits neurotrophic activity in cultures of rat spinal cord neurons. J Neurosci Res. 1996;43:735&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">8984203</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarter J, Bartlett B, Dang T, Schedl T. On the control of oocyte meiotic maturation and ovulation in Caenorhabditis elegans. Dev Biol. 1999;205:111&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">9882501</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MA, Nguyen VQ, Lee MH, Kosinski M, Schedl T, Caprioli RM, Greenstein D. A sperm cytoskeletal protein that signals oocyte meiotic maturation and ovulation. Science (New York, NY. 2001;291:2144&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">11251118</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MA, Ruest PJ, Kosinski M, Hanks SK, Greenstein D. An Eph receptor sperm-sensing control mechanism for oocyte meiotic maturation in Caenorhabditis elegans. Genes Dev. 2003;17:187&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC195972</ArticleId><ArticleId IdType="pubmed">12533508</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annual review of neuroscience. 2005;28:57&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022590</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. The Journal of biological chemistry. 1997;272:4327&#x2013;4334.</Citation><ArticleIdList><ArticleId IdType="pubmed">9020152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira JR, Gillingwater T, Webb J, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. American journal of human genetics. 2004;75:822&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Hayashi M, Inada H, Tanaka T. Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochemical and biophysical research communications. 1999;254:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9920726</ArticleId></ArticleIdList></Reference><Reference><Citation>Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5:3226&#x2013;3245.</Citation><ArticleIdList><ArticleId IdType="pubmed">16104056</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev. 2003;17:1429&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815065</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928710</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennetta G, Hiesinger PR, Fabian-Fine R, Meinertzhagen IA, Bellen HJ. Drosophila VAP-33A directs bouton formation at neuromuscular junctions in a dosage-dependent manner. Neuron. 2002;35:291&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160747</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Ridgway ND. Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Molecular biology of the cell. 2006;17:2604&#x2013;2616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474796</ArticleId><ArticleId IdType="pubmed">16571669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesacreta TC, Byers TJ, Dubreuil R, Kiehart DP, Branton D. Drosophila spectrin: the membrane skeleton during embryogenesis. The Journal of cell biology. 1989;108:1697&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115563</ArticleId><ArticleId IdType="pubmed">2497103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard J, Salinas J, Garcia L, Liebl DJ. EphrinB3 regulates cell proliferation and survival in adult neurogenesis. Mol Cell Neurosci. 2006;31:713&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryoo HD, Domingos PM, Kang MJ, Steller H. Unfolded protein response in a Drosophila model for retinal degeneration. The EMBO journal. 2007;26:242&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782370</ArticleId><ArticleId IdType="pubmed">17170705</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto ES, Bellen HJ. Internalization is required for proper Wingless signaling in Drosophila melanogaster. The Journal of cell biology. 2006;173:95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063794</ArticleId><ArticleId IdType="pubmed">16606693</ArticleId></ArticleIdList></Reference><Reference><Citation>Skehel PA, Fabian-Fine R, Kandel ER. Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:1101&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15535</ArticleId><ArticleId IdType="pubmed">10655491</ArticleId></ArticleIdList></Reference><Reference><Citation>Soussan L, Burakov D, Daniels MP, Toister-Achituv M, Porat A, Yarden Y, Elazar Z. ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles. The Journal of cell biology. 1999;146:301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156184</ArticleId><ArticleId IdType="pubmed">10427086</ArticleId></ArticleIdList></Reference><Reference><Citation>Strigini M, Cohen SM. Wingless gradient formation in the Drosophila wing. Curr Biol. 2000;10:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744972</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Ansorge O. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Human molecular genetics. 2006;15(Spec No 2):R182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987882</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, Akhmanova A, Jaarsma D, Hoogenraad CC. Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci. 2007;27:9801&#x2013;9815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672975</ArticleId><ArticleId IdType="pubmed">17804640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PY, Weng J, Anderson RG. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science (New York, NY. 2005;307:1472&#x2013;1476.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Roy PJ, Holland SJ, Zhang LW, Culotti JG, Pawson T. Multiple ephrins control cell organization in C. elegans using kinase-dependent and -independent functions of the VAB-1 Eph receptor. Mol Cell. 1999;4:903&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10635316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward S, Burke DJ, Sulston JE, Coulson AR, Albertson DG, Ammons D, Klass M, Hogan E. Genomic organization of major sperm protein genes and pseudogenes in the nematode Caenorhabditis elegans. J Mol Biol. 1988;199:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">3351915</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir ML, Klip A, Trimble WS. Identification of a human homologue of the vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (VAP-33): a broadly expressed protein that binds to VAMP. Biochem J. 1998;333(Pt 2):247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1219579</ArticleId><ArticleId IdType="pubmed">9657962</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitten SJ, Miller MA. The role of gap junctions in Caenorhabditis elegans oocyte maturation and fertilization. Dev Biol. 2007;301:432&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto I, Kosinski ME, Greenstein D. Start me up: cell signaling and the journey from oocyte to embryo in C. elegans. Dev Dyn. 2006;235:571&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zallen JA, Kirch SA, Bargmann CI. Genes required for axon pathfinding and extension in the C. elegans nerve ring. Development (Cambridge, England) 1999;126:3679&#x2013;3692.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zallen JA, Yi BA, Bargmann CI. The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C. elegans. Cell. 1998;92:217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9458046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, Stojanovic K, Sagare A, Boillee S, Cleveland DW, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nature neuroscience. 2008;11:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18556397</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials.</ArticleTitle><Pagination><StartPage>568</StartPage><EndPage>574</EndPage><MedlinePgn>568-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e318172b406</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Among Alzheimer disease (AD) patients enrolled in a clinical trial, the authors assessed the ability of a standardized capacity assessment procedure to identify persons who are capable of giving their own informed consent.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional interview.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Thirteen sites participating in a randomized and placebo controlled study of simvastatin for the treatment of mild to moderate AD.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Persons with mild to moderate AD and their study partners enrolled in the simvastatin clinical trial.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Interviews to assess decision-making capacity using the MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Judges blinded to the subject's clinical status had a high rate of agreement on patients capable of giving their own informed consent (kappa = 0.73). The understanding subscale had the best receiver operator characteristic and an analysis of positive and negative predictive values over a range of hypothetical prevalences of incapacity to consent demonstrated the value of a range of understanding cut-points.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among mild to moderate AD patients, enrolled in an actual clinical trial, these results suggest evidence based guidelines for using the MacCAT-CR understanding subscale to help guide judgments about whether a patient has the capacity to consent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Alzheimer's Disease Center, Leonard Davis Institute for Health Economics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, PA, USA. Jason.karlawish@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Scott Y H</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Bryan D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG000247</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG00247</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007258" MajorTopicYN="Y">Informed Consent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="Y">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="Y">Mental Competency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035842" MajorTopicYN="N">Research Subjects</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Marson and Dr. Kim report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18556397</ArticleId><ArticleId IdType="mid">NIHMS551201</ArticleId><ArticleId IdType="pmc">PMC3936673</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318172b406</ArticleId><ArticleId IdType="pii">JGP.0b013e318172b406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Mendelsohn AB, Haley WE, et al. End-of-life care and the effects of bereavement on family caregivers of persons with dementia. N Engl J Med. 2003;349:1936&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614169</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, O&#x2019;Brien A, Bookwala J, et al. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist. 1995;35:771&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S. Do we have a treatment for Alzheimer Disease? Yes Arch Neurol. 1999;56:738&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369316</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryse-Phillips W. Do we have drugs for dementia? No Arch Neurol. 1999;56:735&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Sano M. Treatment of Alzheimer&#x2019;s disease. N Engl J Med. 1999;341:1670&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">10572156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SYH, Caine ED, Currier GW, et al. Assessing the competence of persons with Alzheimer&#x2019;s disease in providing informed consent for participation in research. Am J Psychiatry. 2001;158:710&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329391</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JHT, Casarett DJ, James BD. Alzheimers Disease patients&#x2019; and caregivers&#x2019; capacity, competency and reasons to enroll in an early phase Alzheimers Disease clinical trial. J Am Geriatr Soc. 2002;50:2019&#x2013;2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473015</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BW, Dunn LB, Appelbaum PS, et al. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry. 2005;62:726&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15997013</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelbaum PS, Grisso T. The MacArthur Competence Assessment Tool&#x2014;Clinical Research. Sarasota, Fla: Professional Resources Press; 2000.</Citation></Reference><Reference><Citation>Gordis L. Assessing the validity and reliability of diagnostic and screening tests. Epidemiology. Philadelphia: W.B. Saunders Company; 1996. pp. 58&#x2013;88.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease. Report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Caine ED, Swan JG, et al. Do clinicians follow a risk-sensitive model of capacity-determination? An experimental video survey. Psychosomatics. 2006;47:325&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844891</ArticleId></ArticleIdList></Reference><Reference><Citation>Earnst KS, Marson DC, Harrell LE. Cognitive models of physicians&#x2019; legal standard and personal judgments of competency in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2000;48:919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10968295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Cox C, Caine ED. Impaired decision-making ability in subjects with Alzheimer&#x2019;s disease and willingness to participate in research. Am J Psychiatry. 2002;159:797&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SYH, Appelbaum PS, Swan J, et al. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry. 2007;191:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">17602123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18559859</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>25</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.</ArticleTitle><Pagination><StartPage>8754</StartPage><EndPage>8759</EndPage><MedlinePgn>8754-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0710823105</ELocationID><Abstract><AbstractText>The amyloid hypothesis states that a variety of neurotoxic beta-amyloid (Abeta) species contribute to the pathogenesis of Alzheimer's disease. Accordingly, a key determinant of disease onset and progression is the appropriate balance between Abeta production and clearance. Enzymes responsible for the degradation of Abeta are not well understood, and, thus far, it has not been possible to enhance Abeta catabolism by pharmacological manipulation. We provide evidence that Abeta catabolism is increased after inhibition of plasminogen activator inhibitor-1 (PAI-1) and may constitute a viable therapeutic approach for lowering brain Abeta levels. PAI-1 inhibits the activity of tissue plasminogen activator (tPA), an enzyme that cleaves plasminogen to generate plasmin, a protease that degrades Abeta oligomers and monomers. Because tPA, plasminogen and PAI-1 are expressed in the brain, we tested the hypothesis that inhibitors of PAI-1 will enhance the proteolytic clearance of brain Abeta. Our data demonstrate that PAI-1 inhibitors augment the activity of tPA and plasmin in hippocampus, significantly lower plasma and brain Abeta levels, restore long-term potentiation deficits in hippocampal slices from transgenic Abeta-producing mice, and reverse cognitive deficits in these mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>J Steven</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Departments of Discovery Neuroscience and Chemical and Screening Sciences, Wyeth Research, CN-8000, Princeton, NJ 08543, USA. jacobss@wyeth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comery</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Martone</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Elokdah</LastName><ForeName>Hassan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Crandall</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Oganesian</LastName><ForeName>Aram</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Aschmies</LastName><ForeName>Suzan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kirksey</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Cathleen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Atchison</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zaleska</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Indranil</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Arias</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Bard</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gardell</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Abou-Gharbia</LastName><ForeName>Magid</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Robichaud</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Magolda</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vlasuk</LastName><ForeName>George P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Thorir</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Reinhart</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Pangalos</LastName><ForeName>Menelas N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015849">Plasminogen Inactivators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.68</RegistryNumber><NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.7</RegistryNumber><NameOfSubstance UI="D005341">Fibrinolysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005341" MajorTopicYN="N">Fibrinolysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015849" MajorTopicYN="N">Plasminogen Inactivators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: All coauthors are current or former employees of Wyeth Research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18559859</ArticleId><ArticleId IdType="pmc">PMC2438386</ArticleId><ArticleId IdType="doi">10.1073/pnas.0710823105</ArticleId><ArticleId IdType="pii">0710823105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001;32:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A, Hersh LB. Regulation of amyloid beta-peptide levels by enzymatic degradation. J Alzheimer's Dis. 2002;4:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446966</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh LB. Peptidases, proteases and amyloid beta-peptide catabolism. Curr Pharm Des. 2003;9:449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12570808</ArticleId></ArticleIdList></Reference><Reference><Citation>Periz G, Fortini ME. Proteolysis in Alzheimer's disease. Can plasmin tip the balance? EMBO Rep. 2000;1:477&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083794</ArticleId><ArticleId IdType="pubmed">11263489</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry. 1999;38:11570&#x2013;11576.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hino H, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett. 2001;297:105&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121881</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem. 2000;75:2172&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032907</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci. 2000;20:3937&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772619</ArticleId><ArticleId IdType="pubmed">10818128</ArticleId></ArticleIdList></Reference><Reference><Citation>Exley C, Korchazhkina OV. Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures. Neuroreport. 2001;12:2967&#x2013;2970.</Citation><ArticleIdList><ArticleId IdType="pubmed">11588612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med. 1995;1:138&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-Y, et al. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease. Neurosci Lett. 2007;423:82&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662525</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotti CG, Galvan C, Ledesma MD. Plasmin deficiency in Alzheimer's disease brains: Causal or casual? Neurodegenerative Dis. 2004;1:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908991</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi T, et al. Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia. Experientia. 1992;48:656&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">1639174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gils A, Declerck PJ. Plasminogen activator inhibitor-1. Curr Med Chem. 2004;11:2323&#x2013;2334.</Citation><ArticleIdList><ArticleId IdType="pubmed">15379715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost. 2004;91:425&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">14983217</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21:195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866675</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (A&#x3b2;) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci. 2003;23:8867&#x2013;8871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740393</ArticleId><ArticleId IdType="pubmed">14523088</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall DL, et al. WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation. Biochem Biophys Res Comm. 2003;311:904&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">14623266</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardell SJ, et al. Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action. Mol Pharmacol. 2007;72:897&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, et al. Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. Neurosci Lett. 2004;368:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364412</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005;93:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383744</ArticleId><ArticleId IdType="pubmed">15841309</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Strickland S. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci USA. 2007;104:13473&#x2013;13478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1948906</ArticleId><ArticleId IdType="pubmed">17673549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J Surg Oncol. 2000;74:90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10914816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, et al. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005;14:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gils A, et al. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost. 2002;88:137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997;90:204&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9207454</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmeliet P, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288474</ArticleId><ArticleId IdType="pubmed">8254029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennan JK, et al. Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. JPET. 2005;314:710&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">15860572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005;93:631&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">15841306</ArticleId></ArticleIdList></Reference><Reference><Citation>Dano K, et al. Plasminogen activation and cancer. Thromb Haemost. 2005;93:676&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">15841311</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator. Proc Natl Acad Sci USA. 2006;103:7847&#x2013;7852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472533</ArticleId><ArticleId IdType="pubmed">16682647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlak R, et al. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci USA. 2005;102:18201&#x2013;18206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1312427</ArticleId><ArticleId IdType="pubmed">16330749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. 1997;17:543&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573220</ArticleId><ArticleId IdType="pubmed">8987777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: Relevance to Alzheimer's disease. Int J Biochem Cell Biol. 2003;35:1505&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pubmed">12824062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature. 1996;384:123&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8906786</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature. 1993;361:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">8429885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428515</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem. 2003;278:19054&#x2013;19061.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, et al. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 2000;1:530&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1083779</ArticleId><ArticleId IdType="pubmed">11263499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sappino AP, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest. 1993;92:679&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC294901</ArticleId><ArticleId IdType="pubmed">8349806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18562609</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>25</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6388</StartPage><EndPage>6392</EndPage><MedlinePgn>6388-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0364-08.2008</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive impairments in memory and cognition. Extracellular accumulation of soluble high-molecular-weight (HMW) Abeta oligomers has been proposed to be largely responsible for AD dementia and memory deficits in the Tg2576 mice, a model of AD. In this study, we found that a naturally derived grape seed polyphenolic extract can significantly inhibit amyloid beta-protein aggregation into high-molecular-weight oligomers in vitro. When orally administered to Tg2576 mice, this polyphenolic preparation significantly attenuates AD-type cognitive deterioration coincidentally with reduced HMW soluble oligomeric Abeta in the brain. Our study suggests that grape seed-derived polyphenolics may be useful agents to prevent or treat AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Lap</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Kenjiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rosensweig</LastName><ForeName>Clark</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Linghong</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Humala</LastName><ForeName>Nelson</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>Giulio M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG027818</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AT004511</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AT004511-01</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027818</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010636">Phenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059808">Polyphenols</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059808" MajorTopicYN="N">Polyphenols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027843" MajorTopicYN="Y">Vitis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18562609</ArticleId><ArticleId IdType="mid">NIHMS165481</ArticleId><ArticleId IdType="pmc">PMC2806059</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0364-08.2008</ArticleId><ArticleId IdType="pii">28/25/6388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food Chem Toxicol. 2002;40:1731&#x2013;1743.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem. 2001;276:35176&#x2013;35184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA. 2003;100:330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorozynski A. Wine may prevent dementia. BMJ. 1997;314:997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2126446</ArticleId><ArticleId IdType="pubmed">9112841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004;18:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Stine WB, Jr, Teplow DB. Small assemblies of unmodified amyloid &#x3b2;-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging. 2004;25:569&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172732</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc. 2004;52:540&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066068</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280:37377&#x2013;37382.</Citation><ArticleIdList><ArticleId IdType="pubmed">16162502</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767098</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli L, Bulloj A, Leal MC, Castano EM. Amyloid beta degradation: a challenging task for brain peptidases. Subcell Biochem. 2005;38:129&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709476</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF, Krafft GA, Finch CE. Clusterin (apoJ) alters the aggregation of amyloid &#x3b2;-peptide (A&#x3b2;1&#x2013;42) and forms slowly sedimenting A&#x3b2; complexes that cause oxidative stress. Exp Neurol. 1995;136:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">7589331</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">9296132</ArticleId></ArticleIdList></Reference><Reference><Citation>Percival SS, Sims CA. Wine modifies the effects of alcohol on immune cells of mice. J Nutr. 2000;130:1091&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801903</ArticleId></ArticleIdList></Reference><Reference><Citation>Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des. 2006;67:27&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16492146</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005;25:8807&#x2013;8814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725500</ArticleId><ArticleId IdType="pubmed">16177050</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:2073S&#x2013;2085S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10917926</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001;3:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214075</ArticleId></ArticleIdList></Reference><Reference><Citation>Siva B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of polyphenolics extracts of grape seeds (GSE) on blood pressure (BP) in patients with metabolic syndrome (MetS) FASEB J. 2006;20:A305.</Citation></Reference><Reference><Citation>Vinson JA, Proch J, Bose P. MegaNatural&#xae; Gold grapeseed extract: in vitro antioxidant and in vivo human supplementation studies. J Med Food. 2001;4:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639284</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollers SS, Teplow DB, Bitan G. Determination of peptide oligomerization state using rapid photochemical crosslinking. Methods Mol Biol. 2005;299:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R, Hof PR, Pasinetti GM. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2005;19:659&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006;20:2313&#x2013;2320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077308</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem. 2004;15:506&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350981</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18562603</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>25</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.</ArticleTitle><Pagination><StartPage>6333</StartPage><EndPage>6341</EndPage><MedlinePgn>6333-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0829-08.2008</ELocationID><Abstract><AbstractText>Complement factor C3 is the central component of the complement system and a key inflammatory protein activated in Alzheimer's disease (AD). Previous studies demonstrated that inhibition of C3 by overexpression of soluble complement receptor-related protein y in an AD mouse model led to reduced microgliosis, increased amyloid beta (Abeta) plaque burden, and neurodegeneration. To further address the role of C3 in AD pathology, we generated a complement C3-deficient amyloid precursor protein (APP) transgenic AD mouse model (APP;C3(-/-)). Brains were analyzed at 8, 12, and 17 months of age by immunohistochemical and biochemical methods and compared with age-matched APP transgenic mice. At younger ages (8-12 months), no significant neuropathological differences were observed between the two transgenic lines. In contrast, at 17 months of age, APP;C3(-/-) mice showed significant changes of up to twofold increased total Abeta and fibrillar amyloid plaque burden in midfrontal cortex and hippocampus, which correlated with (1) significantly increased Tris-buffered saline (TBS)-insoluble Abeta(42) levels and reduced TBS-soluble Abeta(42) and Abeta(40) levels in brain homogenates, (2) a trend for increased Abeta levels in the plasma, (3) a significant loss of neuronal-specific nuclear protein-positive neurons in the hippocampus, and (4) differential activation of microglia toward a more alternative phenotype (e.g., significantly increased CD45-positive microglia, increased brain levels of interleukins 4 and 10, and reduced levels of CD68, F4/80, inducible nitric oxide synthase, and tumor necrosis factor). Our results suggest a beneficial role for complement C3 in plaque clearance and neuronal health as well as in modulation of the microglia phenotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liying</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Seabrook</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020159</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20159</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18562603</ArticleId><ArticleId IdType="mid">NIHMS67097</ArticleId><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0829-08.2008</ArticleId><ArticleId IdType="pii">28/25/6333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 1998;188:431&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212467</ArticleId><ArticleId IdType="pubmed">9687521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MR. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2000;2:289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">10758405</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">2565620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol. 1995;154:4309&#x2013;4321.</Citation><ArticleIdList><ArticleId IdType="pubmed">7722289</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol. 1995;154:4726&#x2013;4733.</Citation><ArticleIdList><ArticleId IdType="pubmed">7536777</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmy KY, Katschke KJ, Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124:915&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530040</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. A&#x3b2; deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci USA. 2004;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar &#x3b2;-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25:8240&#x2013;8249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson E, Lindvall O, Kokaia Z. Stereological assessment of vulnerability of immunocytochemically identified striatal and hippocampal neurons after global cerebral ischemia in rats. Brain Res. 2001;913:117&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11549375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging. 2002;23:991&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Evidence for peripheral clearance of A&#x3b2; following chronic, active A&#x3b2; immunization in PSAPP mice. Neurobiol Dis. 2003;14:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678662</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vi-Strauss M, Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol. 1987;139:2361&#x2013;2366.</Citation><ArticleIdList><ArticleId IdType="pubmed">3655365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lledo PM, Alonso M, Grubb MS. Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci. 2006;7:179&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495940</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Seabrook TJ, Lemere CA. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G) Vaccine. 2005;23:5149&#x2013;5159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054274</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA. Short amyloid-&#x3b2; (A&#x3b2;) immunogens reduce cerebral A&#x3b2; load and learning deficits in an Alzheimer's disease mouse model in the absence of an A&#x3b2;-specific cellular immune response. J Neurosci. 2006;26:4717&#x2013;4728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674171</ArticleId><ArticleId IdType="pubmed">16672644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001;158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The possible role of complement activation in Alzheimer disease. Trends Mol Med. 2002;8:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421685</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">2559373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer's therapeutics. J Neuropathol Exp Neurol. 2005;64:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen RJ, Buck CR, Smith AM. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 1992;116:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">1483388</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999;73:303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Tocco G, Sakhi S, Musleh WD, DeSimoni MG, Mascarucci P, Schreiber S, Baudry M, Finch CE. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis. 1996;3:197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980020</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Jiang L, Lee DY, Schachter SC, Ma Z, Lemere CA. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. J Neurosci Res. 2006;84:903&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK, Zwirner J, Wetsel RA, Gerard C, Pekny M, Pekna M. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 2006;25:1364&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422160</ArticleId><ArticleId IdType="pubmed">16498410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374212</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol. 2000;156:489&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850044</ArticleId><ArticleId IdType="pubmed">10666378</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 1997;769:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374211</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol. 2000;12:1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882413</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci. 2003;992:56&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794047</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Bradt B, Rogers J, Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem. 1997;69:388&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol. 1990;81:116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate and essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA. 1995;92:490&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40427</ArticleId><ArticleId IdType="pubmed">8524789</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 1990;296:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 2002;99:10837&#x2013;10842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol. 1999;154:927&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866427</ArticleId><ArticleId IdType="pubmed">10079271</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18566287</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>320</Volume><Issue>5883</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex.</ArticleTitle><Pagination><StartPage>1638</StartPage><EndPage>1643</EndPage><MedlinePgn>1638-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1156120</ELocationID><Abstract><AbstractText>Astrocytes have long been thought to act as a support network for neurons, with little role in information representation or processing. We used two-photon imaging of calcium signals in the ferret visual cortex in vivo to discover that astrocytes, like neurons, respond to visual stimuli, with distinct spatial receptive fields and sharp tuning to visual stimulus features including orientation and spatial frequency. The stimulus-feature preferences of astrocytes were exquisitely mapped across the cortical surface, in close register with neuronal maps. The spatially restricted stimulus-specific component of the intrinsic hemodynamic mapping signal was highly sensitive to astrocyte activation, indicating that astrocytes have a key role in coupling neuronal organization to mapping signals critical for noninvasive brain imaging. Furthermore, blocking astrocyte glutamate transporters influenced the magnitude and duration of adjacent visually driven neuronal responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schummers</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sur</LastName><ForeName>Mriganka</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120673">benzyloxyaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 Jun 20;320(5883):1597-9. doi: 10.1126/science.1160122.</RefSource><PMID Version="1">18566273</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18566287</ArticleId><ArticleId IdType="doi">10.1126/science.1156120</ArticleId><ArticleId IdType="pii">320/5883/1638</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18566660</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries.</ArticleTitle><Pagination><StartPage>e1000099</StartPage><MedlinePgn>e1000099</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1000099</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1000099</ELocationID><Abstract><AbstractText>Hereditary cystatin C amyloid angiopathy (HCCAA) is an autosomal dominant disease with high penetrance, manifest by brain hemorrhages in young normotensive adults. In Iceland, this condition is caused by the L68Q mutation in the cystatin C gene, with contemporary carriers reaching an average age of only 30 years. Here, we report, based both on linkage disequilibrium and genealogical evidence, that all known copies of this mutation derive from a common ancestor born roughly 18 generations ago. Intriguingly, the genealogies reveal that obligate L68Q carriers born 1825 to 1900 experienced a drastic reduction in life span, from 65 years to the present-day average. At the same time, a parent-of-origin effect emerged, whereby maternal inheritance of the mutation was associated with a 9 year reduction in life span relative to paternal inheritance. As these trends can be observed in several different extended families, many generations after the mutational event, it seems likely that some environmental factor is responsible, perhaps linked to radical changes in the life-style of Icelanders during this period. A mutation with such radically different phenotypic effects in reaction to normal variation in human life-style not only opens the possibility of preventive strategies for HCCAA, but it may also provide novel insights into the complex relationship between genotype and environment in human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palsdottir</LastName><ForeName>Astridur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Experimental Pathology, University of Iceland, Keldur, Reykjavik, Iceland. astripal@hi.is</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helgason</LastName><ForeName>Agnar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Palsson</LastName><ForeName>Snaebjorn</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Hans Tomas</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Bragason</LastName><ForeName>Birkir Thor</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Gretarsdottir</LastName><ForeName>Solveig</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Thorsteinsdottir</LastName><ForeName>Unnur</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Olafsson</LastName><ForeName>Elias</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525030">CST3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055316">Cystatin C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015891">Cystatins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RH81L854J</RegistryNumber><NameOfSubstance UI="D005973">Glutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055316" MajorTopicYN="N">Cystatin C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015891" MajorTopicYN="N">Cystatins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="Y">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18566660</ArticleId><ArticleId IdType="pmc">PMC2409978</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1000099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci. 2006;31:465&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M. Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci. 2004;226:41&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537517</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnason A. Apoplexie und ihre vererbung. Acta Psychiat Neruol Suppl VII 1935</Citation></Reference><Reference><Citation>Grubb AO. Cystatin C&#x2013;properties and use as diagnostic marker. Adv Clin Chem. 2000;35:63&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130541</ArticleId><ArticleId IdType="pubmed">11040958</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsdottir A, Abrahamson M, Thorsteinsson L, Arnason A, Olafsson I, et al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet. 1988;2:603&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">2900981</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamson M, Jonsdottir S, Olafsson I, Jensson O, Grubb A. Hereditary cystatin C amyloid angiopathy: identification of the disease-causing mutation and specific diagnosis by polymerase chain reaction based analysis. Hum Genet. 1992;89:377&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">1352269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lofberg H, Grubb AO, Nilsson EK, Jensson O, Gudmundsson G, et al. Immunohistochemical characterization of the amyloid deposits and quantitation of pertinent cerebrospinal fluid proteins in hereditary cerebral hemorrhage with amyloidosis. Stroke. 1987;18:431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">2436360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudmundsson G, Hallgrimsson J, Jonasson TA, Bjarnason O. Hereditary cerebral haemorrhage with amyloidosis. Brain. 1972;95:387&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">4655034</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, et al. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol. 2001;60:94&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11202179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, et al. Cystatin C modulates cerebral beta-amyloidosis. Nat Genet. 2007;39:1437&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet. 2007;39:1440&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgason A, Yngvadottir B, Hrafnkelsson B, Gulcher J, Stefansson K. An Icelandic example of the impact of population structure on association studies. Nat Genet. 2005;37:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sveinbjornsdottir S, Blondal H, Gudmundsson G, Kjartansson O, Jonsdottir S. Progressive dementia and leucoencephalopathy as the initial presentation of late onset hereditary cystatin-C amyloidosis. Clinicopathological presentation of two cases. J Neurol Sci. 1996;140:101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866434</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet. 1999;23:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. Faseb J. 1998;12:949&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">9707167</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 2003;23:5293&#x2013;5300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165709</ArticleId><ArticleId IdType="pubmed">12861015</ArticleId></ArticleIdList></Reference><Reference><Citation>Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat. 2007;28:831&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">17443661</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugge U, Andersson R, Chizari F, Danielsson M, Holmgren G, et al. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet. 1993;30:388&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1016374</ArticleId><ArticleId IdType="pubmed">8100581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensson O, Gudmundsson G, Arnason A, Blondal H, Petursdottir I, et al. Hereditary cystatin C (gamma-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. Acta Neurol Scand. 1987;76:102&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">3673496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjalldal J, Benediktsson K, Sigurdsson J, Ellingsen L. Automated genotyping: combining neural networks and decision trees to perform robust allele calling. 2001</Citation></Reference><Reference><Citation>Palsson B, Palsson F, Perlin M, Gudbjartsson H, Stefansson K, et al. Using quality measures to facilitate allele calling in high-throughput genotyping. Genome Res. 1999;9:1002&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC310819</ArticleId><ArticleId IdType="pubmed">10523529</ArticleId></ArticleIdList></Reference><Reference><Citation>Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995;12:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">7476138</ArticleId></ArticleIdList></Reference><Reference><Citation>Slatkin M, Rannala B. Estimating allele age. Annu Rev Genomics Hum Genet. 2000;1:225&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701630</ArticleId></ArticleIdList></Reference><Reference><Citation>Labuda M, Labuda D, Korab-Laskowska M, Cole DE, Zietkiewicz E, et al. Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am J Hum Genet. 1996;59:633&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914903</ArticleId><ArticleId IdType="pubmed">8751865</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson G, Magnusson M. Hagskinna: Icelandic historical statistics. Reykjavik: Statistics Iceland; 1997.</Citation></Reference><Reference><Citation>A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeve JP, Rannala B. DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics. 2002;18:894&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">12075030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson G. Changes in Food Consumption in Iceland 1770&#x2013;1940. Scandinavian Economic History Review. 1998;XLVI:24&#x2013;41.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18568035</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.</ArticleTitle><Pagination><StartPage>837</StartPage><EndPage>842</EndPage><MedlinePgn>837-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm1782</ELocationID><Abstract><AbstractText>Alzheimer's disease constitutes a rising threat to public health. Despite extensive research in cellular and animal models, identifying the pathogenic agent present in the human brain and showing that it confers key features of Alzheimer's disease has not been achieved. We extracted soluble amyloid-beta protein (Abeta) oligomers directly from the cerebral cortex of subjects with Alzheimer's disease. The oligomers potently inhibited long-term potentiation (LTP), enhanced long-term depression (LTD) and reduced dendritic spine density in normal rodent hippocampus. Soluble Abeta from Alzheimer's disease brain also disrupted the memory of a learned behavior in normal rats. These various effects were specifically attributable to Abeta dimers. Mechanistically, metabotropic glutamate receptors were required for the LTD enhancement, and N-methyl D-aspartate receptors were required for the spine loss. Co-administering antibodies to the Abeta N-terminus prevented the LTP and LTD deficits, whereas antibodies to the midregion or C-terminus were less effective. Insoluble amyloid plaque cores from Alzheimer's disease cortex did not impair LTP unless they were first solubilized to release Abeta dimers, suggesting that plaque cores are largely inactive but sequester Abeta dimers that are synaptotoxic. We conclude that soluble Abeta oligomers extracted from Alzheimer's disease brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tapan H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Munoz</LastName><ForeName>Amaya</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shepardson</LastName><ForeName>Nina E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Imelda</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Brett</LastName><ForeName>Francesca M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Regan</LastName><ForeName>Ciaran M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>Bernardo L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG R01 027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>067660</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS046579</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18568035</ArticleId><ArticleId IdType="mid">NIHMS154255</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pii">nm1782</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 1994;91:12243&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer&#x2019;s disease. Nature. 2000;408:982&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:860&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz PE, Cook EP, Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J Neurosci. 1994;14:5325&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577083</ArticleId><ArticleId IdType="pubmed">7916043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp N, Bashir ZI. Long-term depression: a cascade of induction and expression mechanisms. Prog Neurobiol. 2001;65:339&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek SM, Bear MF. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. Proc Natl Acad Sci U S A. 1992;89:4363&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49082</ArticleId><ArticleId IdType="pubmed">1350090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Malenka RC. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron. 1992;9:967&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">1419003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyszkiewicz JP, Yan Z. beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiol. 2005;93:3102&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox GB, O&#x2019;Connell AW, Murphy KJ, Regan CM. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. J Neurochem. 1995;65:2796&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7595580</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan NC, et al. Temporal change in gene expression in the rat dentate gyrus following passive avoidance learning. J Neurochem. 2007;101:1085&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">17298388</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci. 2005;8:1727&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286931</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725159</ArticleId><ArticleId IdType="pubmed">15758153</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer&#x2019;s disease. J Neurochem. 1986;46:1820&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993;61:1916&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229002</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IC, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. Embo J. 2008;27:224&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206134</ArticleId><ArticleId IdType="pubmed">18059472</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18574238</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>283</Volume><Issue>34</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression.</ArticleTitle><Pagination><StartPage>22992</StartPage><EndPage>23003</EndPage><MedlinePgn>22992-3003</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M804175200</ELocationID><Abstract><AbstractText>The amyloid-beta (Abeta) peptide, which likely plays a key role in Alzheimer disease, is derived from the amyloid-beta precursor protein (APP) through consecutive proteolytic cleavages by beta-site APP-cleaving enzyme and gamma-secretase. Unexpectedly gamma-secretase inhibitors can increase the secretion of Abeta peptides under some circumstances. This "Abeta rise" phenomenon, the same inhibitor causing an increase in Abeta at low concentrations but inhibition at higher concentrations, has been widely observed. Here we show that the Abeta rise depends on the beta-secretase-derived C-terminal fragment of APP (betaCTF) or C99 levels with low levels causing rises. In contrast, the N-terminally truncated form of Abeta, known as "p3," formed by alpha-secretase cleavage, did not exhibit a rise. In addition to the Abeta rise, low betaCTF or C99 expression decreased gamma-secretase inhibitor potency. This "potency shift" may be explained by the relatively high enzyme to substrate ratio under conditions of low substrate because increased concentrations of inhibitor would be necessary to affect substrate turnover. Consistent with this hypothesis, gamma-secretase inhibitor radioligand occupancy studies showed that a high level of occupancy was correlated with inhibition of Abeta under conditions of low substrate expression. The Abeta rise was also observed in rat brain after dosing with the gamma-secretase inhibitor BMS-299897. The Abeta rise and potency shift are therefore relevant factors in the development of gamma-secretase inhibitors and can be evaluated using appropriate choices of animal and cell culture models. Hypothetical mechanisms for the Abeta rise, including the "incomplete processing" and endocytic models, are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burton</LastName><ForeName>Catherine R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>Jere E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Barten</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Margi E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>Carol M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Kieras</LastName><ForeName>Cathy J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Sisk</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Iben</LastName><ForeName>Lawrence G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Polson</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xu-Alan</ForeName><Initials>XA</Initials></Author><Author ValidYN="Y"><LastName>Corsa</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fiedler</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pierdomenico</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Roach</LastName><ForeName>Arthur H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Cantone</LastName><ForeName>Joseph L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Drexler</LastName><ForeName>Dieter M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Bergstrom</LastName><ForeName>Carl P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>McElhone</LastName><ForeName>Kate E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Bronson</LastName><ForeName>Joanne J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Macor</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Blat</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Grafstrom</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Seiffert</LastName><ForeName>Dietmar A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Zaczek</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Albright</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Toyn</LastName><ForeName>Jeremy H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497115">4-(2-((1R)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002087">Butyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006846">Hydrocarbons, Halogenated</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="Y">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006846" MajorTopicYN="N">Hydrocarbons, Halogenated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18574238</ArticleId><ArticleId IdType="doi">10.1074/jbc.M804175200</ArticleId><ArticleId IdType="pii">S0021-9258(19)49355-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18577732</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>299</Volume><Issue>24</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Intra-individual change over time in DNA methylation with familial clustering.</ArticleTitle><Pagination><StartPage>2877</StartPage><EndPage>2883</EndPage><MedlinePgn>2877-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.299.24.2877</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Changes over time in epigenetic marks, which are modifications of DNA such as by DNA methylation, may help explain the late onset of common human diseases. However, changes in methylation or other epigenetic marks over time in a given individual have not yet been investigated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether there are longitudinal changes in global DNA methylation in individuals and to evaluate whether methylation maintenance demonstrates familial clustering.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We measured global DNA methylation by luminometric methylation assay, a quantitative measurement of genome-wide DNA methylation, on DNA sampled at 2 visits on average 11 years apart in 111 individuals from an Icelandic cohort (1991 and 2002-2005) and on average 16 years apart in 126 individuals from a Utah sample (1982-1985 and 1997-2005).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Global methylation changes over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-nine percent of Icelandic individuals showed greater than 10% methylation change over time (P &lt; .001). The family-based Utah sample also showed intra-individual changes over time, and further demonstrated familial clustering of methylation change (P = .003). The family showing the greatest global methylation loss also demonstrated the greatest loss of gene-specific methylation by a separate methylation assay.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data indicate that methylation changes over time and suggest that methylation maintenance may be under genetic control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Hans T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigurdsson</LastName><ForeName>Martin I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>Rafael A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Hengmi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wenqiang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rongione</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Ekstr&#xf6;m</LastName><ForeName>Tomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Tamara B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Eiriksdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Leppert</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Sapienza</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Feinberg</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50-HG003233</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 AG012100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG003233</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG007380</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES015211</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000064</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 RR021967</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00064</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-ES015211</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM083084</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007055" MajorTopicYN="N" Type="Geographic">Iceland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014589" MajorTopicYN="N" Type="Geographic">Utah</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18577732</ArticleId><ArticleId IdType="mid">NIHMS69315</ArticleId><ArticleId IdType="pmc">PMC2581898</ArticleId><ArticleId IdType="doi">10.1001/jama.299.24.2877</ArticleId><ArticleId IdType="pii">299/24/2877</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bjornsson HT, Daniele Fallin M, Feinberg AP.An integrated epigenetic and genetic approach to common human disease Trends Genet Aug 2004208350&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262407</ArticleId></ArticleIdList></Reference><Reference><Citation>Petronis A.Human morbid genetics revisited: relevance of epigenetics Trends Genet Mar 2001173142&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">11226607</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. Annu Rev Genomics Hum Genet. 2004;5:479&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485357</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg AP.Epigenetics at the epicenter of modern medicine Jama Mar 19 2008299111345&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">18349095</ArticleId></ArticleIdList></Reference><Reference><Citation>Reik W.Stability and flexibility of epigenetic gene regulation in mammalian development Nature May 24 20074477143425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinoy DC, Jirtle RL.Environmental epigenomics in human health and disease Environ Mol Mutagen Jan 20084914&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18172876</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg AP.Phenotypic plasticity and the epigenetics of human disease Nature May 24 20074477143433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522677</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteller M.Epigenetics in cancer N Engl J Med Mar 13 2008358111148&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">18337604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill J, Petronis A.Molecular studies of major depressive disorder: the epigenetic perspective Mol Psychiatry Sep 2007129799&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins Proc Natl Acad Sci USA Jul 26 20051023010604&#x2013;10609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174919</ArticleId><ArticleId IdType="pubmed">16009939</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22 Nat Genet Dec 200638121378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082778</ArticleId><ArticleId IdType="pubmed">17072317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandovici I, Leppert M, Hawk PR, Suarez A, Linares Y, Sapienza C.Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions Hum Mol Genet Jul 1 200312131569&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812984</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TB, Launer LJ, Eiriksdottir G, et al. Age, gene/environment susceptibility-reykjavik study: multidisciplinary applied phenomics Am J Epidemiol May 1 200716591076&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723948</ArticleId><ArticleId IdType="pubmed">17351290</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi M, Johansson S, Stach D, et al. LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation Exp Cell Res Jul 1 2006312111989&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays Genome Res Mar 2006163383&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415217</ArticleId><ArticleId IdType="pubmed">16449502</ArticleId></ArticleIdList></Reference><Reference><Citation>S.A.G.E. (Statistical Analysis for Genetic Epidemiology) [computer program] 2006Case Western Reserve University; Version Release 5.2.0, May:</Citation></Reference><Reference><Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP.A comparison of normalization methods for high density oligonucleotide array data based on variance and bias Bioinformatics Jan 22 2003192185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson B.DNA methylation and autoimmune disease Clin Immunol Oct 2003109172&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14585278</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med May 20072615488&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17444888</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBaun MR, Niemitz EL, Feinberg AP.Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19 Am J Hum Genet Jan 2003721156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378620</ArticleId><ArticleId IdType="pubmed">12439823</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterland RA, Lin JR, Smith CA, Jirtle RL.Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus Hum Mol Genet Mar 1 2006155705&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, Ruden DM.Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution Nat Genet Jan 200333170&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner B, Crombie C, Tischler J, Fortunato A, Fraser AG.Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways Nat Genet Aug 2006388896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">16845399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulin-like growth factor-II in Wilms&#x2019; tumor commonly involves altered methylation but not mutations of CTCF or its binding site Cancer Res Jul 1 200161134947&#x2013;4950.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431321</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannucci E.Alcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies J Nutr Sep 200413492475S&#x2013;2481S.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk Science Mar 14 200329956131753&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637750</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg AP, Tycko B.The history of cancer epigenetics Nat Rev Cancer Feb 200442143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation Science Apr 18 20033005618489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano H, Compton LJ, Shiomi N, Steinberg AD, Jackson RA, Sasaki T.Low expression of human histocompatibility leukocyte antigen-DR is associated with hypermethylation of human histocompatibility leukocyte antigen-DR alpha gene regions in B cells from patients with systemic lupus erythematosus J Clin Invest Oct 19857641314&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424064</ArticleId><ArticleId IdType="pubmed">2997276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18579078</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating.</ArticleTitle><Pagination><StartPage>871</StartPage><EndPage>883</EndPage><MedlinePgn>871-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.04.015</ELocationID><Abstract><AbstractText>Mutations in presenilins (PS) are the major cause of familial Alzheimer's disease (FAD) and have been associated with calcium (Ca2+) signaling abnormalities. Here, we demonstrate that FAD mutant PS1 (M146L)and PS2 (N141I) interact with the inositol 1,4,5-trisphosphate receptor (InsP3R) Ca2+ release channel and exert profound stimulatory effects on its gating activity in response to saturating and suboptimal levels of InsP3. These interactions result in exaggerated cellular Ca2+ signaling in response to agonist stimulation as well as enhanced low-level Ca2+signaling in unstimulated cells. Parallel studies in InsP3R-expressing and -deficient cells revealed that enhanced Ca2+ release from the endoplasmic reticulum as a result of the specific interaction of PS1-M146L with the InsP3R stimulates amyloid beta processing,an important feature of AD pathology. These observations provide molecular insights into the "Ca2+ dysregulation" hypothesis of AD pathogenesis and suggest novel targets for therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>King-Ho</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shineman</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Marioly</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>C&#xe1;rdenas</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>J Kevin</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM56328</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM056328</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM056328</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018411" MajorTopicYN="N">Spodoptera</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18579078</ArticleId><ArticleId IdType="mid">NIHMS57659</ArticleId><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.04.015</ArticleId><ArticleId IdType="pii">S0896-6273(08)00367-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol. 2002;34:1259&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392982</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrow PA, Empson RM, Gladwell SJ, Anderson CM, Killick R, Yu X, Jefferys JG, Duff K. Functional phenotype in transgenic mice expressing mutant human presenilin-1. Neurobiol Dis. 2000;7:119&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783295</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413485</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci U S A. 1994;91:4489&#x2013;4493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43811</ArticleId><ArticleId IdType="pubmed">8183935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai W, Hisatsune C, Nakamura K, Nakamura T, Inoue T, Mikoshiba K. Activity-dependent expression of inositol 1,4,5-trisphosphate receptor type 1 in hippocampal neurons. J Biol Chem. 2004;279:23691&#x2013;23698.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedazo-Minguez A, Popescu BO, Ankarcrona M, Nishimura T, Cowburn RF. The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J Biol Chem. 2002;277:36646&#x2013;36655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121968</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem. 2000;275:18195&#x2013;18200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, et al. Mutant presenilins of Alzheimer&#x2019;s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL. Calcium responses in fibroblasts from asymptomatic members of Alzheimer&#x2019;s disease families. Neurobiol Dis. 1998;5:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9702786</ArticleId></ArticleIdList></Reference><Reference><Citation>Foskett JK, White C, Cheung KH, Mak D-OD. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007;87:593&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901638</ArticleId><ArticleId IdType="pubmed">17429043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Doeven MK, Poolman B. Alzheimer disease: presenilin springs a leak. Nat Med. 2006;12:1121&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17024202</ArticleId></ArticleIdList></Reference><Reference><Citation>Genazzani AA, Carafoli E, Guerini D. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. Proc Natl Acad Sci USA. 1999;96:5797&#x2013;5801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21940</ArticleId><ArticleId IdType="pubmed">10318964</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomello M, Barbiero L, Zatti G, Squitti R, Binetti G, Pozzan T, Fasolato C, Ghidoni R, Pizzo P. Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer&#x2019;s disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol Dis. 2005;18:638&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755689</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Furukawa K, Sopher BL, Pham DG, Xie J, Robinson N, Martin GM, Mattson MP. Alzheimer&#x2019;s PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 1996;8:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051814</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A hundred years of Alzheimer&#x2019;s disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Dejaegere T, Horre K, Dabrowski M, Baert V, Annaert W, Hartmann D, De Strooper B. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis. 2004;17:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirashima N, Etcheberrigaray R, Bergamaschi S, Racchi M, Battaini F, Binetti G, Govoni S, Alkon DL. Calcium responses in human fibroblasts: a diagnostic molecular profile for Alzheimer&#x2019;s disease. Neurobiol Aging. 1996;17:549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">8832629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Hardy J. The presenilins and Alzheimer&#x2019;s disease. Hum Mol Genet. 1997;6:1639&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9300655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu L, Cheung KH, Vais H, Mak DO, White C, Foskett JK. Graded recruitment and inactivation of single InsP3 receptor Ca2+-release channels: implications for quantal Ca2+ release. J Physiol. 2006;573:645&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779751</ArticleId><ArticleId IdType="pubmed">16644799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:534&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42983</ArticleId><ArticleId IdType="pubmed">8290560</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JM, Burnett P, Thomas AP, Tezapsidis N. Calcium oscillations in type-1 astrocytes, the effect of a presenilin 1 (PS1) mutation. Neurosci Lett. 2006;395:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly-Tornetta C, Gao ZY, Lee VM, Wolf BA. Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons. J Biol Chem. 1998;273:14015&#x2013;14021.</Citation><ArticleIdList><ArticleId IdType="pubmed">9593752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasri NN, Kocks SL, Verbert L, Hebert SS, Callewaert G, Parys JB, Missiaen L, De Smedt H. Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca(2+) content in presenilin double knock-out cells. Cell Calcium. 2006;40:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675011</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Laude AJ, Tovey SC, Dedos SG, Potter BV, Lummis SC, Taylor CW. Rapid functional assays of recombinant IP3 receptors. Cell Calcium. 2005;38:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15963563</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, LaFerla FM, Callamaras N, Parker I. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiol Dis. 2001;8:469&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442355</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem. 1999a;274:32535&#x2013;32538.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer&#x2019;s presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J Neurochem. 1999b;72:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037477</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard CB, Lussier MP, Cayouette S, Bourque G, Boulay G. The overexpression of presenilin2 and Alzheimer&#x2019;s-disease-linked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells. Cell Signal. 2005;17:437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15601622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak D-OD, McBride S, Foskett JK. Inositol 1,4,5-trisphosphate activation of inositol trisphosphate receptor Ca2+ channel by ligand tuning of Ca2+ inhibition. Proc Natl Acad Sci USA. 1998;95:15821&#x2013;15825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28128</ArticleId><ArticleId IdType="pubmed">9861054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer&#x2019;s disease. Cell Calcium. 2003;34:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12909083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Guo Q. Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer&#x2019;s disease? J Neurosci Res. 1997;50:505&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">9404712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Zhu H, Yu J, Kindy MS. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci. 2000;20:1358&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772370</ArticleId><ArticleId IdType="pubmed">10662826</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev. 1990;70:391&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">2157230</ArticleId></ArticleIdList></Reference><Reference><Citation>Meberg PJ, Miller MW. Culturing hippocampal and cortical neurons. Methods Cell Biol. 2003;71:111&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12884689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007;117:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847535</ArticleId><ArticleId IdType="pubmed">17431506</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YS, Turner RJ. Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. Am J Physiol Cell Physiol. 2006;291:C76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467403</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry. 1994;33:4550&#x2013;4561.</Citation><ArticleIdList><ArticleId IdType="pubmed">8161510</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem. 2001;276:11539&#x2013;11544.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278803</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., 3rd The presenilin hypothesis of Alzheimer&#x2019;s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Boyle JP, Vaughan PF, Pearson HA, Cowburn RF, Peers CS. Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma SH-SY5Y cells expressing a familial Alzheimer&#x2019;s disease presenilin-1 mutation. Brain Res. 2002;949:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213305</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer&#x2019;s disease: recent advances gained from genetically modified animals. Cell Calcium. 2005a;38:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125228</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer&#x2019;s disease. J Neurochem. 2005b;94:1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE. Calcium dysregulation, IP3 signaling, and Alzheimer&#x2019;s disease. Neuroscientist. 2005;11:110&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746379</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer&#x2019;s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer&#x2019;s disease mice. J Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugawara H, Kurosaki M, Takata M, Kurosaki T. Genetic evidence for involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor. Embo Journal. 1997;16:3078&#x2013;3088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169926</ArticleId><ArticleId IdType="pubmed">9214625</ArticleId></ArticleIdList></Reference><Reference><Citation>Supnet C, Grant J, Kong H, Westaway D, Mayne M. Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem. 2006;281:38440&#x2013;38447.</Citation><ArticleIdList><ArticleId IdType="pubmed">17050533</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, et al. Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. Faseb J. 2005;19:2069&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev. 2005;85:201&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">15618481</ArticleId></ArticleIdList></Reference><Reference><Citation>White C, Li C, Yang J, Petrenko NB, Madesh M, Thompson CB, Foskett JK. The endoplasmic reticulum gateway to apoptosis by Bcl-XL modulation of the InsP3R. Nat Cell Biol. 2005;7:1021&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893337</ArticleId><ArticleId IdType="pubmed">16179951</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, et al. Presenilin mutations linked to familial Alzheimer&#x2019;s disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium. 2006;39:539&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">16620965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatti G, Ghidoni R, Barbiero L, Binetti G, Pozzan T, Fasolato C, Pizzo P. The presenilin 2 M239I mutation associated with familial Alzheimer&#x2019;s disease reduces Ca2+ release from intracellular stores. Neurobiol Dis. 2004;15:269&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18584785</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Neurofibrillary changes of the Alzheimer type in very elderly individuals: neither inevitable nor benign: Commentary on "No disease in the brain of a 115-year-old woman".</ArticleTitle><Pagination><StartPage>1133</StartPage><EndPage>1136</EndPage><MedlinePgn>1133-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Tredici</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Clinical Neuroanatomy, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurobiol Aging. 2008 Aug;29(8):1127-32. doi: 10.1016/j.neurobiolaging.2008.04.010.</RefSource><PMID Version="1">18534718</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016330" MajorTopicYN="N">Frail Elderly</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18584785</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.04.016</ArticleId><ArticleId IdType="pii">S0197-4580(08)00143-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18585350</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.</ArticleTitle><Pagination><StartPage>1149</StartPage><EndPage>1161</EndPage><MedlinePgn>1149-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2008.05.048</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a genetically heterogeneous disorder characterized by early hippocampal atrophy and cerebral amyloid-beta (Abeta) peptide deposition. Using TissueInfo to screen for genes preferentially expressed in the hippocampus and located in AD linkage regions, we identified a gene on 10q24.33 that we call CALHM1. We show that CALHM1 encodes a multipass transmembrane glycoprotein that controls cytosolic Ca(2+) concentrations and Abeta levels. CALHM1 homomultimerizes, shares strong sequence similarities with the selectivity filter of the NMDA receptor, and generates a large Ca(2+) conductance across the plasma membrane. Importantly, we determined that the CALHM1 P86L polymorphism (rs2986017) is significantly associated with AD in independent case-control studies of 3404 participants (allele-specific OR = 1.44, p = 2 x 10(-10)). We further found that the P86L polymorphism increases Abeta levels by interfering with CALHM1-mediated Ca(2+) permeability. We propose that CALHM1 encodes an essential component of a previously uncharacterized cerebral Ca(2+) channel that controls Abeta levels and susceptibility to late-onset AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dreses-Werringloer</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, North Shore-LIJ, Manhasset, NY 11030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Vingtdeux</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Haitian</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vais</LastName><ForeName>Horia</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Siebert</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Ankit</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Koppel</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rovelet-Lecrux</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>J Kevin</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Campagne</LastName><ForeName>Fabien</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Marambaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C530077">CALHM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2008 Dec 12;135(6):993-4; author reply 994-6. doi: 10.1016/j.cell.2008.11.030.</RefSource><PMID Version="1">19070563</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002879" MajorTopicYN="N">Chromosomes, Human, Pair 10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18585350</ArticleId><ArticleId IdType="mid">NIHMS56596</ArticleId><ArticleId IdType="pmc">PMC2577842</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2008.05.048</ArticleId><ArticleId IdType="pii">S0092-8674(08)00751-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">12838335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, et al. Evidence for genetic linkage of Alzheimer&#x2019;s disease to chromosome 10q. Science. 2000;290:2302&#x2013;2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125142</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Hsiao M, Lange C, Blacker D, Tanzi RE. Single-nucleotide polymorphism rs498055 on chromosome 10q24 is not associated with Alzheimer disease in two independent family samples. Am J Hum Genet. 2006;79:180&#x2013;183. author reply 183&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474135</ArticleId><ArticleId IdType="pubmed">16773580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, et al. Results of a high-resolution genome screen of 437 Alzheimer&#x2019;s disease families. Hum Mol Genet. 2003;12:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol. 1978;108:299&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">727199</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagne F, Skrabanek L. Mining expressed sequence tags identifies cancer markers of clinical interest. BMC Bioinformatics. 2006;7:481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635568</ArticleId><ArticleId IdType="pubmed">17078886</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Vianna C, Freeman M, Davies P. A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2002;99:7751&#x2013;7756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124341</ArticleId><ArticleId IdType="pubmed">12032355</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2007;1097:114&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer&#x2019;s disease pedigrees. Science. 2000;290:2303&#x2013;2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125143</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Baldwin CT. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet. 2003;12:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouaux E, Mackinnon R. Principles of selective ion transport in channels and pumps. Science. 2005;310:1461&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">16322449</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, Kauwe JS, Maxwell TJ, Cherny S, Doil L, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet. 2006;78:78&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380225</ArticleId><ArticleId IdType="pubmed">16385451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasprzyk A, Keefe D, Smedley D, London D, Spooner W, Melsopp C, Hammond M, Rocca-Serra P, Cox T, Birney E. EnsMart: a generic system for fast and flexible access to biological data. Genome Res. 2004;14:160&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314293</ArticleId><ArticleId IdType="pubmed">14707178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, et al. A full genome scan for late onset Alzheimer&#x2019;s disease. Hum Mol Genet. 1999;8:237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science. 2003;302:822&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593167</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Calcium, membranes, aging, and Alzheimer&#x2019;s disease. Introduction and overview. Ann N Y Acad Sci. 1989;568:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2629579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, Higuchi S, Urakami K, Kakita A, Takahashi H, et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer&#x2019;s disease. Hum Mol Genet. 2006;15:2170&#x2013;2182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16740596</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Amouyel P. Genetic heterogeneity of Alzheimer&#x2019;s disease: Complexity and advances. Psychoneuroendocrinology 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17659844</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Robakis NK. Genetic and molecular aspects of Alzheimer&#x2019;s disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav. 2005;4:134&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810902</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer&#x2019;s disease amyloid-beta peptides. J Biol Chem. 2005;280:37377&#x2013;37382.</Citation><ArticleIdList><ArticleId IdType="pubmed">16162502</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Minster RL, DeKosky ST, Kamboh MI. Lack of association of two chromosome 10q24 SNPs with Alzheimer&#x2019;s disease. Neurosci Lett. 2006;408:170&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1673299</ArticleId><ArticleId IdType="pubmed">17000046</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, et al. Susceptibility locus for Alzheimer&#x2019;s disease on chromosome 10. Science. 2000;290:2304&#x2013;2305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125144</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Goate AM. Molecular genetics of Alzheimer&#x2019;s disease. Curr Psychiatry Rep. 2004;6:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">15038915</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya I, Douglas WW. Calcium channels in rat melanotrophs are permeable to manganese, cobalt, cadmium, and lanthanum, but not to nickel: evidence provided by fluorescence changes in fura-2-loaded cells. Endocrinology. 1992;131:1936&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">1327724</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrabanek L, Campagne F. TissueInfo: high-throughput identification of tissue expression profiles and specificity. Nucleic Acids Res. 2001;29:E102&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60201</ArticleId><ArticleId IdType="pubmed">11691939</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilquet V, De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol. 2004;14:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollmuth LP, Sobolevsky AI. Structure and gating of the glutamate receptor ion channel. Trends Neurosci. 2004;27:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18591429</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-8140</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production.</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1116</EndPage><MedlinePgn>1107-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.200706171</ELocationID><Abstract><AbstractText>In addition to disrupting the regulated intramembraneous proteolysis of key substrates, mutations in the presenilins also alter calcium homeostasis, but the mechanism linking presenilins and calcium regulation is unresolved. At rest, cytosolic Ca(2+) is maintained at low levels by pumping Ca(2+) into stores in the endoplasmic reticulum (ER) via the sarco ER Ca(2+)-ATPase (SERCA) pumps. We show that SERCA activity is diminished in fibroblasts lacking both PS1 and PS2 genes, despite elevated SERCA2b steady-state levels, and we show that presenilins and SERCA physically interact. Enhancing presenilin levels in Xenopus laevis oocytes accelerates clearance of cytosolic Ca(2+), whereas higher levels of SERCA2b phenocopy PS1 overexpression, accelerating Ca(2+) clearance and exaggerating inositol 1,4,5-trisphosphate-mediated Ca(2+) liberation. The critical role that SERCA2b plays in the pathogenesis of Alzheimer's disease is underscored by our findings that modulating SERCA activity alters amyloid beta production. Our results point to a physiological role for the presenilins in Ca(2+) signaling via regulation of the SERCA pump.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demuro</LastName><ForeName>Angelo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Yama</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hitt</LastName><ForeName>Brian D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ian F</ForeName><Initials>IF</Initials></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM048071</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM048071</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM48071</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17968</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017968</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>85166-31-0</RegistryNumber><NameOfSubstance UI="D015544">Inositol 1,4,5-Trisphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.8</RegistryNumber><NameOfSubstance UI="D053498">Sarcoplasmic Reticulum Calcium-Transporting ATPases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ReprintIn"><RefSource>J Gen Physiol. 2008 Aug;132(2):i1. doi: 10.1085/JGP1322OIA1.</RefSource><PMID Version="1">18663130</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015544" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053498" MajorTopicYN="N">Sarcoplasmic Reticulum Calcium-Transporting ATPases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18591429</ArticleId><ArticleId IdType="pmc">PMC2442205</ArticleId><ArticleId IdType="doi">10.1083/jcb.200706171</ArticleId><ArticleId IdType="pii">jcb.200706171</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aubier, M., and N. Viires. 1998. Calcium ATPase and respiratory muscle function. Eur. Respir. J. 11:758&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596133</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba-Aissa, F., L. Raeymaekers, F. Wuytack, L. Dode, and R. Casteels. 1998. Distribution and isoform diversity of the organellar Ca2+ pumps in the brain. Mol. Chem. Neuropathol. 33:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9642673</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge, M.J., P. Lipp, and M.D. Bootman. 2000. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413485</ArticleId></ArticleIdList></Reference><Reference><Citation>Callamaras, N., and I. Parker. 1999. Radial localization of inositol 1,4,5-trisphosphate-sensitive Ca2+ release sites in Xenopus oocytes resolved by axial confocal linescan imaging. J. Gen. Physiol. 113:199&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223371</ArticleId><ArticleId IdType="pubmed">9925819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Q., and D. Schubert. 2002. Presenilin-interacting proteins. Expert Rev. Mol. Med. 4:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14585160</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro, A., E. Mina, R. Kayed, S.C. Milton, I. Parker, and C.G. Glabe. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff, K., C. Eckman, C. Zehr, X. Yu, C.M. Prada, J. Perez-tur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, et al. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass, M.R., and B.A. Yankner. 2005. A {gamma }-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J. Biol. Chem. 280:36895&#x2013;36904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1562327</ArticleId><ArticleId IdType="pubmed">16103124</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms, J., I. Schneider, I. Dewachter, N. Caluwaerts, H. Kretzschmar, and F. Van Leuven. 2003. Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J. Biol. Chem. 278:2484&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431992</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman, A., D. Hartmann, W. Annaert, P. Saftig, K. Craessaerts, L. Serneels, L. Umans, V. Schrijvers, F. Checler, H. Vanderstichele, et al. 1999. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. Natl. Acad. Sci. USA. 96:11872&#x2013;11877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasri, N.N., S.L. Kocks, L. Verbert, S.S. Hebert, G. Callewaert, J.B. Parys, L. Missiaen, and H. De Smedt. 2006. Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca2+ content in presenilin double knock-out cells. Cell Calcium. 40:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675011</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla, F.M. 2002. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring, M.A., I. Parker, and F.M. LaFerla. 1999. a. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals. J. Biol. Chem. 274:32535&#x2013;32538.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring, M.A., B.A. Paul, I. Parker, C.W. Cotman, and F.M. LaFerla. 1999. b. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J. Neurochem. 72:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037477</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring, M.A., Y. Akbari, C.M. Fanger, M.D. Cahalan, M.P. Mattson, and F.M. LaFerla. 2000. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring, M.A., M.P. Murphy, T.R. Mead, Y. Akbari, M.C. Sugarman, M. Jannatipour, B. Anliker, U. Muller, P. Saftig, B. De Strooper, et al. 2002. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. USA. 99:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123710</ArticleId><ArticleId IdType="pubmed">11917117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lytton, J., M. Westlin, and M.R. Hanley. 1991. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J. Biol. Chem. 266:17067&#x2013;17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832668</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrot, N., P. Ghisdal, A.S. Caumont, and J.N. Octave. 2004. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J. Neurochem. 88:1140&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009669</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth, H.W., and D.J. Selkoe. 1994. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry. 33:4550&#x2013;4561.</Citation><ArticleIdList><ArticleId IdType="pubmed">8161510</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth, H.W., J. Jiang, J.D. Geiger, and D.J. Selkoe. 1997. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. J. Neurochem. 69:1580&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326287</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, I.F., J.P. Boyle, P.F. Vaughan, H.A. Pearson, R.F. Cowburn, and C.S. Peers. 2002. Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells expressing a familial Alzheimer's disease presenilin-1 mutation. Brain Res. 949:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213305</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann, G.E., A. Caccamo, F.M. LaFerla, and I. Parker. 2004. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J. Neurosci. 24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu, H., O. Nelson, A. Bezprozvanny, Z. Wang, S.F. Lee, Y.H. Hao, L. Serneels, B. De Strooper, G. Yu, and I. Bezprozvanny. 2006. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, J., A. Capell, J. Grunberg, B. Pesold, A. Schindzielorz, R. Prior, M.B. Podlisny, P. Fraser, P.S. Hyslop, D.J. Selkoe, and C. Haass. 1996. The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol. Med. 2:673&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230134</ArticleId><ArticleId IdType="pubmed">8972483</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano, K., O.H. Petersen, and A.V. Tepikin. 2004. Dual sensitivity of sarcoplasmic/endoplasmic Ca2+-ATPase to cytosolic and endoplasmic reticulum Ca2+ as a mechanism of modulating cytosolic Ca2+ oscillations. Biochem. J. 383:353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134077</ArticleId><ArticleId IdType="pubmed">15260801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, A.S., I. Cheng, S. Chung, T.Z. Grenfell, H. Lee, E. Pack-Chung, M. Handler, J. Shen, W. Xia, G. Tesco, et al. 2000. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S.L., A.V. Yeromin, X.H. Zhang, Y. Yu, O. Safrina, A. Penna, J. Roos, K.A. Stauderman, and M.D. Cahalan. 2006. Genome-wide RNAi screen of Ca(2+) influx identifies genes that regulate Ca(2+) release-activated Ca(2+) channel activity. Proc. Natl. Acad. Sci. USA. 103:9357&#x2013;9362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482614</ArticleId><ArticleId IdType="pubmed">16751269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z., P. Nadeau, W. Song, D. Donoviel, M. Yuan, A. Bernstein, and B.A. Yankner. 2000. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat. Cell Biol. 2:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>